


**CUMULATIVE
SUPPLEMENT 6
JUNE 2017**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

37th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2017

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

37th EDITION

**Cumulative Supplement 6
June 2017**

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	v
1.1 How to use the Cumulative Supplement.....	v
1.2 Cumulative Supplement Content	vi
1.3 Applicant Name Changes	vii
1.4 Levothyroxine Sodium.....	vii
1.5 Availability of the Edition	viii
1.6 Report of Counts for the Prescription Drug Product List.....	ix
1.7 Cumulative Supplement Legend	x
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

37th EDITION

**CUMULATIVE SUPPLEMENT 6
June 2017**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 37th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the

next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

JAI PHARMA LTD
(JAI PHARMA LTD)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

MYLAN LABORATORIES LTD
(MYLAN LABS LTD)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharms NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (Alara NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	021342	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucml29689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2016</u>	<u>MAR 2017</u>	<u>JUN 2017</u>	<u>SEP 2017</u>	<u>DEC 2017</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	18130 2646 (14.6%)	18391 2688 (14.6%)	18711 2708 (14.5%)		
MULTISOURCE	15484 (85.4%)	15703 (85.4%)	16003 (85.5%)		
THERAPEUTICALLY EQUIVALENT	15335 (84.7%)	15581 (84.7%)	15882 (84.9%)		
NOT THERAPEUTICALLY EQUIVALENT	129 (0.7%)	122 (0.7%)	121 (0.6%)		
EXCEPTIONS ¹	73 (0.4%)	73 (0.4%)	73 (0.4%)		
NEW MOLECULAR ENTITIES APPROVED	7	14	17		
NUMBER OF APPLICANTS	1051	1053	1050		

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug

Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >D>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN**	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CHRS	Change. Reference Standard.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

****Note:**

The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 240 character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE; LAMIVUDINE

TABLET; ORAL

ABACAVIR SULFATE AND LAMIVUDINE

AB	AUROBINDO PHARMA LTD	EQ 600MG BASE; 300MG	A206151	001	Mar 28, 2017	Mar	NEWA
AB	CIPLA LTD	EQ 600MG BASE; 300MG	A091144	001	Mar 28, 2017	Mar	NEWA
AB	LUPIN LTD	EQ 600MG BASE; 300MG	A204990	001	Mar 28, 2017	Mar	NEWA

ABALOPARATIDE

SOLUTION; SUBCUTANEOUS
TYMLOS

+	RADIUS HEALTH INC	3.12MG/1.56ML (2MG/ML)	N208743	001	Apr 28, 2017	Apr	NEWA
---	-------------------	------------------------	---------	-----	--------------	-----	------

ABIRATERONE ACETATE

TABLET; ORAL

ZYTIGA

+	JANSSEN BIOTECH	500MG	N202379	002	Apr 14, 2017	May	NEWA
---	-----------------	-------	---------	-----	--------------	-----	------

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE; ORAL
ACAMPROSATE CALCIUM

AB	ZYDUS PHARMS USA INC	333MG	A205995	001	May 26, 2017	May	NEWA
----	----------------------	-------	---------	-----	--------------	-----	------

ACETAMINOPHEN

SOLUTION; IV (INFUSION)
ACETAMINOPHEN

AP	CUSTOPHARM INC	1GM/100ML (10MG/ML)	A202605	001	Jun 13, 2016	Jan	CAHN
----	----------------	---------------------	---------	-----	--------------	-----	------

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL

BUTALBITAL AND ACETAMINOPHEN

AA	TEDOR PHARMA INC	300MG; 50MG	A207635	001	Jun 05, 2017	May	NEWA
----	------------------	-------------	---------	-----	--------------	-----	------

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA	ACTAVIS LABS UT INC	325MG; 50MG; 40MG	A088616	001	Nov 09, 1984	Apr	CTNA
AA	MALLINCKRODT INC	325MG; 50MG; 40MG	A087804	001	Jan 24, 1985	Mar	CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

>A>	AA	ABHAI LLC	300MG; 5MG	A209036	001	Jun 21, 2017	Jun	NEWA
>A>	AA		300MG; 7.5MG	A209036	002	Jun 21, 2017	Jun	NEWA
>A>	AA		300MG; 10MG	A209036	003	Jun 21, 2017	Jun	NEWA
>A>	AA		325MG; 5MG	A209037	001	Jun 21, 2017	Jun	NEWA
>A>	AA		325MG; 7.5MG	A209037	002	Jun 21, 2017	Jun	NEWA
>A>	AA		325MG; 10MG	A209037	003	Jun 21, 2017	Jun	NEWA
>A>	AA	AMNEAL PHARMS NY	300MG; 5MG	A206869	001	Jun 23, 2017	Jun	NEWA
>A>	AA	LANNETT HOLDINGS INC	300MG; 5MG	A207171	001	Jun 20, 2017	Jun	NEWA
>A>	AA		300MG; 7.5MG	A207171	002	Jun 20, 2017	Jun	NEWA
>A>	AA		300MG; 10MG	A207171	003	Jun 20, 2017	Jun	NEWA
>A>	AA		325MG; 5MG	A207172	001	Jun 22, 2017	Jun	NEWA
>A>	AA		325MG; 7.5MG	A207172	002	Jun 22, 2017	Jun	NEWA
>A>	AA		325MG; 10MG	A207172	003	Jun 22, 2017	Jun	NEWA
	AA	MALLINCKRODT INC	300MG; 5MG	A206718	001	Mar 31, 2017	Mar	NEWA
	AA		300MG; 7.5MG	A206718	002	Mar 31, 2017	Mar	NEWA
	AA		300MG; 10MG	A206718	003	Mar 31, 2017	Mar	NEWA
	AA	! MIKART	300MG; 5MG	A040658	002	Mar 24, 2006	May	CHRS
	AA		300MG; 7.5MG	A040658	002	Mar 24, 2006	Apr	CMS1
	AA	!	300MG; 10MG	A040658	003	Jun 23, 2004	May	CHRS
	AA		300MG; 10MG	A040658	003	Jun 23, 2004	Apr	CMS1
>D>	AA	UPSHER-SMITH LABS	325MG; 5MG	A206484	001	Mar 24, 2017	Jun	CAHN
>A>	AA		325MG; 5MG	A206484	001	Mar 24, 2017	Jun	CAHN
	AA		325MG; 5MG	A206484	001	Mar 24, 2017	Mar	NEWA
>D>	AA		325MG; 7.5MG	A206484	002	Mar 24, 2017	Jun	CAHN
>A>	AA		325MG; 7.5MG	A206484	002	Mar 24, 2017	Jun	CAHN
	AA		325MG; 7.5MG	A206484	002	Mar 24, 2017	Mar	NEWA
>D>	AA		325MG; 10MG	A206484	003	Mar 24, 2017	Jun	CAHN
>A>	AA		325MG; 10MG	A206484	003	Mar 24, 2017	Jun	CAHN
	AA		325MG; 10MG	A206484	003	Mar 24, 2017	Mar	NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

AA	AMNEAL PHARMS	325MG; 5MG	A040777	001	Nov 27, 2007	May CAHN
AA	ASCENT PHARMS INC	325MG; 2.5MG	A207419	001	Mar 22, 2017	Mar NEWA
AA		325MG; 5MG	A207419	002	Mar 22, 2017	Mar NEWA
AA		325MG; 7.5MG	A207419	003	Mar 22, 2017	Mar NEWA
AA		325MG; 10MG	A207419	004	Mar 22, 2017	Mar NEWA
AA	NOVEL LABS INC	325MG; 2.5MG	A204407	001	Feb 24, 2017	Feb NEWA
AA		325MG; 5MG	A204407	002	Feb 24, 2017	Feb NEWA
AA		325MG; 7.5MG	A204407	003	Feb 24, 2017	Feb NEWA
AA		325MG; 10MG	A204407	004	Feb 24, 2017	Feb NEWA
	PERCOCET					
AA	! VINTAGE PHARMS LLC	325MG; 7.5MG	A040330	003	Nov 23, 2001	Jan CMS1
AA	!	325MG; 10MG	A040330	004	Nov 23, 2001	Jan CMS1

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB	AUROBINDO PHARMA LTD	325MG; 37.5MG	A207152	001	Mar 22, 2017	Mar NEWA
AB	MACLEODS PHARMS LTD	325MG; 37.5MG	A206885	001	May 02, 2017	Apr NEWA

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

>A>	AP	PAR STERILE PRODUCTS	EQ 500MG BASE/VIAL	A205358	001	Jun 20, 2017	Jun NEWA
-----	----	----------------------	--------------------	---------	-----	--------------	----------

ACETIC ACID, GLACIAL

SOLUTION; IRRIGATION, URETHRAL

ACETIC ACID 0.25% IN PLASTIC CONTAINER

AT	ICU MEDICAL INC	250MG/100ML	N017656	001		Feb CAHN
----	-----------------	-------------	---------	-----	--	----------

ACETOHEXAMIDE

TABLET; ORAL

ACETOHEXAMIDE

@ WATSON LABS TEVA

250MG

A071893 001 Nov 25, 1987 May CAHN

@

500MG

A071894 001 Nov 25, 1987 May CAHN

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

SEMPREX-D

+! AUXILIUM PHARMS LLC 8MG; 60MG

N019806 001 Mar 25, 1994 May CAHN

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

AB	BOSCOGEN	200MG	A075090	001	Jan 26, 1999	May CAHN
----	----------	-------	---------	-----	--------------	----------

@ CHARTWELL MOLECULES

200MG

A074872 001 Apr 22, 1997 Jan CAHN

>D>	AB	MYLAN	200MG	A074727	001	Apr 22, 1997	Jun DISC
-----	----	-------	-------	---------	-----	--------------	----------

>A>		@	200MG	A074727	001	Apr 22, 1997	Jun DISC
-----	--	---	-------	---------	-----	--------------	----------

ZOVIRAX

AB	+! MYLAN PHARMS INC	200MG	N018828	001	Jan 25, 1985	Jan CAHN
----	---------------------	-------	---------	-----	--------------	----------

SUSPENSION; ORAL

ZOVIRAX

AB	+! MYLAN PHARMS INC	200MG/5ML	N019909	001	Dec 22, 1989	Jan CAHN
----	---------------------	-----------	---------	-----	--------------	----------

TABLET; BUCCAL

SITAVIG

>D>	+! CIPHER PHARMS US	50MG	N203791	001	Apr 12, 2013	Jun CAHN
-----	---------------------	------	---------	-----	--------------	----------

>A>	+! EPI HLTH	50MG	N203791	001	Apr 12, 2013	Jun CAHN
-----	-------------	------	---------	-----	--------------	----------

TABLET; ORAL

ACYCLOVIR

@ CHARTWELL MOLECULES

400MG

A074834 001 Apr 24, 1997 Jan CAHN

@

800MG

A074834 002 Apr 24, 1997 Jan CAHN

AB	HERITAGE PHARMS INC	400MG	A074891	001	Oct 31, 1997	Apr CMFD
----	---------------------	-------	---------	-----	--------------	----------

AB		800MG	A074891	002	Oct 31, 1997	Apr CMFD
----	--	-------	---------	-----	--------------	----------

AB	MYLAN PHARMS INC	400MG	A075211	001	Sep 28, 1998	Mar CAHN
----	------------------	-------	---------	-----	--------------	----------

AB		800MG	A075211	002	Sep 28, 1998	Mar CAHN
----	--	-------	---------	-----	--------------	----------

ZOVIRAX

AB	+ MYLAN PHARMS INC	400MG	N020089	001	Apr 30, 1991	Jan CAHN
----	--------------------	-------	---------	-----	--------------	----------

AB	+!	800MG	N020089	002	Apr 30, 1991	Jan CAHN
----	----	-------	---------	-----	--------------	----------

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

	@	ATHENEX INC	EQ 500MG BASE/VIAL	A074596	002	Apr 22, 1997	Mar CAHN
	@		EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Mar CAHN
AP	!	HIKMA PHARMS LLC	EQ 1GM BASE/VIAL	A205771	002	Feb 29, 2016	Mar CTEC
AP		MYLAN LABS LTD	EQ 500MG BASE/VIAL	A203927	001	Mar 29, 2017	Mar NEWA
AP			EQ 1GM BASE/VIAL	A203927	002	Mar 29, 2017	Mar NEWA
AP		ZYDUS PHARMS USA INC	EQ 500MG BASE/VIAL	A206606	001	Jun 13, 2017	May NEWA
AP			EQ 1GM BASE/VIAL	A206606	002	Jun 13, 2017	May NEWA

ADENOSINE

INJECTABLE; INJECTION

ADENOSINE

AP		WEST-WARD PHARMS INT	3MG/ML	A076404	001	Jun 16, 2004	Jan CAHN
AP			3MG/ML	A076500	001	Jun 16, 2004	Jan CAHN
	@		3MG/ML	A076501	001	Jun 16, 2004	Jan CAHN

ALBENDAZOLE

TABLET; ORAL

ALBENZA

>D>	+	AMEDRA PHARMS LLC	200MG	N020666	001	Jun 11, 1996	Jun CAHN
>A>	+	IMPAX LABS INC	200MG	N020666	001	Jun 11, 1996	Jun CAHN

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION

PROVENTIL-HFA

BX	+	3M DRUG DELIVERY	EQ 0.09MG BASE/INH	N020503	001	Aug 15, 1996	May CAHN
----	---	------------------	--------------------	---------	-----	--------------	----------

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

AN		WATSON LABS TEVA	EQ 0.083% BASE; 0.017%	A077063	001	Dec 31, 2007	Feb CAHN
----	--	------------------	------------------------	---------	-----	--------------	----------

ALENDRONATE SODIUM

TABLET; ORAL

ALENDRONATE SODIUM

>D>	@	UPSHER-SMITH LABS	EQ 5MG BASE	A075871	001	Apr 22, 2009	Jun CAHN
>A>	@		EQ 5MG BASE	A075871	001	Apr 22, 2009	Jun CAHN
>D>	@		EQ 10MG BASE	A075871	002	Apr 22, 2009	Jun CAHN
>A>	@		EQ 10MG BASE	A075871	002	Apr 22, 2009	Jun CAHN
>D>	@		EQ 35MG BASE	A075871	004	Apr 22, 2009	Jun CAHN
>A>	@		EQ 35MG BASE	A075871	004	Apr 22, 2009	Jun CAHN
>D>	@		EQ 40MG BASE	A075871	003	Apr 22, 2009	Jun CAHN
>A>	@		EQ 40MG BASE	A075871	003	Apr 22, 2009	Jun CAHN
>D>	@		EQ 70MG BASE	A075871	005	Apr 22, 2009	Jun CAHN
>A>	@		EQ 70MG BASE	A075871	005	Apr 22, 2009	Jun CAHN

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

ALOSETRON HYDROCHLORIDE

AB		AMNEAL PHARMS	EQ 0.5MG BASE	A206647	001	Dec 22, 2016	May CAHN
AB			EQ 1MG BASE	A206647	002	Dec 22, 2016	May CAHN

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

INJECTABLE; INJECTION

INFUVITE ADULT

+	!	SANDOZ INC	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 0.03MG/ML	N021163	001	May 18, 2000	May CAHN
---	---	------------	---	---------	-----	--------------	----------

INJECTABLE; IV (INFUSION)

INFUVITE ADULT

+	!	SANDOZ INC	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 30MCG/ML	N021559	001	Jun 16, 2003	May CAHN
---	---	------------	--	---------	-----	--------------	----------

ALPRAZOLAMTABLET; ORAL
ALPRAZOLAM

AB	ACTAVIS ELIZABETH	0.25MG	A074342	001	Oct 31, 1993	Apr CAHN
AB		0.5MG	A074342	002	Oct 31, 1993	Apr CAHN
AB		1MG	A074342	003	Oct 31, 1993	Apr CAHN
AB		2MG	A074342	004	Oct 31, 1993	Apr CAHN

TABLET, EXTENDED RELEASE; ORAL
ALPRAZOLAM

AB	AUROBINDO PHARMA LTD	0.5MG	A090871	001	Jun 07, 2011	Jan CAHN
AB		1MG	A090871	002	Jun 07, 2011	Jan CAHN
AB		2MG	A090871	003	Jun 07, 2011	Jan CAHN
AB		3MG	A090871	004	Jun 07, 2011	Jan CAHN
	@ IMPAX LABS INC	0.5MG	A077996	001	Jan 31, 2007	Feb CAHN
	@	1MG	A077996	002	Jan 31, 2007	Feb CAHN
	@	2MG	A077996	003	Jan 31, 2007	Feb CAHN
	@	3MG	A077996	004	Jan 31, 2007	Feb CAHN

ALPROSTADILINJECTABLE; INJECTION
EDEX

	@ AUXILIUM PHARMS LLC	0.005MG/VIAL	N020649	001	Jun 12, 1997	May CAHN
AP	+	0.01MG/VIAL	N020649	002	Jun 12, 1997	May CAHN
	+	0.01MG/VIAL	N020649	005	Jul 30, 1998	May CAHN
AP	+	0.02MG/VIAL	N020649	003	Jun 12, 1997	May CAHN
	+	0.02MG/VIAL	N020649	006	Jul 30, 1998	May CAHN
AP	+	0.04MG/VIAL	N020649	004	Jun 12, 1997	May CAHN
	+	0.04MG/VIAL	N020649	007	Jul 30, 1998	May CAHN

SUPPOSITORY; URETHRAL
MUSE

	+	MYLAN SPECIALITY LP	0.125MG	N020700	001	Nov 19, 1996	Mar CAHN
	+		0.25MG	N020700	002	Nov 19, 1996	Mar CAHN
	+		0.5MG	N020700	003	Nov 19, 1996	Mar CAHN
	+		1MG	N020700	004	Nov 19, 1996	Mar CAHN

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

>A>	AB	ALEMBIC PHARMS LTD	100MG	A208966	001	Jun 21, 2017	Jun NEWA
	AB	HERITAGE PHARMA	100MG	A209171	001	Jun 12, 2017	May NEWA
	AB	LANNETT HOLDINGS INC	100MG	A209221	001	Jun 15, 2017	May NEWA
	AB	STRIDES PHARMA	100MG	A209047	001	Jun 07, 2017	May NEWA
>D>	AB	USL PHARMA	100MG	A070589	001	Aug 05, 1986	Jun CAHN
>A>	AB		100MG	A070589	001	Aug 05, 1986	Jun CAHN

SYRUP; ORAL

AMANTADINE HYDROCHLORIDE

AA	!	CMP PHARMA INC	50MG/5ML	A075819	001	Sep 11, 2002	Apr CAHN
AA	!	PHARM ASSOC	50MG/5ML	A074509	001	Jul 17, 1995	May CAHN
		SYMMETREL					
	+	@ ENDO PHARMS	50MG/5ML	N016023	002		Jan CRLD

TABLET; ORAL

AMANTADINE HYDROCHLORIDE

	AB	NEWGEN PHARMS LLC	100MG	A207571	001	Jan 31, 2017	Jan NEWA
	AB	STRIDES PHARMA	100MG	A209035	001	Jun 09, 2017	May NEWA
>D>	AB	!	USL PHARMA	A076186	001	Dec 16, 2002	Jun CAHN
>A>	AB	!		A076186	001	Dec 16, 2002	Jun CAHN

AMCINONIDE

CREAM; TOPICAL

CYCLOCORT

>D>		@ ASTELLAS	0.025%	N018116	001		Jun CRLD
>A>		+	@	N018116	001		Jun CRLD
>D>		@	0.1%	N018116	002		Jun CRLD
>A>		+	@	N018116	002		Jun CRLD

LOTION; TOPICAL

CYCLOCORT

>D>		@ ASTELLAS	0.1%	N019729	001	Jun 13, 1988	Jun CRLD
>A>		+	@	N019729	001	Jun 13, 1988	Jun CRLD

OINTMENT; TOPICAL

CYCLOCORT

>D>		@ ASTELLAS	0.1%	N018498	001		Jun CRLD
-----	--	------------	------	---------	-----	--	----------

OINTMENT; TOPICAL							
CYCLOCORT							
>A>	+ @	0.1%		N018498	001		Jun CRLD
<u>AMIFOSTINE</u>							
INJECTABLE; INJECTION							
AMIFOSTINE							
AP	SUN PHARMA GLOBAL	500MG/VIAL		A077126	001	Mar 14, 2008	Apr CAHN
<u>AMINO ACIDS</u>							
INJECTABLE; INJECTION							
AMINOSYN 10%							
	ICU MEDICAL INC	10% (10GM/100ML)		N017673	003		Feb CAHN
AMINOSYN 10% (PH6)							
	ICU MEDICAL INC	10% (10GM/100ML)		N017673	008	Nov 18, 1985	Feb CAHN
AMINOSYN 3.5%							
	ICU MEDICAL INC	3.5% (3.5GM/100ML)		N017789	004		Feb CAHN
AMINOSYN 5%							
	ICU MEDICAL INC	5% (5GM/100ML)		N017673	001		Feb CAHN
AMINOSYN 7%							
	ICU MEDICAL INC	7% (7GM/100ML)		N017673	002		Feb CAHN
AMINOSYN 7% (PH6)							
	ICU MEDICAL INC	7% (7GM/100ML)		N017673	006	Nov 18, 1985	Feb CAHN
AMINOSYN 8.5%							
	ICU MEDICAL INC	8.5% (8.5GM/100ML)		N017673	004		Feb CAHN
AMINOSYN 8.5% (PH6)							
	ICU MEDICAL INC	8.5% (8.5GM/100ML)		N017673	007	Nov 18, 1985	Feb CAHN
AMINOSYN II 10%							
	ICU MEDICAL INC	10% (10GM/100ML)		N019438	005	Apr 03, 1986	Feb CAHN
AMINOSYN II 10% IN PLASTIC CONTAINER							
	ICU MEDICAL INC	10% (10GM/100ML)		N020015	001	Dec 19, 1991	Feb CAHN
AMINOSYN II 15% IN PLASTIC CONTAINER							
	ICU MEDICAL INC	15% (15GM/100ML)		N020041	001	Dec 19, 1991	Feb CAHN
AMINOSYN II 3.5%							
@	ICU MEDICAL INC	3.5% (3.5GM/100ML)		N019438	001	Apr 03, 1986	Feb CAHN
AMINOSYN II 5%							
@	ICU MEDICAL INC	5% (5GM/100ML)		N019438	002	Apr 03, 1986	Feb CAHN
AMINOSYN II 7%							
	ICU MEDICAL INC	7% (7GM/100ML)		N019438	003	Apr 03, 1986	Feb CAHN
AMINOSYN II 8.5%							
	ICU MEDICAL INC	8.5% (8.5GM/100ML)		N019438	004	Apr 03, 1986	Feb CAHN
AMINOSYN-HBC 7%							
	ICU MEDICAL INC	7% (7GM/100ML)		N019374	001	Jul 12, 1985	Feb CAHN
AMINOSYN-HF 8%							
>D>	HOSPIRA	8% (8GM/100ML)		A020345	001	Apr 04, 1996	Jun CAHN
>A>	ICU MEDICAL INC	8% (8GM/100ML)		A020345	001	Apr 04, 1996	Jun CAHN
AMINOSYN-PF 10%							
	ICU MEDICAL INC	10% (10GM/100ML)		N019492	002	Oct 17, 1986	Feb CAHN
AMINOSYN-PF 7%							
	ICU MEDICAL INC	7% (7GM/100ML)		N019398	001	Sep 06, 1985	Feb CAHN
AMINOSYN-RF 5.2%							
	ICU MEDICAL INC	5.2% (5.2GM/100ML)		N018429	001		Apr CAHN
<u>AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE</u>							
INJECTABLE; INJECTION							
AMINOSYN 3.5% M							
	ICU MEDICAL INC	3.5%; 21MG/100ML; 40MG/100ML; 128MG/100ML; 234MG/100ML		N017789	003		Feb CAHN
<u>AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE</u>							
INJECTABLE; INJECTION							
AMINOSYN 3.5% M							
@	ICU MEDICAL INC	3.5%; 21MG/100ML; 128MG/100ML; 234MG/100ML		N017789	005		Feb CAHN
<u>AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE</u>							
INJECTABLE; INJECTION							
AMINOSYN II 10% W/ ELECTROLYTES							
	ICU MEDICAL INC	10%; 102MG/100ML; 45MG/100ML; 522MG/100ML; 410MG/100ML		N019437	004	Apr 03, 1986	Apr CAHN

INJECTABLE;INJECTION

AMINOSYN II 7% W/ ELECTROLYTES

@ ICU MEDICAL INC	7%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML	N019437	006	Apr 03, 1986	Apr CAHN
-------------------	---	---------	-----	--------------	----------

AMINOSYN II 8.5% W/ ELECTROLYTES

ICU MEDICAL INC	8.5%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML	N019437	005	Apr 03, 1986	Apr CAHN
-----------------	---	---------	-----	--------------	----------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE;INJECTION

AMINOSYN II 3.5% M

@ ICU MEDICAL INC	3.5%;30MG/100ML;97MG/100ML;120MG/100ML;49MG/100ML	N019437	007	Apr 03, 1986	Apr CAHN
-------------------	---	---------	-----	--------------	----------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN 7% W/ ELECTROLYTES

ICU MEDICAL INC	7%;102MG/100ML;522MG/100ML;410MG/100ML	N017789	002		Feb CAHN
-----------------	--	---------	-----	--	----------

AMINOSYN 8.5% W/ ELECTROLYTES

ICU MEDICAL INC	8.5%;102MG/100ML;522MG/100ML;410MG/100ML	N017673	005		Feb CAHN
-----------------	--	---------	-----	--	----------

AMINOLEVULINIC ACID HYDROCHLORIDE

FOR SOLUTION;ORAL

>A> GLEOLAN

>A> +! NXDC	1.5GM/VIAL	N208630	001	Jun 06, 2017	Jun NEWA
-------------	------------	---------	-----	--------------	----------

AMIODARONE HYDROCHLORIDE

TABLET;ORAL

AMIODARONE HYDROCHLORIDE

AB	MAYNE PHARMA INC	200MG	A075389	001	Jan 25, 2001	Jan CAHN
	@ MYLAN	200MG	A075188	001	Feb 24, 1999	Mar DISC
AB	! SANDOZ	200MG	A075315	001	Dec 23, 1998	Mar CHRS
AB	TARO PHARM	100MG	A075424	002	Dec 18, 2002	Mar CAHN
AB		200MG	A075424	001	Mar 30, 2001	Mar CAHN
		300MG	A076362	002	Dec 02, 2003	Mar CAHN
AB		400MG	A076362	001	Nov 29, 2002	Mar CAHN

CORDARONE

+ @ WYETH PHARMS INC

	PACERONE	200MG	N018972	001	Dec 24, 1985	Jan DISC
--	----------	-------	---------	-----	--------------	----------

>D> AB	UPSHER SMITH	100MG	A075135	002	Apr 12, 2005	Jun CAHN
>D> AB		200MG	A075135	001	Apr 30, 1998	Jun CAHN
>A> AB	UPSHER-SMITH LABS	100MG	A075135	002	Apr 12, 2005	Jun CAHN
>A> AB		200MG	A075135	001	Apr 30, 1998	Jun CAHN

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

ELAVIL

+ @	ASTRAZENECA	10MG	N012703	001		Mar CRLD
+ @		25MG	N012703	003		Mar CRLD
+ @		50MG	N012703	004		Mar CRLD
+ @		75MG	N012703	005		Mar CRLD
+ @		100MG	N012703	006		Mar CRLD
+ @		150MG	N012703	007		Mar CRLD

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

@ WATSON LABS TEVA	EQ 12.5MG BASE;5MG	A072052	001	Dec 16, 1988	May CAHN
--------------------	--------------------	---------	-----	--------------	----------

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

AB	MYLAN PHARMS INC	EQ 2.5MG BASE	A076418	001	Oct 03, 2005	Mar CAHN
	@	EQ 2.5MG BASE	A078224	001	Feb 27, 2008	May DISC
AB		EQ 5MG BASE	A076418	002	Oct 03, 2005	Mar CAHN
	@	EQ 5MG BASE	A078224	002	Feb 27, 2008	May DISC
AB		EQ 10MG BASE	A076418	003	Oct 03, 2005	Mar CAHN
	@	EQ 10MG BASE	A078224	003	Feb 27, 2008	May DISC
>D> AB	UPSHER SMITH	EQ 2.5MG BASE	A077759	001	Jul 09, 2007	Jun CAHN
>D> AB		EQ 5MG BASE	A077759	002	Jul 09, 2007	Jun CAHN

TABLET; ORAL

AMLODIPINE BESYLATE

>D>	AB		EQ 10MG BASE	A077759	003	Jul 09, 2007	Jun CAHN
>A>	AB	UPSHER-SMITH LABS	EQ 2.5MG BASE	A077759	001	Jul 09, 2007	Jun CAHN
>A>	AB		EQ 5MG BASE	A077759	002	Jul 09, 2007	Jun CAHN
>A>	AB		EQ 10MG BASE	A077759	003	Jul 09, 2007	Jun CAHN

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

AB	AUROBINDO PHARMA LTD	EQ 5MG BASE; 20MG	A206906	001	May 15, 2017	May NEWA	
AB		EQ 5MG BASE; 40MG	A206906	002	May 15, 2017	May NEWA	
AB		EQ 10MG BASE; 20MG	A206906	003	May 15, 2017	May NEWA	
AB		EQ 10MG BASE; 40MG	A206906	004	May 15, 2017	May NEWA	
>A>	AB	GLENMARK PHARMS LTD	EQ 5MG BASE; 20MG	A207807	001	Jul 05, 2017	Jun NEWA
>A>	AB		EQ 5MG BASE; 40MG	A207807	002	Jul 05, 2017	Jun NEWA
>A>	AB		EQ 10MG BASE; 20MG	A207807	003	Jul 05, 2017	Jun NEWA
>A>	AB		EQ 10MG BASE; 40MG	A207807	004	Jul 05, 2017	Jun NEWA
AB	JUBILANT GENERICS	EQ 5MG BASE; 20MG	A207450	001	May 15, 2017	May NEWA	
AB		EQ 5MG BASE; 40MG	A207450	002	May 15, 2017	May NEWA	
AB		EQ 10MG BASE; 20MG	A207450	003	May 15, 2017	May NEWA	
AB		EQ 10MG BASE; 40MG	A207450	004	May 15, 2017	May NEWA	
AB	TORRENT PHARMS LTD	EQ 5MG BASE; 20MG	A202933	001	Nov 25, 2016	Apr CAHN	
AB		EQ 5MG BASE; 40MG	A202933	002	Nov 25, 2016	Apr CAHN	
AB		EQ 10MG BASE; 20MG	A202933	003	Nov 25, 2016	Apr CAHN	
AB		EQ 10MG BASE; 40MG	A202933	004	Nov 25, 2016	Apr CAHN	

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

AP	GEN HOSP	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A207025	001	Feb 03, 2016	May CAHN
----	----------	------------------------------------	---------	-----	--------------	----------

AMMONIUM LACTATE

LOTION; TOPICAL

LAC-HYDRIN

+	@ RANBAXY	EQ 12% BASE	N019155	001	Apr 24, 1985	Jan CRLD
---	-----------	-------------	---------	-----	--------------	----------

AMOXAPINE

TABLET; ORAL

AMOXAPINE

>D>	@ UPSHER-SMITH LABS	25MG	A072943	001	Jun 28, 1991	Jun CAHN
>A>	@	25MG	A072943	001	Jun 28, 1991	Jun CAHN
>D>	@	50MG	A072944	001	Jun 28, 1991	Jun CAHN
>A>	@	50MG	A072944	001	Jun 28, 1991	Jun CAHN
>D>	@	100MG	A072878	001	Jun 28, 1991	Jun CAHN
>A>	@	100MG	A072878	001	Jun 28, 1991	Jun CAHN
>D>	@	150MG	A072879	001	Jun 28, 1991	Jun CAHN
>A>	@	150MG	A072879	001	Jun 28, 1991	Jun CAHN
	@ WATSON PHARMS TEVA	25MG	A072418	001	May 11, 1989	Feb CAHN
	@	50MG	A072419	001	May 11, 1989	Feb CAHN
	@	100MG	A072420	001	May 11, 1989	Feb CAHN
	@	150MG	A072421	001	May 11, 1989	Feb CAHN

AMOXICILLIN

FOR SUSPENSION; ORAL

AMOXIL

@	DR REDDYS LABS INC	200MG/5ML	N050760	001	Apr 15, 1999	Feb DISC
@		400MG/5ML	N050760	002	Apr 15, 1999	Feb DISC

TABLET; ORAL

AMOXIL

+	@ DR REDDYS LABS INC	500MG	N050754	002	Jul 10, 1998	Mar DISC
+	@	875MG	N050754	001	Jul 10, 1998	Mar DISC

TABLET, CHEWABLE; ORAL

AMOXICILLIN

	TEVA	125MG	A064013	002	Sep 11, 1995	Feb CTEC
!		250MG	A064013	001	Dec 22, 1992	Feb CTEC
	AMOXIL					
+	@ DR REDDYS LABS INC	125MG	N050542	002		Feb DISC
+	@	250MG	N050542	001		Feb DISC

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AUGMENTIN '200'

+ @ DR REDDYS LABS INC	200MG/5ML;EQ 28.5MG BASE/5ML	N050725	001	May 31, 1996	Feb DISC
------------------------	------------------------------	---------	-----	--------------	----------

AUGMENTIN '400'

+ @ DR REDDYS LABS INC	400MG/5ML;EQ 57MG BASE/5ML	N050725	002	May 31, 1996	Feb DISC
------------------------	----------------------------	---------	-----	--------------	----------

AUGMENTIN ES-600

+ @ DR REDDYS LABS INC	600MG/5ML;EQ 42.9MG BASE/5ML	N050755	001	Jun 22, 2001	Feb DISC
------------------------	------------------------------	---------	-----	--------------	----------

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB ! SANDOZ	250MG;EQ 125MG BASE	A065189	001	Aug 23, 2005	Feb CHRS
-------------	---------------------	---------	-----	--------------	----------

AB ! SANDOZ INC	500MG;EQ 125MG BASE	A065117	001	Nov 27, 2002	Feb CHRS
-----------------	---------------------	---------	-----	--------------	----------

AUGMENTIN '250'

+ @ DR REDDYS LABS INC	250MG;EQ 125MG BASE	N050564	001	Aug 06, 1984	Feb DISC
------------------------	---------------------	---------	-----	--------------	----------

AUGMENTIN '500'

+ @ DR REDDYS LABS INC	500MG;EQ 125MG BASE	N050564	002	Aug 06, 1984	Feb DISC
------------------------	---------------------	---------	-----	--------------	----------

TABLET, CHEWABLE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

TEVA	200MG;EQ 28.5MG BASE	A065205	001	Feb 09, 2005	Feb CTEC
------	----------------------	---------	-----	--------------	----------

!	400MG;EQ 57MG BASE	A065205	002	Feb 09, 2005	Feb CTEC
---	--------------------	---------	-----	--------------	----------

AUGMENTIN '200'

+ @ DR REDDYS LABS INC	200MG;EQ 28.5MG BASE	N050726	001	May 31, 1996	Feb DISC
------------------------	----------------------	---------	-----	--------------	----------

AUGMENTIN '400'

+ @ DR REDDYS LABS INC	400MG;EQ 57MG BASE	N050726	002	May 31, 1996	Feb DISC
------------------------	--------------------	---------	-----	--------------	----------

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

MYDAYIS

>A> + SHIRE DEV LLC	3.125MG;3.125MG;3.125MG;3.125MG	N022063	001	Jun 20, 2017	Jun NEWA
---------------------	---------------------------------	---------	-----	--------------	----------

>A> +	6.25MG;6.25MG;6.25MG;6.25MG	N022063	002	Jun 20, 2017	Jun NEWA
-------	-----------------------------	---------	-----	--------------	----------

>A> +	9.375MG;9.375MG;9.375MG;9.375MG	N022063	003	Jun 20, 2017	Jun NEWA
-------	---------------------------------	---------	-----	--------------	----------

>A> +	12.5MG;12.5MG;12.5MG;12.5MG	N022063	004	Jun 20, 2017	Jun NEWA
-------	-----------------------------	---------	-----	--------------	----------

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB EPIC PHARMA LLC	1.25MG;1.25MG;1.25MG;1.25MG	A040444	001	Jun 19, 2002	May CAHN
--------------------	-----------------------------	---------	-----	--------------	----------

AB	1.875MG;1.875MG;1.875MG;1.875MG	A040444	005	Nov 03, 2014	May CAHN
----	---------------------------------	---------	-----	--------------	----------

AB	2.5MG;2.5MG;2.5MG;2.5MG	A040444	002	Jun 19, 2002	May CAHN
----	-------------------------	---------	-----	--------------	----------

AB	3.125MG;3.125MG;3.125MG;3.125MG	A040444	006	Nov 03, 2014	May CAHN
----	---------------------------------	---------	-----	--------------	----------

AB	3.75MG;3.75MG;3.75MG;3.75MG	A040444	007	Nov 03, 2014	May CAHN
----	-----------------------------	---------	-----	--------------	----------

AB	5MG;5MG;5MG;5MG	A040444	003	Jun 19, 2002	May CAHN
----	-----------------	---------	-----	--------------	----------

AB	7.5MG;7.5MG;7.5MG;7.5MG	A040444	004	Jun 19, 2002	May CAHN
----	-------------------------	---------	-----	--------------	----------

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

@ WEST-WARD PHARMS INT	EQ 125MG BASE/VIAL	A062692	001	Jun 24, 1986	Jan CAHN
------------------------	--------------------	---------	-----	--------------	----------

@	EQ 250MG BASE/VIAL	A062692	002	Jun 24, 1986	Jan CAHN
---	--------------------	---------	-----	--------------	----------

@	EQ 500MG BASE/VIAL	A062692	003	Jun 24, 1986	Jan CAHN
---	--------------------	---------	-----	--------------	----------

@	EQ 1GM BASE/VIAL	A062692	004	Jun 24, 1986	Jan CAHN
---	------------------	---------	-----	--------------	----------

@	EQ 2GM BASE/VIAL	A062692	005	Jun 24, 1986	Jan CAHN
---	------------------	---------	-----	--------------	----------

@	EQ 10GM BASE/VIAL	A062692	006	Jun 24, 1986	Jan CAHN
---	-------------------	---------	-----	--------------	----------

PENBRITIN-S

>D> @ WYETH AYERST	EQ 125MG BASE/VIAL	N050072	001		Jun CRLD
--------------------	--------------------	---------	-----	--	----------

>A> + @	EQ 125MG BASE/VIAL	N050072	001		Jun CRLD
---------	--------------------	---------	-----	--	----------

>D> @	EQ 250MG BASE/VIAL	N050072	002		Jun CRLD
-------	--------------------	---------	-----	--	----------

>A> + @	EQ 250MG BASE/VIAL	N050072	002		Jun CRLD
---------	--------------------	---------	-----	--	----------

>D> @	EQ 500MG BASE/VIAL	N050072	003		Jun CRLD
-------	--------------------	---------	-----	--	----------

>A> + @	EQ 500MG BASE/VIAL	N050072	003		Jun CRLD
---------	--------------------	---------	-----	--	----------

>D> @	EQ 1GM BASE/VIAL	N050072	004		Jun CRLD
-------	------------------	---------	-----	--	----------

>A> + @	EQ 1GM BASE/VIAL	N050072	004		Jun CRLD
---------	------------------	---------	-----	--	----------

>D> @	EQ 2GM BASE/VIAL	N050072	005		Jun CRLD
-------	------------------	---------	-----	--	----------

>A> + @	EQ 2GM BASE/VIAL	N050072	005		Jun CRLD
---------	------------------	---------	-----	--	----------

>D> @	EQ 4GM BASE/VIAL	N050072	006		Jun CRLD
-------	------------------	---------	-----	--	----------

>A> + @	EQ 4GM BASE/VIAL	N050072	006		Jun CRLD
---------	------------------	---------	-----	--	----------

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

AP WEST-WARD PHARMS INT	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065074	001	Mar 19, 2002	Jan CAHN
-------------------------	-------------------------------------	---------	-----	--------------	----------

AP	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065074	002	Mar 19, 2002	Jan CAHN
----	-----------------------------------	---------	-----	--------------	----------

INJECTABLE; INJECTION
AMPICILLIN AND SULBACTAM

AP EQ 10GM BASE/VIAL; EQ 5GM BASE/VIAL A065076 001 Mar 19, 2002 Jan CAHN

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

ANAGRELIDE HYDROCHLORIDE

	@ MYLAN PHARMS INC	EQ 0.5MG BASE	A076811	001	Apr 18, 2005	May DISC
AB		EQ 0.5MG BASE	A076811	001	Apr 18, 2005	Mar CAHN
	@	EQ 0.5MG BASE	A077613	001	Jun 27, 2006	May DISC
	@	EQ 1MG BASE	A076811	002	Apr 18, 2005	May DISC
AB		EQ 1MG BASE	A076811	002	Apr 18, 2005	Mar CAHN
	@	EQ 1MG BASE	A077613	002	Jun 27, 2006	May DISC
>A> AB	TORRENT PHARMS LTD	EQ 0.5MG BASE	A209151	001	Jun 30, 2017	Jun NEWA
>A> AB		EQ 1MG BASE	A209151	002	Jun 30, 2017	Jun NEWA
>D>	@ UPSHER-SMITH LABS	EQ 0.5MG BASE	A076683	001	Apr 18, 2005	Jun CAHN
>A>	@	EQ 0.5MG BASE	A076683	001	Apr 18, 2005	Jun CAHN
>D>	@	EQ 1MG BASE	A076683	002	Apr 18, 2005	Jun CAHN
>A>	@	EQ 1MG BASE	A076683	002	Apr 18, 2005	Jun CAHN

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

	@ WATSON LABS TEVA	1MG	A078984	001	Jun 28, 2010	May CAHN
	ARIMIDEX					
AB	+! ASTRAZENECA PHARMS	1MG	N020541	001	Dec 27, 1995	May CAHN

ARGATROBAN

INJECTABLE; INJECTION

ARGATROBAN

	+! HIKMA PHARM CO LTD	50MG/50ML (1MG/ML)	N203049	002	Sep 30, 2016	Feb NEWA
>A> AP	+! NOVARTIS PHARMS CORP	250MG/2.5ML (100MG/ML)	N020883	001	Jun 30, 2000	Jun CAHN
>D> AP	+! PFIZER	250MG/2.5ML (100MG/ML)	N020883	001	Jun 30, 2000	Jun CAHN

INJECTABLE; IV (INFUSION)

ARGATROBAN IN SODIUM CHLORIDE

AP	GLAND PHARMA LTD	125MG/125ML (1MG/ML)	A205570	001	May 22, 2017	May NEWA
AP	+! SANDOZ	125MG/125ML (1MG/ML)	N022485	001	May 09, 2011	May CFTG

ARIPIPIRAZOLE

TABLET; ORAL

ARIPIPIRAZOLE

AB	ORCHID HLTHCARE	2MG	A202683	001	May 23, 2017	May NEWA
AB		5MG	A202683	002	May 23, 2017	May NEWA
AB		10MG	A202683	003	May 23, 2017	May NEWA
AB		15MG	A202683	004	May 23, 2017	May NEWA
AB		20MG	A202683	005	May 23, 2017	May NEWA
AB		30MG	A202683	006	May 23, 2017	May NEWA
AB	SANTOS BIOTECH	2MG	A091279	001	Jan 09, 2017	May CAHN
AB		5MG	A091279	002	Jan 09, 2017	May CAHN
AB		10MG	A091279	003	Jan 09, 2017	May CAHN
AB		15MG	A091279	004	Jan 09, 2017	May CAHN
AB		20MG	A091279	005	Jan 09, 2017	May CAHN
AB		30MG	A091279	006	Jan 09, 2017	May CAHN

ARIPIPIRAZOLE LAUROXIL

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

ARISTADA

>A>	+ ALKERMES INC	1064MG/3.9ML (272.82MG/ML)	N207533	004	Jun 05, 2017	Jun NEWA
-----	----------------	----------------------------	---------	-----	--------------	----------

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

SEPTOCAINE

>D>	+! DEPROCO	4%; EQ 0.0085MG BASE/1.7ML (4%; EQ 0.005MG BASE/ML)	N022010	001	Mar 30, 2006	Jun CFTG
>A> AP	+!	4%; EQ 0.0085MG BASE/1.7ML (4%; EQ 0.005MG BASE/ML)	N022010	001	Mar 30, 2006	Jun CFTG
>A>	ULTACAN					
>A> AP	HANSAMED INC	4%; EQ 0.0085MG BASE/1.7ML (4%; EQ 0.005MG BASE/ML)	A201751	001	Jul 11, 2017	Jun NEWA
>A>	ULTACAN FORTE					
>A> AP	HANSAMED INC	4%; EQ 0.017MG BASE/1.7ML (4%; EQ 0.01MG BASE/ML)	A201750	001	Jul 11, 2017	Jun NEWA

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE;IV (INFUSION)

INFUVITE PEDIATRIC

+	!	SANDOZ INC	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14 MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/V IAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N021265	001	Feb 21, 2001	May CAHN
		INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)					
+	!	SANDOZ INC	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14 MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/V IAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N021646	001	Jan 29, 2004	May CAHN

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET;ORAL

FIORINAL

+	@	ALLERGAN SALES LLC	325MG;50MG;40MG	N017534	003	Apr 16, 1986	Jan CRLD
---	---	--------------------	-----------------	---------	-----	--------------	----------

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE;ORAL

ASPIRIN AND DIPYRIDAMOLE

AB		AMNEAL PHARMS	25MG;200MG	A206392	001	Mar 08, 2016	May CAHN
AB		IMPAX LABS INC	25MG;200MG	A206964	001	Jan 18, 2017	Jan NEWA
AB		PAR PHARM INC	25MG;200MG	A207944	001	Jan 18, 2017	Jan NEWA
AB		SANDOZ INC	25MG;200MG	A206739	001	Jan 18, 2017	Jan NEWA

ATENOLOL

TABLET;ORAL

ATENOLOL

@		WATSON LABS TEVA	100MG	A073353	001	Dec 27, 1991	May CAHN
---	--	------------------	-------	---------	-----	--------------	----------

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

AB		APOTEX INC	10MG	A078983	001	May 30, 2017	May NEWA
AB			18MG	A078983	002	May 30, 2017	May NEWA
AB			25MG	A078983	003	May 30, 2017	May NEWA
AB			40MG	A078983	004	May 30, 2017	May NEWA
AB			60MG	A078983	005	May 30, 2017	May NEWA
AB			80MG	A078983	006	May 30, 2017	May NEWA
AB			100MG	A078983	007	May 30, 2017	May NEWA
AB		AUROBINDO PHARMA LTD	10MG	A079016	001	May 30, 2017	May NEWA
AB			18MG	A079016	002	May 30, 2017	May NEWA
AB			25MG	A079016	003	May 30, 2017	May NEWA
AB			40MG	A079016	004	May 30, 2017	May NEWA
AB			60MG	A079016	005	May 30, 2017	May NEWA
AB			80MG	A079016	006	May 30, 2017	May NEWA
AB			100MG	A079016	007	May 30, 2017	May NEWA
AB		GLENMARK PHARMS LTD	10MG	A079019	001	May 30, 2017	May NEWA
AB			18MG	A079019	002	May 30, 2017	May NEWA
AB			25MG	A079019	003	May 30, 2017	May NEWA
AB			40MG	A079019	004	May 30, 2017	May NEWA
AB			60MG	A079019	005	May 30, 2017	May NEWA
AB			80MG	A079019	006	May 30, 2017	May NEWA
AB			100MG	A079019	007	May 30, 2017	May NEWA
AB		TEVA PHARMS USA	10MG	A079022	001	May 30, 2017	May NEWA
AB			18MG	A079022	002	May 30, 2017	May NEWA
AB			25MG	A079022	003	May 30, 2017	May NEWA
AB			40MG	A079022	004	May 30, 2017	May NEWA
AB			60MG	A079022	005	May 30, 2017	May NEWA
AB			80MG	A079022	006	May 30, 2017	May NEWA
AB			100MG	A079022	007	May 30, 2017	May NEWA
		STRATTERA					
AB	+	LILLY	10MG	N021411	002	Nov 26, 2002	May CFTG
AB	+		18MG	N021411	003	Nov 26, 2002	May CFTG
AB	+		25MG	N021411	004	Nov 26, 2002	May CFTG
AB	+		40MG	N021411	005	Nov 26, 2002	May CFTG
AB	+	!	60MG	N021411	006	Nov 26, 2002	May CFTG
AB	+		80MG	N021411	007	Feb 14, 2005	May CFTG
AB	+		100MG	N021411	008	Feb 14, 2005	May CFTG

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

AB	TEVA PHARMS USA	EQ 10MG BASE	A205300	001	Mar 27, 2017	Mar NEWA
AB		EQ 20MG BASE	A205300	002	Mar 27, 2017	Mar NEWA
AB		EQ 40MG BASE	A205300	003	Mar 27, 2017	Mar NEWA
AB		EQ 80MG BASE	A205300	004	Mar 27, 2017	Mar NEWA

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET; ORAL

EZETIMIBE AND ATORVASTATIN CALCIUM

	WATSON LABS TEVA	EQ 10MG BASE;10MG	A206084	001	Apr 26, 2017	Apr NEWA
		EQ 20MG BASE;10MG	A206084	002	Apr 26, 2017	Apr NEWA
		EQ 40MG BASE;10MG	A206084	003	Apr 26, 2017	Apr NEWA
!		EQ 80MG BASE;10MG	A206084	004	Apr 26, 2017	Apr NEWA

ATOVAQUONE

SUSPENSION; ORAL

ATOVAQUONE

AB	PADDOCK LLC	750MG/5ML	A207833	001	Apr 28, 2017	Apr NEWA
----	-------------	-----------	---------	-----	--------------	----------

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

>A>	AP	MYLAN LABS LTD	10MG/ML	A206096	001	Jun 22, 2017	Jun NEWA
		@ WATSON PHARMS TEVA	10MG/ML	A074945	001	Jul 28, 1998	Feb CAHN
		ATRACURIUM BESYLATE PRESERVATIVE FREE					
	AP	MYLAN LABS LTD	10MG/ML	A206001	001	Apr 07, 2017	Mar NEWA
		TRACRIUM					
	+	@ HOSPIRA	10MG/ML	N018831	002	Jun 20, 1985	Apr CMS1
		TRACRIUM PRESERVATIVE FREE					
	+	@ HOSPIRA	10MG/ML	N018831	001	Nov 23, 1983	Apr CMS1

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

>D>		@ ANI PHARMS INC	0.025MG;2.5MG	A086727	001		Jun CMFD
>A>	AA		0.025MG;2.5MG	A086727	001		Jun CMFD

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER; IV (INFUSION)

AVYCAZ

+	!	CEREXA	EQ 0.5GM BASE;2GM/VIAL	N206494	001	Feb 25, 2015	May CAHN
---	---	--------	------------------------	---------	-----	--------------	----------

AZACITIDINE

POWDER; IV (INFUSION), SUBCUTANEOUS

AZACITIDINE

	AP	ACTAVIS LLC	100MG/VIAL	N208216	001	Apr 29, 2016	Mar CTEC
	AP	DR REDDYS LABS LTD	100MG/VIAL	A201537	001	Sep 16, 2013	Mar CDFR
	AP	MYLAN INSTITUTIONAL	100MG/VIAL	A204949	001	Apr 28, 2016	Mar CDFR
>A>	AP	NATCO PHARMA LTD	100MG/VIAL	A207234	001	Jun 23, 2017	Jun NEWA
	AP	SHILPA MEDICARE	100MG/VIAL	A207518	001	Sep 29, 2016	Mar CDFR
		VIDAZA					
	AP	+	!	CELGENE			
			100MG/VIAL	N050794	001	May 19, 2004	Mar CDFR

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AZELASTINE HYDROCHLORIDE

	AT	SANDOZ INC	0.05%	A202305	001	May 31, 2012	Feb CAHN
		OPTIVAR					
	AT	+	!	MYLAN SPECIALITY LP			
			0.05%	N021127	001	May 22, 2000	Mar CAHN
		SPRAY, METERED; NASAL					
		ASTELIN					
	AB	+	!	MYLAN SPECIALITY LP			
			EQ 0.125MG BASE/SPRAY	N020114	001	Nov 01, 1996	Mar CAHN
		ASTEPRO					
		@ MYLAN SPECIALITY LP	EQ 0.125MG BASE/SPRAY	N022203	001	Oct 15, 2008	Mar CAHN
	AB	+	!				
			EQ 0.1876MG BASE/SPRAY	N022203	002	Aug 31, 2009	Mar CAHN
		AZELASTINE HYDROCHLORIDE					
	AB	BRECKENRIDGE PHARM	EQ 0.125MG BASE/SPRAY	A090176	001	Jul 28, 2015	Feb CAHN
>D>	AB	UPSHER-SMITH LABS	EQ 0.125MG BASE/SPRAY	A202609	001	Mar 17, 2017	Jun CAHN
>A>	AB		EQ 0.125MG BASE/SPRAY	A202609	001	Mar 17, 2017	Jun CAHN

SPRAY, METERED;NASAL
 AZELASTINE HYDROCHLORIDE

AB		EQ 0.125MG BASE/SPRAY	A202609	001	Mar 17, 2017	Mar NEWA
----	--	-----------------------	---------	-----	--------------	----------

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL
 AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE

AB	APOTEX INC	EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY	A207712	001	Apr 28, 2017	Apr NEWA
----	------------	------------------------------------	---------	-----	--------------	----------

AB	MYLAN SPECIALITY LP	EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY	N202236	001	May 01, 2012	Apr CFTG
	+	EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY	N202236	001	May 01, 2012	Mar CAHN

AZITHROMYCIN

INJECTABLE;INJECTION
 AZITHROMYCIN

AP	MYLAN LABS LTD	EQ 500MG BASE/VIAL	A204732	001	Jan 26, 2017	Jan NEWA
----	----------------	--------------------	---------	-----	--------------	----------

TABLET;ORAL
 AZITHROMYCIN

>D>	AB	MYLAN	EQ 250MG BASE	A065365	001	May 30, 2007	Jun DISC
>A>		@	EQ 250MG BASE	A065365	001	May 30, 2007	Jun DISC
		@	EQ 500MG BASE	A065366	001	May 30, 2007	May DISC

		ZITHROMAX					
AB	+	PFIZER	EQ 250MG BASE	N050711	001	Jul 18, 1996	Apr CRLD
AB	+		EQ 500MG BASE	N050784	001	May 24, 2002	Apr CRLD

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;TOPICAL
 CORTISPORIN

	+	MONARCH PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM	N050168	002	May 04, 1984	Feb CAHN
--	---	----------------	--	---------	-----	--------------	----------

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC
 NEOSPORIN

AT	+	CASPER PHARMA LLC	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050417	001		Apr CMFD
----	---	-------------------	--	---------	-----	--	----------

BACLOFEN

INJECTABLE;INTRATHECAL
 BACLOFEN

AP	EMERALD INTL LTD	0.05MG/ML	A091193	001	May 03, 2016	Mar CAHN
AP		0.5MG/ML	A091193	002	May 03, 2016	Mar CAHN
AP		2MG/ML	A091193	003	May 03, 2016	Mar CAHN

GABLOFEN

	+	MALLINCKRODT INC	1MG/ML	N022462	004	Jun 22, 2012	Mar CRLD
AP		PIRAMAL CRITICAL	0.05MG/ML	N022462	001	Nov 19, 2010	Apr CAHN
AP			0.5MG/ML	N022462	002	Nov 19, 2010	Apr CAHN
	+		1MG/ML	N022462	004	Jun 22, 2012	Apr CAHN
AP			2MG/ML	N022462	003	Nov 19, 2010	Apr CAHN

TABLET;ORAL

BACLOFEN

		@ MYLAN	10MG	A077181	001	Jul 29, 2005	May DISC
AB		OXFORD PHARMS	10MG	A077088	002	Oct 31, 2007	Apr CMS1
>D>	AB	USL PHARMA	10MG	A074584	001	Aug 19, 1996	Jun CAHN
>A>	AB		10MG	A074584	001	Aug 19, 1996	Jun CAHN
>D>	AB		20MG	A074584	002	Aug 19, 1996	Jun CAHN
>A>	AB		20MG	A074584	002	Aug 19, 1996	Jun CAHN

BALSALAZIDE DISODIUM

CAPSULE;ORAL
 BALSALAZIDE DISODIUM

BX	WEST-WARD PHARMS INT	750MG	A077806	001	Dec 28, 2007	Apr CTEC
----	----------------------	-------	---------	-----	--------------	----------

BARIUM SULFATE

FOR SUSPENSION;ORAL
 E-Z-HD

	+	BRACCO	98% (334GM/BOTTLE)	N208036	001	Jan 11, 2016	Apr CPOT
--	---	--------	--------------------	---------	-----	--------------	----------

E-Z-PAQUE

	+	BRACCO	96% (169GM/BOTTLE)	N208036	002	Apr 07, 2017	Apr NEWA
--	---	--------	--------------------	---------	-----	--------------	----------

SUSPENSION;ORAL
LIQUID E-Z-PAQUE

+	!	BRACCO	60% (213GM/355ML)	N208143	003	Mar 01, 2017	Mar NEWA
---	---	--------	-------------------	---------	-----	--------------	----------

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE

AB		AMNEAL PHARMS	5MG	A076820	001	Feb 03, 2006	Apr CAHN
AB			10MG	A076820	002	Feb 03, 2006	Apr CAHN
AB			20MG	A076820	003	Feb 03, 2006	Apr CAHN
AB			40MG	A076820	004	Feb 03, 2006	Apr CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

LOTENSIN HCT

+	@	US PHARMS HOLDINGS I	5MG;6.25MG	N020033	001	May 19, 1992	May DISC
---	---	----------------------	------------	---------	-----	--------------	----------

BENDROFLUMETHIAZIDE; NADOLOL

TABLET;ORAL

CORZIDE

AB	+	KING PHARMS LLC	5MG;40MG	N018647	001	May 25, 1983	Mar CAHN
AB	+	!	5MG;80MG	N018647	002	May 25, 1983	Mar CAHN

BENZONATATE

CAPSULE;ORAL

TESSALON

AA	+	PFIZER	100MG	N011210	001		Apr CRLD
----	---	--------	-------	---------	-----	--	----------

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

>A>	AB		TOLMAR	5%;EQ 1% BASE	A204087	001	Jun 27, 2017	Jun NEWA
-----	----	--	--------	---------------	---------	-----	--------------	----------

BENZPHETAMINE HYDROCHLORIDE

TABLET;ORAL

BENZPHETAMINE HYDROCHLORIDE

		@	EPIC PHARMA LLC	50MG	A040714	001	Oct 29, 2007	May CAHN
AA			TWI PHARMS INC	50MG	A040578	001	Apr 17, 2006	Mar CAHN

BENZTROPINE MESYLATE

TABLET;ORAL

BENZTROPINE MESYLATE

AA			EPIC PHARMA LLC	0.5MG	A072264	001	Feb 27, 1989	May CAHN
AA				1MG	A072265	001	Feb 27, 1989	May CAHN
AA				2MG	A072266	001	Feb 27, 1989	May CAHN
			OXFORD PHARMS	0.5MG	A040706	002	Feb 14, 2008	May CMS1
				1MG	A040706	003	Feb 14, 2008	May CMS1
>D>	AA	!	UPSHER-SMITH LABS	0.5MG	A040103	001	Dec 12, 1996	Jun CAHN
	AA	!		0.5MG	A040103	001	Dec 12, 1996	Feb CAHN
>D>	AA	!		1MG	A040103	002	Dec 12, 1996	Jun CAHN
	AA	!		1MG	A040103	002	Dec 12, 1996	Feb CAHN
>D>	AA	!		2MG	A040103	003	Dec 12, 1996	Jun CAHN
	AA	!		2MG	A040103	003	Dec 12, 1996	Feb CAHN
>A>	AA	!	USL PHARMA	0.5MG	A040103	001	Dec 12, 1996	Jun CAHN
>A>	AA	!		1MG	A040103	002	Dec 12, 1996	Jun CAHN
>A>	AA	!		2MG	A040103	003	Dec 12, 1996	Jun CAHN

BETAMETHASONE DIPROPIONATE

LOTION;TOPICAL

BETAMETHASONE DIPROPIONATE

AB	!	FOUGERA PHARMS INC	EQ 0.05% BASE	A070275	001	Aug 12, 1985	Jan CAHN	
		@	TARO	EQ 0.05% BASE	A074272	001	Sep 30, 1994	Apr CAHN

DIPROSONE

+	@	SCHERING	EQ 0.05% BASE	N017781	001		Jan CRLD
---	---	----------	---------------	---------	-----	--	----------

OINTMENT;TOPICAL

BETAMETHASONE DIPROPIONATE

AB			TARO	EQ 0.05% BASE	A074271	001	Sep 15, 1994	Apr CAHN
----	--	--	------	---------------	---------	-----	--------------	----------

BETAMETHASONE VALERATE

AEROSOL, FOAM;TOPICAL

BETAMETHASONE VALERATE

AB	PERRIGO UK FINCO	0.12%	A078337	001	Nov 26, 2012	Apr CAHN
AB	RICONPHARMA LLC	0.12%	A207144	001	May 24, 2017	May NEWA
AB	TARO PHARM	0.12%	A208204	001	May 24, 2017	May NEWA
LUXIQ						
AB	+! MYLAN PHARMS INC	0.12%	N020934	001	Feb 28, 1999	Jan CAHN

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

AT	TELIGENT	EQ 0.5% BASE	A075630	001	Apr 12, 2001	Apr CAHN
----	----------	--------------	---------	-----	--------------	----------

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE

	@ IMPAX LABS	5MG	A040721	001	Nov 01, 2006	Jan CMS1
	@	10MG	A040721	002	Nov 01, 2006	Jan CMS1
	@	25MG	A040721	003	Nov 01, 2016	Jan CMS1
AA	LANNETT HOLDINGS INC	5MG	A040677	002	Mar 27, 2008	May CMS1
AA		10MG	A040677	003	Mar 27, 2008	May CMS1
AA		25MG	A040677	004	Mar 27, 2008	May CMS1
>D> AA	UPSHER SMITH	5MG	A040633	001	Jun 01, 2005	Jun CAHN
>D> AA		10MG	A040634	001	Jun 01, 2005	Jun CAHN
>D> AA		25MG	A040635	001	Jun 01, 2005	Jun CAHN
>D> AA		50MG	A040636	001	Jun 01, 2005	Jun CAHN
>A> AA	UPSHER-SMITH LABS	5MG	A040633	001	Jun 01, 2005	Jun CAHN
>A> AA		10MG	A040634	001	Jun 01, 2005	Jun CAHN
>A> AA		25MG	A040635	001	Jun 01, 2005	Jun CAHN
>A> AA		50MG	A040636	001	Jun 01, 2005	Jun CAHN

>A> BETRIXABAN

>A> CAPSULE;ORAL

>A> BEVYXXA

>A>	+ PORTOLA PHARMS INC	40MG	N208383	001	Jun 23, 2017	Jun NEWA
>A>	+!	80MG	N208383	002	Jun 23, 2017	Jun NEWA

BICALUTAMIDE

TABLET;ORAL

BICALUTAMIDE

AB	SANTOS BIOTECH	50MG	A091011	001	Jun 10, 2015	May CAHN
AB	WATSON LABS TEVA	50MG	A078634	001	Aug 28, 2009	May CAHN
CASODEX						
AB	+! ASTRAZENECA PHARMS	50MG	N020498	001	Oct 04, 1995	May CAHN

BIMATOPROST

SOLUTION/DROPS;OPHTHALMIC

BIMATOPROST

AT	SANDOZ INC	0.03%	A202565	001	May 05, 2015	Mar CAHN
----	------------	-------	---------	-----	--------------	----------

BISOPROLOL FUMARATE

TABLET;ORAL

BISOPROLOL FUMARATE

AB	ORIT LABS LLC	5MG	A204891	001	Jan 11, 2017	Jan NEWA
AB		10MG	A204891	002	Jan 11, 2017	Jan NEWA

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

	@ WATSON LABS TEVA	2.5MG; 6.25MG	A075469	001	Sep 25, 2000	May CAHN
	@	5MG; 6.25MG	A075469	002	Sep 25, 2000	May CAHN
	@	10MG; 6.25MG	A075469	003	Sep 25, 2000	May CAHN
ZIAC						
AB	+ TEVA BRANDED PHARM	2.5MG; 6.25MG	N020186	003	Mar 26, 1993	Jan CAHN
AB	+	5MG; 6.25MG	N020186	001	Mar 26, 1993	Jan CAHN
AB	+!	10MG; 6.25MG	N020186	002	Mar 26, 1993	Jan CAHN

BIVALIRUDIN

INJECTABLE; INTRAVENOUS
BIVALIRUDIN

>A>	AP	APOTEX INC	250MG/VIAL	A204876	001	Jul 06, 2017	Jun NEWA
	AP	DR REDDYS LABS LTD	250MG/VIAL	A201577	001	May 26, 2017	May NEWA

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION
BRETYLIUM TOSYLATE

	@	WEST-WARD PHARMS INT	50MG/ML	A070545	001	May 14, 1986	Jan CAHN
--	---	----------------------	---------	---------	-----	--------------	----------

BRIGATINIB

TABLET; ORAL
ALUNBRIG

	+	ARIAD	30MG	N208772	001	Apr 28, 2017	Apr NEWA
	+	!	90MG	N208772	002	Apr 28, 2017	Apr NEWA

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC
BRIMONIDINE TARTRATE

AT		SANDOZ INC	0.2%	A076254	001	Sep 16, 2003	Feb CAHN
AT			0.2%	A078075	001	Jan 30, 2008	Mar CAHN
		QOLIANA					
AT		SANDOZ INC	0.15%	N021764	001	May 22, 2006	Mar CAHN

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC
BROMFENAC SODIUM

AT1		AMRING PHARMS	EQ 0.09% ACID	A202030	001	Jan 09, 2013	Mar CAHN
AT1	!	APOTEX INC	EQ 0.09% ACID	A202435	001	Jun 19, 2014	Feb CHRS
		@ COASTAL PHARMS	EQ 0.09% ACID	A201211	001	May 11, 2011	Feb DISC
AT2	!	HI-TECH PHARMACAL	EQ 0.09% ACID	A203395	001	Jan 22, 2014	Mar CHRS

BROMPHENIRAMINE MALEATE

TABLET; ORAL

BROMPHENIRAMINE MALEATE

>D>		@ UPSHER-SMITH LABS	4MG	A083215	001		Jun CAHN
>A>		@	4MG	A083215	001		Jun CAHN

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA		TARO PHARM	2MG/5ML; 10MG/5ML; 30MG/5ML	A205112	001	Feb 27, 2017	Feb NEWA
----	--	------------	-----------------------------	---------	-----	--------------	----------

BUDESONIDE

CAPSULE; ORAL

BUDESONIDE

AB		APPCO PHARMA LLC	3MG	A207367	001	Apr 07, 2017	Mar NEWA
AB		ZYDUS PHARMS USA INC	3MG	A206134	001	May 04, 2017	Apr NEWA

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

AP	!	ATHENEX INC	0.25MG/ML	A074441	001	Jan 27, 1995	Mar CAHN
AP		WEST-WARD PHARMS INT	0.25MG/ML	A079196	001	Apr 30, 2008	Jan CAHN

BUMEX

>A>		+ @ VALIDUS PHARMS	0.25MG/ML	N018226	001	Feb 28, 1983	Jun CAHN
>D>		+ @ VALIDUS PHARMS INC	0.25MG/ML	N018226	001	Feb 28, 1983	Jun CAHN

TABLET; ORAL

BUMEX

>A>	AB	+	VALIDUS PHARMS	0.5MG	N018225	002	Feb 28, 1983	Jun CAHN
>A>	AB	+		1MG	N018225	001	Feb 28, 1983	Jun CAHN
>A>	AB	+		2MG	N018225	003	Jun 14, 1985	Jun CAHN
>D>	AB	+	VALIDUS PHARMS INC	0.5MG	N018225	002	Feb 28, 1983	Jun CAHN
>D>	AB	+		1MG	N018225	001	Feb 28, 1983	Jun CAHN
>D>	AB	+		2MG	N018225	003	Jun 14, 1985	Jun CAHN

BUPRENORPHINE HYDROCHLORIDEFILM;BUCCAL
BELBUCA

+	BDSI	EQ 0.075MG BASE	N207932	001	Oct 23, 2015	Jan CAHN
+		EQ 0.15MG BASE	N207932	002	Oct 23, 2015	Jan CAHN
+		EQ 0.3MG BASE	N207932	003	Oct 23, 2015	Jan CAHN
+		EQ 0.45MG BASE	N207932	004	Oct 23, 2015	Jan CAHN
+		EQ 0.6MG BASE	N207932	005	Oct 23, 2015	Jan CAHN
+		EQ 0.75MG BASE	N207932	006	Oct 23, 2015	Jan CAHN
+	!	EQ 0.9MG BASE	N207932	007	Oct 23, 2015	Jan CAHN

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

AB	RHODES PHARMS	EQ 2MG BASE	A207276	001	Mar 27, 2017	Mar NEWA
AB		EQ 8MG BASE	A207276	002	Mar 27, 2017	Mar NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB	AMNEAL PHARMS	EQ 8MG BASE;EQ 2MG BASE	A203136	002	Feb 22, 2013	May CAHN
AB	AMNEAL PHARMS	EQ 2MG BASE;EQ 0.5MG BASE	A203136	001	Feb 22, 2013	May CAHN
	ZUBSOLV					
+	OREXO US INC	EQ 5.7MG BASE;EQ 1.4MG BASE	N204242	002	Jul 03, 2013	Jan CHRS
+	!	EQ 11.4MG BASE;EQ 2.9MG BASE	N204242	004	Dec 11, 2014	Jan CHRS

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

>A>	AB3	ANBISON LAB CO LTD	150MG	A207224	001	Jun 30, 2017	Jun NEWA	
>A>	AB3		300MG	A207224	002	Jun 30, 2017	Jun NEWA	
>A>	AB3	JUBILANT GENERICS	150MG	A207459	001	Jun 30, 2017	Jun NEWA	
>A>	AB3		300MG	A207459	002	Jun 30, 2017	Jun NEWA	
	AB3	LUPIN LTD	150MG	A090693	001	Apr 06, 2017	Mar NEWA	
	AB3		300MG	A090693	002	Apr 06, 2017	Mar NEWA	
	AB3	SCIEGEN PHARMS INC	150MG	A207479	001	Apr 12, 2017	Mar NEWA	
	AB3		300MG	A207479	002	Apr 12, 2017	Mar NEWA	
		FORFIVO XL						
	+	!	ALVOGEN	450MG	N022497	001	Nov 10, 2011	Jan CAHN

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

AB	AMNEAL PHARMS CO	5MG	A208829	001	May 24, 2017	May NEWA	
AB		7.5MG	A208829	002	May 24, 2017	May NEWA	
AB		10MG	A208829	003	May 24, 2017	May NEWA	
AB		15MG	A208829	004	May 24, 2017	May NEWA	
AB		30MG	A208829	005	May 24, 2017	May NEWA	
>D>	AB	MYLAN	5MG	A075467	001	Feb 28, 2002	Jun DISC
>A>	@	5MG	A075467	001	Feb 28, 2002	Jun DISC	
>D>	AB		10MG	A075467	003	Feb 28, 2002	Jun DISC
>A>	@	10MG	A075467	003	Feb 28, 2002	Jun DISC	
>D>	AB		15MG	A075467	004	Feb 28, 2002	Jun DISC
>A>	@	15MG	A075467	004	Feb 28, 2002	Jun DISC	
AB	STRIDES PHARMA	5MG	A202330	001	Aug 25, 2014	Apr CAHN	
AB		10MG	A202330	002	Aug 25, 2014	Apr CAHN	
AB		15MG	A202330	003	Aug 25, 2014	Apr CAHN	
AB		30MG	A202330	004	Aug 25, 2014	Apr CAHN	

BUSULFAN

INJECTABLE;INJECTION

BUSULFAN

AP	PHARMASCIENCE INC	6MG/ML	A207050	001	Mar 24, 2017	Mar NEWA	
>A>	AP	SANDOZ INC	6MG/ML	A205106	001	Jul 07, 2017	Jun NEWA

BUTABARBITAL SODIUM

TABLET;ORAL

BUTISOL SODIUM

	@	MYLAN SPECIALITY LP	15MG	N000793	002		Mar CAHN
+	!		30MG	N000793	004		Mar CAHN
	@		50MG	N000793	003		Mar CAHN
	@		100MG	N000793	005		Mar CAHN

BUTORPHANOL TARTRATE

INJECTABLE;INJECTION

BUTORPHANOL TARTRATE PRESERVATIVE FREE

AP	WEST-WARD PHARMS INT	1MG/ML	A075045	001	Aug 12, 1998	Jan CAHN
AP		2MG/ML	A075045	002	Aug 12, 1998	Jan CAHN

CALCIPOTRIENEAEROSOL, FOAM;TOPICAL
SORILUX

+	MAYNE PHARMA	0.005%	N022563	001	Oct 06, 2010	Jan CAHN
---	--------------	--------	---------	-----	--------------	----------

OINTMENT;TOPICAL
CALCIPOTRIENE

!	GLENMARK PHARMS INC	0.005%	A090633	001	Mar 24, 2010	May CAHN
---	---------------------	--------	---------	-----	--------------	----------

CALCITONIN SALMONSPRAY, METERED;NASAL
CALCITONIN-SALMON

AB	!	APOTEX INC	200 IU/SPRAY	A076396	001	Nov 17, 2008	Apr CHRS
----	---	------------	--------------	---------	-----	--------------	----------

MIACALCIN

+	@	MYLAN IRELAND LTD	200 IU/SPRAY	N020313	002	Aug 17, 1995	Apr DISC
---	---	-------------------	--------------	---------	-----	--------------	----------

CALCITONIN SALMON RECOMBINANTSPRAY, METERED;NASAL
FORTICAL

>D>	@	UPSHER SMITH	200 IU/SPRAY	N021406	001	Aug 12, 2005	Jun CAHN
-----	---	--------------	--------------	---------	-----	--------------	----------

>A>	@	UPSHER-SMITH LABS	200 IU/SPRAY	N021406	001	Aug 12, 2005	Jun CAHN
-----	---	-------------------	--------------	---------	-----	--------------	----------

CALCITRIOLCAPSULE;ORAL
CALCITRIOL

AB		AMNEAL PHARMS	0.25MCG	A203289	002	Jun 14, 2017	May NEWA
----	--	---------------	---------	---------	-----	--------------	----------

AB			0.5MCG	A203289	001	Jun 14, 2017	May NEWA
----	--	--	--------	---------	-----	--------------	----------

INJECTABLE;INJECTION
CALCIJEX

+	@	ABBVIE	0.001MG/ML	N018874	001	Sep 25, 1986	May CRLD
---	---	--------	------------	---------	-----	--------------	----------

+	@		0.002MG/ML	N018874	002	Sep 25, 1986	May CRLD
---	---	--	------------	---------	-----	--------------	----------

CALCITRIOL

!		AKORN	0.001MG/ML	A078066	001	Jan 29, 2008	May CHRS
---	--	-------	------------	---------	-----	--------------	----------

CALCIUM ACETATECAPSULE;ORAL
CALCIUM ACETATE

AB		CHARTWELL RX	667MG	A091312	001	Jun 01, 2012	Mar CAHN
----	--	--------------	-------	---------	-----	--------------	----------

TABLET;ORAL

CALCIUM ACETATE

AB	!	PADDOCK LLC	667MG	A091561	001	Apr 13, 2011	Apr CHRS
----	---	-------------	-------	---------	-----	--------------	----------

ELIPHOS

AB		CYPRESS PHARM	667MG	A078502	001	Nov 25, 2008	Apr CHRS
----	--	---------------	-------	---------	-----	--------------	----------

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP		ICU MEDICAL INC	20MG/100ML;5GM/100ML;30MG/100ML;60	N017608	001		Feb CAHN
----	--	-----------------	------------------------------------	---------	-----	--	----------

0MG/100ML;310MG/100ML

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

@		ICU MEDICAL INC	20MG/100ML;5GM/100ML;104MG/100ML;6	N019685	005	Oct 17, 1988	Feb CAHN
---	--	-----------------	------------------------------------	---------	-----	--------------	----------

00MG/100ML;310MG/100ML

@ 20MG/100ML;5GM/100ML;179MG/100ML;6

00MG/100ML;310MG/100ML

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

@		ICU MEDICAL INC	20MG/100ML;5GM/100ML;254MG/100ML;6	N019685	007	Oct 17, 1988	Feb CAHN
---	--	-----------------	------------------------------------	---------	-----	--------------	----------

00MG/100ML;310MG/100ML

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP		ICU MEDICAL INC	20MG/100ML;5GM/100ML;179MG/100ML;6	N019685	002	Oct 17, 1988	Feb CAHN
----	--	-----------------	------------------------------------	---------	-----	--------------	----------

00MG/100ML;310MG/100ML

AP			20MG/100ML;5GM/100ML;328MG/100ML;6	N019685	008	Oct 17, 1988	Feb CAHN
----	--	--	------------------------------------	---------	-----	--------------	----------

00MG/100ML;310MG/100ML

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

@		ICU MEDICAL INC	20MG/100ML;5GM/100ML;254MG/100ML;6	N019685	003	Oct 17, 1988	Feb CAHN
---	--	-----------------	------------------------------------	---------	-----	--------------	----------

00MG/100ML;310MG/100ML

INJECTABLE;INJECTION

AP	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER									
	ICU MEDICAL INC	20MG/100ML;5GM/100ML;328MG/100ML;6	N019685	004	Oct 17, 1988	Feb	CAHN			
	00MG/100ML;310MG/100ML									
	POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER									
@	ICU MEDICAL INC	20MG/100ML;5GM/100ML;104MG/100ML;6	N019685	001	Oct 17, 1988	Feb	CAHN			
		00MG/100ML;310MG/100ML								

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

	RINGER'S IN PLASTIC CONTAINER							
AP	ICU MEDICAL INC	33MG/100ML;30MG/100ML;860MG/100ML	N018251	001		Feb	CAHN	
	SOLUTION;IRRIGATION							
	RINGER'S IN PLASTIC CONTAINER							
AT	ICU MEDICAL INC	33MG/100ML;30MG/100ML;860MG/100ML	N017635	001		Feb	CAHN	

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER									
AP	ICU MEDICAL INC	20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N017641	001			Feb	CAHN	
SOLUTION;IRRIGATION									
LACTATED RINGER'S IN PLASTIC CONTAINER									
AT	+! ICU MEDICAL INC	20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N019416	001	Jan 17, 1986		Feb	CAHN	

CALCIUM GLUCONATE

>A>	SOLUTION;IV (INFUSION)								
>A>	CALCIUM GLUCONATE								
>A>	ICU MEDICAL INC	1GM/10ML (100MG/ML)	N208418	001	Jun 15, 2017	Jun	NEWA		
>A>	ICU MEDICAL INC	5GM/50ML (100MG/ML)	N208418	002	Jun 15, 2017	Jun	NEWA		
>A>	ICU MEDICAL INC	10GM/100ML (100MG/ML)	N208418	003	Jun 15, 2017	Jun	NEWA		

CANDESARTAN CILEXETIL

TABLET;ORAL

CANDESARTAN CILEXETIL									
>A>	AB	ALEMBIC PHARMS LTD	32MG	A209119	001	Jun 20, 2017	Jun	NEWA	

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE									
AB	MYLAN PHARMS INC	16MG;12.5MG	A090704	001	Dec 04, 2012	May	CAHN		
AB		32MG;12.5MG	A090704	002	Dec 04, 2012	May	CAHN		
AB		32MG;25MG	A090704	003	Dec 04, 2012	May	CAHN		

CAPECITABINE

TABLET;ORAL

CAPECITABINE									
AB	AMNEAL PHARMS	150MG	A204741	001	Feb 28, 2017	Feb	NEWA		
AB		500MG	A204741	002	Feb 28, 2017	Feb	NEWA		

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL									
@ BOSCOGEN									
		12.5MG	A074677	004	May 30, 1997	May	CAHN		
		25MG	A074677	002	May 30, 1997	May	CAHN		
		50MG	A074677	001	May 30, 1997	May	CAHN		
		100MG	A074677	003	May 30, 1997	May	CAHN		
AB	MYLAN PHARMS INC	12.5MG	A074434	001	Feb 13, 1996	Mar	CAHN		
AB		25MG	A074434	002	Feb 13, 1996	Mar	CAHN		
AB		50MG	A074434	003	Feb 13, 1996	Mar	CAHN		
AB	!	100MG	A074434	004	Feb 13, 1996	Mar	CAHN		

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE;ORAL

EQUETRO

>A>	+	VALIDUS PHARMS	100MG	N021710	001	Dec 10, 2004	Jun	CAHN	
>A>	+		200MG	N021710	002	Dec 10, 2004	Jun	CAHN	
>A>	+		300MG	N021710	003	Dec 10, 2004	Jun	CAHN	
>D>	+	VALIDUS PHARMS INC	100MG	N021710	001	Dec 10, 2004	Jun	CAHN	
>D>	+		200MG	N021710	002	Dec 10, 2004	Jun	CAHN	
>D>	+		300MG	N021710	003	Dec 10, 2004	Jun	CAHN	

SOLUTION; IV (INFUSION)							
CARNEXIV							
+	LUNDBECK PHARMS LLC	200MG/20ML (10MG/ML)	N206030	001	Oct 07, 2016	Jan	CAHN
SUSPENSION; ORAL							
TERIL							
AB	TARO PHARM	100MG/5ML	A076729	001	Sep 20, 2004	Mar	CAHN
<u>CARBOPLATIN</u>							
INJECTABLE; INJECTION							
CARBOPLATIN							
	@ WATSON LABS TEVA	50MG/VIAL	A076162	001	Oct 14, 2004	May	CAHN
	@	150MG/VIAL	A076162	002	Oct 14, 2004	May	CAHN
	@	450MG/VIAL	A076162	003	Oct 14, 2004	May	CAHN
INJECTABLE; IV (INFUSION)							
CARBOPLATIN							
AP	ACCORD HLTHCARE	50MG/5ML (10MG/ML)	A206775	001	Feb 09, 2017	Jan	NEWA
AP		150MG/15ML (10MG/ML)	A206775	002	Feb 09, 2017	Jan	NEWA
AP		450MG/45ML (10MG/ML)	A206775	003	Feb 09, 2017	Jan	NEWA
AP		600MG/60ML (10MG/ML)	A206775	004	Feb 09, 2017	Jan	NEWA
AP	GLAND PHARMA LTD	50MG/5ML (10MG/ML)	A207324	001	Feb 15, 2017	Jan	NEWA
AP		150MG/15ML (10MG/ML)	A207324	002	Feb 15, 2017	Jan	NEWA
AP		450MG/45ML (10MG/ML)	A207324	003	Feb 15, 2017	Jan	NEWA
AP		600MG/60ML (10MG/ML)	A207324	004	Feb 15, 2017	Jan	NEWA
AP	INGENUS PHARMS LLC	50MG/5ML (10MG/ML)	A208487	001	Apr 26, 2017	Apr	NEWA
AP		150MG/15ML (10MG/ML)	A208487	002	Apr 26, 2017	Apr	NEWA
AP		450MG/45ML (10MG/ML)	A208487	003	Apr 26, 2017	Apr	NEWA
AP		600MG/60ML (10MG/ML)	A208487	004	Apr 26, 2017	Apr	NEWA
<u>CARISOPRODOL</u>							
CAPSULE; ORAL							
SOMA							
	@ MYLAN SPECIALITY LP	250MG	N011792	003		Mar	CAHN
TABLET; ORAL							
CARISOPRODOL							
	@ EPIC PHARMA LLC	350MG	A040397	001	Sep 21, 2000	May	CAHN
AA	HIKMA INTL PHARMS	350MG	A040124	001	Jan 24, 1996	Apr	CMFD
AB	NOSTRUM LABS INC	250MG	A207237	001	May 11, 2017	Apr	NEWA
	@ WATSON LABS TEVA	350MG	A086179	001		May	CAHN
SOMA							
AB	! MYLAN SPECIALITY LP	250MG	N011792	004	Sep 13, 2007	Mar	CAHN
AA	+	350MG	N011792	001		Mar	CAHN
<u>CARTEOLOL HYDROCHLORIDE</u>							
SOLUTION/DROPS; OPHTHALMIC							
CARTEOLOL HYDROCHLORIDE							
AT	! SANDOZ INC	1%	A075476	001	Jan 03, 2000	May	CHRS
AT		1%	A075476	001	Jan 03, 2000	Mar	CAHN
OCUPRESS							
	+ @ NOVARTIS	1%	N019972	001	May 23, 1990	May	DISC
<u>CASPOFUNGIN ACETATE</u>							
POWDER; IV (INFUSION)							
CANCIDAS							
AP	! MERCK	50MG/VIAL	N021227	001	Jan 26, 2001	Mar	CDFR
AP	!	70MG/VIAL	N021227	002	Jan 26, 2001	Mar	CDFR
<u>CEFDINIR</u>							
CAPSULE; ORAL							
OMNICEF							
	+ @ ABBVIE	300MG	N050739	001	Dec 04, 1997	Jan	CRLD
FOR SUSPENSION; ORAL							
OMNICEF							
	+ @ ABBVIE	125MG/5ML	N050749	001	Dec 04, 1997	Jan	CRLD
	+ @	250MG/5ML	N050749	002	Jul 29, 2004	Jan	CRLD
<u>CEFIXIME</u>							
FOR SUSPENSION; ORAL							
CEFIXIME							
AB	BELCHER PHARMS LLC	100MG/5ML	A206938	001	Feb 06, 2017	Jan	NEWA
AB		200MG/5ML	A206938	002	Feb 06, 2017	Jan	NEWA
AB		500MG/5ML	A206939	001	Feb 06, 2017	Jan	NEWA

FOR SUSPENSION;ORAL							
SUPRAX							
AB	+	LUPIN LTD	500MG/5ML	N202091	001	Feb 20, 2013	Jan CFTG
<u>CEFOTETAN DISODIUM</u>							
INJECTABLE;INJECTION							
CEFOTAN							
AP	+	TELIGENT	EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Apr CAHN
AP	+		EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Apr CAHN
	@		EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988	Apr CAHN
CEFOTAN IN PLASTIC CONTAINER							
	@	TELIGENT	EQ 20MG BASE/ML	N050694	002	Jul 30, 1993	Apr CAHN
	@		EQ 40MG BASE/ML	N050694	001	Jul 30, 1993	Apr CAHN
<u>CEFOXITIN SODIUM</u>							
INJECTABLE;INJECTION							
CEFOXITIN							
AP		WEST-WARD PHARMS INT	EQ 1GM BASE/VIAL	A065051	001	Sep 11, 2000	Jan CAHN
AP			EQ 2GM BASE/VIAL	A065051	002	Sep 11, 2000	Jan CAHN
AP			EQ 10GM BASE/VIAL	A065050	001	Sep 11, 2000	Jan CAHN
<u>CEFPROZIL</u>							
FOR SUSPENSION;ORAL							
CEFZIL							
	+	@ CORDEN PHARMA	125MG/5ML	N050665	001	Dec 23, 1991	May CRLD
	+	@	250MG/5ML	N050665	002	Dec 23, 1991	May CRLD
TABLET;ORAL							
CEFPROZIL							
AB		AUROBINDO PHARMA LTD	250MG	A065340	001	May 24, 2007	Jan CAHN
AB			500MG	A065340	002	May 24, 2007	Jan CAHN
CEFZIL							
	+	@ CORDEN PHARMA	250MG	N050664	001	Dec 23, 1991	May CRLD
	+	@	500MG	N050664	002	Dec 23, 1991	May CRLD
<u>CEFTAZIDIME</u>							
INJECTABLE;INJECTION							
FORTAZ							
AP	+	TELIGENT	500MG/VIAL	N050578	001	Jul 19, 1985	Apr CAHN
AP	+		1GM/VIAL	N050578	002	Jul 19, 1985	Apr CAHN
AP	+		2GM/VIAL	N050578	003	Jul 19, 1985	Apr CAHN
AP	+		6GM/VIAL	N050578	004	Jul 19, 1985	Apr CAHN
<u>CEFTAZIDIME SODIUM</u>							
INJECTABLE;INJECTION							
FORTAZ IN PLASTIC CONTAINER							
	@	TELIGENT	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989	May CAHN
	+		EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	May CAHN
	+		EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	May CAHN
<u>CEFTRIAXONE SODIUM</u>							
INJECTABLE;INJECTION							
CEFTRIAXONE SODIUM							
AP		SAGENT PHARMS	EQ 10GM BASE/VIAL	A091117	001	Jan 20, 2017	Jan NEWA
ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER							
	+	@ HOFFMANN LA ROCHE	EQ 10MG BASE/ML	N050624	001	Feb 11, 1987	Jan CRLD
	+	@	EQ 20MG BASE/ML	N050624	002	Feb 11, 1987	Jan CRLD
	+	@	EQ 40MG BASE/ML	N050624	003	Feb 11, 1987	Jan CRLD
<u>CEFUROXIME AXETIL</u>							
TABLET;ORAL							
CEFUROXIME AXETIL							
AB		AUROBINDO PHARMA LTD	EQ 125MG BASE	A065308	001	Mar 29, 2006	Jan CAHN
AB			EQ 250MG BASE	A065308	002	Mar 29, 2006	Jan CAHN
AB			EQ 500MG BASE	A065308	003	Mar 29, 2006	Jan CAHN
<u>CEFUROXIME SODIUM</u>							
INJECTABLE;INJECTION							
ZINACEF							
AP	+	TELIGENT	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	May CAHN
AP	+		EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	May CAHN

INJECTABLE;INJECTION

ZINACEF IN PLASTIC CONTAINER

@ TELIGENT	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	May CAHN
+!	EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	May CAHN

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS
ZINACEF

AB	+! TELIGENT	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	May CAHN
----	-------------	--------------------	---------	-----	--------------	----------

CELECOXIB

CAPSULE;ORAL

CELECOXIB

AB	JUBILANT GENERICS	50MG	A207061	001	Apr 04, 2017	Mar NEWA
AB		100MG	A207061	002	Apr 04, 2017	Mar NEWA
AB		200MG	A207061	003	Apr 04, 2017	Mar NEWA
AB		400MG	A207061	004	Apr 04, 2017	Mar NEWA

CEPHALEXIN

CAPSULE;ORAL

CEPHALEXIN

AB	AUROBINDO PHARMA LTD	EQ 250MG BASE	A065253	001	Nov 16, 2005	Jan CAHN
AB		EQ 500MG BASE	A065253	002	Nov 16, 2005	Jan CAHN

CEPHAPIRIN SODIUM

INJECTABLE;INJECTION

CEPHAPIRIN SODIUM

@ WEST-WARD PHARMS INT	EQ 500MG BASE/VIAL	A062720	001	Jul 02, 1987	Jan CAHN
@	EQ 1GM BASE/VIAL	A062720	002	Jul 02, 1987	Jan CAHN
@	EQ 2GM BASE/VIAL	A062720	003	Jul 02, 1987	Jan CAHN
@	EQ 20GM BASE/VIAL	A062720	004	Jul 02, 1987	Jan CAHN

CETIRIZINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

ZERVIAE

+! NICOX OPHTHALMICS	EQ 0.24% BASE	N208694	001	May 30, 2017	May NEWA
----------------------	---------------	---------	-----	--------------	----------

SYRUP;ORAL

CETIRIZINE HYDROCHLORIDE

AA	ALLIED PHARMA INC	5MG/5ML	A090191	001	Nov 12, 2009	Apr CAHN
----	-------------------	---------	---------	-----	--------------	----------

CEVIMELINE HYDROCHLORIDE

CAPSULE;ORAL

CEVIMELINE HYDROCHLORIDE

AB	RISING PHARMS INC	30MG	A203775	001	Jun 04, 2014	May CAHN
----	-------------------	------	---------	-----	--------------	----------

CHENODIOL

TABLET;ORAL

CHENIX

+ @ LEADIANT BIOSCI INC	250MG	N018513	002	Jul 28, 1983	Feb CAHN
-------------------------	-------	---------	-----	--------------	----------

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE;INJECTION

CHLOROMYCETIN

+ @ PARKEDALE	EQ 1GM BASE/VIAL	N050155	001		Mar CRLD
---------------	------------------	---------	-----	--	----------

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE;ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

>D>	@ UPSHER-SMITH LABS	5MG	A084678	001		Jun CAHN
>A>	@	5MG	A084678	001		Jun CAHN
>D>	@	10MG	A084041	001		Jun CAHN
>A>	@	10MG	A084041	001		Jun CAHN
>D>	@	25MG	A084679	002		Jun CAHN
>A>	@	25MG	A084679	002		Jun CAHN
	@ USL PHARMA	10MG	A084623	001		Apr DISC

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL

PERIOGARD

AT	COLGATE PALMOLIVE CO	0.12%	A073695	001	Jan 14, 1994	May CAHN
----	----------------------	-------	---------	-----	--------------	----------

CHLORPHENESIN CARBAMATE

TABLET; ORAL

MAOLATE

@ PAMLAB LLC

400MG

N014217 002

Mar CAHN

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE

AA

ACELLA PHARMS LLC

4MG/5ML; 5MG/5ML

A206891 001 Jun 09, 2017

May NEWA

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA

BIO-PHARM INC

4MG/5ML; 5MG/5ML; 60MG/5ML

A206660 001 May 15, 2017

May NEWA

CHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

>D>

USL PHARMA

10MG

A083386 001

Jun CAHN

>A>

10MG

A083386 001

Jun CAHN

10MG

A083386 001

May CTEC

>D>

!

25MG

A084112 001

Jun CAHN

>A>

!

25MG

A084112 001

Jun CAHN

!

25MG

A084112 001

May CHRS

>D>

50MG

A084113 001

Jun CAHN

>A>

50MG

A084113 001

Jun CAHN

50MG

A084113 001

May CTEC

>D>

!

100MG

A084114 001

Jun CAHN

>A>

!

100MG

A084114 001

Jun CAHN

!

100MG

A084114 001

May CHRS

>D>

200MG

A084115 001

Jun CAHN

>A>

200MG

A084115 001

Jun CAHN

200MG

A084115 001

May CTEC

THORAZINE

@ GLAXOSMITHKLINE

10MG

N009149 002

May CRLD

@

25MG

N009149 007

May CRLD

@

50MG

N009149 013

May CRLD

@

100MG

N009149 018

May CRLD

@

200MG

N009149 020

May CRLD

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

@ ANI PHARMS INC

250MG

A087353 001

Jan CAHN

@ WATSON LABS TEVA

100MG

A088852 001 Sep 26, 1984

May CAHN

@

250MG

A088826 001 Sep 26, 1984

May CAHN

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

AB

RICONPHARMA LLC

25MG

A206904 001 Mar 30, 2017

Mar NEWA

AB

50MG

A206904 002 Mar 30, 2017

Mar NEWA

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

AB

ZYDUS PHARMS USA INC EQ 4GM RESIN/SCOOPFUL

A202902 001 Apr 25, 2017 Apr NEWA

PREVALITE

>D>

AB

UPSHER SMITH

EQ 4GM RESIN/PACKET

A073263 001 Feb 22, 1996

Jun CAHN

>D>

AB

EQ 4GM RESIN/SCOOPFUL

A073263 002 Oct 30, 1997

Jun CAHN

>A>

AB

UPSHER-SMITH LABS

EQ 4GM RESIN/PACKET

A073263 001 Feb 22, 1996

Jun CAHN

>A>

AB

EQ 4GM RESIN/SCOOPFUL

A073263 002 Oct 30, 1997

Jun CAHN

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

FENOFIBRIC ACID

AB

ALEMBIC PHARMS LTD

EQ 45MG FENOFIBRIC ACID

A208705 001 May 12, 2017

May NEWA

AB

EQ 135MG FENOFIBRIC ACID

A208705 002 May 12, 2017

May NEWA

CICLOPIROX

CREAM; TOPICAL							
CICLOPIROX							
AB	PERRIGO NEW YORK	0.77%	A077364	001	Mar 03, 2006	Apr	CAHN
SHAMPOO; TOPICAL							
CICLOPIROX							
AT	PERRIGO CO	1%	A078594	001	Feb 16, 2010	Apr	CAHN

CILOSTAZOL

TABLET; ORAL							
CILOSTAZOL							
	@ EPIC PHARMA LLC	50MG	A077150	001	Mar 11, 2005	May	CAHN
	@	100MG	A077022	001	Nov 23, 2004	May	CAHN
	@ MYLAN	50MG	A077323	002	Apr 20, 2006	May	DISC
	@	100MG	A077323	001	Apr 20, 2006	May	DISC
	@ MYLAN PHARMS INC	50MG	A077019	001	Nov 23, 2004	Mar	DISC
	@	100MG	A077019	002	Nov 23, 2004	Mar	DISC
	@ PLIVA HRVATSKA DOO	50MG	A077898	001	Oct 29, 2007	Mar	DISC
	@	100MG	A077898	002	Oct 29, 2007	Mar	DISC
PLETAL							
+	@ OTSUKA	50MG	N020863	001	Jan 15, 1999	Jan	CRLD
+	@	100MG	N020863	002	Jan 15, 1999	Jan	CRLD

CIMETIDINE

TABLET; ORAL							
CIMETIDINE							
	@ CHARTWELL MOLECULES	200MG	A074281	001	May 17, 1994	Jan	CAHN
	@	300MG	A074281	002	May 17, 1994	Jan	CAHN
	@	400MG	A074281	003	May 17, 1994	Jan	CAHN
	@	800MG	A074329	001	May 17, 1994	Jan	CAHN
	@ SANDOZ INC	200MG	A074250	001	Jun 29, 1995	Mar	CAHN
	@	300MG	A074250	002	Jun 29, 1995	Mar	CAHN
	@	400MG	A074250	003	Jun 29, 1995	Mar	CAHN
	@	800MG	A074250	004	Jun 29, 1995	Mar	CAHN
>D>	@ UPSHER-SMITH LABS	200MG	A074506	001	Jan 24, 1996	Jun	CAHN
>A>	@	200MG	A074506	001	Jan 24, 1996	Jun	CAHN
>D>	@	300MG	A074506	002	Jan 24, 1996	Jun	CAHN
>A>	@	300MG	A074506	002	Jan 24, 1996	Jun	CAHN
>D>	@	400MG	A074506	003	Jan 24, 1996	Jun	CAHN
>A>	@	400MG	A074506	003	Jan 24, 1996	Jun	CAHN
>D>	@	800MG	A074506	004	Jan 24, 1996	Jun	CAHN
>A>	@	800MG	A074506	004	Jan 24, 1996	Jun	CAHN

CIMETIDINE HYDROCHLORIDE

SOLUTION; ORAL							
CIMETIDINE HYDROCHLORIDE							
AA	PHARM ASSOC	EQ 300MG BASE/5ML	A074553	001	Jan 27, 1997	May	CAHN

CIPROFLOXACIN

INJECTABLE; INJECTION							
CIPRO							
+	@ BAYER HLTHCARE	400MG/40ML (10MG/ML)	N019847	001	Dec 26, 1990	Feb	DISC
+	@	200MG/20ML (10MG/ML)	N019847	002	Dec 26, 1990	Feb	DISC
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER							
+	@ BAYER HLTHCARE	200MG/100ML	N019857	001	Dec 26, 1990	Feb	DISC
+	@	400MG/200ML	N019857	002	Dec 26, 1990	Feb	DISC
CIPROFLOXACIN							
AP	! CLARIS	200MG/20ML (10MG/ML)	A078062	001	Apr 29, 2008	Feb	CHRS
AP	!	400MG/40ML (10MG/ML)	A078062	002	Apr 29, 2008	Feb	CHRS
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER							
AP	! HOSPIRA	200MG/100ML	A077753	001	Mar 18, 2008	Feb	CHRS
AP	!	400MG/200ML	A077753	002	Mar 18, 2008	Feb	CHRS

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC							
CIPROFLOXACIN HYDROCHLORIDE							
AT	AMRING PHARMS	EQ 0.3% BASE	A078598	001	Jan 16, 2008	Mar	CAHN
AT	TELIGENT	EQ 0.3% BASE	A076754	001	Jun 09, 2004	Apr	CAHN
TABLET; ORAL							
CIPROFLOXACIN HYDROCHLORIDE							
AB	TARO PHARM	EQ 100MG BASE	A076912	001	Feb 18, 2005	Mar	CAHN

TABLET;ORAL

CIPROFLOXACIN HYDROCHLORIDE

AB		EQ 250MG BASE	A076912	002	Oct 06, 2004	Mar CAHN
AB		EQ 500MG BASE	A076912	003	Oct 06, 2004	Mar CAHN
AB		EQ 750MG BASE	A076912	004	Oct 06, 2004	Mar CAHN

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE

>A>	AP	ACCORD HLTHCARE	EQ 2MG BASE/ML	A205873	001	Jun 16, 2017	Jun NEWA
		CISATRACURIUM BESYLATE PRESERVATIVE FREE					
>A>	AP	ACCORD HLTHCARE	EQ 2MG BASE/ML	A205872	001	Jun 16, 2017	Jun NEWA
>A>	AP		EQ 10MG BASE/ML	A205872	002	Jun 16, 2017	Jun NEWA
	AP	JIANGSU HENGRUI MED	EQ 2MG BASE/ML	A204960	001	Jan 27, 2017	Jan NEWA

CISPLATIN

INJECTABLE;INJECTION

CISPLATIN

AP		GLAND PHARMA LTD	1MG/ML	A207323	001	Mar 17, 2017	Mar NEWA
AP	+	HQ SPCLT PHARMA	1MG/ML	N018057	004	Nov 08, 1988	Mar CRLD
		PLATINOL					
	+	@ HQ SPCLT PHARMA	10MG/VIAL	N018057	001		Mar CRLD
	+	@	50MG/VIAL	N018057	002		Mar CRLD
		PLATINOL-AQ					
	+	@ HQ SPCLT PHARMA	0.5MG/ML	N018057	003	Jul 18, 1984	Mar CRLD

CITALOPRAM HYDROBROMIDE

CAPSULE;ORAL

CITALOPRAM HYDROBROMIDE

	@	MYLAN PHARMS INC	EQ 10MG BASE	A077668	001	Feb 28, 2007	Mar DISC
	@		EQ 20MG BASE	A077668	002	Feb 28, 2007	Mar DISC
	@		EQ 40MG BASE	A077668	003	Feb 28, 2007	Mar DISC

SOLUTION;ORAL

CITALOPRAM HYDROBROMIDE

AA		AUROBINDO PHARMA LTD	EQ 10MG BASE/5ML	A077812	001	Aug 28, 2006	Jan CAHN
----	--	----------------------	------------------	---------	-----	--------------	----------

TABLET;ORAL

CITALOPRAM HYDROBROMIDE

	@	EPIC PHARMA LLC	EQ 10MG BASE	A077036	001	Oct 28, 2004	May CAHN
	@		EQ 20MG BASE	A077036	002	Oct 28, 2004	May CAHN
	@		EQ 40MG BASE	A077036	003	Oct 28, 2004	May CAHN
>D>	AB	MYLAN	EQ 10MG BASE	A077039	001	Feb 03, 2005	Jun DISC
>A>		@	EQ 10MG BASE	A077039	001	Feb 03, 2005	Jun DISC
>D>	AB		EQ 20MG BASE	A077039	002	Feb 03, 2005	Jun DISC
>A>		@	EQ 20MG BASE	A077039	002	Feb 03, 2005	Jun DISC
>D>	AB		EQ 40MG BASE	A077039	003	Feb 03, 2005	Jun DISC
>A>		@	EQ 40MG BASE	A077039	003	Feb 03, 2005	Jun DISC
	@	MYLAN PHARMS INC	EQ 10MG BASE	A077037	001	Nov 05, 2004	May DISC
	@		EQ 20MG BASE	A077037	002	Nov 05, 2004	May DISC
	@		EQ 40MG BASE	A077037	003	Nov 05, 2004	May DISC

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

FOR SOLUTION;ORAL

PREPOPIK

+	!	FERRING PHARMS INC	12GM/PACKET;3.5GM/PACKET;10MG/PACK ET	N202535	001	Jul 16, 2012	Mar CAHN
---	---	--------------------	--	---------	-----	--------------	----------

CLARITHROMYCIN

TABLET;ORAL

CLARITHROMYCIN

	@	MYLAN	250MG	A065195	001	Mar 11, 2005	May DISC
	@		500MG	A065195	002	Mar 11, 2005	May DISC

CLEMASTINE FUMARATE

TABLET;ORAL

CLEMASTINE FUMARATE

	@	SANDOZ	2.68MG	A073459	001	Oct 31, 1993	Feb DISC
!		TEVA	2.68MG	A073283	001	Jan 31, 1992	Feb CTEC

CLINDAMYCIN HYDROCHLORIDE

CAPSULE;ORAL

CLINDAMYCIN HYDROCHLORIDE

AB	EPIC PHARMA LLC	EQ 150MG BASE	A065194	001	Mar 22, 2004	May CAHN
AB		EQ 300MG BASE	A065194	002	Mar 22, 2004	May CAHN
	@ MYLAN PHARMS INC	EQ 75MG BASE	A091225	001	May 31, 2011	May DISC
	@	EQ 150MG BASE	A091225	002	May 31, 2011	May DISC
	@	EQ 300MG BASE	A091225	003	May 31, 2011	May DISC

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

>D> AA	INVAGEN PHARMS	EQ 75MG BASE/5ML	A206958	001	May 05, 2017	Jun CAHN
AA		EQ 75MG BASE/5ML	A206958	001	May 05, 2017	Apr NEWA
>A> AA	ORIT LABS LLC	EQ 75MG BASE/5ML	A206958	001	May 05, 2017	Jun CAHN
AA	PADDOCK LLC	EQ 75MG BASE/5ML	A090902	001	Jul 07, 2010	Apr CAHN

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM;TOPICAL

EVOCLIN

AT	+! MYLAN PHARMS INC	1%	N050801	001	Oct 22, 2004	Jan CAHN
----	---------------------	----	---------	-----	--------------	----------

INJECTABLE;INJECTION

CLINDAMYCIN PHOSPHATE

AP	SAGENT PHARMS	EQ 150MG BASE/ML	A090109	001	Sep 30, 2011	Apr CAHN
AP	WEST-WARD PHARMS INT	EQ 150MG BASE/ML	A065206	001	Sep 24, 2004	Jan CAHN

CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER

>A> AP	CELERITY PHARMS	EQ 6MG BASE/ML	A208084	001	Jun 28, 2017	Jun NEWA
>A> AP		EQ 12MG BASE/ML	A208084	002	Jun 28, 2017	Jun NEWA
>A> AP		EQ 18MG BASE/ML	A208084	003	Jun 28, 2017	Jun NEWA

SOLUTION;IV (INFUSION)

CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE

+!	BAXTER HLTHCARE CORP	EQ 300MG BASE/50ML (EQ 6MG BASE/ML)	N208083	001	Apr 20, 2017	May CAHN
+!		EQ 600MG BASE/50ML (EQ 12MG BASE/ML)	N208083	002	Apr 20, 2017	May CAHN
+!		EQ 900MG BASE/50ML (EQ 18MG BASE/ML)	N208083	003	Apr 20, 2017	May CAHN
+!	CELERITY PHARMS	EQ 300MG BASE/50ML (EQ 6MG BASE/ML)	N208083	001	Apr 20, 2017	Apr NEWA
+!		EQ 600MG BASE/50ML (EQ 12MG BASE/ML)	N208083	002	Apr 20, 2017	Apr NEWA
+!		EQ 900MG BASE/50ML (EQ 18MG BASE/ML)	N208083	003	Apr 20, 2017	Apr NEWA

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

AT	FOUGERA PHARMS INC	EQ 1% BASE	A064159	001	Jun 05, 1997	Jan CAHN
----	--------------------	------------	---------	-----	--------------	----------

SWAB;TOPICAL

CLINDETS

AT	PERRIGO CO	EQ 1% BASE	A064136	001	Sep 30, 1996	Apr CAHN
----	------------	------------	---------	-----	--------------	----------

CLOBAZAM

SUSPENSION;ORAL

ONFI

+!	LUNDBECK PHARMS LLC	2.5MG/ML	N203993	001	Dec 14, 2012	Jan CAHN
----	---------------------	----------	---------	-----	--------------	----------

TABLET;ORAL

ONFI

@	LUNDBECK PHARMS LLC	5MG	N202067	001	Oct 21, 2011	Jan CAHN
+		10MG	N202067	002	Oct 21, 2011	Jan CAHN
+!		20MG	N202067	003	Oct 21, 2011	Jan CAHN

CLOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

OLUX

AB1	+! MYLAN PHARMS INC	0.05%	N021142	001	May 26, 2000	Jan CAHN
	OLUX E					

AB2	+! MYLAN PHARMS INC	0.05%	N022013	001	Jan 12, 2007	Jan CAHN
-----	---------------------	-------	---------	-----	--------------	----------

CREAM;TOPICAL

CLOBETASOL PROPIONATE

AB1	FOUGERA PHARMS INC	0.05%	A074392	001	Sep 30, 1996	Jan CAHN
AB1	MYLAN PHARMS INC	0.05%	A075338	001	Feb 09, 2001	May CMFD
	@	0.05%	A075338	001	Feb 09, 2001	Jan CAHN
AB1	TARO	0.05%	A074249	001	Jul 08, 1996	Apr CAHN

GEL;TOPICAL

CLOBETASOL PROPIONATE

AB	PERRIGO CO	0.05%	A075027	001	Oct 31, 1997	Apr CAHN
AB	TARO	0.05%	A075279	001	May 28, 1999	Apr CAHN
AB	TELIGENT PHARMA INC	0.05%	A208881	001	Mar 06, 2017	Feb NEWA

OINTMENT;TOPICAL

CLOBETASOL PROPIONATE

AB	GLENMARK PHARMS	0.05%	A208933	001	Mar 20, 2017	Mar NEWA
AB1	MYLAN PHARMS INC	0.05%	A075057	001	Aug 12, 1998	May CMFD
	@	0.05%	A075057	001	Aug 12, 1998	Jan CAHN
AB	TARO	0.05%	A074248	001	Jul 12, 1996	Apr CAHN
	TEMOVATE					
	+ @ FOUGERA PHARMS	0.05%	N019323	001	Dec 27, 1985	Jan CRLD

SOLUTION;TOPICAL

CLOBETASOL PROPIONATE

AT	TARO	0.05%	A075224	001	Nov 16, 1998	Apr CAHN
----	------	-------	---------	-----	--------------	----------

SPRAY;TOPICAL

CLOBETASOL PROPIONATE

AT	AKORN	0.05%	A207218	001	Apr 28, 2017	Apr NEWA
AT	ZYDUS PHARMS USA INC	0.05%	A206378	001	Feb 16, 2017	Feb NEWA

CLOFARABINE

INJECTABLE;IV (INFUSION)

CLOFARABINE

AP	ABON PHARMS LLC	20MG/20ML (1MG/ML)	A204029	001	May 09, 2017	Apr NEWA
	CLOLAR					
AP	+! GENZYME	20MG/20ML (1MG/ML)	N021673	001	Dec 28, 2004	Apr CFTG

CLOFIBRATE

CAPSULE;ORAL

CLOFIBRATE

>D>	@ USL PHARMA	500MG	A070531	001	Jun 16, 1986	Jun CAHN
>A>	@	500MG	A070531	001	Jun 16, 1986	Jun CAHN

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL

CLOMIPRAMINE HYDROCHLORIDE

AB	SANDOZ	25MG	A074953	001	Jun 25, 1997	Feb CMFD
AB		50MG	A074953	002	Jun 25, 1997	Feb CMFD
AB		75MG	A074953	003	Jun 25, 1997	Feb CMFD

CLONAZEPAM

TABLET;ORAL

CLONAZEPAM

	@ MYLAN PHARMS INC	0.5MG	A074940	001	Oct 30, 1997	Mar DISC
	@	1MG	A074940	002	Oct 30, 1997	Mar DISC
	@	2MG	A074940	003	Oct 30, 1997	Mar DISC
AB	PRINSTON INC	0.5MG	A077856	001	Jun 28, 2006	Feb CAHN
AB		1MG	A077856	002	Jun 28, 2006	Feb CAHN
AB		2MG	A077856	003	Jun 28, 2006	Feb CAHN

CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

	@ CHARTWELL MOLECULES	0.1MG	A071783	001	Apr 05, 1988	Feb CAHN
	@	0.3MG	A071785	001	Apr 05, 1988	Feb CAHN
AB	PRINSTON INC	0.1MG	A077901	001	Mar 09, 2007	Feb CAHN
AB		0.2MG	A077901	002	Mar 09, 2007	Feb CAHN
AB		0.3MG	A077901	003	Mar 09, 2007	Feb CAHN

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

AB2	ACTAVIS ELIZABETH	0.1MG	A202792	001	May 15, 2015	Apr CAHN
AB1		0.1MG	A203320	001	May 15, 2015	Apr CAHN
	@	0.2MG	A202792	002	May 15, 2015	Apr CAHN
	@	0.2MG	A203320	002	May 15, 2015	Apr CAHN

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

AB	ALLIED PHARMA INC	EQ 75MG BASE	A078004	001	May 17, 2012	Mar CAHN
AB	CSPC OUYI PHARM CO	EQ 75MG BASE	A204359	001	Feb 02, 2017	Jan NEWA

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM

AB	TARO PHARM	3.75MG	A075731	003	Apr 27, 2000	Mar CAHN
AB		7.5MG	A075731	002	Apr 27, 2000	Mar CAHN
AB		15MG	A075731	001	Apr 27, 2000	Mar CAHN

CLOTRIMAZOLE

SOLUTION; TOPICAL

CLOTRIMAZOLE

AT	!	TARO	1%	A074580	001	Jul 29, 1996	Apr CAHN
----	---	------	----	---------	-----	--------------	----------

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

@ PHARM ASSOC 10MG/5ML; 6.25MG/5ML

A089647	001	Dec 22, 1988	May CAHN
---------	-----	--------------	----------

CODEINE SULFATE

SOLUTION; ORAL

CODEINE SULFATE

@ WEST-WARD PHARMS INT 30MG/5ML

N202245	001	Jun 30, 2011	Jan CAHN
---------	-----	--------------	----------

TABLET; ORAL

CODEINE SULFATE

AB	+	WEST-WARD PHARMS INT	15MG	N022402	001	Jul 16, 2009	Jan CAHN
AB	+		30MG	N022402	002	Jul 16, 2009	Jan CAHN
AB	+	!	60MG	N022402	003	Jul 16, 2009	Jan CAHN

CORTICOTROPIN

INJECTABLE; INJECTION

PURIFIED CORTROPHIN GEL

@ ANI PHARMS INC 40 UNITS/ML

N008975	001		May CAHN
---------	-----	--	----------

@ 80 UNITS/ML

N008975	002		May CAHN
---------	-----	--	----------

CORTICOTROPIN-ZINC HYDROXIDE

INJECTABLE; INJECTION

CORTROPHIN-ZINC

@ ANI PHARMS INC 40 UNITS/ML

N009854	001		May CAHN
---------	-----	--	----------

CORTISONE ACETATE

TABLET; ORAL

CORTONE

+ @ MERCK 25MG

N007750	003		Mar CRLD
---------	-----	--	----------

COSYNTROPIN

SOLUTION; INTRAVENOUS

COSYNTROPIN

@ SANDOZ INC 0.25MG/ML (0.25MG/ML)

N022028	001	Feb 21, 2008	May CAHN
---------	-----	--------------	----------

CROMOLYN SODIUM

AEROSOL, METERED; INHALATION

INTAL

@ KING PHARMS LLC 0.8MG/INH

N018887	001	Dec 05, 1985	May CAHN
---------	-----	--------------	----------

CONCENTRATE; ORAL

GASTROCROM

AA	+	MYLAN SPECIALITY LP	100MG/5ML	N020479	001	Feb 29, 1996	Mar CAHN
----	---	---------------------	-----------	---------	-----	--------------	----------

SOLUTION; INHALATION

CROMOLYN SODIUM

AN		BAUSCH AND LOMB	10MG/ML	A075585	001	Dec 21, 2000	Feb CAHN
----	--	-----------------	---------	---------	-----	--------------	----------

INTAL

@ KING PHARMS LLC 10MG/ML

N018596	001	May 28, 1982	May CAHN
---------	-----	--------------	----------

CYANOCOBALAMIN

INJECTABLE; INJECTION
CYANOCOBALAMIN

AP	MYLAN LABS LTD	1MG/ML	A204829	001	Jun 05, 2017	May NEWA
	DODEX					
>A>	@ ACCORD HLTHCARE	1MG/ML	A083022	001		Jun CAHN
>D>	@ ORGANON SUB MERCK	1MG/ML	A083022	001		Jun CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL
CYCLOBENZAPRINE HYDROCHLORIDE

AB	OXFORD PHARMS	5MG	A077209	002	Feb 03, 2006	May CMS1
AB	PRINSTON INC	5MG	A077797	001	Feb 28, 2007	Feb CAHN
AB		10MG	A077797	002	Feb 28, 2007	Feb CAHN
AB	RUBICON RES PVT LTD	5MG	A208170	001	May 31, 2017	May NEWA
AB		7.5MG	A208170	002	May 31, 2017	May NEWA
AB		10MG	A208170	003	May 31, 2017	May NEWA
>D>	@ UPSHER-SMITH LABS	5MG	A072854	002	Feb 03, 2006	Jun CAHN
>A>	@	5MG	A072854	002	Feb 03, 2006	Jun CAHN
>D>	@	10MG	A072854	001	Nov 19, 1991	Jun CAHN
>A>	@	10MG	A072854	001	Nov 19, 1991	Jun CAHN

CYCLOPHOSPHAMIDE

CAPSULE; ORAL
CYCLOPHOSPHAMIDE

+	WEST-WARD PHARMS INT	25MG	N203856	001	Sep 16, 2013	Jan CAHN
+	!	50MG	N203856	002	Sep 16, 2013	Jan CAHN

INJECTABLE; INJECTION
CYTOXAN (LYOPHILIZED)

+	@ BAXTER HLTHCARE	500MG/VIAL	N012142	003		Feb CRLD
+	@	1GM/VIAL	N012142	004	Aug 30, 1982	Feb CRLD
+	@	2GM/VIAL	N012142	005	Aug 30, 1982	Feb CRLD

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL
PERIACTIN

+	@ MERCK	2MG/5ML	N013220	002		Jan CRLD
---	---------	---------	---------	-----	--	----------

TABLET; ORAL
CYPROHEPTADINE HYDROCHLORIDE

AA	APNAR PHARMA LP	4MG	A207555	001	Jan 31, 2017	Jan NEWA
AA	IMPAX LABS INC	4MG	A040537	001	Sep 30, 2003	Feb CAHN
AA	SANTOS BIOTECH	4MG	A040644	001	May 30, 2006	May CAHN
AA	ZYDUS PHARMS USA INC	4MG	A208938	001	May 19, 2017	May NEWA

CYSTEAMINE BITARTRATE

CAPSULE, DELAYED RELEASE; ORAL
PROCYSBI

+	HORIZON PHARMA USA	EQ 25MG BASE	N203389	001	Apr 30, 2013	Mar CAHN
+	!	EQ 75MG BASE	N203389	002	Apr 30, 2013	Mar CAHN

CYSTEAMINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
CYSTARAN

+	!	LEADIANT BIOSCI INC	EQ 0.44% BASE	N200740	001	Oct 02, 2012	Feb CAHN
---	---	---------------------	---------------	---------	-----	--------------	----------

CYTARABINE

INJECTABLE; INJECTION
CYTARABINE

AP	MYLAN LABS LTD	20MG/ML	A200915	001	Dec 13, 2011	Mar CAHN
	WEST-WARD PHARMS INT	100MG/VIAL	A071471	001	Aug 02, 1989	Mar CTEC
!		500MG/VIAL	A071472	001	Aug 02, 1989	Mar CHRS
!		1GM/VIAL	A074245	001	Aug 31, 1994	Mar CHRS
!		2GM/VIAL	A074245	002	Aug 31, 1994	Mar CHRS
	CYTOSAR-U					
	@ TEVA PHARMS USA	100MG/VIAL	A075206	001	Dec 30, 1998	Mar DISC
	@	500MG/VIAL	A075206	002	Dec 30, 1998	Mar DISC
	@	1GM/VIAL	A075206	004	Dec 30, 1998	Mar DISC
	@	2GM/VIAL	A075206	003	Dec 30, 1998	Mar DISC

DACARBAZINEINJECTABLE; INJECTION
DACARBAZINE

AP	!	FRESENIUS KABI USA	100MG/VIAL	A075371	001	Aug 27, 1999	Feb CHRS
AP	!		200MG/VIAL	A075371	002	Aug 27, 1999	Feb CHRS
		DTIC-DOME					
	+	@ BAYER HLTHCARE	100MG/VIAL	N017575	001		Apr DISC
	+	@	200MG/VIAL	N017575	002		Apr DISC

DALFAMPRIDINETABLET, EXTENDED RELEASE; ORAL
AMPYRA

AB	+	! ACORDA	10MG	N022250	001	Jan 22, 2010	Jan CFTG
		DALFAMPRIDINE					
AB		ACTAVIS LABS FL INC	10MG	A206836	001	Jan 23, 2017	Jan NEWA
AB		AUROBINDO PHARMA LTD	10MG	A206811	001	Jan 23, 2017	Jan NEWA

DANTROLENE SODIUMINJECTABLE; INJECTION
DANTROLENE SODIUM

>A>	AP		HIKMA PHARMS LLC	20MG/VIAL	A204762	001	Jun 19, 2017	Jun NEWA
-----	----	--	------------------	-----------	---------	-----	--------------	----------

DAPAGLIFLOZIN PROPANEDIOL; SAXAGLIPTIN HYDROCHLORIDETABLET; ORAL
QTERN

	+	!	ASTRAZENECA AB	EQ 10MG BASE; EQ 5MG BASE	N209091	001	Feb 27, 2017	Feb NEWA
--	---	---	----------------	---------------------------	---------	-----	--------------	----------

DAPSONETABLET; ORAL
DAPSONE

AB		ACTAVIS LLC	25MG	A204380	001	Mar 23, 2017	Mar NEWA
AB			100MG	A204380	002	Mar 23, 2017	Mar NEWA

DECITABINEINJECTABLE; INTRAVENOUS
DECITABINE

AP		ACCORD HLTHCARE	50MG/VIAL	A203475	001	Feb 27, 2017	Feb NEWA
AP		PHARMASCIENCE INC	50MG/VIAL	A204607	001	May 31, 2017	May NEWA

DEFERASIROXGRANULE; ORAL
JADENU SPRINKLE

	+		NOVARTIS PHARMS CORP	90MG	N207968	001	May 18, 2017	May NEWA
	+			180MG	N207968	002	May 18, 2017	May NEWA
	+	!		360MG	N207968	003	May 18, 2017	May NEWA

DEFLAZACORTSUSPENSION; ORAL
EMFLAZA

	+	!	MARATHON PHARMS LLC	22.75MG/ML	N208685	001	Feb 09, 2017	Feb NEWA
	+	!	PTC THERAP	22.75MG/ML	N208685	001	Feb 09, 2017	Apr CAHN

TABLET; ORAL
EMFLAZA

	+		MARATHON PHARMS LLC	6MG	N208684	001	Feb 09, 2017	Feb NEWA
	+			18MG	N208684	002	Feb 09, 2017	Feb NEWA
	+			30MG	N208684	003	Feb 09, 2017	Feb NEWA
	+	!		36MG	N208684	004	Feb 09, 2017	Feb NEWA
	+		PTC THERAP	6MG	N208684	001	Feb 09, 2017	Apr CAHN
	+			18MG	N208684	002	Feb 09, 2017	Apr CAHN
	+			30MG	N208684	003	Feb 09, 2017	Apr CAHN
	+	!		36MG	N208684	004	Feb 09, 2017	Apr CAHN

>A> DELAFLUXACIN MEGLUMINE

POWDER; IV (INFUSION)

BAXDELA

>A>		+	!	MELINTA THERAPS INC	EQ 300MG BASE/VIAL	N208611	001	Jun 19, 2017	Jun NEWA
>A>				TABLET; ORAL					
>A>				BAXDELA					
>A>		+	!	MELINTA THERAPS INC	EQ 450MG BASE	N208610	001	Jun 19, 2017	Jun NEWA

DESIPRAMINE HYDROCHLORIDE

TABLET;ORAL

DESIPRAMINE HYDROCHLORIDE

AB	IMPAX LABS INC	10MG	A205153	001	Oct 28, 2016	Feb CAHN
AB		25MG	A205153	002	Oct 28, 2016	Feb CAHN
AB		50MG	A205153	003	Oct 28, 2016	Feb CAHN
AB		75MG	A205153	004	Oct 28, 2016	Feb CAHN
AB		100MG	A205153	005	Oct 28, 2016	Feb CAHN
AB		150MG	A205153	006	Oct 28, 2016	Feb CAHN

DESMETHYL PIROXICAM

CAPSULE;ORAL

PIROXICAM

SUN PHARM INDS

10MG

A073536 002 Jan 23, 2008 Mar CMS1

DESMOPRESSIN ACETATESPRAY, METERED;NASAL
NOCTIVA

+	SERENITY PHARMS LLC	0.00083MG/SPRAY
+	!	0.00166MG/SPRAY

N201656	001	Mar 03, 2017	Mar NEWA
N201656	002	Mar 03, 2017	Mar NEWA

STIMATE

>D>	@ CSL BEHRING	0.15MG/SPRAY
>A>	@ FERRING PHARMS INC	0.15MG/SPRAY

N020355	001	Mar 07, 1994	Jun CAHN
N020355	001	Mar 07, 1994	Jun CAHN

STIMATE (NEEDS NO REFRIGERATION)

>D>	+	CSL BEHRING	0.15MG/SPRAY
>A>	+	FERRING PHARMS INC	0.15MG/SPRAY

N020355	002	Oct 24, 2007	Jun CAHN
N020355	002	Oct 24, 2007	Jun CAHN

TABLET;ORAL

DESMOPRESSIN ACETATE

AB	HERITAGE PHARMA	0.1MG
AB		0.1MG
AB		0.2MG
AB		0.2MG

A207880	001	May 26, 2017	May NEWA
A207880	001	May 26, 2017	May CAHN
A207880	002	May 26, 2017	May NEWA
A207880	002	May 26, 2017	May CAHN

DESOGESTREL; ETHINYL ESTRADIOL

TABLET;ORAL-28

DESOGESTREL AND ETHINYL ESTRADIOL

AB	ACCORD HLTHCARE	0.15MG,N/A;0.02MG,0.01MG
AB	AUROBINDO PHARMA LTD	0.15MG,N/A;0.02MG,0.01MG
	KALLIGA	
AB	AUROBINDO PHARMA LTD	0.15MG;0.03MG

A209170	001	Jun 05, 2017	May NEWA
A206853	001	Mar 22, 2017	Mar NEWA
A207081	001	May 17, 2017	May NEWA

DESONIDE

OINTMENT;TOPICAL

DESONIDE

AB	HI-TECH PHARMACAL	0.05%
----	-------------------	-------

A208836 001 Mar 27, 2017 Mar NEWA

DESOXIMETASONE

CREAM;TOPICAL

TOPICORT

AB	!	TARO	0.05%
AB	!		0.25%
	+	@	0.25%
		TOPICORT LP	
	+	@ TARO	0.05%

A073210	001	Nov 30, 1990	Apr CAHN
A073193	001	Nov 30, 1990	Apr CAHN
N017856	001		May CAHN
N018309	001		May CAHN

GEL;TOPICAL

DESOXIMETASONE

AB	RISING PHARMS INC	0.05%	
	TOPICORT		
AB	!	TARO	0.05%
	+	@	0.05%
	+	@ TARO PHARMS NORTH	0.05%

A204675	001	Aug 12, 2016	May CAHN
A074904	001	Jul 14, 1998	Apr CAHN
N018586	001	Mar 29, 1982	May CAHN
N018586	001	Mar 29, 1982	Jan CRLD

OINTMENT;TOPICAL

DESOXIMETASONE

AB	RISING PHARMS INC	0.25%		
	TOPICORT			
AB	+	!	TARO	0.05%
AB	!		0.25%	
	+	@	0.25%	

A204272	001	Nov 30, 2016	May CAHN
N018594	001	Jan 17, 1985	May CAHN
A074286	001	Jun 07, 1996	Apr CAHN
N018763	001	Sep 30, 1983	May CAHN

SPRAY; TOPICAL
DESOXIMETASONE

AT	PERRIGO ISRAEL	0.25%	A206441	001	Jan 20, 2017	Jan NEWA
----	----------------	-------	---------	-----	--------------	----------

AT	+! TARO	0.25%	N204141	001	Apr 11, 2013	Jan CFTG
----	---------	-------	---------	-----	--------------	----------

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL
DESVENLAFAXINE SUCCINATE

AB	ACTAVIS LABS FL	EQ 25MG BASE	A204065	001	Jul 29, 2016	May CAHN
AB		EQ 50MG BASE	A204065	002	Jul 29, 2016	May CAHN
AB		EQ 100MG BASE	A204065	003	Jul 29, 2016	May CAHN

DEUTETRABENAZINE

TABLET; ORAL
AUSTEDO

+	TEVA BRANDED PHARM	6MG	N208082	001	Apr 03, 2017	Apr NEWA
+		9MG	N208082	002	Apr 03, 2017	Apr NEWA
+		12MG	N208082	003	Apr 03, 2017	Apr NEWA

DEXAMETHASONE

TABLET; ORAL
DEXAMETHASONE

BP	PAR PHARM	6MG	A088481	001	Nov 28, 1983	May CHRS
>D>	@ UPSHER SMITH	0.75MG	A087534	001		Jun CAHN
>A>	@	0.75MG	A087534	001		Jun CAHN
>D>	@	1.5MG	A087533	001		Jun CAHN
>A>	@	1.5MG	A087533	001		Jun CAHN

DEXAMETHASONE ACETATE

INJECTABLE; INJECTION
DEXAMETHASONE ACETATE

@	WATSON LABS TEVA	EQ 16MG BASE/ML	A087711	001	May 24, 1982	May CAHN
---	------------------	-----------------	---------	-----	--------------	----------

DEXAMETHASONE SODIUM PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC, OTIC
DEXAMETHASONE SODIUM PHOSPHATE

AT	! SANDOZ INC	EQ 0.1% PHOSPHATE	A088771	001	Jan 16, 1985	Feb CAHN
----	--------------	-------------------	---------	-----	--------------	----------

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC
MAXITROL

AT	SANDOZ INC	0.1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML	A062341	001	May 22, 1984	Feb CAHN
----	------------	---	---------	-----	--------------	----------

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE; ORAL
DEXILANT

AB	+! TAKEDA PHARMS USA	60MG	N022287	002	Jan 30, 2009	Apr CFTG
AB	PAR PHARM INC	60MG	A202294	001	Apr 19, 2017	Apr NEWA

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
DEXMEDETOMIDINE HYDROCHLORIDE

AP	ACCORD HLTHCARE	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204023	001	Feb 09, 2016	Mar CAHN
AP	LUITPOLD PHARMS INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A203773	001	May 12, 2017	May CAHN
AP	PHARMAFORCE	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A203773	001	May 12, 2017	May NEWA
AP	WEST-WARD PHARMS INT	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A205046	001	Apr 26, 2017	Apr NEWA

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
DEXMETHYLPHENIDATE HYDROCHLORIDE

>A>	AB	IMPAX LABS INC	25MG	A203614	001	Jul 05, 2017	Jun NEWA
>A>	AB		35MG	A203614	002	Jul 05, 2017	Jun NEWA
>A>	AB	TEVA PHARMS USA	25MG	A202731	001	Jul 05, 2017	Jun NEWA
>A>	AB		35MG	A202731	004	Jul 05, 2017	Jun NEWA

DEXTROAMPHETAMINE SULFATECAPSULE, EXTENDED RELEASE;ORAL
DEXTROAMPHETAMINE SULFATE

>A>	AB	NESHER PHARMS	5MG	A209111	001	Jun 27, 2017	Jun	NEWA
>A>	AB		10MG	A209111	002	Jun 27, 2017	Jun	NEWA
>A>	AB		15MG	A209111	003	Jun 27, 2017	Jun	NEWA
TABLET;ORAL								
DEXTROAMPHETAMINE SULFATE								
	@	EPIC PHARMA LLC	5MG	A090652	001	Mar 07, 2014	May	CAHN
	@		10MG	A090652	002	Mar 07, 2014	May	CAHN

DEXTROSE

INJECTABLE;INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER

AP	+	ICU MEDICAL INC	10GM/100ML	N018080	001		Feb	CAHN
----	---	-----------------	------------	---------	-----	--	-----	------

DEXTROSE 20% IN PLASTIC CONTAINER

AP	+	ICU MEDICAL INC	20GM/100ML	N018564	001	Mar 23, 1982	Feb	CAHN
----	---	-----------------	------------	---------	-----	--------------	-----	------

DEXTROSE 30% IN PLASTIC CONTAINER

AP	+	ICU MEDICAL INC	30GM/100ML	N019345	001	Jan 26, 1985	Feb	CAHN
----	---	-----------------	------------	---------	-----	--------------	-----	------

DEXTROSE 40% IN PLASTIC CONTAINER

AP	+	ICU MEDICAL INC	40GM/100ML	N018562	001	Mar 23, 1982	May	CAHN
----	---	-----------------	------------	---------	-----	--------------	-----	------

DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	ICU MEDICAL INC	50MG/ML	N016367	002		Feb	CAHN
----	---	-----------------	---------	---------	-----	--	-----	------

DEXTROSE 50% IN PLASTIC CONTAINER

>D>		@	HOSPIRA	50GM/100ML	N019894	001	Dec 26, 1989	Jun	CAHN
-----	--	---	---------	------------	---------	-----	--------------	-----	------

AP	+	ICU MEDICAL INC	50GM/100ML	N018563	001	Mar 23, 1982	Feb	CAHN
----	---	-----------------	------------	---------	-----	--------------	-----	------

>A>		@		50GM/100ML	N019894	001	Dec 26, 1989	Jun	CAHN
-----	--	---	--	------------	---------	-----	--------------	-----	------

DEXTROSE 70% IN PLASTIC CONTAINER

AP	+	ICU MEDICAL INC	70GM/100ML	N018561	001	Mar 23, 1982	Apr	CAHN
----	---	-----------------	------------	---------	-----	--------------	-----	------

AP	+		70GM/100ML	N019893	001	Dec 26, 1989	Feb	CAHN
----	---	--	------------	---------	-----	--------------	-----	------

DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER

		ICU MEDICAL INC	5GM/100ML;21MG/100ML;128MG/100ML;2	N017610	001		Feb	CAHN
--	--	-----------------	------------------------------------	---------	-----	--	-----	------

34MG/100ML

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE;INJECTION

IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER

		ICU MEDICAL INC	5GM/100ML;30MG/100ML;141MG/100ML;1	N019513	001	May 08, 1986	Feb	CAHN
--	--	-----------------	------------------------------------	---------	-----	--------------	-----	------

5MG/100ML;260MG/100ML;25MG/100ML

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER

		ICU MEDICAL INC	5GM/100ML;30MG/100ML;37MG/100ML;22	N017609	001		Feb	CAHN
--	--	-----------------	------------------------------------	---------	-----	--	-----	------

2MG/100ML;526MG/100ML;502MG/100ML

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

		ICU MEDICAL INC	5GM/100ML;149MG/100ML	N018371	001		Apr	CAHN
--	--	-----------------	-----------------------	---------	-----	--	-----	------

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		ICU MEDICAL INC	5GM/100ML;224MG/100ML	N018371	003		Apr	CAHN
----	--	-----------------	-----------------------	---------	-----	--	-----	------

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

		ICU MEDICAL INC	5GM/100ML;298MG/100ML	N018371	002		Apr	CAHN
--	--	-----------------	-----------------------	---------	-----	--	-----	------

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

		ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;225MG/100ML	N018365	002	Jul 05, 1983	Feb	CAHN
--	--	-----------------	------------------------------------	---------	-----	--------------	-----	------

			5GM/100ML;149MG/100ML;225MG/100ML	N018365	006	Mar 28, 1988	Feb	CAHN
--	--	--	-----------------------------------	---------	-----	--------------	-----	------

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

>D>		HOSPIRA	5GM/100ML;74.5MG/100ML;300MG/100ML	N018876	001	Jan 17, 1986	Jun	CAHN
-----	--	---------	------------------------------------	---------	-----	--------------	-----	------

>D>			5GM/100ML;149MG/100ML;300MG/100ML	N018876	006	Mar 28, 1988	Jun	CAHN
-----	--	--	-----------------------------------	---------	-----	--------------	-----	------

>A>		ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;300MG/100ML	N018876	001	Jan 17, 1986	Jun	CAHN
-----	--	-----------------	------------------------------------	---------	-----	--------------	-----	------

>A>			5GM/100ML;149MG/100ML;300MG/100ML	N018876	006	Mar 28, 1988	Jun	CAHN
-----	--	--	-----------------------------------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION

	POTASSIUM CHLORIDE 10MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
AP	ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 450MG/100ML	N018362	005	Mar 28, 1988	Feb CAHN
AP		5GM/100ML; 74.5MG/100ML; 450MG/100ML	N018362	009	Jul 05, 1983	Feb CAHN
	POTASSIUM CHLORIDE 10MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP	ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 900MG/100ML	N019691	002	Mar 24, 1988	Apr CAHN
AP		5GM/100ML; 149MG/100ML; 900MG/100ML	N019691	004	Mar 24, 1988	Apr CAHN
	POTASSIUM CHLORIDE 15MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
	ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 225MG/100ML	N018365	008	Mar 28, 1988	Feb CAHN
	POTASSIUM CHLORIDE 15MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
>D>	HOSPIRA	5GM/100ML; 224MG/100ML; 300MG/100ML	N018876	007	Mar 28, 1988	Jun CAHN
>A>	ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 300MG/100ML	N018876	007	Mar 28, 1988	Jun CAHN
	POTASSIUM CHLORIDE 15MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
AP	ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 450MG/100ML	N018362	006	Mar 28, 1988	Feb CAHN
	POTASSIUM CHLORIDE 15MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP	ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 900MG/100ML	N019691	006	Mar 24, 1988	Apr CAHN
	POTASSIUM CHLORIDE 20MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
	ICU MEDICAL INC	5GM/100ML; 149MG/100ML; 225MG/100ML	N018365	001		Feb CAHN
		5GM/100ML; 298MG/100ML; 225MG/100ML	N018365	009	Mar 28, 1988	Feb CAHN
	POTASSIUM CHLORIDE 20MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
>D>	HOSPIRA	5GM/100ML; 298MG/100ML; 300MG/100ML	N018876	008	Mar 28, 1988	Jun CAHN
>A>	ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 300MG/100ML	N018876	008	Mar 28, 1988	Jun CAHN
	POTASSIUM CHLORIDE 20MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
AP	ICU MEDICAL INC	5GM/100ML; 149MG/100ML; 450MG/100ML	N018362	010	Jul 05, 1983	Feb CAHN
AP		5GM/100ML; 298MG/100ML; 450MG/100ML	N018362	007	Mar 28, 1988	Feb CAHN
	POTASSIUM CHLORIDE 20MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP	ICU MEDICAL INC	5GM/100ML; 149MG/100ML; 900MG/100ML	N019691	005	Mar 24, 1988	Apr CAHN
AP		5GM/100ML; 298MG/100ML; 900MG/100ML	N019691	008	Mar 24, 1988	Apr CAHN
	POTASSIUM CHLORIDE 20MEQ	IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
>D>	HOSPIRA	5GM/100ML; 149MG/100ML; 300MG/100ML	N018876	002	Jan 17, 1986	Jun CAHN
>A>	ICU MEDICAL INC	5GM/100ML; 149MG/100ML; 300MG/100ML	N018876	002	Jan 17, 1986	Jun CAHN
	POTASSIUM CHLORIDE 30MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
	ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 225MG/100ML	N018365	003	Jul 05, 1983	Feb CAHN
	POTASSIUM CHLORIDE 30MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
>D>	HOSPIRA	5GM/100ML; 224MG/100ML; 300MG/100ML	N018876	003	Jan 17, 1986	Jun CAHN
>A>	ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 300MG/100ML	N018876	003	Jan 17, 1986	Jun CAHN
	POTASSIUM CHLORIDE 30MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
AP	ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 450MG/100ML	N018362	002		Feb CAHN
	POTASSIUM CHLORIDE 30MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP	ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 900MG/100ML	N019691	007	Mar 24, 1988	Apr CAHN
	POTASSIUM CHLORIDE 40MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
	ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 225MG/100ML	N018365	004	Jul 05, 1983	Feb CAHN
	POTASSIUM CHLORIDE 40MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
>D>	HOSPIRA	5GM/100ML; 298MG/100ML; 300MG/100ML	N018876	004	Mar 28, 1988	Jun CAHN
>A>	ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 300MG/100ML	N018876	004	Mar 28, 1988	Jun CAHN
	POTASSIUM CHLORIDE 40MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
AP	ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 450MG/100ML	N018362	003		Feb CAHN
	POTASSIUM CHLORIDE 40MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP	ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 900MG/100ML	N019691	009	Mar 24, 1988	Apr CAHN
	POTASSIUM CHLORIDE 5MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
	ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 225MG/100ML	N018365	005	Mar 28, 1988	Feb CAHN
		5GM/100ML; 149MG/100ML; 225MG/100ML	N018365	007	Mar 28, 1988	Feb CAHN
	POTASSIUM CHLORIDE 5MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
>D>	HOSPIRA	5GM/100ML; 74.5MG/100ML; 300MG/100ML	N018876	005	Mar 28, 1988	Jun CAHN
>D>		5GM/100ML; 149MG/100ML; 300MG/100ML	N018876	009	Mar 28, 1988	Jun CAHN
>A>	ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 300MG/100ML	N018876	005	Mar 28, 1988	Jun CAHN
>A>		5GM/100ML; 149MG/100ML; 300MG/100ML	N018876	009	Mar 28, 1988	Jun CAHN
	POTASSIUM CHLORIDE 5MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
AP	ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 450MG/100ML	N018362	008	Mar 28, 1988	Feb CAHN
AP		5GM/100ML; 149MG/100ML; 450MG/100ML	N018362	004	Mar 28, 1988	Feb CAHN
	POTASSIUM CHLORIDE 5MEQ	IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP	ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 900MG/100ML	N019691	001	Mar 24, 1988	Apr CAHN
AP		5GM/100ML; 149MG/100ML; 900MG/100ML	N019691	003	Mar 24, 1988	Apr CAHN

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

	DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
+	ICU MEDICAL INC	5GM/100ML; 225MG/100ML	N017606	001		Feb CAHN
	DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
+	ICU MEDICAL INC	5GM/100ML; 300MG/100ML	N017799	001		Feb CAHN

INJECTABLE;INJECTION

DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER									
AP	ICU MEDICAL INC	5GM/100ML;450MG/100ML	N017607	001				Feb	CAHN
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER									
AP	ICU MEDICAL INC	5GM/100ML;900MG/100ML	N017585	001				Feb	CAHN

DIAZEPAM

TABLET;ORAL

DIAZEPAM

>D>	@ UPSHER-SMITH LABS	2MG	A070302	001	Dec 20, 1985	Jun	CAHN
>A>	@	2MG	A070302	001	Dec 20, 1985	Jun	CAHN
>D>	@	5MG	A070303	001	Dec 20, 1985	Jun	CAHN
>A>	@	5MG	A070303	001	Dec 20, 1985	Jun	CAHN
>D>	@	10MG	A070304	001	Dec 20, 1985	Jun	CAHN
>A>	@	10MG	A070304	001	Dec 20, 1985	Jun	CAHN
	@ VIRTUS PHARMS	2MG	A070462	001	Feb 25, 1986	Feb	CAHN
	@	5MG	A070463	001	Feb 25, 1986	Feb	CAHN
	@	10MG	A070464	001	Feb 25, 1986	Feb	CAHN

DICLOFENAC POTASSIUM

TABLET;ORAL

DICLOFENAC POTASSIUM

@	WATSON LABS TEVA	50MG	A075152	001	Nov 27, 1998	May	CAHN
---	------------------	------	---------	-----	--------------	-----	------

DICLOFENAC SODIUM

SOLUTION;TOPICAL

DICLOFENAC SODIUM

AT	ACTAVIS LABS UT INC	2%	A207238	001	May 15, 2017	May	NEWA
AT	TWI PHARMS INC	1.5%	A202393	001	Nov 24, 2014	Mar	CAHN
PENNSAID							
AT	+! HORIZON PHARMA	2%	N204623	001	Jan 16, 2014	May	CFTG
	+ @ NUVO PHARMS INC	1.5%	N020947	001	Nov 04, 2009	Apr	CAHN
	+ @ NUVO RES INC	1.5%	N020947	001	Nov 04, 2009	Feb	DISC

SOLUTION/DROPS;OPHTHALMIC

DICLOFENAC SODIUM

AT	SANDOZ INC	0.1%	A078031	001	Feb 06, 2008	Feb	CAHN
----	------------	------	---------	-----	--------------	-----	------

TABLET, DELAYED RELEASE;ORAL

DICLOFENAC SODIUM

@	ALLIED PHARMA INC	50MG	A074986	001	Feb 26, 1999	Apr	CAHN
@		75MG	A074986	002	Feb 26, 1999	Apr	CAHN

TABLET, EXTENDED RELEASE;ORAL

DICLOFENAC SODIUM

@	ACTAVIS ELIZABETH	100MG	A075910	001	Jan 07, 2002	Apr	DISC
AB	! DEXCEL LTD	100MG	A076201	001	Nov 06, 2002	Apr	CHRS

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE;ORAL

DICLOFENAC SODIUM AND MISOPROSTOL

AB	EAGLE PHARMS	50MG;0.2MG	A200540	001	Mar 14, 2014	Jan	CAHN
AB		75MG;0.2MG	A200540	002	Mar 14, 2014	Jan	CAHN
AB	EXELA HOLDINGS	50MG;0.2MG	A200540	001	Mar 14, 2014	Mar	CAHN
AB		75MG;0.2MG	A200540	002	Mar 14, 2014	Mar	CAHN

DICYCLOMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DICYCLOMINE HYDROCHLORIDE

AP	LUITPOLD PHARMS INC	10MG/ML	A208353	001	Feb 17, 2017	Feb	NEWA
----	---------------------	---------	---------	-----	--------------	-----	------

DIDANOSINE

CAPSULE, DELAYED REL PELLETS;ORAL

DIDANOSINE

@	MYLAN PHARMS INC	125MG	A090788	001	Apr 08, 2010	May	DISC
@		200MG	A090788	002	Apr 08, 2010	May	DISC
@		250MG	A090788	003	Apr 08, 2010	May	DISC
@		400MG	A090788	004	Apr 08, 2010	May	DISC

DIENOGEST; ESTRADIOL VALERATE

TABLET; ORAL

NATAZIA

+!	BAYER HLTHCARE	N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1M	N022252	001	May 06, 2010	Apr	CTEC
		G, N/A					

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

DIETHYLPROPION HYDROCHLORIDE

@ EPIC PHARMA LLC

25MG

A040828 001 Nov 05, 2008 May CAHN

DIFLORASONE DIACETATE

OINTMENT; TOPICAL

DIFLORASONE DIACETATE

AB RICONPHARMA LLC 0.05%

A207440 001 Feb 27, 2017 Feb NEWA

AB ! TARO 0.05%

A075331 001 May 14, 1999 Apr CAHN

PSORCON

+ @ PHARMACIA AND UPJOHN 0.05%

N019260 001 Aug 28, 1985 Mar CRLD

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

>A> AB ZYDUS PHARMS USA INC 500MG

A203547 001 Jun 16, 2017 Jun NEWA

DIGOXIN

ELIXIR; ORAL

DIGOXIN

+! WEST-WARD PHARMS INT 0.05MG/ML

N021648 001 Aug 26, 2004 Jan CAHN

INJECTABLE; INJECTION

DIGOXIN

AP SANDOZ INC 0.25MG/ML

A040481 001 Aug 21, 2003 Mar CAHN

LANOXIN

AP +! COVIS PHARMA BV 0.25MG/ML

N009330 002 May CAHN

LANOXIN PEDIATRIC

+! COVIS PHARMA BV 0.1MG/ML

N009330 004 May CAHN

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION

DIHYDROERGOTAMINE MESYLATE

AP WEST-WARD PHARMS INT 1MG/ML

A040453 001 Jun 09, 2003 Jan CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HYDROCHLORIDE

AB3 SUN PHARM INDS LTD 120MG

A203023 001 Jun 08, 2017 May NEWA

AB3 180MG

A203023 002 Jun 08, 2017 May NEWA

AB3 240MG

A203023 003 Jun 08, 2017 May NEWA

AB3 300MG

A203023 004 Jun 08, 2017 May NEWA

AB3 360MG

A203023 005 Jun 08, 2017 May NEWA

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

AP ! ATHENEX INC 5MG/ML

A074617 001 Feb 28, 1996 Mar CAHN

AP WEST-WARD PHARMS INT 5MG/ML

A078538 001 Dec 17, 2008 Jan CAHN

TABLET; ORAL

DILTIAZEM HYDROCHLORIDE

@ CHARTWELL MOLECULES 30MG

A074093 001 Nov 05, 1992 Feb CAHN

@ 60MG

A074093 002 Nov 05, 1992 Feb CAHN

@ 90MG

A074093 003 Nov 05, 1992 Feb CAHN

@ 120MG

A074093 004 Nov 05, 1992 Feb CAHN

DIMENHYDRINATE

INJECTABLE; INJECTION

DIMENHYDRINATE

@ WATSON LABS TEVA 50MG/ML

A080615 001 May CAHN

DIPHENHYDRAMINE HYDROCHLORIDE

ELIXIR; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

! PHARM ASSOC 12.5MG/5ML

A087513 001 Feb 10, 1982 May CAHN

INJECTABLE; INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE

@ WATSON LABS TEVA 10MG/ML

A080873 001

May CAHN

@ 50MG/ML

A080873 002

May CAHN

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

@ WATSON LABS TEVA 50MG/ML

A080873 003

May CAHN

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

AP ! ATHENEX INC 5MG/ML

A074939 001 Apr 13, 1998 Mar CAHN

DISULFIRAM

TABLET; ORAL

DISULFIRAM

AB CHARTWELL MOLECULES 250MG

A091563 001

Dec 31, 2012 Jan CAHN

AB 500MG

A091563 002

Dec 31, 2012 Jan CAHN

@ WATSON LABS TEVA 500MG

A086890 001

May CAHN

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE; ORAL

DIVALPROEX SODIUM

AB PRINSTON INC EQ 125MG VALPROIC ACID

A090210 001

Nov 30, 2009 Feb CAHN

AB EQ 250MG VALPROIC ACID

A090210 002

Nov 30, 2009 Feb CAHN

AB EQ 500MG VALPROIC ACID

A090210 003

Nov 30, 2009 Feb CAHN

>D> AB UPSHER SMITH EQ 125MG VALPROIC ACID

A078182 001

Jul 29, 2008 Jun CAHN

>D> AB EQ 250MG VALPROIC ACID

A078182 002

Jul 29, 2008 Jun CAHN

>D> AB EQ 500MG VALPROIC ACID

A078182 003

Jul 29, 2008 Jun CAHN

>A> AB UPSHER-SMITH LABS EQ 125MG VALPROIC ACID

A078182 001

Jul 29, 2008 Jun CAHN

>A> AB EQ 250MG VALPROIC ACID

A078182 002

Jul 29, 2008 Jun CAHN

>A> AB EQ 500MG VALPROIC ACID

A078182 003

Jul 29, 2008 Jun CAHN

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

AP ACTAVIS LLC 20MG/ML (20MG/ML)

N203551 001

Apr 12, 2013 Feb CAHN

AP 80MG/4ML (20MG/ML)

N203551 002

Apr 12, 2013 Feb CAHN

140MG/7ML (20MG/ML)

N203551 003

Apr 12, 2013 Feb CAHN

AP DFB ONCOLOGY LTD 20MG/ML (20MG/ML)

A206177 001

Jan 20, 2017 Jan NEWA

AP 80MG/4ML (20MG/ML)

A206177 002

Jan 20, 2017 Jan NEWA

200MG/10ML (20MG/ML)

A206177 003

Jan 20, 2017 Jan NEWA

+ HOSPIRA INC 160MG/8ML (20MG/ML)

N022234 007

Jan 24, 2017 Jan NEWA

! JIANGSU HENGRUI MED 40MG/ML

A203170 001

Feb 15, 2017 Jan NEWA

@ PFIZER LABS 20MG/2ML (10MG/ML)

N202356 001

Mar 13, 2014 Jan DISC

@ 80MG/8ML (10MG/ML)

N202356 002

Mar 13, 2014 Jan DISC

@ 130MG/13ML (10MG/ML)

N202356 003

Mar 13, 2014 Jan DISC

@ 200MG/20ML (10MG/ML)

N202356 004

Mar 13, 2014 Jan DISC

DOFETILIDE

CAPSULE; ORAL

DOFETILIDE

AB MAYNE PHARMA INC 0.125MG

A207058 001

Jun 06, 2016 Feb CAHN

AB 0.25MG

A207058 002

Jun 06, 2016 Feb CAHN

AB 0.5MG

A207058 003

Jun 06, 2016 Feb CAHN

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

>A> AB ACI HEALTHCARE LTD 5MG

A078662 001

May 31, 2011 Jun CAHN

>A> AB 10MG

A078662 002

May 31, 2011 Jun CAHN

>D> AB ALLIED PHARMA INC 5MG

A078662 001

May 31, 2011 Jun CAHN

AB 5MG

A078662 001

May 31, 2011 Mar CAHN

>D> AB 10MG

A078662 002

May 31, 2011 Jun CAHN

AB 10MG

A078662 002

May 31, 2011 Mar CAHN

AB ZHEJIANG HISUN PHARM 23MG

A202410 001

Mar 24, 2017 Mar NEWA

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE

AB	AMNEAL PHARMS	10MG;14MG	A208328	001	Jan 27, 2017	Jan NEWA
AB		10MG;28MG	A208328	002	Jan 27, 2017	Jan NEWA
	NAMZARIC					
AB	+ FOREST LABS LLC	10MG;14MG	N206439	001	Dec 23, 2014	Jan CFTG
AB	+!	10MG;28MG	N206439	002	Dec 23, 2014	Jan CFTG

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HYDROCHLORIDE

@ TELIGENT	40MG/ML	N018656	001	Jun 28, 1983	May CAHN
------------	---------	---------	-----	--------------	----------

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

AT	SANDOZ INC	EQ 2% BASE	A078748	001	Nov 06, 2008	Mar CAHN
AT		EQ 2% BASE	A078981	001	Apr 13, 2009	Feb CAHN

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT	SANDOZ INC	EQ 2% BASE; EQ 0.5% BASE	A090604	001	Nov 18, 2009	Mar CAHN
----	------------	--------------------------	---------	-----	--------------	----------

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOXAPRAM HYDROCHLORIDE

AP	ATHENEX INC	20MG/ML	A076266	001	Jan 10, 2003	Mar CAHN
----	-------------	---------	---------	-----	--------------	----------

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

>A> AB	ZYDUS PHARMS USA INC	EQ 1MG BASE	A208719	001	Jul 07, 2017	Jun NEWA
>A> AB		EQ 2MG BASE	A208719	002	Jul 07, 2017	Jun NEWA
>A> AB		EQ 4MG BASE	A208719	003	Jul 07, 2017	Jun NEWA
>A> AB		EQ 8MG BASE	A208719	004	Jul 07, 2017	Jun NEWA

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

>A> AB	AMNEAL PHARMS CO	EQ 10MG BASE	A207482	001	Jun 28, 2017	Jun NEWA
>A> AB		EQ 25MG BASE	A207482	002	Jun 28, 2017	Jun NEWA
>A> AB		EQ 50MG BASE	A207482	003	Jun 28, 2017	Jun NEWA
>A> AB		EQ 75MG BASE	A207482	004	Jun 28, 2017	Jun NEWA
>A> AB		EQ 100MG BASE	A207482	005	Jun 28, 2017	Jun NEWA
	@ WATSON LABS TEVA	EQ 50MG BASE	A072987	001	Mar 29, 1991	May CAHN
	CREAM; TOPICAL					
	ZONALON					
	+! MYLAN PHARMS INC	5%	N020126	001	Apr 01, 1994	Jan CAHN

DOXERCALCIFEROL

INJECTABLE; INJECTION

DOXERCALCIFEROL

AP	AMNEAL PHARMS CO	2MCG/ML (2MCG/ML)	A208974	001	May 24, 2017	May NEWA
AP		4MCG/2ML (2MCG/ML)	A208974	002	May 24, 2017	May NEWA
AP		4MCG/2ML (2MCG/ML)	A208975	001	May 24, 2017	May NEWA

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

AP	AMNEAL PHARMS CO	20MG/VIAL	A208888	001	Feb 17, 2017	Feb NEWA
AP		50MG/VIAL	A208888	002	Feb 17, 2017	Feb NEWA

INJECTABLE, LIPOSOMAL; INJECTION

DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

AB	DR REDDYS LABS LTD	20MG/10ML (2MG/ML)	A208657	001	May 15, 2017	May NEWA
AB		50MG/25ML (2MG/ML)	A208657	002	May 15, 2017	May NEWA

DOXYCYCLINE HYCLATEINJECTABLE; INJECTION
VIBRAMYCIN

+ @ PFIZER	EQ 100MG BASE/VIAL	N050442	002		Jan	CRLD
+ @	EQ 200MG BASE/VIAL	N050442	001		Jan	CRLD

TABLET; ORAL
ACTICLATE

>D>	+	AQUA PHARMS LLC	EQ 75MG BASE	N205931	001	Jul 25, 2014	Jun	CFTG
>A> AB	+		EQ 75MG BASE	N205931	001	Jul 25, 2014	Jun	CFTG
>D>	+	!	EQ 150MG BASE	N205931	002	Jul 25, 2014	Jun	CFTG
>A> AB	+	!	EQ 150MG BASE	N205931	002	Jul 25, 2014	Jun	CFTG

DOXYCYCLINE HYCLATE

		CARIBE HOLDINGS	EQ 50MG BASE	A062269	003		Mar	CMFD
		@	EQ 50MG BASE	A062269	003		Jan	CAHN
AB			EQ 100MG BASE	A062269	002	Nov 08, 1982	Jan	CAHN
		@ EPIC PHARMA LLC	EQ 20MG BASE	A065182	001	May 13, 2005	May	CAHN
AB		MAYNE PHARMA INC	EQ 75MG BASE	A208765	001	Jun 14, 2017	May	NEWA
AB			EQ 150MG BASE	A208765	002	Jun 14, 2017	May	NEWA

DRONABINOLSOLUTION; ORAL
SYNDROS

+!	INSYS DEV CO INC	5MG/ML	N205525	001	Mar 23, 2017	Mar	NEWA
----	------------------	--------	---------	-----	--------------	-----	------

DULOXETINE HYDROCHLORIDECAPSULE, DELAYED REL PELLETS; ORAL
DULOXETINE HYDROCHLORIDE

AB		MACLEODS PHARMS LTD	EQ 20MG BASE	A204815	001	Mar 23, 2017	Mar	NEWA
AB			EQ 30MG BASE	A204815	002	Mar 23, 2017	Mar	NEWA
AB			EQ 60MG BASE	A204815	003	Mar 23, 2017	Mar	NEWA
AB		PRINSTON INC	EQ 20MG BASE	A206653	001	May 18, 2017	May	NEWA
AB			EQ 30MG BASE	A206653	002	May 18, 2017	May	NEWA
AB			EQ 60MG BASE	A206653	003	May 18, 2017	May	NEWA
AB		ZYDUS HLTHCARE	EQ 20MG BASE	A090739	001	Jan 08, 2014	Apr	CAHN
AB			EQ 30MG BASE	A090739	002	Jan 08, 2014	Apr	CAHN
AB			EQ 60MG BASE	A090739	003	Jan 08, 2014	Apr	CAHN

DUTASTERIDECAPSULE; ORAL
DUTASTERIDE

AB		AMNEAL PHARMS	0.5MG	A203118	001	Nov 20, 2015	May	CAHN
AB		MARKSANS PHARMA	0.5MG	A204376	001	Apr 07, 2017	Mar	NEWA

DYPHYLLINETABLET; ORAL
LUFYLLIN

	@	MYLAN SPECIALITY LP	200MG	A084566	001		Mar	CAHN
	@		400MG	A084566	002		Mar	CAHN

ECONAZOLE NITRATEAEROSOL, FOAM; TOPICAL
ECOZA

+!	CHEMO RESEARCH SL	1%	N205175	001	Oct 24, 2013	May	CAHN
	CREAM; TOPICAL						
	SPECTAZOLE						
+	@ ALVOGEN MALTA	1%	N018751	001	Dec 23, 1982	Mar	CMS1

EDARAVONESOLUTION; IV (INFUSION)
RADICAVA

+!	MITSUBISHI TANABE	30MG/100ML (0.3MG/ML)	N209176	001	May 05, 2017	May	NEWA
----	-------------------	-----------------------	---------	-----	--------------	-----	------

EDROPHONIUM CHLORIDEINJECTABLE; INJECTION
TENSILON

+	@ TELIGENT	10MG/ML	N007959	001		Apr	CAHN
	TENSILON PRESERVATIVE FREE						
+	@ TELIGENT	10MG/ML	N007959	002		Apr	CAHN

ELETRIPTAN HYDROBROMIDE

TABLET; ORAL

ELETRIPTAN HYDROBROMIDE

>A>	AB	TEVA PHARMS USA	EQ 20MG BASE	A202040	001	Jun 27, 2017	Jun NEWA
>A>	AB		EQ 40MG BASE	A202040	002	Jun 27, 2017	Jun NEWA
>A>	AB	ZYDUS PHARMS USA INC	EQ 20MG BASE	A206409	001	Jun 16, 2017	Jun NEWA
>A>	AB		EQ 40MG BASE	A206409	002	Jun 16, 2017	Jun NEWA
RELPAK							
>D>	+	PFIZER IRELAND	EQ 20MG BASE	N021016	001	Dec 26, 2002	Jun CFTG
>A>	AB	+	EQ 20MG BASE	N021016	001	Dec 26, 2002	Jun CFTG
>D>		+	EQ 40MG BASE	N021016	002	Dec 26, 2002	Jun CFTG
>A>	AB	+	EQ 40MG BASE	N021016	002	Dec 26, 2002	Jun CFTG

ELVITEGRAVIR

TABLET; ORAL

VITEKTA

	+	@ GILEAD SCIENCES INC	85MG	N203093	001	Sep 24, 2014	May DISC
	+	@	150MG	N203093	002	Sep 24, 2014	May DISC

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

AB		TEVA PHARMS USA	200MG;300MG	A090894	001	Jun 08, 2017	May NEWA
		TRUVADA					
AB	+	GILEAD	200MG;300MG	N021752	001	Aug 02, 2004	May CFTG

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

>D>	@	UPSHER-SMITH LABS	5MG;12.5MG	A076116	001	Sep 19, 2001	Jun CAHN
>A>	@		5MG;12.5MG	A076116	001	Sep 19, 2001	Jun CAHN
>D>	@		10MG;25MG	A076116	002	Sep 19, 2001	Jun CAHN
>A>	@		10MG;25MG	A076116	002	Sep 19, 2001	Jun CAHN

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

AP	!	ATHENEX INC	1.25MG/ML	A075634	001	Aug 22, 2000	Mar CAHN
		VASOTEC					
	+	@ BIOVAIL LABS INTL	1.25MG/ML	N019309	001	Feb 09, 1988	Mar CRLD

ENTACAPONE

TABLET; ORAL

ENTACAPONE

AB		MACLEODS PHARMS LTD	200MG	A207210	001	Jun 05, 2017	May NEWA
	@	MYLAN PHARMS INC	200MG	A202394	001	May 13, 2013	May DISC

ENTECAVIR

TABLET; ORAL

ENTECAVIR

AB		SANDOZ INC	0.5MG	A206672	001	May 11, 2017	May NEWA
AB			1MG	A206672	002	May 11, 2017	May NEWA
>A>	AB	ZYDUS PHARMS USA INC	0.5MG	A206745	001	Jun 23, 2017	Jun NEWA
>A>	AB		1MG	A206745	002	Jun 23, 2017	Jun NEWA

EPHEDRINE SULFATE

SOLUTION; INTRAVENOUS

AKOVAZ

AP	+	FLAMEL IRELAND LTD	50MG/ML (50MG/ML)	N208289	001	Apr 29, 2016	Mar CTEC
		EPHEDRINE SULFATE					
AP		AKORN INC	50MG/ML (50MG/ML)	N208609	001	Mar 01, 2017	Mar NEWA
		SOLUTION; IV (INFUSION)					
		CORPHEDRA					
		PAR STERILE PRODUCTS	50MG/ML (50MG/ML)	N208943	001	Jan 27, 2017	Jan NEWA

EPINASTINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
EPINASTINE HYDROCHLORIDE

AT	AKORN	0.05%	A204055	001	May 05, 2017	Apr NEWA
AT	SANDOZ INC	0.05%	A203384	001	Dec 07, 2016	Mar CAHN

EPINEPHRINEINJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS
ADRENALINE

>D> BX	+	AMEDRA PHARMS	EQ 0.15MG/DELIVERY	N020800	003	Nov 25, 2009	Jun CAHN
>D> BX	+		EQ 0.3MG/DELIVERY	N020800	004	Nov 25, 2009	Jun CAHN
>A> BX	+	IMPAX LABS INC	EQ 0.15MG/DELIVERY	N020800	003	Nov 25, 2009	Jun CAHN
>A> BX	+		EQ 0.3MG/DELIVERY	N020800	004	Nov 25, 2009	Jun CAHN
		TWINJECT 0.15					
>D>	@	AMEDRA PHARMS	EQ 0.15MG/DELIVERY	N020800	002	May 28, 2004	Jun CAHN
>A>	@	IMPAX LABS INC	EQ 0.15MG/DELIVERY	N020800	002	May 28, 2004	Jun CAHN
		TWINJECT 0.3					
>D>	@	AMEDRA PHARMS	EQ 0.3MG/DELIVERY	N020800	001	May 30, 2003	Jun CAHN
>A>	@	IMPAX LABS INC	EQ 0.3MG/DELIVERY	N020800	001	May 30, 2003	Jun CAHN
>A>		SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS					
>A>		SYMJEPI					
>A>	+	ADAMIS PHARMS CORP	0.3MG/ML (0.3MG/ML)	N207534	001	Jun 15, 2017	Jun NEWA

EPINEPHRINE; LIDOCAINE HYDROCHLORIDEINJECTABLE;INJECTION
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

@	BELMORA LLC	0.01MG/ML;2%	A080504	004	Oct 19, 1983	Feb CAHN
@		0.02MG/ML;2%	A080504	005	Oct 19, 1983	Feb CAHN
@	WEST-WARD PHARMS INT	0.01MG/ML;1%	A080406	001		Mar CAHN
@		0.01MG/ML;2%	A080406	002		Mar CAHN

EPLERENONETABLET;ORAL
EPLERENONE

AB	MYLAN PHARMS INC	25MG	A203896	001	Feb 02, 2017	Jan NEWA
AB		50MG	A203896	002	Feb 02, 2017	Jan NEWA

EPTIFIBATIDEINJECTABLE;INJECTION
EPTIFIBATIDE

AP	AKORN	2MG/ML	A204589	001	Apr 18, 2017	Apr NEWA
AP		75MG/100ML	A204589	002	Apr 18, 2017	Apr NEWA
AP	AMNEAL PHARMS	2MG/ML	A205581	001	Dec 08, 2016	May CAHN
AP		75MG/100ML	A205581	002	Dec 08, 2016	May CAHN

ERGOLOID MESYLATESTABLET;ORAL
ERGOLOID MESYLATES

!	SUN PHARM INDS	1MG	A081113	001	Oct 31, 1991	May CHRS
	HYDERGINE					
+	@ NOVARTIS	1MG	N017993	001		May DISC

ERYTHROMYCINGEL;TOPICAL
E-GLADES

	@	MYLAN PHARMS INC	2%	A065009	001	Mar 18, 2002	Jan CAHN
		ERYGEL					
AT	+	MYLAN PHARMS INC	2%	N050617	001	Oct 21, 1987	Jan CAHN
		ERYTHROMYCIN					
AT		PERRIGO CO	2%	A063211	001	Jan 29, 1993	Apr CAHN
		SOLUTION;TOPICAL					
		A/T/S					
	@	TARO	2%	A062405	001	Nov 18, 1982	Apr CAHN
		SWAB;TOPICAL					
		ERYTHROMYCIN					
	@	MYLAN PHARMS INC	2%	A064128	001	Jul 03, 1996	Jan CAHN
AT	!	PERRIGO CO	2%	A064126	001	Jul 03, 1996	Apr CAHN

ESCITALOPRAM OXALATE

TABLET; ORAL

ESCITALOPRAM OXALATE

AB	AMNEAL PHARMS	EQ 5MG BASE	A205619	001	May 17, 2017	May NEWA
AB		EQ 10MG BASE	A205619	002	May 17, 2017	May NEWA
AB		EQ 20MG BASE	A205619	003	May 17, 2017	May NEWA

ESOMEPRAZOLE MAGNESIUM

FOR SUSPENSION, DELAYED RELEASE; ORAL

NEXIUM

+	ASTRAZENECA PHARMS	EQ 10MG BASE/PACKET	N022101	001	Feb 27, 2008	May CRLD
---	--------------------	---------------------	---------	-----	--------------	----------

ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS

ESOMEPRAZOLE SODIUM

AP	!	AUROBINDO PHARMA LTD	EQ 20MG BASE/VIAL	A204657	001	Aug 10, 2016	May CHRS
AP	!		EQ 40MG BASE/VIAL	A204657	002	Aug 10, 2016	May CHRS
AP		DEVA HOLDING AS	EQ 40MG BASE/VIAL	A207181	001	Mar 06, 2017	Feb NEWA
AP		MYLAN LABS LTD	EQ 20MG BASE/VIAL	A202686	001	May 17, 2017	May NEWA
AP			EQ 40MG BASE/VIAL	A202686	002	May 17, 2017	May NEWA
		NEXIUM IV					
+	@	ASTRAZENECA PHARMS	EQ 20MG BASE/VIAL	N021689	001	Mar 31, 2005	May DISC
+	@		EQ 40MG BASE/VIAL	N021689	002	Mar 31, 2005	May DISC

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

ESTRADERM

+	@	NOVARTIS	0.05MG/24HR	N019081	002	Sep 10, 1986	May DISC
+	@		0.1MG/24HR	N019081	003	Sep 10, 1986	May DISC
		VIVELLE					
	@	NOVARTIS	0.05MG/24HR	N020323	002	Oct 28, 1994	May DISC
	@		0.1MG/24HR	N020323	004	Oct 28, 1994	May DISC

GEL, METERED; TRANSDERMAL

ELESTRIN

+	!	MYLAN SPECIALITY LP	0.06% (0.87GM/ACTIVATION)	N021813	001	Dec 15, 2006	Mar CAHN
		SPRAY; TRANSDERMAL					
		EVAMIST					
+	!	PERRIGO PHARMA INTL	1.53MG/SPRAY	N022014	001	Jul 27, 2007	May CAHN

ESTRADIOL ACETATE

>D>		TABLET; ORAL					
>D>		FEMTRACE					
>D>	+	APIL	0.45MG	N021633	001	Aug 20, 2004	Jun DISC
>A>	+	@	0.45MG	N021633	001	Aug 20, 2004	Jun DISC
>D>	+		0.9MG	N021633	002	Aug 20, 2004	Jun DISC
>A>	+	@	0.9MG	N021633	002	Aug 20, 2004	Jun DISC
>D>	+	!	1.8MG	N021633	003	Aug 20, 2004	Jun DISC
>A>	+	@	1.8MG	N021633	003	Aug 20, 2004	Jun DISC

ESTRADIOL VALERATE

INJECTABLE; INJECTION

ESTRADIOL VALERATE

@	SANDOZ INC	10MG/ML	A040628	001	Oct 04, 2007	Apr CAHN
@		20MG/ML	A040628	002	Oct 04, 2007	Apr CAHN
@		40MG/ML	A040628	003	Oct 04, 2007	Apr CAHN

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

ESTRADIOL AND NORETHINDRONE ACETATE

AB	MYLAN LABS LTD	0.5MG; 0.1MG	A207261	001	Feb 10, 2017	Jan NEWA
AB		1MG; 0.5MG	A207261	002	Feb 10, 2017	Jan NEWA

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET; ORAL

ENJUWIA

	TEVA BRANDED PHARM	0.3MG	N021443	001	Dec 20, 2004	Apr CAHN
		0.45MG	N021443	002	Dec 20, 2004	Apr CAHN
@		0.625MG	N021443	003	May 10, 2004	Apr CAHN
		0.9MG	N021443	005	Apr 27, 2007	Apr CAHN
@		1.25MG	N021443	004	May 10, 2004	Apr CAHN

ESTROGENS, ESTERIFIEDTABLET; ORAL
MENEST

>D>	MONARCH PHARMS	0.3MG	A084951	001		Jun	CAHN
>A>		0.3MG	A084951	001		Jun	CAHN
>D>		0.625MG	A084948	001		Jun	CAHN
>A>		0.625MG	A084948	001		Jun	CAHN
>D>		1.25MG	A084950	001		Jun	CAHN
>A>		1.25MG	A084950	001		Jun	CAHN
>D>	!	2.5MG	A084949	001		Jun	CAHN
>A>	!	2.5MG	A084949	001		Jun	CAHN

ESTRONEINJECTABLE; INJECTION
ESTRONE

@	WATSON LABS TEVA	5MG/ML	A085239	001		May	CAHN
---	------------------	--------	---------	-----	--	-----	------

ESTROPIRATETABLET; ORAL
ESTROPIRATE

@	BARR	0.75MG	A040135	001	Nov 27, 1996	May	DISC
@		1.5MG	A040135	002	Nov 27, 1996	May	DISC
@		3MG	A040135	003	Nov 27, 1996	May	DISC
!	WATSON LABS TEVA	3MG	A081215	001	Sep 23, 1993	May	CHRS
AB		3MG	A081215	001	Sep 23, 1993	Feb	CAHN
	OGEN .625						
@	PHARMACIA AND UPJOHN	0.75MG	A083220	001		May	DISC
	OGEN 1.25						
@	PHARMACIA AND UPJOHN	1.5MG	A083220	002		May	DISC
	OGEN 2.5						
@	PHARMACIA AND UPJOHN	3MG	A083220	003		May	DISC

ETELCALCETIDESOLUTION; INTRAVENOUS
PARSABIV

+	!	KAI PHARMS INC	2.5MG/0.5ML (2.5MG/0.5ML)	N208325	001	Feb 07, 2017	Feb	NEWA
+	!		5MG/ML (5MG/ML)	N208325	002	Feb 07, 2017	Feb	NEWA
+	!		10MG/2ML (5MG/ML)	N208325	003	Feb 07, 2017	Feb	NEWA

ETHACRYNIC ACIDTABLET; ORAL
ETHACRYNIC ACID

AB	WEST-WARD PHARMS INT	25MG	A207262	001	Feb 23, 2017	Feb	NEWA
----	----------------------	------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-21

ZOVIA 1/35E-21

@	WATSON PHARMS TEVA	0.035MG; 1MG	A072720	001	Dec 30, 1991	Mar	CAHN
---	--------------------	--------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

LO SIMPESSE

AB	AUROBINDO PHARMA LTD	0.02MG, 0.01MG; 0.01MG, N/A	A206852	001	Apr 28, 2017	Apr	NEWA
----	----------------------	-----------------------------	---------	-----	--------------	-----	------

SIMPESSE

AB	AUROBINDO PHARMA LTD	0.03MG, 0.01MG; 0.15MG, N/A	A206851	001	Apr 07, 2017	Mar	NEWA
----	----------------------	-----------------------------	---------	-----	--------------	-----	------

TABLET; ORAL-28

ELIFEMME

AB	LABS LEON FARMA	0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG	A202507	001	Dec 04, 2015	Feb	CAHN
----	-----------------	--	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; NORELGESTROMINFILM, EXTENDED RELEASE; TRANSDERMAL
XULANE

AB	!	MYLAN TECHNOLOGIES	0.035MG/24HR; 0.15MG/24HR	A200910	001	Apr 16, 2014	Mar	CAHN
----	---	--------------------	---------------------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

NORETHIN 1/35E-21

@	WATSON PHARMS TEVA	0.035MG; 1MG	A071480	001	Apr 12, 1988	Mar	CAHN
---	--------------------	--------------	---------	-----	--------------	-----	------

TABLET;ORAL-21

NORETHINDRONE AND ETHINYL ESTRADIOL

@ WATSON PHARMS TEVA 0.035MG;1MG

A070685 001 Jan 29, 1987 Mar CAHN

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

@ WATSON LABS TEVA 0.035MG;0.035MG;0.5MG,1MG

A071041 001 Sep 24, 1991 May CAHN

TABLET;ORAL-28

NORETHINDRONE AND ETHINYL ESTRADIOL

AB ACCORD HLTHCARE 0.035MG;1MG

A206864 001 Apr 28, 2017 Apr NEWA

AB WATSON LABS TEVA 0.035MG;1MG

A070687 001 Jan 29, 1987 May CAHN

NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)

WATSON LABS TEVA 0.035MG;0.035MG;0.5MG,1MG

A071044 001 Apr 01, 1988 May CAHN

TABLET, CHEWABLE;ORAL

NEXESTA FE

AB AUROBINDO PHARMA LTD 0.035MG;0.4MG

A207535 001 Feb 02, 2017 Jan NEWA

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB ACCORD HLTHCARE 0.035MG;0.4MG

A207066 001 Mar 29, 2017 Mar NEWA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

>A> AUROVELA 24 FE

>A> AB AUROBINDO PHARMA LTD 0.02MG;1MG

A207504 001 Jun 15, 2017 Jun NEWA

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB MYLAN LABS LTD 0.0025MG;0.5MG

A207260 001 Feb 02, 2017 Jan NEWA

TABLET;ORAL-21

>A> AUROVELA 1.5/30

>A> AB AUROBINDO PHARMA LTD 0.03MG;1.5MG

A207581 001 Jun 26, 2017 Jun NEWA

>A> AUROVELA 1/20

>A> AB AUROBINDO PHARMA LTD 0.02MG;1MG

A207506 001 Jun 16, 2017 Jun NEWA

TABLET;ORAL-28

AUROVELA FE 1.5/30

AB AUROBINDO PHARMA LTD 0.03MG;1.5MG

A207580 001 Jun 15, 2017 May NEWA

>A> AUROVELA FE 1/20

>A> AB AUROBINDO PHARMA LTD 0.02MG;1MG

A207505 001 Jun 16, 2017 Jun NEWA

ETHINYL ESTRADIOL; NORGESTREL

TABLET;ORAL-28

NORGESTREL AND ETHINYL ESTRADIOL

AB MYLAN LABS LTD 0.05MG;0.5MG

A202875 001 May 08, 2017 Apr NEWA

OGESTREL 0.5/50-28

AB ! WATSON LABS 0.05MG;0.5MG

A075406 002 Dec 15, 1999 May CTEC

ETHOSUXIMIDE

SYRUP;ORAL

ETHOSUXIMIDE

AA PHARM ASSOC 250MG/5ML

A040253 001 Nov 22, 2000 May CAHN

ZARONTIN

AA ! PARKE-DAVIS 250MG/5ML

A080258 001 Mar CAHN

ETIDRONATE DISODIUM

TABLET;ORAL

>D> DIDRONE

>D> AB + APIL 200MG

N017831 001 Jun DISC

>A> + @ 200MG

N017831 001 Jun DISC

>D> AB +! 400MG

N017831 002 Jun DISC

>A> + @ 400MG

N017831 002 Jun DISC

ETIDRONATE DISODIUM

>D> AB MYLAN 200MG

A075800 001 Jan 24, 2003 Jun CTEC

>A> 200MG

A075800 001 Jan 24, 2003 Jun CTEC

>D> AB 400MG

A075800 002 Jan 24, 2003 Jun CHRS

>A> ! 400MG

A075800 002 Jan 24, 2003 Jun CHRS

ETODOLAC

CAPSULE;ORAL

ETODOLAC

@ CHARTWELL MOLECULES 200MG

A074842 001 Jul 17, 1997 Mar CAHN

@ 300MG

A074842 002 Jul 17, 1997 Mar CAHN

@ CHARTWELL PHARMS LLC 200MG

A074842 001 Jul 17, 1997 Jan CAHN

@ 300MG

A074842 002 Jul 17, 1997 Jan CAHN

@ ECI PHARMS LLC 300MG

A074929 001 Jan 30, 1998 Apr CAHN

TABLET; ORAL

ETODOLAC

	@ CHARTWELL MOLECULES	400MG	A074841	001	Jun 27, 1997	Jan CAHN
	@ ECI PHARMS LLC	400MG	A074927	001	Oct 30, 1997	Apr CAHN
	@ MYLAN PHARMS INC	400MG	A075104	001	Feb 06, 1998	May DISC
AB		400MG	A075104	001	Feb 06, 1998	Mar CAHN
	@	500MG	A075104	002	Nov 20, 1998	May DISC
AB		500MG	A075104	002	Nov 20, 1998	Mar CAHN

ETOMIDATE

INJECTABLE; INJECTION

ETOMIDATE

AP	AUROBINDO PHARMA LTD	2MG/ML	A206126	001	Feb 24, 2017	Feb NEWA
AP	GLAND PHARMA LTD	2MG/ML	A209058	001	Apr 18, 2017	Apr NEWA
AP	MYLAN LABS LTD	2MG/ML	A201044	001	Feb 07, 2017	Jan NEWA
AP	WEST-WARD PHARMS INT	2MG/ML	A074593	001	Nov 04, 1996	Jan CAHN

EXEMESTANE

TABLET; ORAL

EXEMESTANE

AB	MYLAN PHARMS INC	25MG	A203315	001	Mar 10, 2017	Feb NEWA
----	------------------	------	---------	-----	--------------	----------

EZETIMIBE

TABLET; ORAL

EZETIMIBE

AB	AMNEAL PHARMS CO	10MG	A208803	001	Jun 12, 2017	May NEWA
AB	APOTEX INC	10MG	A208332	001	Jun 12, 2017	May NEWA
AB	OHM LABS INC	10MG	A207311	001	Jun 12, 2017	May NEWA
AB	SANDOZ INC	10MG	A203931	001	Jun 12, 2017	May NEWA
AB	TEVA PHARMS USA	10MG	A078724	001	Jun 12, 2017	May NEWA
AB	WATSON LABS INC	10MG	A200831	001	Jun 12, 2017	May NEWA
AB	ZYDUS PHARMS USA INC	10MG	A204331	001	Jun 12, 2017	May NEWA

EZETIMIBE; SIMVASTATIN

TABLET; ORAL

EZETIMIBE AND SIMVASTATIN

AB	DR REDDYS LABS INTL	10MG; 10MG	A200909	001	Apr 26, 2017	Apr NEWA
AB		10MG; 20MG	A200909	002	Apr 26, 2017	Apr NEWA
AB		10MG; 40MG	A200909	003	Apr 26, 2017	Apr NEWA
AB		10MG; 80MG	A200909	004	Apr 26, 2017	Apr NEWA
AB	DR REDDYS LABS SA	10MG; 10MG	A200909	001	Apr 26, 2017	May CAHN
AB		10MG; 20MG	A200909	002	Apr 26, 2017	May CAHN
AB		10MG; 40MG	A200909	003	Apr 26, 2017	May CAHN
AB		10MG; 80MG	A200909	004	Apr 26, 2017	May CAHN
AB	IMPAX LABS INC	10MG; 10MG	A201890	001	Apr 26, 2017	Apr NEWA
AB		10MG; 20MG	A201890	002	Apr 26, 2017	Apr NEWA
AB		10MG; 40MG	A201890	003	Apr 26, 2017	Apr NEWA
AB		10MG; 80MG	A201890	004	Apr 26, 2017	Apr NEWA
AB	WATSON LABS INC	10MG; 10MG	A202968	001	Apr 26, 2017	Apr NEWA
AB		10MG; 20MG	A202968	002	Apr 26, 2017	Apr NEWA
AB		10MG; 40MG	A202968	003	Apr 26, 2017	Apr NEWA
AB		10MG; 80MG	A202968	004	Apr 26, 2017	Apr NEWA
VYTORIN						
AB	+ MSD INTL	10MG; 10MG	N021687	001	Jul 23, 2004	Apr CFTG
AB	+	10MG; 20MG	N021687	002	Jul 23, 2004	Apr CFTG
AB	+	10MG; 40MG	N021687	003	Jul 23, 2004	Apr CFTG
AB	+!	10MG; 80MG	N021687	004	Jul 23, 2004	Apr CFTG

FAMCICLOVIR

TABLET; ORAL

FAMCICLOVIR

AB	! TEVA PHARMS	500MG	A077487	003	Aug 24, 2007	Jan CHRS
	FAMVIR					
	+ @ NOVARTIS	125MG	N020363	003	Dec 11, 1995	Jan DISC
	+ @	250MG	N020363	001	Apr 26, 1996	Jan DISC
	+ @	500MG	N020363	002	Jun 29, 1994	Jan DISC

FAMOTIDINEINJECTABLE; INJECTION
FAMOTIDINE

AP	ATHENEX INC	10MG/ML	A075651	001	Apr 16, 2001	Mar CAHN
AP		10MG/ML	A075684	001	Apr 16, 2001	Mar CAHN
	FAMOTIDINE PRESERVATIVE FREE					
AP	ATHENEX INC	10MG/ML	A075622	001	Apr 16, 2001	Mar CAHN
AP		10MG/ML	A075825	001	Apr 17, 2001	Mar CAHN

TABLET; ORAL
FAMOTIDINE

AB	PERRIGO R AND D	20MG	A077352	002	Jul 27, 2005	Apr CAHN
AB		40MG	A077352	001	Jul 27, 2005	Apr CAHN

FELBAMATESUSPENSION; ORAL
FELBAMATE

>A>	AB	TARO PHARM	600MG/5ML	A206314	001	Jun 16, 2017	Jun NEWA
		FELBATOL					
	AB	+! MYLAN SPECIALITY LP	600MG/5ML	N020189	003	Jul 29, 1993	Mar CAHN
		TABLET; ORAL					
		FELBAMATE					
	AB	IMPAX LABS INC	400MG	A202284	001	Nov 04, 2015	Feb CAHN
	AB		600MG	A202284	002	Nov 04, 2015	Feb CAHN
	AB	TARO PHARM	400MG	A207093	001	Apr 20, 2017	Apr NEWA
	AB		600MG	A207093	002	Apr 20, 2017	Apr NEWA
	AB	ZYDUS PHARMS USA INC	400MG	A208970	001	May 30, 2017	May NEWA
	AB		600MG	A208970	002	May 30, 2017	May NEWA
		FELBATOL					
	AB	+ MYLAN SPECIALITY LP	400MG	N020189	001	Jul 29, 1993	Mar CAHN
	AB	+!	600MG	N020189	002	Jul 29, 1993	Mar CAHN

FENOFIBRATECAPSULE; ORAL
FENOFIBRATE (MICRONIZED)

	AB	GLENMARK PHARMS LTD	67MG	A205566	001	Apr 07, 2017	Mar NEWA
	AB		134MG	A205566	002	Apr 07, 2017	Mar NEWA
	AB		200MG	A205566	003	Apr 07, 2017	Mar NEWA
>D>	AB	IMPAX LABS	200MG	A075868	003	Oct 27, 2003	Jun CHRS
>A>	AB	!	200MG	A075868	003	Oct 27, 2003	Jun CHRS
	AB	INVAGEN PHARMS	67MG	A207378	001	Mar 28, 2017	Mar NEWA
	AB		134MG	A207378	002	Mar 28, 2017	Mar NEWA
	AB		200MG	A207378	003	Mar 28, 2017	Mar NEWA
>D>	AB	! RHODES PHARMS	200MG	A075753	003	Apr 09, 2002	Jun CHRS
>A>	AB		200MG	A075753	003	Apr 09, 2002	Jun CHRS
		TABLET; ORAL					
		FENOFIBRATE					
	AB	! IMPAX LABS	160MG	A076509	002	Mar 26, 2008	Mar CHRS
	AB	RHODES PHARMS	160MG	A076433	002	May 13, 2005	Mar CHRS

FENOLDOPAM MESYLATEINJECTABLE; INJECTION
FENOLDOPAM MESYLATE

AP	SANDOZ INC	EQ 10MG BASE/ML	A077155	001	Feb 15, 2005	Mar CAHN
----	------------	-----------------	---------	-----	--------------	----------

FENOPROFEN CALCIUMTABLET; ORAL
FENOPROFEN CALCIUM

	@ WATSON LABS TEVA	EQ 600MG BASE	A072407	001	Aug 17, 1988	May CAHN
--	--------------------	---------------	---------	-----	--------------	----------

FENTANYLFILM, EXTENDED RELEASE; TRANSDERMAL
FENTANYL-100

AB	3M DRUG DELIVERY	100MCG/HR	A202097	005	Nov 04, 2016	Mar CAHN
AB	ACTAVIS LABS UT INC	100MCG/HR	A076709	004	Aug 20, 2007	Mar CAHN
AB	MAYNE PHARMA	100MCG/HR	A077062	004	Aug 20, 2007	Mar CAHN

FENTANYL-12

AB	3M DRUG DELIVERY	12.5MCG/HR	A202097	001	Nov 04, 2016	Mar CAHN
----	------------------	------------	---------	-----	--------------	----------

FENTANYL-25

AB	3M DRUG DELIVERY	25MCG/HR	A202097	002	Nov 04, 2016	Mar CAHN
AB	ACTAVIS LABS UT INC	25MCG/HR	A076709	001	Aug 20, 2007	Mar CAHN
AB	MAYNE PHARMA	25MCG/HR	A077062	001	Aug 20, 2007	Mar CAHN

FILM, EXTENDED RELEASE;TRANSDERMAL
FENTANYL-50

AB	3M DRUG DELIVERY	50MCG/HR	A202097	003	Nov 04, 2016	Mar CAHN
AB	ACTAVIS LABS UT INC	50MCG/HR	A076709	002	Aug 20, 2007	Mar CAHN
AB	MAYNE PHARMA	50MCG/HR	A077062	002	Aug 20, 2007	Mar CAHN

FENTANYL-75

AB	3M DRUG DELIVERY	75MCG/HR	A202097	004	Nov 04, 2016	Mar CAHN
AB	ACTAVIS LABS UT INC	75MCG/HR	A076709	003	Aug 20, 2007	Mar CAHN
AB	MAYNE PHARMA	75MCG/HR	A077062	003	Aug 20, 2007	Mar CAHN

SPRAY;SUBLINGUAL
SUBSYS

+	INSYS DEV CO INC	0.1MG	N202788	001	Jan 04, 2012	May CAHN
+		0.2MG	N202788	002	Jan 04, 2012	May CAHN
+	!	0.4MG	N202788	003	Jan 04, 2012	May CAHN
+		0.6MG	N202788	004	Jan 04, 2012	May CAHN
+		0.8MG	N202788	005	Jan 04, 2012	May CAHN
+		1.2MG	N202788	006	Aug 30, 2012	May CAHN
+		1.6MG	N202788	007	Aug 30, 2012	May CAHN

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

FESOTERODINE FUMARATE

AB	AUROBINDO PHARMA LTD	4MG	A205007	001	Feb 17, 2017	Feb NEWA
AB		8MG	A205007	002	Feb 17, 2017	Feb NEWA

FINASTERIDE

TABLET;ORAL

FINASTERIDE

AB	ACCORD HLTHCARE	1MG	A091643	001	Nov 05, 2013	Mar CAHN
AB	ACTAVIS TOTOWA TEVA	5MG	A077914	001	Mar 28, 2007	May CAHN

FLUCONAZOLE

FOR SUSPENSION;ORAL

FLUCONAZOLE

AB	AUROBINDO PHARMA LTD	50MG/5ML	A079150	001	Sep 18, 2009	Jan CAHN
AB		200MG/5ML	A079150	002	Sep 18, 2009	Jan CAHN

INJECTABLE;INJECTION

DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER

+	@ PFIZER	200MG/100ML (2MG/ML)	N019950	003	Sep 29, 1992	Mar DISC
+	@	400MG/200ML (2MG/ML)	N019950	005	Jul 08, 1994	Mar DISC

DIFLUCAN IN SODIUM CHLORIDE 0.9%

+	@ PFIZER	200MG/100ML (2MG/ML)	N019950	001	Jan 29, 1990	Mar DISC
+	@	400MG/200ML (2MG/ML)	N019950	006	Jan 29, 1990	Mar DISC

DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+	@ PFIZER	200MG/100ML (2MG/ML)	N019950	002	Jan 29, 1990	Mar DISC
+	@	400MG/200ML (2MG/ML)	N019950	004	Jan 29, 1990	Mar DISC

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	!	HOSPIRA	200MG/100ML (2MG/ML)	A076304	001	Jul 29, 2004	Mar CHRS
AP	!		400MG/200ML (2MG/ML)	A076304	002	Jul 29, 2004	Mar CHRS

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

		WEST-WARD PHARMS INT	100MG/50ML (2MG/ML)	A076087	002	Sep 26, 2008	Jan CAHN
AP			200MG/100ML (2MG/ML)	A076087	001	Jul 29, 2004	Jan CAHN
AP			400MG/200ML (2MG/ML)	A076087	003	Jul 29, 2004	Jan CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	!	ACS DOBFAR INFO SA	200MG/100ML (2MG/ML)	A079104	001	Jul 30, 2009	Mar CHRS
AP	!		400MG/200ML (2MG/ML)	A079104	002	Jul 30, 2009	Mar CHRS
AP		WEST-WARD PHARMS INT	200MG/100ML (2MG/ML)	A078107	001	Jul 30, 2008	Jan CAHN
AP			400MG/200ML (2MG/ML)	A078107	002	Jul 30, 2008	Jan CAHN

TABLET;ORAL

FLUCONAZOLE

AB	UNIQUE PHARM LABS	150MG	A076957	004	Feb 27, 2017	Feb NEWA
AB	ZYDUS PHARMS USA INC	50MG	A208963	001	Feb 16, 2017	Feb NEWA
AB		100MG	A208963	002	Feb 16, 2017	Feb NEWA
AB		150MG	A208963	003	Feb 16, 2017	Feb NEWA
AB		200MG	A208963	004	Feb 16, 2017	Feb NEWA

FLUCYTOSINE

CAPSULE;ORAL

FLUCYTOSINE

>A>	AB	NOVEL LABS INC	250MG	A204652	001	Jul 07, 2017	Jun NEWA
>A>	AB		500MG	A204652	002	Jul 07, 2017	Jun NEWA

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION
FLUDARABINE PHOSPHATE

AP	ACTAVIS LLC	50MG/2ML (25MG/ML)	A203738	001	Feb 28, 2017	Feb NEWA
----	-------------	--------------------	---------	-----	--------------	----------

FLUMAZENIL

INJECTABLE; INJECTION
FLUMAZENIL

AP	SANDOZ INC	0.5MG/5ML (0.1MG/ML)	A077071	001	May 03, 2005	Apr CAHN
AP		1MG/10ML (0.1MG/ML)	A077071	002	May 03, 2005	Apr CAHN
AP	WEST-WARD PHARMS INT	0.5MG/5ML (0.1MG/ML)	A076256	002	Oct 12, 2004	Jan CAHN
AP		0.5MG/5ML (0.1MG/ML)	A076787	002	Oct 12, 2004	Jan CAHN
AP		1MG/10ML (0.1MG/ML)	A076256	001	Oct 12, 2004	Jan CAHN
AP		1MG/10ML (0.1MG/ML)	A076787	001	Oct 12, 2004	Jan CAHN

FLUNISOLIDE

AEROSOL, METERED; INHALATION
AEROSPAN HFA

+	MYLAN SPECIALITY LP	0.078MG/INH	N021247	001	Jan 27, 2006	Mar CAHN
---	---------------------	-------------	---------	-----	--------------	----------

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL
FLUOCINOLONE ACETONIDE

AT	FOUGERA PHARMS INC	0.01%	A088170	001	Dec 16, 1982	Jan CAHN
AT		0.025%	A088169	001	Dec 16, 1982	Jan CAHN
	@ TARO	0.01%	A040035	001	Oct 31, 1994	Apr CAHN
	@	0.025%	A040042	001	Oct 31, 1994	Apr CAHN

OINTMENT; TOPICAL
FLUOCINOLONE ACETONIDE

AT	FOUGERA PHARMS INC	0.025%	A088168	001	Dec 16, 1982	Jan CAHN
AT	TARO	0.025%	A040041	001	Sep 15, 1994	Apr CAHN

SOLUTION; TOPICAL
FLUOCINOLONE ACETONIDE

AT	FOUGERA PHARMS INC	0.01%	A088167	001	Dec 16, 1982	Jan CAHN
----	--------------------	-------	---------	-----	--------------	----------

FLUOCINONIDE

CREAM; TOPICAL
FLUOCINONIDE

AB1	FOUGERA PHARMS INC	0.05%	A073030	001	Oct 17, 1994	Jan CAHN
AB	PERRIGO ISRAEL	0.1%	A090256	001	Jan 14, 2014	Apr CAHN
AB1	TARO	0.05%	A071500	001	Jun 10, 1987	Mar CMFD

FLUOCINONIDE EMULSIFIED BASE

AB2	G AND W LABS INC	0.05%	A074204	001	Jun 13, 1995	May CMFD
-----	------------------	-------	---------	-----	--------------	----------

GEL; TOPICAL
FLUOCINONIDE

AB	FOUGERA PHARMS INC	0.05%	A072933	001	Dec 30, 1994	Jan CAHN
AB	! TARO	0.05%	A074935	001	Jul 29, 1997	Apr CAHN

OINTMENT; TOPICAL
FLUOCINONIDE

AB	! TARO	0.05%	A075008	001	Jun 30, 1999	Apr CAHN
----	--------	-------	---------	-----	--------------	----------

SOLUTION; TOPICAL
FLUOCINONIDE

AT	! TARO	0.05%	A074799	001	Dec 31, 1996	Apr CAHN
	LIDEX					

AT	+ CNTY LINE PHARMS	0.05%	N018849	001	Apr 06, 1984	Mar CRLD
----	--------------------	-------	---------	-----	--------------	----------

FLUOROURACIL

CREAM; TOPICAL
FLUOROURACIL

>A>	AB	MYLAN PHARMS INC	0.5%	A203122	001	Apr 20, 2015	Jun CAHN
>D>	AB	SPEAR PHARMS INC	0.5%	A203122	001	Apr 20, 2015	Jun CAHN

INJECTABLE; INJECTION
FLUOROURACIL

AP	SAGENT PHARMS	500MG/10ML (50MG/ML)	A203608	001	May 11, 2017	May NEWA
AP		1GM/20ML (50MG/ML)	A203608	002	May 11, 2017	May NEWA
	+ @ SPECTRUM PHARMS	500MG/10ML (50MG/ML)	N012209	001		Jan CRLD

SOLUTION; TOPICAL
FLUOROURACIL

AT	TARO PHARM	2%	A076526	001	Nov 05, 2003	Mar CAHN
AT		5%	A076526	002	Nov 05, 2003	Mar CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE HYDROCHLORIDE

>D>	AB1	MYLAN	EQ 10MG BASE	A075207	001	Jan 30, 2002	Jun DISC
>A>		@	EQ 10MG BASE	A075207	001	Jan 30, 2002	Jun DISC
>D>	AB1		EQ 20MG BASE	A075207	002	Jan 30, 2002	Jun DISC
>A>		@	EQ 20MG BASE	A075207	002	Jan 30, 2002	Jun DISC
>D>	AB		EQ 40MG BASE	A075207	003	May 25, 2007	Jun DISC
>A>		@	EQ 40MG BASE	A075207	003	May 25, 2007	Jun DISC

SOLUTION;ORAL

FLUOXETINE HYDROCHLORIDE

AA		AUROBINDO PHARMA LTD	EQ 20MG BASE/5ML	A079209	001	Mar 20, 2009	Jan CAHN
AA	!	PHARM ASSOC	EQ 20MG BASE/5ML	A076015	001	Jan 30, 2002	May CAHN

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

AB		ALEMBIC PHARMS LTD	EQ 10MG BASE	A208698	001	Apr 05, 2017	Mar NEWA
AB			EQ 20MG BASE	A208698	002	Apr 05, 2017	Mar NEWA
	+	ALVOGEN	EQ 60MG BASE	N202133	001	Oct 06, 2011	Jan CAHN

FLUOXYMESTERONE

TABLET;ORAL

FLUOXYMESTERONE

>D>	!	USL PHARMA	10MG	A088342	001	Oct 21, 1983	Jun CAHN
>A>	!		10MG	A088342	001	Oct 21, 1983	Jun CAHN

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE;ORAL

FLUPHENAZINE HYDROCHLORIDE

	@	ANI PHARMS INC	5MG/ML	A073058	001	Aug 30, 1991	Jan CAHN
	!	PHARM ASSOC	5MG/ML	A074725	001	Sep 16, 1996	May CAHN

ELIXIR;ORAL

FLUPHENAZINE HYDROCHLORIDE

	!	PHARM ASSOC	2.5MG/5ML	A040146	001	Aug 21, 1996	May CAHN
--	---	-------------	-----------	---------	-----	--------------	----------

FLURANDRENOLIDE

CREAM;TOPICAL

FLURANDRENOLIDE

>A>	AT	CINTEX SVCS	0.05%	A205342	001	Apr 13, 2016	Jun CAHN
>D>	AT	TELIGENT PHARMA INC	0.05%	A205342	001	Apr 13, 2016	Jun CAHN

LOTION;TOPICAL

FLURANDRENOLIDE

>A>	AT	CINTEX SVCS	0.05%	A205343	001	Dec 22, 2016	Jun CAHN
>D>	AT	TELIGENT PHARMA INC	0.05%	A205343	001	Dec 22, 2016	Jun CAHN

FLURAZEPAM HYDROCHLORIDE

CAPSULE;ORAL

FLURAZEPAM HYDROCHLORIDE

	@	AUROLIFE PHARMA LLC	15MG	A071717	002	Jul 31, 1991	Jan CMS1
--	---	---------------------	------	---------	-----	--------------	----------

FLUTAMIDE

CAPSULE;ORAL

FLUTAMIDE

>D>	AB	MYLAN	125MG	A076224	001	May 09, 2003	Jun DISC
>A>		@	125MG	A076224	001	May 09, 2003	Jun DISC

FLUTICASONE PROPIONATE

POWDER;INHALATION

ARMONAIR RESPICLICK

+	TEVA PHARM	0.055MG/INH	N208798	001	Jan 27, 2017	Jan NEWA
+		0.113MG/INH	N208798	002	Jan 27, 2017	Jan NEWA
+	!	0.232MG/INH	N208798	003	Jan 27, 2017	Jan NEWA

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

POWDER;INHALATION

AIRDUO RESPICLICK

+	TEVA PHARM	0.055MG/INH;EQ 0.014MG BASE/INH	N208799	001	Jan 27, 2017	Jan NEWA
+		0.113MG/INH;EQ 0.014MG BASE/INH	N208799	002	Jan 27, 2017	Jan NEWA
+	!	0.232MG/INH;EQ 0.014MG BASE/INH	N208799	003	Jan 27, 2017	Jan NEWA

FLUVASTATIN SODIUM

CAPSULE;ORAL

FLUVASTATIN SODIUM

AB	!	MYLAN PHARMS INC	EQ 40MG BASE	A090595	002	Apr 11, 2012	May CHRS
		LESCOL					
	+	@ NOVARTIS	EQ 20MG BASE	N020261	001	Dec 31, 1993	May DISC
	+	@	EQ 40MG BASE	N020261	002	Dec 31, 1993	May DISC

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL

FLUVOXAMINE MALEATE

AB	!	ACTAVIS ELIZABETH	150MG	A091482	002	Nov 18, 2013	Apr CHRS
		LUVOX CR					
	+	@ JAZZ PHARMS	100MG	N022033	001	Feb 28, 2008	Apr DISC
	+	@	150MG	N022033	002	Feb 28, 2008	Apr DISC

TABLET;ORAL

FLUVOXAMINE MALEATE

	@	ECI PHARMS LLC	25MG	A075900	001	Feb 23, 2006	May CAHN
	@		50MG	A075900	002	Feb 23, 2006	May CAHN
	@		100MG	A075900	003	Feb 23, 2006	May CAHN
>D>	@	UPSHER-SMITH LABS	25MG	A075887	001	Jan 05, 2001	Jun CAHN
>A>	@		25MG	A075887	001	Jan 05, 2001	Jun CAHN
>D> AB			25MG	A075888	001	Nov 29, 2000	Jun CAHN
>A> AB			25MG	A075888	001	Nov 29, 2000	Jun CAHN
>D>	@		50MG	A075887	002	Jan 05, 2001	Jun CAHN
>A>	@		50MG	A075887	002	Jan 05, 2001	Jun CAHN
>D> AB			50MG	A075888	002	Nov 29, 2000	Jun CAHN
>A> AB			50MG	A075888	002	Nov 29, 2000	Jun CAHN
>D>	@		100MG	A075887	003	Jan 05, 2001	Jun CAHN
>A>	@		100MG	A075887	003	Jan 05, 2001	Jun CAHN
>D> AB	!		100MG	A075888	003	Nov 29, 2000	Jun CAHN
>A> AB	!		100MG	A075888	003	Nov 29, 2000	Jun CAHN

FOLIC ACID

TABLET;ORAL

FOLIC ACID

	@	CONTRACT PHARMACAL	1MG	A085061	001		Mar DISC
--	---	--------------------	-----	---------	-----	--	----------

FORMOTEROL FUMARATE

POWDER; INHALATION

FORADIL

	+	@ NOVARTIS	0.012MG/INH	N020831	001	Feb 16, 2001	Feb DISC
--	---	------------	-------------	---------	-----	--------------	----------

FORMOTEROL FUMARATE; GLYCOPYRROLATE

AEROSOL, METERED; INHALATION

BEVESPI AEROSPHERE

	+	!	ASTRAZENECA PHARMS	0.0048MG/INH;0.0090MG/INH	N208294	001	Apr 25, 2016	Mar CAHN
--	---	---	--------------------	---------------------------	---------	-----	--------------	----------

FOSINOPRIL SODIUM

TABLET;ORAL

FOSINOPRIL SODIUM

>D>	@	UPSHER-SMITH LABS	10MG	A076188	001	Oct 08, 2004	Jun CAHN
>A>	@		10MG	A076188	001	Oct 08, 2004	Jun CAHN
>D> AB			10MG	A076483	001	Apr 23, 2004	Jun CAHN
>A> AB			10MG	A076483	001	Apr 23, 2004	Jun CAHN
>D>	@		20MG	A076188	002	Oct 08, 2004	Jun CAHN
>A>	@		20MG	A076188	002	Oct 08, 2004	Jun CAHN
>D> AB			20MG	A076483	002	Apr 23, 2004	Jun CAHN
>A> AB			20MG	A076483	002	Apr 23, 2004	Jun CAHN
>D>	@		40MG	A076188	003	Oct 08, 2004	Jun CAHN
>A>	@		40MG	A076188	003	Oct 08, 2004	Jun CAHN
>D> AB			40MG	A076483	003	Apr 23, 2004	Jun CAHN
>A> AB			40MG	A076483	003	Apr 23, 2004	Jun CAHN

MONOPRIL

	+	@	BRISTOL MYERS SQUIBB	10MG	N019915	002	May 16, 1991	Jan CRLD
	+	@		20MG	N019915	003	May 16, 1991	Jan CRLD
	+	@		40MG	N019915	004	Mar 28, 1995	Jan CRLD

FOSPHENYTOIN SODIUMINJECTABLE;INJECTION
FOSPHENYTOIN SODIUM

>D>	@ FRESenius KABI USA	EQ 50MG PHENYTOIN NA/ML	A078052	001	Aug 06, 2007	Jun CMFD	
>A>	AP	EQ 50MG PHENYTOIN NA/ML	A078052	001	Aug 06, 2007	Jun CMFD	
	@ HOSPIRA	EQ 50MG PHENYTOIN NA/ML	A078158	001	Aug 06, 2007	Mar DISC	
	AP	WEST-WARD PHARMS INT	EQ 50MG PHENYTOIN NA/ML	A077481	001	Aug 06, 2007	Jan CAHN
	AP	EQ 50MG PHENYTOIN NA/ML	A077989	001	Aug 06, 2007	Jan CAHN	

FUROSEMIDEINJECTABLE;INJECTION
FUROSEMIDE

>A>	@ ACCORD HLTHCARE	10MG/ML	A070017	001	Dec 15, 1986	Jun CAHN
>D>	@ ORGANON USA INC	10MG/ML	A070017	001	Dec 15, 1986	Jun CAHN

TABLET;ORAL
FUROSEMIDE

BX	IPCA LABS LTD	20MG	A078010	001	Sep 18, 2006	Apr CTEC
BX		40MG	A078010	002	Sep 18, 2006	Apr CTEC
BX		80MG	A078010	003	Sep 18, 2006	Apr CTEC
AB	PRINSTON INC	20MG	A076796	001	Mar 26, 2004	Feb CAHN
AB		40MG	A076796	002	Mar 26, 2004	Feb CAHN
AB		80MG	A076796	003	Mar 26, 2004	Feb CAHN
	@ SUN PHARM INDS INC	20MG	A091258	001	Apr 01, 2014	May DISC
	@	40MG	A091258	002	Apr 01, 2014	May DISC
	@	80MG	A091258	003	Apr 01, 2014	May DISC
	@ WATSON LABS TEVA	20MG	A070449	001	Nov 22, 1985	May CAHN
	@	80MG	A070528	001	Jan 07, 1986	May CAHN
AB	WEST-WARD PHARMS INT	20MG	N018823	001	Nov 10, 1983	Jan CAHN
AB		40MG	N018823	002	Nov 10, 1983	Jan CAHN

GABAPENTINCAPSULE;ORAL
GABAPENTIN

AB	AUROBINDO PHARMA LTD	100MG	A078787	001	Jan 31, 2008	Jan CAHN
AB		300MG	A078787	002	Jan 31, 2008	Jan CAHN
AB		400MG	A078787	003	Jan 31, 2008	Jan CAHN
AB	EPIC PHARMA LLC	100MG	A207099	001	Mar 24, 2017	Mar NEWA
AB		300MG	A207099	002	Mar 24, 2017	Mar NEWA
AB		400MG	A207099	003	Mar 24, 2017	Mar NEWA

TABLET;ORAL
GABAPENTIN

AB	GLENMARK PHARMS LTD	600MG	A077662	001	Aug 18, 2006	May CAHN
AB		800MG	A077662	002	Aug 18, 2006	May CAHN
AB	TEVA PHARMS USA	600MG	A205807	001	Mar 10, 2017	Feb NEWA
AB		800MG	A205807	002	Mar 10, 2017	Feb NEWA

GANCICLOVIRSOLUTION;IV (INFUSION)
GANCICLOVIR

+	EXELA PHARMA SCS LLC	500MG/250ML (2MG/ML)	N209347	001	Feb 17, 2017	Feb NEWA
---	----------------------	----------------------	---------	-----	--------------	----------

GATIFLOXACINSOLUTION/DROPS;OPHTHALMIC
GATIFLOXACIN

AT	SANDOZ INC	0.5%	A204227	001	Jul 11, 2016	Feb CAHN
----	------------	------	---------	-----	--------------	----------

GEMCITABINE HYDROCHLORIDEINJECTABLE;INJECTION
GEMCITABINE HYDROCHLORIDE

AP	APOTEX INC	200MG/5.26ML (38MG/ML)	A206776	001	May 23, 2017	May NEWA
AP		1GM/26.3ML (38MG/ML)	A206776	002	May 23, 2017	May NEWA
AP		2GM/52.6ML (38MG/ML)	A206776	003	May 23, 2017	May NEWA

GEMFIBROZILTABLET;ORAL
GEMFIBROZIL

AB	CARIBE HOLDINGS	600MG	A078012	001	Mar 26, 2007	Jan CAHN
----	-----------------	-------	---------	-----	--------------	----------

GEMIFLOXACIN MESYLATETABLET; ORAL
FACTIVE

AB	+!	LG CHEM LTD	EQ 320MG BASE	N021158	001	Apr 04, 2003	Mar CAHN
----	----	-------------	---------------	---------	-----	--------------	----------

GENTAMICIN SULFATECREAM; TOPICAL
GENTAMICIN SULFATE

	@	FOUGERA PHARMS INC	EQ 0.1% BASE	A062531	001	Jul 05, 1984	Jan DISC
AT	!	PERRIGO NEW YORK	EQ 0.1% BASE	A062307	001		Jan CHRS
	@	TARO	EQ 0.1% BASE	A062427	001	May 26, 1983	Jan DISC

OINTMENT; TOPICAL
GENTAMICIN SULFATE

AT		FOUGERA PHARMS INC	EQ 0.1% BASE	A062533	001	Oct 05, 1984	Jan CAHN
----	--	--------------------	--------------	---------	-----	--------------	----------

SOLUTION/DROPS; OPHTHALMIC
GENTAMICIN SULFATE

AT		SANDOZ INC	EQ 0.3% BASE	A062196	001		Mar CAHN
----	--	------------	--------------	---------	-----	--	----------

GLIMEPIRIDETABLET; ORAL
GLIMEPIRIDE

	@	EPIC PHARMA LLC	1MG	A077274	001	Oct 06, 2005	May CAHN
	@		2MG	A077274	002	Oct 06, 2005	May CAHN
	@		4MG	A077274	003	Oct 06, 2005	May CAHN
AB		PRINSTON INC	1MG	A077370	001	Dec 23, 2005	Feb CAHN
AB			2MG	A077370	002	Dec 23, 2005	Feb CAHN
AB			4MG	A077370	003	Dec 23, 2005	Feb CAHN
AB			8MG	A077370	004	Dec 23, 2005	Feb CAHN

GLIPIZIDETABLET; ORAL
GLIPIZIDE

AB		WATSON LABS TEVA	5MG	A074223	001	Feb 27, 1995	May CAHN
AB			10MG	A074223	002	Feb 27, 1995	May CAHN

TABLET, EXTENDED RELEASE; ORAL
GLIPIZIDE

AB		AUROBINDO PHARMA LTD	2.5MG	A206928	001	May 12, 2017	May NEWA
AB			5MG	A206928	002	May 12, 2017	May NEWA
AB			10MG	A206928	003	May 12, 2017	May NEWA

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

AB		EPIC PHARMA LLC	2.5MG; 250MG	A077507	001	Oct 27, 2005	May CAHN
AB			2.5MG; 500MG	A077507	002	Oct 27, 2005	May CAHN
AB			5MG; 500MG	A077507	003	Oct 27, 2005	May CAHN

METAGLIP

	+ @	BRISTOL MYERS SQUIBB	2.5MG; 250MG	N021460	001	Oct 21, 2002	Jan CRLD
	+ @		2.5MG; 500MG	N021460	002	Oct 21, 2002	Jan CRLD
	+ @		5MG; 500MG	N021460	003	Oct 21, 2002	Jan CRLD

GLUTETHIMIDETABLET; ORAL
GLUTETHIMIDE

>D>	@	UPSHER-SMITH LABS	500MG	A083234	002		Jun CAHN
>A>	@		500MG	A083234	002		Jun CAHN

GLYBURIDETABLET; ORAL
GLYBURIDE

AB1		EPIC PHARMA LLC	1.25MG	A076257	001	Jun 27, 2002	May CAHN
AB1			2.5MG	A076257	002	Jun 27, 2002	May CAHN
AB1			5MG	A076257	003	Jun 27, 2002	May CAHN
AB2		IMPAX LABS INC	1.25MG	A206079	001	Sep 30, 2015	Feb CAHN
AB2			2.5MG	A206079	002	Sep 30, 2015	Feb CAHN
AB2			5MG	A206079	003	Sep 30, 2015	Feb CAHN

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

@ IMPAX LABS INC 1.25MG; 250MG
 @ 2.5MG; 500MG
 @ 5MG; 500MG

A076731 001 Nov 19, 2004 Feb CAHN
 A076731 002 Nov 19, 2004 Feb CAHN
 A076731 003 Nov 19, 2004 Feb CAHN

GLYCINE

SOLUTION; IRRIGATION

GLYCINE 1.5% IN PLASTIC CONTAINER

AT ICU MEDICAL INC 1.5GM/100ML

N018315 001 Feb CAHN

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

>A> AP AMNEAL PHARMS CO 0.2MG/ML
 >A> AP SOMERSET THERAPS LLC 0.2MG/ML

A208973 001 Jun 15, 2017 Jun NEWA
 A207639 001 Jun 23, 2017 Jun NEWA

POWDER; INHALATION

SEEBRI

+! SUNOVION PHARMS INC 15.6MCG/INH

N207923 001 Oct 29, 2015 Jan CAHN

TABLET; ORAL

GLYCOPYRROLATE

@ EPIC PHARMA LLC 1MG
 @ 2MG
 AA SANTOS BIOTECH 1MG
 AA 2MG

A040568 001 Dec 22, 2004 May CAHN
 A040568 002 Dec 22, 2004 May CAHN
 A091182 001 Feb 03, 2014 May CAHN
 A091182 002 Feb 03, 2014 May CAHN

GLYCOPYRROLATE ; INDACATEROL MALEATE

POWDER; INHALATION

UTIBRON

+! SUNOVION PHARMS INC 15.6MCG/INH; 27.5MCG/INH

N207930 001 Oct 29, 2015 Jan CAHN

GONADORELIN HYDROCHLORIDE

INJECTABLE; INJECTION

FACTREL

@ WEST-WARD PHARMS INT EQ 0.1MG BASE/VIAL
 @ EQ 0.2MG BASE/VIAL
 @ EQ 0.5MG BASE/VIAL

N018123 001 Sep 30, 1982 Mar CAHN
 N018123 002 Sep 30, 1982 Mar CAHN
 N018123 003 Sep 30, 1982 Mar CAHN

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION

CHORIONIC GONADOTROPIN

+! FERRING 5,000 UNITS/VIAL

N017016 006 Jan CMFD

GOSERELIN ACETATE

IMPLANT; IMPLANTATION

ZOLADEX

+! TERSERA THERAPS LLC EQ 3.6MG BASE
 +! EQ 10.8MG BASE

N019726 001 Dec 29, 1989 May CAHN
 N020578 001 Jan 11, 1996 May CAHN

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

AT AMRING PHARMS 0.025MG/ML; EQ 1.75MG
BASE/ML; 10,000 UNITS/ML

A065187 001 Oct 28, 2005 Mar CAHN

NEOSPORIN

AT ! MONARCH PHARMS 0.025MG/ML; EQ 1.75MG
BASE/ML; 10,000 UNITS/ML

A060582 001 Apr CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

AP MYLAN LABS LTD EQ 0.1MG BASE/ML (EQ 0.1MG
BASE/ML)
 AP EQ 1MG BASE/ML (EQ 1MG BASE/ML)
 AP EQ 4MG BASE/4ML (EQ 1MG BASE/ML)
 AP SANDOZ INC EQ 0.1MG BASE/ML (EQ 0.1MG
BASE/ML)
 AP EQ 1MG BASE/ML (EQ 1MG BASE/ML)
 AP EQ 4MG BASE/4ML (EQ 1MG BASE/ML)
 AP WEST-WARD PHARMS INT EQ 0.1MG BASE/ML (EQ 0.1MG
BASE/ML)

A203454 001 Apr 04, 2017 Mar NEWA
 A203454 002 Apr 04, 2017 Mar NEWA
 A203453 001 Jan 31, 2017 Jan NEWA
 A078534 001 Apr 30, 2009 Mar CAHN
 A078531 001 Apr 30, 2009 Mar CAHN
 A078531 002 Apr 30, 2009 Mar CAHN
 A077913 001 Jun 26, 2008 Jan CAHN

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077186	001	Jun 30, 2008	Jan CAHN
AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077187	001	Jun 30, 2008	Jan CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077177	001	Dec 31, 2007	Jan CAHN

TABLET; ORAL

GRANISETRON HYDROCHLORIDE

	@ EPIC PHARMA LLC	EQ 1MG BASE	A078260	001	Dec 31, 2007	May CAHN
AB	TARO PHARM	EQ 1MG BASE	A090817	001	May 28, 2010	Mar CAHN

GRISEOFULVIN, MICROSIZE

SUSPENSION; ORAL

GRISEOFULVIN

>A>	AB	CHARTWELL RX	125MG/5ML	A065200	001	Mar 02, 2005	Jun CAHN
>D>	AB	PERRIGO CO TENNESSEE	125MG/5ML	A065200	001	Mar 02, 2005	Jun CAHN

HALOBETASOL PROPIONATE

CREAM; TOPICAL

HALOBETASOL PROPIONATE

AB	!	G AND W LABS	0.05%	A078162	001	Apr 24, 2007	Apr CHRS
		ULTRAVATE					
AB	+	SUN PHARM INDS LTD	0.05%	N019967	001	Dec 27, 1990	Apr CHRS
AB	+	!	0.05%	N019967	001	Dec 27, 1990	Mar CAHN

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

>D>	AB	G AND W LABS	0.05%	A077721	001	Sep 07, 2006	Jun CHRS
>A>	AB	!	0.05%	A077721	001	Sep 07, 2006	Jun CHRS
	AB	PERRIGO ISRAEL	0.05%	A076872	001	Dec 16, 2004	Apr CAHN
		ULTRAVATE					
>D>	AB	+	!	RANBAXY	0.05%	N019968	001
>A>	AB	+	0.05%	N019968	001	Dec 17, 1990	Jun CHRS
				N019968	001	Dec 17, 1990	Jun CHRS

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

	@ FRONTIDA BIOPHARM	20MG	A071177	001	Jan 07, 1988	Feb CAHN
--	---------------------	------	---------	-----	--------------	----------

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

AO		GLAND PHARMA LTD	EQ 50MG BASE/ML	A205241	001	May 12, 2017	May NEWA
AO			EQ 100MG BASE/ML	A205241	002	May 12, 2017	May NEWA
	@ SANDOZ INC		EQ 50MG BASE/ML	A076463	001	Jun 24, 2005	Mar CAHN
	@		EQ 100MG BASE/ML	A076463	002	Jun 24, 2005	Mar CAHN

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALOPERIDOL

AA		PHARM ASSOC	EQ 2MG BASE/ML	A073037	001	Feb 26, 1993	May CAHN
----	--	-------------	----------------	---------	-----	--------------	----------

INJECTABLE; INJECTION

HALOPERIDOL

	@ SANDOZ INC	EQ 5MG BASE/ML	A076464	001	Sep 29, 2004	Mar CAHN
--	--------------	----------------	---------	-----	--------------	----------

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

AP		GLAND PHARMA LTD	5,000 UNITS/ML	A205323	001	Feb 06, 2017	Jan NEWA
----	--	------------------	----------------	---------	-----	--------------	----------

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA		ABHAI LLC	1.5MG/5ML; 5MG/5ML	A207487	001	Feb 21, 2017	Feb NEWA
AA		BIO-PHARM INC	1.5MG/5ML; 5MG/5ML	A204765	001	Mar 06, 2017	Feb NEWA
AA		NOVEL LABS INC	1.5MG/5ML; 5MG/5ML	A203535	001	Feb 13, 2017	Jan NEWA
AA		PADDOCK LLC	1.5MG/5ML; 5MG/5ML	A205731	001	Feb 15, 2017	Jan NEWA

TABLET; ORAL

TUSSIGON

AA	!	KING PHARMS	1.5MG; 5MG	A088508	001	Jul 30, 1985	Feb CAHN
----	---	-------------	------------	---------	-----	--------------	----------

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

AA	SCIEGEN PHARMS INC	10MG	A205236	001	May 26, 2017	May NEWA
AA		25MG	A205236	002	May 26, 2017	May NEWA
AA		50MG	A205236	003	May 26, 2017	May NEWA
AA		100MG	A205236	004	May 26, 2017	May NEWA
>D>	@ UPSHER-SMITH LABS	10MG	A083241	001		Jun CAHN
>A>	@	10MG	A083241	001		Jun CAHN
>D>	@	25MG	A083560	001		Jun CAHN
>A>	@	25MG	A083560	001		Jun CAHN
>D>	@	50MG	A083561	001		Jun CAHN
>A>	@	50MG	A083561	001		Jun CAHN

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

AB	PRINSTON INC	12.5MG	A075907	001	Sep 17, 2002	Feb CAHN
AB	PRINSTON INC	25MG	A040412	001	Mar 29, 2002	Feb CAHN
AB		50MG	A040412	002	Mar 29, 2002	Feb CAHN
	@ WATSON LABS TEVA	50MG	A083232	001		May CAHN

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB	ATLAS PHARMS LLC	12.5MG;150MG	A203036	001	Jan 15, 2016	Mar CAHN
AB		12.5MG;300MG	A203036	002	Jan 15, 2016	Mar CAHN
AB		25MG;300MG	A203036	003	Jan 15, 2016	Mar CAHN
AB	WEST-WARD PHARMS INT	25MG;300MG	A090351	003	Jun 08, 2017	May NEWA

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

AB	INVAGEN PHARMS	12.5MG;10MG	A204058	001	May 23, 2017	May NEWA
AB		12.5MG;20MG	A204058	002	May 23, 2017	May NEWA
AB		25MG;20MG	A204058	003	May 23, 2017	May NEWA
	PRINZIDE					
+	@ MERCK	12.5MG;10MG	N019778	003	Nov 18, 1993	Jan CRLD
+	@	12.5MG;20MG	N019778	001	Feb 16, 1989	Jan CRLD

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

	@ CHARTWELL RX	12.5MG;7.5MG	A090096	001	Sep 25, 2008	Mar CAHN
	@	12.5MG;15MG	A090096	002	Sep 25, 2008	Mar CAHN
	@	25MG;15MG	A090096	003	Sep 25, 2008	Mar CAHN
AB	HERITAGE PHARMS INC	12.5MG;7.5MG	A202150	001	Mar 07, 2014	Jan CMS1
AB		12.5MG;15MG	A202150	002	Mar 07, 2014	Jan CMS1
AB		25MG;15MG	A202150	003	Mar 07, 2014	Jan CMS1

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC PHARMS LTD	12.5MG;20MG	A204233	001	Apr 24, 2017	Apr NEWA
AB		12.5MG;40MG	A204233	002	Apr 24, 2017	Apr NEWA
AB		25MG;40MG	A204233	003	Apr 24, 2017	Apr NEWA
AB	AUROBINDO PHARMA LTD	12.5MG;20MG	A205391	001	Apr 24, 2017	Apr NEWA
AB		12.5MG;40MG	A205391	002	Apr 24, 2017	Apr NEWA
AB		25MG;40MG	A205391	003	Apr 24, 2017	Apr NEWA
AB	PRINSTON INC	12.5MG;20MG	A207804	001	Apr 24, 2017	Apr NEWA
AB		12.5MG;40MG	A207804	002	Apr 24, 2017	Apr NEWA
AB		25MG;40MG	A207804	003	Apr 24, 2017	Apr NEWA
AB	TEVA PHARMS USA	12.5MG;20MG	A200532	001	Apr 24, 2017	Apr NEWA
AB		12.5MG;40MG	A200532	002	Apr 24, 2017	Apr NEWA
AB		25MG;40MG	A200532	003	Apr 24, 2017	Apr NEWA
AB	TORRENT PHARMS LTD	12.5MG;20MG	A206515	001	May 03, 2017	Apr NEWA
AB		12.5MG;40MG	A206515	002	May 03, 2017	Apr NEWA
AB		25MG;40MG	A206515	003	May 03, 2017	Apr NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

>D>	AB	INVAGEN PHARMS	12.5MG;10MG	A201356	001	Apr 20, 2011	Jun CMS1
>A>	AB		12.5MG;EQ 10MG BASE	A201356	001	Apr 20, 2011	Jun CMS1
>D>	AB		12.5MG;20MG	A201356	002	Apr 20, 2011	Jun CMS1
>A>	AB		12.5MG;EQ 20MG BASE	A201356	002	Apr 20, 2011	Jun CMS1
>D>	AB		25MG;20MG	A201356	003	Apr 20, 2011	Jun CMS1
>A>	AB		25MG;EQ 20MG BASE	A201356	003	Apr 20, 2011	Jun CMS1
>D>	AB	SUN PHARM INDS LTD	12.5MG;EQ 10MG BASE	A078211	001	Mar 04, 2009	Jun DISC
>A>	@		12.5MG;EQ 10MG BASE	A078211	001	Mar 04, 2009	Jun DISC
>D>	AB		12.5MG;EQ 20MG BASE	A078211	002	Mar 04, 2009	Jun DISC
>A>	@		12.5MG;EQ 20MG BASE	A078211	002	Mar 04, 2009	Jun DISC
>D>	AB		25MG;EQ 20MG BASE	A078211	003	Mar 04, 2009	Jun DISC
>A>	@		25MG;EQ 20MG BASE	A078211	003	Mar 04, 2009	Jun DISC

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE

>D>	@	UPSHER SMITH	25MG;25MG	A087553	001		Jun CAHN
>A>	@		25MG;25MG	A087553	001		Jun CAHN

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

AB		ALEMBIC PHARMS LTD	12.5MG;80MG	A201662	001	Mar 21, 2013	May CAHN
AB			12.5MG;160MG	A201662	002	Mar 21, 2013	May CAHN
AB			12.5MG;320MG	A201662	003	Mar 21, 2013	May CAHN
AB			25MG;160MG	A201662	004	Mar 21, 2013	May CAHN
AB			25MG;320MG	A201662	005	Mar 21, 2013	May CAHN
AB		WATSON LABS TEVA	12.5MG;80MG	A091519	001	Mar 21, 2013	May CAHN
AB			12.5MG;160MG	A091519	002	Mar 21, 2013	May CAHN
AB			12.5MG;320MG	A091519	003	Mar 21, 2013	May CAHN
AB			25MG;160MG	A091519	004	Mar 21, 2013	May CAHN
AB			25MG;320MG	A091519	005	Mar 21, 2013	May CAHN

HYDROCODONE BITARTRATE

TABLET, EXTENDED RELEASE; ORAL

VANTRELA ER

+	TEVA BRANDED PHARM	15MG	N207975	001	Jan 17, 2017	Jan NEWA
+		30MG	N207975	002	Jan 17, 2017	Jan NEWA
+		45MG	N207975	003	Jan 17, 2017	Jan NEWA
+		60MG	N207975	004	Jan 17, 2017	Jan NEWA
+		90MG	N207975	005	Jan 17, 2017	Jan NEWA

HYDROCORTISONE

CREAM; TOPICAL

HYDROCORTISONE

AT	!	FOUGERA PHARMS INC	1%	A080693	003		Jan CAHN
AT	!		2.5%	A089414	001	Dec 16, 1986	Jan CAHN

LOTION; TOPICAL

STIE-CORT

	@	PERRIGO CO	1%	A089066	001	Nov 25, 1985	Apr CAHN
AT			2.5%	A089074	001	Nov 26, 1985	Apr CAHN

OINTMENT; TOPICAL

HYDROCORTISONE

AT	!	FOUGERA PHARMS INC	2.5%	A081203	001	May 28, 1993	Jan CAHN
		HYDROCORTISONE IN ABSORBASE					
AT		CMP PHARMA INC	1%	A088138	001	Sep 06, 1985	Apr CAHN

TABLET; ORAL

HYDROCORTISONE

AB		PII	5MG	A207029	001	Apr 27, 2017	Apr NEWA
AB			10MG	A207029	002	Apr 27, 2017	Apr NEWA
AB			20MG	A207029	003	Apr 27, 2017	Apr NEWA

HYDROCORTISONE ACETATE

AEROSOL, METERED; RECTAL

CORTIFOAM

+	!	MYLAN SPECIALITY LP	10%	N017351	001	Feb 10, 1982	Mar CAHN
---	---	---------------------	-----	---------	-----	--------------	----------

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATECREAM;TOPICAL
CORTISPORIN

+	!	MONARCH PHARMS	0.5%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050218	001	Aug 09, 1985	Feb CAHN
---	---	----------------	---------------------------------------	---------	-----	--------------	----------

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDEAEROSOL, METERED;TOPICAL
EPIFOAM

BX		MYLAN SPECIALITY LP	1%;1%	A086457	001		Mar CAHN
----	--	---------------------	-------	---------	-----	--	----------

BX		MYLAN SPECIALITY LP	1%;1%	A086195	001		Mar CAHN
----	--	---------------------	-------	---------	-----	--	----------

HYDROCORTISONE VALERATECREAM;TOPICAL
HYDROCORTISONE VALERATE

AB	!	TARO	0.2%	A075042	001	Aug 25, 1998	Apr CAHN
----	---	------	------	---------	-----	--------------	----------

OINTMENT;TOPICAL
HYDROCORTISONE VALERATE

	!	TARO	0.2%	A075043	001	Aug 25, 1998	Apr CAHN
--	---	------	------	---------	-----	--------------	----------

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATESOLUTION/DROPS;OTIC
CORTISPORIN

AT	+	!	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050479	001	Apr CAHN
----	---	---	----------------	-------------------------------------	---------	-----	----------

AT			NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE AMRING PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A065216	001	Oct 31, 2005	Mar CAHN
----	--	--	--	-------------------------------------	---------	-----	--------------	----------

AT			SANDOZ INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062423	001	Aug 25, 1983	Feb CAHN
----	--	--	------------	-------------------------------------	---------	-----	--------------	----------

SUSPENSION/DROPS;OPHTHALMIC
CORTISPORIN

	@		MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050169	001		Apr CAHN
--	---	--	----------------	-------------------------------------	---------	-----	--	----------

	!		SANDOZ INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062874	001	May 11, 1988	Feb CAHN
--	---	--	------------	-------------------------------------	---------	-----	--------------	----------

SUSPENSION/DROPS;OTIC

AT			NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE AMRING PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A065219	001	May 01, 2006	Mar CAHN
----	--	--	--	-------------------------------------	---------	-----	--------------	----------

AT			SANDOZ INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062488	001	Nov 06, 1985	Feb CAHN
----	--	--	------------	-------------------------------------	---------	-----	--------------	----------

PEDIOTIC

	@		MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062822	001	Sep 29, 1987	Apr CAHN
--	---	--	----------------	-------------------------------------	---------	-----	--------------	----------

HYDROMORPHONE HYDROCHLORIDEINJECTABLE;INJECTION
DILAUDID

AP	+	!	FRESENIUS KABI USA	1MG/ML	N019034	003	Apr 30, 2009	Jan CAHN
----	---	---	--------------------	--------	---------	-----	--------------	----------

AP	+	!		2MG/ML	N019034	004	Apr 30, 2009	Jan CAHN
----	---	---	--	--------	---------	-----	--------------	----------

AP	+	!		4MG/ML	N019034	005	Apr 30, 2009	Jan CAHN
----	---	---	--	--------	---------	-----	--------------	----------

DILAUDID-HP

AP	+	!	FRESENIUS KABI USA	10MG/ML	N019034	001	Jan 11, 1984	Jan CAHN
----	---	---	--------------------	---------	---------	-----	--------------	----------

SOLUTION;ORAL
DILAUDID

>D>	AA	+	!	PURDUE PHARM PRODS	5MG/5ML	N019891	001	Dec 07, 1992	Jun CAHN
-----	----	---	---	--------------------	---------	---------	-----	--------------	----------

>A>	AA	+	!	RHODES PHARMS	5MG/5ML	N019891	001	Dec 07, 1992	Jun CAHN
-----	----	---	---	---------------	---------	---------	-----	--------------	----------

TABLET;ORAL
DILAUDID

>D>	AB	+		PURDUE PHARM PRODS	2MG	N019892	003	Nov 09, 2007	Jun CAHN
-----	----	---	--	--------------------	-----	---------	-----	--------------	----------

>D>	AB	+			4MG	N019892	002	Nov 09, 2007	Jun CAHN
-----	----	---	--	--	-----	---------	-----	--------------	----------

	AB	+			4MG	N019892	002	Nov 09, 2007	May CAHN
--	----	---	--	--	-----	---------	-----	--------------	----------

>D>	AB	+	!		8MG	N019892	001	Dec 07, 1992	Jun CAHN
-----	----	---	---	--	-----	---------	-----	--------------	----------

	AB	+	!		8MG	N019892	001	Dec 07, 1992	May CAHN
--	----	---	---	--	-----	---------	-----	--------------	----------

>A>	AB	+		RHODES PHARMS	2MG	N019892	003	Nov 09, 2007	Jun CAHN
-----	----	---	--	---------------	-----	---------	-----	--------------	----------

>A>	AB	+			4MG	N019892	002	Nov 09, 2007	Jun CAHN
-----	----	---	--	--	-----	---------	-----	--------------	----------

>A>	AB	+	!		8MG	N019892	001	Dec 07, 1992	Jun CAHN
-----	----	---	---	--	-----	---------	-----	--------------	----------

HYDROXOCOBALAMININJECTABLE; INJECTION
HYDROXOCOBALAMIN

! ACTAVIS LLC 1MG/ML A085998 001 Feb CAHN

HYDROXYZINE HYDROCHLORIDEINJECTABLE; INJECTION
VISTARIL

+ @ PFIZER 25MG/ML N011111 001 Jan CRLD

+ @ 50MG/ML N011111 002 Jan CRLD

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

@ AUROLIFE PHARMA LLC 10MG A087871 002 Dec 20, 1982 Jan CMS1

@ 25MG A087871 003 Dec 20, 1982 Jan CMS1

AB NUVO PHARM INC 10MG A207120 001 Mar 29, 2017 Mar NEWA

AB 25MG A207121 001 Mar 29, 2017 Mar NEWA

AB 50MG A207122 001 Mar 29, 2017 Mar NEWA

AB PRINSTON INC 10MG A040579 001 May 27, 2005 Feb CAHN

AB 25MG A040574 001 May 27, 2005 Feb CAHN

AB 50MG A040580 001 May 27, 2005 Feb CAHN

@ SUN PHARM INDS INC 10MG A040899 001 Jun 10, 2008 Apr DISC

@ 25MG A040899 002 Jun 10, 2008 Apr DISC

@ 50MG A040899 003 Jun 10, 2008 Apr DISC

IBANDRONATE SODIUM

TABLET; ORAL

IBANDRONATE SODIUM

AB @ MYLAN PHARMS INC EQ 150MG BASE A078995 001 Mar 19, 2012 May DISC

WATSON LABS TEVA EQ 150MG BASE A079003 001 Mar 20, 2012 May CAHN

IBUPROFEN

SUSPENSION; ORAL

IBUPROFEN

>A> AB ! ACTAVIS MID ATLANTIC 100MG/5ML A074978 001 Mar 25, 1998 May CAHN

AB TARO 100MG/5ML A209204 001 Jun 23, 2017 Jun NEWA

MOTRIN

+ @ MCNEIL CONSUMER 100MG/5ML N019842 001 Sep 19, 1989 Jan CRLD

TABLET; ORAL

IBUPROFEN

@ MYLAN PHARMS INC 400MG A070045 001 Sep 24, 1985 Mar CAHN

IBUPROFEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

>D> OXYCODONE HYDROCHLORIDE AND IBUPROFEN

>D> BX WATSON LABS 400MG; 5MG A078394 001 Nov 26, 2007 Jun DISC

>A> @ 400MG; 5MG A078394 001 Nov 26, 2007 Jun DISC

BX 400MG; 5MG A078394 001 Nov 26, 2007 Apr CTEC

ICOSAPENT ETHYL

CAPSULE; ORAL

VASCEPA

+ AMARIN PHARMS 500MG N202057 002 Feb 16, 2017 Mar NEWA

IFOSFAMIDE; MESNA

INJECTABLE; INTRAVENOUS

IFOSFAMIDE/MESNA KIT

@ TEVA PHARMS USA 1GM/20ML; 1GM/10ML A075874 001 Feb 26, 2002 Mar DISC

(50MG/ML; 100MG/ML)

@ 3GM/60ML; 1GM/10ML A075874 002 Feb 26, 2002 Mar DISC

(50MG/ML; 100MG/ML)

IMATINIB MESYLATE

TABLET; ORAL

IMATINIB MESYLATE

>A> AB MYLAN PHARMS INC EQ 100MG BASE A204644 001 Jun 21, 2017 Jun NEWA

>A> AB EQ 400MG BASE A204644 002 Jun 21, 2017 Jun NEWA

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

OXFORD PHARMS

10MG

A040751 003 Feb 28, 2008 May CMS1

25MG

A040751 002 Feb 28, 2008 May CMS1

IMIPRAMINE PAMOATE

CAPSULE; ORAL

IMIPRAMINE PAMOATE

>D> AB MYLAN PHARMS INC

EQ 75MG HCL

A202338 001 Jun 28, 2013 Jun DISC

>A>

@

EQ 75MG HCL

A202338 001 Jun 28, 2013 Jun DISC

>D> AB

EQ 100MG HCL

A202338 002 Jun 28, 2013 Jun DISC

>A>

@

EQ 100MG HCL

A202338 002 Jun 28, 2013 Jun DISC

>D> AB

EQ 125MG HCL

A202338 003 Jun 28, 2013 Jun DISC

>A>

@

EQ 125MG HCL

A202338 003 Jun 28, 2013 Jun DISC

>D> AB

EQ 150MG HCL

A202338 004 Jun 28, 2013 Jun DISC

>A>

@

EQ 150MG HCL

A202338 004 Jun 28, 2013 Jun DISC

INDACATEROL MALEATE

POWDER; INHALATION

ARCAPTA NEOHALER

+! SUNOVION PHARMS INC EQ 75MCG BASE

N022383 001 Jul 01, 2011 Jan CAHN

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN

@ CHARTWELL MOLECULES

25MG

N018829 002 Aug 06, 1984 Feb CAHN

@

50MG

A070651 001 Mar 05, 1986 Apr CAHN

@

50MG

N018829 001 Aug 06, 1984 Feb CAHN

CAPSULE, EXTENDED RELEASE; ORAL

INDOMETHACIN

>A> AB CHARTWELL RX

75MG

A200529 001 Nov 30, 2010 Jun CAHN

>A> AB

GLENMARK PHARMS LTD

75MG

A203501 001 Jun 22, 2017 Jun NEWA

AB

NOVAST LABS LTD

75MG

A204853 001 May 08, 2017 Apr NEWA

>D> AB

PADDOCK LLC

75MG

A200529 001 Nov 30, 2010 Jun CAHN

@ WATSON LABS INC

75MG

A202572 001 Dec 09, 2013 Feb DISC

IOPAMIDOL

INJECTABLE; INJECTION

SCANLUX-300

AP MYLAN IRELAND LTD

61%

A090394 001 Jun 18, 2010 Jan CAHN

AP SANOCHEMIA CORP USA

61%

A090394 001 Jun 18, 2010 Feb CAHN

SCANLUX-370

AP MYLAN IRELAND LTD

76%

A090394 002 Jun 18, 2010 Jan CAHN

AP SANOCHEMIA CORP USA

76%

A090394 002 Jun 18, 2010 Feb CAHN

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

AP INGENUS PHARMS LLC 40MG/2ML (20MG/ML)

A206935 001 May 26, 2017 May NEWA

AP 100MG/5ML (20MG/ML)

A206935 002 May 26, 2017 May NEWA

AP WEST-WARD PHARMS INT 40MG/2ML (20MG/ML)

A078753 001 Dec 24, 2008 Jan CAHN

AP 100MG/5ML (20MG/ML)

A078753 002 Dec 24, 2008 Jan CAHN

INJECTABLE, LIPOSOMAL; IV (INFUSION)

ONIVYDE

+! IPSEN INC EQ 43MG BASE/10ML (EQ 4.3MG
BASE/ML)

N207793 001 Oct 22, 2015 Apr CAHN

ISONIAZID

INJECTABLE; INJECTION

ISONIAZID

! SANDOZ INC 100MG/ML

A040648 001 Jul 05, 2005 Mar CAHN

SYRUP; ORAL

ISONIAZID

! CMP PHARMA INC 50MG/5ML

A088235 001 Nov 10, 1983 Apr CAHN

ISOSORBIDE DINITRATE

TABLET;SUBLINGUAL

ISOSORBIDE DINITRATE

@ WATSON LABS TEVA 5MG

A086031 001 Sep 29, 1987 May CAHN

TABLET, EXTENDED RELEASE;ORAL

ISOSORBIDE DINITRATE

@ IMPAX LABS INC 40MG

A040723 001 Mar 17, 2008 Feb CAHN

ISRADIPINE

CAPSULE;ORAL

ISRADIPINE

AB WATSON LABS TEVA 2.5MG

A077317 001 Jan 05, 2006 May CAHN

AB ! 5MG

A077317 002 Jan 05, 2006 May CAHN

ITRACONAZOLE

CAPSULE;ORAL

ITRACONAZOLE

AB ALKEM LABS LTD 100MG

A208591 001 Jun 12, 2017 May NEWA

AB JUBILANT GENERICS 100MG

A203445 001 Feb 23, 2017 Feb NEWA

KANAMYCIN SULFATE

INJECTABLE;INJECTION

KANAMYCIN

@ WEST-WARD PHARMS INT EQ 75MG BASE/2ML

A062324 001 Jan CAHN

@ EQ 500MG BASE/2ML

A062324 002 Jan CAHN

@ EQ 1GM BASE/3ML

A062324 003 Jan CAHN

KETOCONAZOLE

AEROSOL, FOAM;TOPICAL

EXTINA

AT +! MYLAN PHARMS INC 2%

N021738 001 Jun 12, 2007 Jan CAHN

CREAM;TOPICAL

NIZORAL

+ @ JANSSEN PHARMA 2%

N019084 001 Dec 31, 1985 May CRLD

KETOPROFEN

CAPSULE;ORAL

KETOPROFEN

AB HERITAGE PHARMS INC 25MG

A074014 001 Jan 29, 1993 Feb CAHN

AB 50MG

A074014 002 Jan 29, 1993 Feb CAHN

AB 75MG

A074014 003 Jan 29, 1993 Feb CAHN

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION

KETOROLAC TROMETHAMINE

@ SANDOZ INC 15MG/ML

A076271 001 Oct 06, 2004 Mar CAHN

AP 30MG/ML

A076271 002 Oct 06, 2004 Mar CAHN

SOLUTION/DROPS;OPHTHALMIC

KETOROLAC TROMETHAMINE

AT SANDOZ INC 0.5%

A076583 001 Nov 05, 2009 Feb CAHN

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION

LABETALOL HYDROCHLORIDE

AP SAGENT AGILA LLC 5MG/ML

A079134 001 Feb 03, 2010 Feb CAHN

LACOSAMIDE

TABLET;ORAL

LACOSAMIDE

AB AMNEAL PHARMS 50MG

A204857 001 Sep 09, 2016 May CAHN

AB 100MG

A204857 002 Sep 09, 2016 May CAHN

AB 150MG

A204857 003 Sep 09, 2016 May CAHN

AB 200MG

A204857 004 Sep 09, 2016 May CAHN

LACTULOSE

SOLUTION;ORAL

LACTULOSE

AA PHARM ASSOC 10GM/15ML

A074623 001 Jul 30, 1996 May CAHN

LAMIVUDINE

TABLET; ORAL
LAMIVUDINE

AB	CIPLA LTD	150MG	A077221	001	Mar 03, 2017	Feb NEWA
AB		300MG	A077221	002	Mar 03, 2017	Feb NEWA

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL
LAMIVUDINE AND ZIDOVUDINE

AB	AUROBINDO PHARMA LTD	150MG;300MG	A077558	001	May 05, 2017	Apr NEWA
BX	PHARMACARE	150MG;300MG	N022018	001	Mar 17, 2017	Mar NEWA

LAMOTRIGINE

TABLET; ORAL
LAMOTRIGINE

	@ MYLAN LABS LTD	25MG	A078443	001	Feb 11, 2009	Mar CAHN
	@	100MG	A078443	002	Feb 11, 2009	Mar CAHN
	@	150MG	A078443	003	Feb 11, 2009	Mar CAHN
	@	200MG	A078443	004	Feb 11, 2009	Mar CAHN

TABLET, CHEWABLE; ORAL

LAMOTRIGINE

AB	GLENMARK PHARMS LTD	5MG	A079099	001	Feb 19, 2009	May CAHN
AB		25MG	A079099	002	Feb 19, 2009	May CAHN
>D> AB	MYLAN	5MG	A076630	001	Jan 22, 2009	Jun DISC
>A>	@	5MG	A076630	001	Jan 22, 2009	Jun DISC
>D> AB		25MG	A076630	002	Jan 22, 2009	Jun DISC
>A>	@	25MG	A076630	002	Jan 22, 2009	Jun DISC

TABLET, EXTENDED RELEASE; ORAL

LAMOTRIGINE

AB	ACTAVIS ELIZABETH	250MG	A203733	001	Nov 13, 2013	Apr CAHN
AB	HANDA PHARMS LLC	25MG	A202887	001	Jun 17, 2013	Jan CAHN
AB		50MG	A202887	002	Jun 17, 2013	Jan CAHN
AB		100MG	A202887	003	Jun 17, 2013	Jan CAHN
AB		200MG	A202887	004	Jun 17, 2013	Jan CAHN

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC

LATANOPROST

AT	AMRING PHARMS	0.005%	A200925	001	Mar 22, 2011	Mar CAHN
AT	SANDOZ INC	0.005%	A091449	001	Mar 22, 2011	Feb CAHN

LETROZOLE

TABLET; ORAL
LETROZOLE

>D> AB	KREMERS URBAN PHARMS	2.5MG	A091098	001	Jun 03, 2011	Jun DISC
>A>	@	2.5MG	A091098	001	Jun 03, 2011	Jun DISC
>D> AB	LANNETT HOLDINGS INC	2.5MG	A202048	001	Oct 29, 2014	Jun DISC
>A>	@	2.5MG	A202048	001	Oct 29, 2014	Jun DISC

LETROZOLE; RIBOCICLIB SUCCINATE

TABLET, TABLET; ORAL

KISQALI FEMARA CO-PACK (COPACKAGED)

+!	NOVARTIS PHARMS CORP	2.5MG,N/A;N/A,EQ 200MG BASE	N209935	001	May 04, 2017	May NEWA
----	----------------------	-----------------------------	---------	-----	--------------	----------

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM PRESERVATIVE FREE

AP	MYLAN LABS LTD	EQ 100MG BASE/VIAL	A203800	001	May 19, 2017	May NEWA
AP		EQ 200MG BASE/VIAL	A203800	002	May 19, 2017	May NEWA
AP		EQ 350MG BASE/VIAL	A203800	003	May 19, 2017	May NEWA

TABLET; ORAL

LEUCOVORIN CALCIUM

	@ EPIC PHARMA LLC	EQ 5MG BASE	A074544	001	Aug 28, 1997	May CAHN
	@	EQ 25MG BASE	A074544	002	Aug 28, 1997	May CAHN

WELLCOVORIN

>D>	@ GLAXOSMITHKLINE	EQ 5MG BASE	N018342	001	Jul 08, 1983	Jun CRLD
>A>	+ @	EQ 5MG BASE	N018342	001	Jul 08, 1983	Jun CRLD
>D>	@	EQ 25MG BASE	N018342	002	Jul 08, 1983	Jun CRLD
>A>	+ @	EQ 25MG BASE	N018342	002	Jul 08, 1983	Jun CRLD

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

AN	AUROBINDO PHARMA LTD	EQ 0.25% BASE	A207628	001	Jan 31, 2017	Jan NEWA
----	----------------------	---------------	---------	-----	--------------	----------

LEVETIRACETAM

SOLUTION; ORAL

LEVETIRACETAM

AA	ALLIED PHARMA INC	100MG/ML	A078582	001	Jan 15, 2009	Mar CAHN
AA	AUROBINDO PHARMA LTD	100MG/ML	A079063	001	Jan 15, 2009	Jan CAHN

TABLET; ORAL

LEVETIRACETAM

>A>	AB	ACI HEALTHCARE LTD	250MG	A078042	001	Jan 15, 2009	Jun CAHN
>A>	AB		500MG	A078042	002	Jan 15, 2009	Jun CAHN
>A>	AB		750MG	A078042	003	Jan 15, 2009	Jun CAHN
>A>	AB		1GM	A078042	004	Jan 15, 2009	Jun CAHN
>D>	AB	ALLIED PHARMA INC	250MG	A078042	001	Jan 15, 2009	Jun CAHN
	AB		250MG	A078042	001	Jan 15, 2009	Mar CAHN
>D>	AB		500MG	A078042	002	Jan 15, 2009	Jun CAHN
	AB		500MG	A078042	002	Jan 15, 2009	Mar CAHN
>D>	AB		750MG	A078042	003	Jan 15, 2009	Jun CAHN
	AB		750MG	A078042	003	Jan 15, 2009	Mar CAHN
>D>	AB		1GM	A078042	004	Jan 15, 2009	Jun CAHN
	AB		1GM	A078042	004	Jan 15, 2009	Mar CAHN

ROWEEPRA

AB	LOTUS PHARM CO LTD	250MG	A090906	002	Oct 31, 2016	Apr NEWA
AB		500MG	A090906	001	Nov 05, 2010	Apr CTNA
AB		750MG	A090906	003	Oct 31, 2016	Apr NEWA
AB		1GM	A090906	004	Oct 31, 2016	Apr NEWA

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

AB	ECI PHARMS LLC	500MG	A204754	001	Aug 26, 2016	Mar CAHN
AB		750MG	A204754	002	Aug 26, 2016	Mar CAHN
	@ MYLAN PHARMS INC	500MG	A200475	001	Dec 19, 2011	Apr DISC
	@	750MG	A200475	002	Dec 19, 2011	Apr DISC
	@	1GM	A200475	003	Dec 07, 2015	Apr DISC
AB	PRINSTON INC	500MG	A202533	001	Jul 20, 2012	Feb CAHN
AB		750MG	A202533	002	Jul 20, 2012	Feb CAHN
AB	VIRTUS PHARMS	500MG	A091291	001	Sep 12, 2011	Feb CAHN
AB		750MG	A091291	002	Sep 12, 2011	Feb CAHN

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

LEVOBUNOLOL HYDROCHLORIDE

	@ ALCON LABS INC	0.25%	A074851	001	Oct 28, 1996	Feb DISC
AT	SANDOZ INC	0.5%	A074850	001	Oct 28, 1996	Feb CAHN

LEVOCARNITINE

INJECTABLE; INJECTION

CARNITOR

AP	+! LEADIANT BIOSCI INC	200MG/ML	N020182	001	Dec 16, 1992	Mar CAHN
----	------------------------	----------	---------	-----	--------------	----------

SOLUTION; ORAL

CARNITOR

	@ LEADIANT BIOSCI INC	1GM/10ML	N018948	002	Apr 27, 1988	Mar CAHN
AA	+!	1GM/10ML	N019257	001	Apr 10, 1986	Mar CAHN

CARNITOR SF

AA	+ LEADIANT BIOSCI INC	1GM/10ML	N019257	002	Mar 28, 2007	Mar CAHN
----	-----------------------	----------	---------	-----	--------------	----------

TABLET; ORAL

CARNITOR

AB	+! LEADIANT BIOSCI INC	330MG	N018948	001	Dec 27, 1985	Mar CAHN
----	------------------------	-------	---------	-----	--------------	----------

LEVOCARNITINE

AB	IMPAX LABS INC	330MG	A076858	001	Sep 20, 2004	Feb CAHN
----	----------------	-------	---------	-----	--------------	----------

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AA	SILARX PHARMS INC	2.5MG/ML	A204599	001	May 15, 2017	May NEWA
----	-------------------	----------	---------	-----	--------------	----------

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB	ALLIED PHARMA INC	5MG	A204323	001	Dec 20, 2016	Apr CAHN
----	-------------------	-----	---------	-----	--------------	----------

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER

+ @	JANSSEN PHARMS	EQ 250MG/50ML (EQ 5MG/ML)	N020635	002	Dec 20, 1996	Jan CRLD
+ @		EQ 500MG/100ML (EQ 5MG/ML)	N020635	003	Dec 20, 1996	Jan CRLD
+ @		EQ 750MG/150ML (EQ 5MG/ML)	N020635	005	Dec 20, 1996	Jan CRLD

LEVOFLOXACIN

>A>	AP	SAGENT AGILA LLC	EQ 500MG/20ML (EQ 25MG/ML)	A200560	001	Jun 20, 2011	Jun CAHN
>A>	AP		EQ 750MG/30ML (EQ 25MG/ML)	A200560	002	Jun 20, 2011	Jun CAHN
>D>	AP	SAGENT PHARMS	EQ 500MG/20ML (EQ 25MG/ML)	A200560	001	Jun 20, 2011	Jun CAHN
>D>	AP		EQ 750MG/30ML (EQ 25MG/ML)	A200560	002	Jun 20, 2011	Jun CAHN
	AP	ZYDUS PHARMS USA INC	EQ 500MG/20ML (EQ 25MG/ML)	A205968	001	Jun 01, 2017	May NEWA
	AP		EQ 750MG/30ML (EQ 25MG/ML)	A205968	002	Jun 01, 2017	May NEWA

SOLUTION/DROPS; OPHTHALMIC

LEVOFLOXACIN

AT		WATSON LABS TEVA	0.5%	A076826	001	Feb 10, 2011	Feb CAHN
----	--	------------------	------	---------	-----	--------------	----------

TABLET; ORAL

LEVOFLOXACIN

>D>	AB	MYLAN	750MG	A077097	001	Jun 20, 2011	Jun DISC
>A>		@	750MG	A077097	001	Jun 20, 2011	Jun DISC

LEVOLEUCOVORIN CALCIUM

POWDER; IV (INFUSION)

LEVOLEUCOVORIN CALCIUM

AP		ACTAVIS LLC	EQ 50MG BASE/VIAL	A206516	001	Feb 13, 2017	Jan NEWA
	+	!	EQ 175MG BASE/VIAL	N208723	001	Sep 29, 2016	May CRLD
AP		AMNEAL PHARMS CO	EQ 50MG BASE/VIAL	A207547	001	Feb 13, 2017	Jan NEWA

LEVONORDEFIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ISOCAINE HYDROCHLORIDE W/ LEVONORDEFIN

@	SEPTODONT INC	0.05MG/ML; 2%	A084697	001			May CAHN
---	---------------	---------------	---------	-----	--	--	----------

MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFIN

@	BELMORA LLC	0.05MG/ML; 2%	A084850	002	Oct 21, 1983	Feb CAHN
---	-------------	---------------	---------	-----	--------------	----------

LEVOTHYROXINE SODIUM

SOLUTION; ORAL

>D>		TIROSINT-SOL					
>D>	+	IBSA INST BIO	25MCG/ML	N206977	002	Dec 15, 2016	Jun DISC
>D>	+	INSTITUT BIOCHIMIQUE	13MCG/ML	N206977	001	Dec 15, 2016	Jun DISC
>A>	+	@	13MCG/ML	N206977	001	Dec 15, 2016	Jun DISC
>A>	+	@	25MCG/ML	N206977	002	Dec 15, 2016	Jun DISC
>D>	+		50MCG/ML	N206977	003	Dec 15, 2016	Jun DISC
>A>	+	@	50MCG/ML	N206977	003	Dec 15, 2016	Jun DISC
>D>	+		75MCG/ML	N206977	004	Dec 15, 2016	Jun DISC
>A>	+	@	75MCG/ML	N206977	004	Dec 15, 2016	Jun DISC
>D>	+		88MCG/ML	N206977	005	Dec 15, 2016	Jun DISC
>A>	+	@	88MCG/ML	N206977	005	Dec 15, 2016	Jun DISC
>D>	+		100MCG/ML	N206977	006	Dec 15, 2016	Jun DISC
>A>	+	@	100MCG/ML	N206977	006	Dec 15, 2016	Jun DISC
>D>	+		112MCG/ML	N206977	007	Dec 15, 2016	Jun DISC
>A>	+	@	112MCG/ML	N206977	007	Dec 15, 2016	Jun DISC
>D>	+		125MCG/ML	N206977	008	Dec 15, 2016	Jun DISC
>A>	+	@	125MCG/ML	N206977	008	Dec 15, 2016	Jun DISC
>D>	+		137MCG/ML	N206977	009	Dec 15, 2016	Jun DISC
>A>	+	@	137MCG/ML	N206977	009	Dec 15, 2016	Jun DISC
>D>	+		150MCG/ML	N206977	010	Dec 15, 2016	Jun DISC
>A>	+	@	150MCG/ML	N206977	010	Dec 15, 2016	Jun DISC
>D>	+		175MCG/ML	N206977	011	Dec 15, 2016	Jun DISC
>A>	+	@	175MCG/ML	N206977	011	Dec 15, 2016	Jun DISC
>D>	+	!	200MCG/ML	N206977	012	Dec 15, 2016	Jun DISC
>A>	+	@	200MCG/ML	N206977	012	Dec 15, 2016	Jun DISC

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET; ORAL

LEVOXYL

AB1,	+	KING PHARMS	0.025MG	N021301	001	May 25, 2001	May CAHN
AB3							
AB1,	+		0.05MG	N021301	002	May 25, 2001	May CAHN
AB3							
AB1,	+		0.075MG	N021301	003	May 25, 2001	May CAHN

TABLET;ORAL
LEVOXYL

AB3							
AB1, +	0.088MG	N021301	004	May 25, 2001	May	CAHN	
AB3							
AB1, +	0.1MG	N021301	005	May 25, 2001	May	CAHN	
AB3							
AB1, +	0.112MG	N021301	006	May 25, 2001	May	CAHN	
AB3							
AB1, +	0.125MG	N021301	007	May 25, 2001	May	CAHN	
AB3							
AB1, +	0.137MG	N021301	008	May 25, 2001	May	CAHN	
AB3							
AB1, +	0.15MG	N021301	009	May 25, 2001	May	CAHN	
AB3							
AB1, +	0.175MG	N021301	010	May 25, 2001	May	CAHN	
AB3							
AB1, +!	0.2MG	N021301	011	May 25, 2001	May	CAHN	
AB3							
+ @	0.3MG	N021301	012	May 25, 2001	May	CAHN	

LIDOCAINE

OINTMENT;TOPICAL
LIDOCAINE

AT	ALKEM LABS LTD	5%	A207810	001	Mar 10, 2017	Feb	NEWA
AT	! FOUGERA PHARMS INC	5%	A080198	001		Jan	CAHN
	XYLOCAINE						
+ @	ASTRAZENECA	5%	N008048	001		Jan	CRLD

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION
LIDOCAINE HYDROCHLORIDE
@ BELMORA LLC

2%

A080504 001

Feb CAHN

LIDOCAINE; TETRACAINE

CREAM;TOPICAL
PLIAGLIS

+! TARO PHARMS 7%;7%

N021717 001 Jun 29, 2006 May CAHN

LINACLOTIDE

CAPSULE;ORAL
LINEZESS

+ FOREST LABS LLC 72MCG

N202811 003 Jan 25, 2017 Jan NEWA

LINEZOLID

SOLUTION;IV (INFUSION)
LINEZOLID

>A>	AP	HQ SPCLT PHARMA	200MG/100ML (2MG/ML)	A207001	001	Jul 07, 2017	Jun	NEWA
>A>	AP		600MG/300ML (2MG/ML)	A207001	002	Jul 07, 2017	Jun	NEWA
	AP	SAGENT PHARMS	200MG/100ML (2MG/ML)	A204696	001	Mar 02, 2017	Feb	NEWA
	AP		600MG/300ML (2MG/ML)	A204696	002	Mar 02, 2017	Feb	NEWA

TABLET;ORAL
LINEZOLID

AB	ZYDUS PHARMS USA INC	600MG	A206097	001	Feb 22, 2017	Feb	NEWA
----	----------------------	-------	---------	-----	--------------	-----	------

LIOTHYRONINE SODIUM

TABLET;ORAL
CYTOMEL

AB	+ KING PHARMS	EQ 0.005MG BASE	N010379	001		Mar	CAHN
AB	+	EQ 0.025MG BASE	N010379	002		Mar	CAHN
AB	+!	EQ 0.05MG BASE	N010379	003		Mar	CAHN

LISDEXAMFETAMINE DIMESYLATE

TABLET, CHEWABLE;ORAL
VYVANSE

+	SHIRE DEV LLC	10MG	N208510	001	Jan 28, 2017	Jan	NEWA
+		20MG	N208510	002	Jan 28, 2017	Jan	NEWA
+		30MG	N208510	003	Jan 28, 2017	Jan	NEWA
+		40MG	N208510	004	Jan 28, 2017	Jan	NEWA
+		50MG	N208510	005	Jan 28, 2017	Jan	NEWA
+		60MG	N208510	006	Jan 28, 2017	Apr	CHRS
+		60MG	N208510	006	Jan 28, 2017	Jan	NEWA

LISINOPRIL

TABLET;ORAL
LISINOPRIL

AB	PRINSTON INC	2.5MG	A075743	001	Jul 01, 2002	Feb CAHN
AB		5MG	A075743	002	Jul 01, 2002	Feb CAHN
AB		10MG	A075743	003	Jul 01, 2002	Feb CAHN
AB		20MG	A075743	004	Jul 01, 2002	Feb CAHN
AB		30MG	A075743	005	Jul 01, 2002	Feb CAHN
AB		40MG	A075743	006	Jul 01, 2002	Feb CAHN

LITHIUM CARBONATE

CAPSULE;ORAL

LITHIUM CARBONATE

AB	MYLAN PHARMS INC	150MG	A076243	002	Feb 24, 2003	Jan CAHN
AB		300MG	A076243	001	Jun 27, 2002	Jan CAHN
AB		600MG	A078763	001	Apr 15, 2008	Jan CAHN
AB	+ WEST-WARD PHARMS INT	150MG	N017812	002	Jan 28, 1987	Jan CAHN
AB	+	300MG	N017812	001		Jan CAHN
AB	+	600MG	N017812	003	Jan 28, 1987	Jan CAHN

TABLET;ORAL

LITHIUM CARBONATE

AB	+	WEST-WARD PHARMS INT	300MG	N018558	001	Jan 29, 1982	Jan CAHN
----	---	----------------------	-------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL

LITHIUM CARBONATE

AB	UNIQUE PHARM LABS	450MG	A205663	001	Jun 05, 2017	May NEWA
----	-------------------	-------	---------	-----	--------------	----------

LITHIUM CITRATE

SYRUP;ORAL

LITHIUM CITRATE

AA	+	WEST-WARD PHARMS INT	EQ 300MG CARBONATE/5ML	N018421	001		Jan CAHN
----	---	----------------------	------------------------	---------	-----	--	----------

LORAZEPAM

INJECTABLE;INJECTION

LORAZEPAM

AP	SAGENT AGILA LLC	2MG/ML	A200217	001	Apr 04, 2017	Mar NEWA
AP		2MG/ML	A200542	001	Apr 28, 2017	Apr NEWA
AP		4MG/ML	A200217	002	Apr 04, 2017	Mar NEWA
AP		4MG/ML	A200542	002	Apr 28, 2017	Apr NEWA
	@ WEST-WARD PHARMS INT	2MG/ML	A074496	001	Sep 28, 1998	Mar CAHN
	@	4MG/ML	A074496	002	Sep 28, 1998	Mar CAHN

TABLET;ORAL

LORAZEPAM

AB	SANDOZ	0.5	A071141	002	Apr 21, 1987	Apr CMS1
AB		1MG	A071141	003	Apr 21, 1987	Apr CMS1

LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM

>D>	AB	UPSHER SMITH	25MG	A090544	001	Oct 06, 2010	Jun CAHN
>D>	AB		50MG	A090544	002	Oct 06, 2010	Jun CAHN
>D>	AB		100MG	A090544	003	Oct 06, 2010	Jun CAHN
>A>	AB	UPSHER-SMITH LABS	25MG	A090544	001	Oct 06, 2010	Jun CAHN
>A>	AB		50MG	A090544	002	Oct 06, 2010	Jun CAHN
>A>	AB		100MG	A090544	003	Oct 06, 2010	Jun CAHN

LOVASTATIN

TABLET;ORAL

LOVASTATIN

@ MYLAN

@

@

@

TABLET, EXTENDED RELEASE;ORAL

ALTOPREV

@ COVIS PHARMA BV

		10MG	A075935	001	Dec 17, 2001	Mar DISC
		20MG	A075935	002	Dec 17, 2001	Mar DISC
		40MG	A075935	003	Dec 17, 2001	Mar DISC
	+	10MG	N021316	001	Jun 26, 2002	Apr CAHN
	+	20MG	N021316	002	Jun 26, 2002	Apr CAHN
	+	40MG	N021316	003	Jun 26, 2002	Apr CAHN
	+	60MG	N021316	004	Jun 26, 2002	Apr CAHN

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

NORMOSOL-R IN PLASTIC CONTAINER

ICU MEDICAL INC	30MG/100ML;37MG/100ML;222MG/100ML;	N017586	001			Feb CAHN
	526MG/100ML;502MG/100ML					

SOLUTION;IRRIGATION

PHYSIOSOL IN PLASTIC CONTAINER

ICU MEDICAL INC	30MG/100ML;37MG/100ML;222MG/100ML;	N017637	002	Jul 08, 1982		Feb CAHN
	526MG/100ML;502MG/100ML					

MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION;ORAL

SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE

AA	NOVEL LABS INC	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A202511	001	Feb 23, 2017	Feb NEWA
	SUPREP BOWEL PREP KIT					

AA	+! BRAINTREE LABS	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	N022372	001	Aug 05, 2010	Feb CFTG
----	-------------------	---------------------------------	---------	-----	--------------	----------

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION;ORAL

SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE

AA	NOVEL LABS INC	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A202511	001	Feb 23, 2017	May CAIN
	SUPREP BOWEL PREP KIT					

AA	+! BRAINTREE LABS	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	N022372	001	Aug 05, 2010	May CAIN
----	-------------------	---------------------------------	---------	-----	--------------	----------

MALATHION

LOTION;TOPICAL

OVIDE

AT	+! TARO PHARM	0.5%	N018613	001	Aug 02, 1982	May CAHN
----	---------------	------	---------	-----	--------------	----------

MANNITOL

INJECTABLE;INJECTION

MANNITOL 10% IN PLASTIC CONTAINER

AP	ICU MEDICAL INC	10GM/100ML	N019603	002	Jan 08, 1987	Feb CAHN
----	-----------------	------------	---------	-----	--------------	----------

MANNITOL 15% IN PLASTIC CONTAINER

AP	ICU MEDICAL INC	15GM/100ML	N019603	003	Jan 08, 1990	Feb CAHN
----	-----------------	------------	---------	-----	--------------	----------

MANNITOL 20% IN PLASTIC CONTAINER

AP	ICU MEDICAL INC	20GM/100ML	N019603	004	Jan 08, 1990	Feb CAHN
----	-----------------	------------	---------	-----	--------------	----------

MANNITOL 5% IN PLASTIC CONTAINER

AP	ICU MEDICAL INC	5GM/100ML	N019603	001	Jan 08, 1987	Feb CAHN
----	-----------------	-----------	---------	-----	--------------	----------

MANNITOL; SORBITOL

SOLUTION;IRRIGATION

SORBITOL-MANNITOL IN PLASTIC CONTAINER

ICU MEDICAL INC	540MG/100ML;2.7GM/100ML	N018316	001			Feb CAHN
-----------------	-------------------------	---------	-----	--	--	----------

MAPROTIline HYDROCHLORIDE

TABLET;ORAL

MAPROTIline HYDROCHLORIDE

@ WATSON LABS TEVA	25MG	A072162	001	Jun 01, 1988		May CAHN
--------------------	------	---------	-----	--------------	--	----------

@	50MG	A072163	001	Jun 01, 1988		May CAHN
---	------	---------	-----	--------------	--	----------

MEBENDAZOLE

TABLET, CHEWABLE;ORAL

EMVERM

>D>	! AMEDRA PHARMS LLC	100MG	A073580	001	Jan 04, 1995	Jun CAHN
-----	---------------------	-------	---------	-----	--------------	----------

>A>	! IMPAX LABS INC	100MG	A073580	001	Jan 04, 1995	Jun CAHN
-----	------------------	-------	---------	-----	--------------	----------

MECAMYLAMINE HYDROCHLORIDE

TABLET;ORAL

MECAMYLAMINE HYDROCHLORIDE

! NEXGEN PHARMA	2.5MG	A204054	001	Mar 19, 2013		May CHRS
-----------------	-------	---------	-----	--------------	--	----------

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

MECLIZINE HYDROCHLORIDE

AA	AMNEAL PHARMS	12.5MG	A201451	001	Feb 23, 2011	May CAHN
----	---------------	--------	---------	-----	--------------	----------

AA		25MG	A201451	002	Feb 23, 2011	May CAHN
----	--	------	---------	-----	--------------	----------

@	50MG	A201451	003	Feb 23, 2011		May CAHN
---	------	---------	-----	--------------	--	----------

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLOFENAMATE SODIUM

@ WATSON LABS TEVA

EQ 100MG BASE

A071469 001 Apr 15, 1987 May CAHN

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

MEDROXYPROGESTERONE ACETATE

>D> AB SANDOZ INC 150MG/ML

A078711 001 May 20, 2009 Jun DISC

>A> @ 150MG/ML

A078711 001 May 20, 2009 Jun DISC

AB 150MG/ML

A078711 001 May 20, 2009 Mar CAHN

AB TEVA PHARMS USA 150MG/ML

A076553 001 Jul 28, 2004 Jan CAHN

TABLET; ORAL

MEDROXYPROGESTERONE ACETATE

>D> @ USL PHARMA 10MG

A088484 001 Jul 26, 1984 Jun CAHN

>A> @ 10MG

A088484 001 Jul 26, 1984 Jun CAHN

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

MEFLOQUINE HYDROCHLORIDE

AB ! BARR 250MG

A076392 001 Dec 29, 2003 Apr CHRS

@ SANDOZ 250MG

A076175 001 Feb 20, 2002 Apr DISC

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGACE

+ @ BRISTOL MYERS SQUIBB 40MG/ML

N020264 001 Sep 10, 1993 Feb DISC

MEGESTROL ACETATE

AB HI-TECH PHARMACAL 40MG/ML

A203960 001 Jun 09, 2017 May NEWA

AB ! WEST-WARD PHARMS INT 40MG/ML

A075997 001 Feb 15, 2002 Feb CHRS

MELOXICAM

TABLET; ORAL

MELOXICAM

@ SUN PHARM INDS INC 7.5MG

A077937 001 Jul 19, 2006 Apr DISC

@ 15MG

A077937 002 Jul 19, 2006 Apr DISC

MELPHALAN

TABLET; ORAL

ALKERAN

AB +! APOTEX INC 2MG

N014691 002 Mar CFTG

MELPHALAN

AB ALVOGEN MALTA 2MG

A207809 001 Mar 22, 2017 Mar NEWA

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

ALKERAN

+ @ APOTEX INC EQ 50MG BASE/VIAL

N020207 001 Nov 18, 1992 May DISC

MELPHALAN HYDROCHLORIDE

AP ! MYLAN INSTITUTIONAL EQ 50MG BASE/VIAL

A090270 001 Jun 09, 2009 May CHRS

AP SAGENT PHARMS EQ 50MG BASE/VIAL

A201379 001 Feb 28, 2017 Feb NEWA

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MEMANTINE HYDROCHLORIDE

AB AMNEAL PHARMS 7MG

A205825 001 Oct 12, 2016 May CAHN

AB 14MG

A205825 002 Oct 12, 2016 May CAHN

AB 21MG

A205825 003 Oct 12, 2016 May CAHN

AB 28MG

A205825 004 Oct 12, 2016 May CAHN

AB ANCHEN PHARMS 7MG

A205784 001 Jun 09, 2017 May NEWA

AB 14MG

A205784 002 Jun 09, 2017 May NEWA

AB 21MG

A205784 003 Jun 09, 2017 May NEWA

AB 28MG

A205784 004 Jun 09, 2017 May NEWA

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

AB AMNEAL PHARMS 5MG

A090041 001 Apr 10, 2015 May CAHN

AB 10MG

A090041 002 Apr 10, 2015 May CAHN

AB STRIDES PHARMA 5MG

A202350 001 May 23, 2017 May NEWA

AB 10MG

A202350 002 May 23, 2017 May NEWA

>D> AB UPSHER-SMITH LABS 5MG

A090043 001 Jul 31, 2015 Jun CAHN

>A> AB 5MG

A090043 001 Jul 31, 2015 Jun CAHN

TABLET;ORAL

MEMANTINE HYDROCHLORIDE

>D>	AB		10MG	A090043	002	Jul 31, 2015	Jun CAHN
>A>	AB		10MG	A090043	002	Jul 31, 2015	Jun CAHN
>A>	AB	ZYDUS PHARMS USA INC	5MG	A090961	001	Jul 10, 2017	Jun NEWA
>A>	AB		10MG	A090961	002	Jul 10, 2017	Jun NEWA

MEPERIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

MEPERIDINE HYDROCHLORIDE

AP		WEST-WARD PHARMS INT	25MG/ML	A080445	001		Jan CAHN
AP			25MG/ML	A080455	007		Jan CAHN
AP			50MG/ML	A080445	002		Jan CAHN
AP			50MG/ML	A080455	008		Jan CAHN
AP			75MG/ML	A080445	003		Jan CAHN
AP			75MG/ML	A080455	009		Jan CAHN
AP			100MG/ML	A080445	004		Jan CAHN
AP			100MG/ML	A080455	010		Jan CAHN
		MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE					
AP	!	ICU MEDICAL INC	10MG/ML	A088432	001	Aug 16, 1984	Apr CAHN
	@	MALLINCKRODT INC	10MG/ML	A040163	001	May 12, 1997	Mar CAHN
AP		WEST-WARD PHARMS INT	10MG/ML	A081002	001	Jul 30, 1993	Apr CAHN

MEPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

ISOCAINE HYDROCHLORIDE

AP	!	SEPTODONT INC	3%	A080925	001		May CAHN
		MEPIVACAINE HYDROCHLORIDE					
	@	BELMORA LLC	3%	A083559	001		Feb CAHN

MERCAPTOPURINE

TABLET;ORAL

MERCAPTOPURINE

>D>	AB	DR REDDYS LABS INTL	50MG	A040461	001	Feb 11, 2004	Jun CAHN
>A>	AB	DR REDDYS LABS SA	50MG	A040461	001	Feb 11, 2004	Jun CAHN

MEROPENEM

INJECTABLE;INJECTION

MEROPENEM

AP		AUROBINDO PHARMA LTD	500MG/VIAL	A205835	001	Mar 27, 2017	Mar NEWA
AP			1GM/VIAL	A205835	002	Mar 27, 2017	Mar NEWA
>D>	AP	SANDOZ	500MG/VIAL	A091201	001	Mar 29, 2011	Jun DISC
>A>		@	500MG/VIAL	A091201	001	Mar 29, 2011	Jun DISC
>D>	AP		1GM/VIAL	A091201	002	Mar 29, 2011	Jun DISC
>A>		@	1GM/VIAL	A091201	002	Mar 29, 2011	Jun DISC
		MERREM					
>D>	AP	+! ASTRAZENECA	500MG/VIAL	N050706	003	Jun 21, 1996	Jun CAHN
>D>	AP	+!	1GM/VIAL	N050706	001	Jun 21, 1996	Jun CAHN
>A>	AP	+! PFIZER	500MG/VIAL	N050706	003	Jun 21, 1996	Jun CAHN
>A>	AP	+!	1GM/VIAL	N050706	001	Jun 21, 1996	Jun CAHN

MESALAMINE

ENEMA;RECTAL

ROWASA

AB	+!	MYLAN SPECIALITY LP	4GM/60ML	N019618	001	Dec 24, 1987	Mar CAHN
		SFROWASA					
AB	+	MYLAN SPECIALITY LP	4GM/60ML	N019618	002	Jun 20, 2008	Mar CAHN
		TABLET, DELAYED RELEASE;ORAL					
		LIALDA					
AB	+!	SHIRE	1.2GM	N022000	001	Jan 16, 2007	May CFTG
		MESALAMINE					
AB		ZYDUS PHARMS USA INC	1.2GM	A091640	001	Jun 05, 2017	May NEWA

METAXALONE

TABLET;ORAL

METAXALONE

>A>	AB	ACTAVIS LABS FL INC	800MG	A203695	001	Jun 15, 2017	Jun NEWA
		@ EPIC PHARMA LLC	640MG	N022503	001	Jun 01, 2015	May CAHN
		IMPAX LABS INC	400MG	A040486	001	Feb 27, 2015	Feb CAHN
		SKELAXIN					
		+ @ KING PHARMS	400MG	N013217	001		May CAHN
AB		+!	800MG	N013217	003	Aug 30, 2002	May CAHN

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

@ MYLAN PHARMS INC 500MG
 @ 850MG
 @ 1GM
 @ WATSON LABS FLORIDA 500MG
 @ 850MG
 @ 1GM

A075969 001 Jan 29, 2002 May DISC
 A075969 002 Jan 29, 2002 May DISC
 A075969 003 Jan 29, 2002 May DISC
 A075961 001 Jan 25, 2002 Mar DISC
 A075961 002 Jan 25, 2002 Mar DISC
 A075961 003 Jan 25, 2002 Mar DISC

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

AB1 INTELLIPHARMACEUTICS 500MG
 AB 750MG
 AB1 TORRENT PHARMS LTD 500MG

A202306 001 Feb 23, 2017 Feb NEWA
 A202306 002 Feb 23, 2017 Feb NEWA
 A090014 001 Dec 30, 2009 Apr CAHN

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

TEVA 500MG; EQ 1MG BASE

A077337 005 May 19, 2017 May NEWA

METHADONE HYDROCHLORIDE

CONCENTRATE; ORAL

METHADOSE

AA +! MALLINCKRODT INC 10MG/ML
 POWDER; FOR RX COMPOUNDING
 METHADONE HYDROCHLORIDE
 MALLINCKRODT INC 50GM/BOT
 100GM/BOT
 500GM/BOT

N017116 002 Apr CAHN
 N006383 002 Apr CAHN
 N006383 003 Apr CAHN
 N006383 004 Apr CAHN

SYRUP; ORAL

DOLOPHINE HYDROCHLORIDE

@ WEST-WARD PHARMS INT 10MG/30ML

N006134 004 Jan CAHN

TABLET; ORAL

DOLOPHINE HYDROCHLORIDE

AA +! WEST-WARD PHARMS INT 5MG
 AA +! 10MG
 METHADONE HYDROCHLORIDE
 EPIC PHARMA LLC 5MG
 AA 10MG

N006134 002 Jan CAHN
 N006134 010 Jan CAHN
 A090065 001 Aug 18, 2015 May CAHN
 A090065 002 Aug 18, 2015 May CAHN

TABLET, FOR SUSPENSION; ORAL

METHADONE HYDROCHLORIDE

AA +! WEST-WARD PHARMS INT 40MG

N017058 001 Jan CAHN

METHENAMINE HIPPURATE

TABLET; ORAL

METHENAMINE HIPPURATE

AB IMPAX LABS INC 1GM

A076411 001 Jun 20, 2003 Feb CAHN

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

@ ECI PHARMS LLC 15MG

A040619 003 Jul 12, 2005 May CAHN

TAPAZOLE

AB KING PHARMS LLC 5MG
 AB 10MG

A040320 001 Mar 31, 2000 Feb CAHN
 A040320 002 Mar 31, 2000 Feb CAHN

METHOCARBAMOL

SOLUTION; IM-IV

METHOCARBAMOL

>A> AP LUITPOLD PHARMS INC 1GM/10ML (100MG/ML)
 AP RENAISSANCE PHARMA 1GM/10ML (100MG/ML)
 AP RENAISSANCE SSA LLC 1GM/10ML (100MG/ML)

A207496 001 Jun 22, 2017 Jun NEWA
 A208116 001 Jan 19, 2017 Jan NEWA
 A208116 001 Jan 19, 2017 Mar CAHN

TABLET; ORAL

METHOCARBAMOL

AA ATLAS PHARMS LLC 500MG
 AA 750MG
 >D> @ UPSHER SMITH 500MG
 >A> @ 500MG
 >D> @ 750MG
 >A> @ 750MG

A203550 001 Feb 08, 2017 Jan NEWA
 A203550 002 Feb 08, 2017 Jan NEWA
 A087453 001 Jun CAHN
 A087453 001 Jun CAHN
 A087454 001 Jun CAHN
 A087454 001 Jun CAHN

METHOTREXATESOLUTION;SUBCUTANEOUS
RASUVO

>D>	MEDAC PHARMA INC	27.5MG/0.55ML (27.5MG/0.55ML)	N205776	009	Jul 10, 2014	Jun DISC
>A>	@	27.5MG/0.55ML (27.5MG/0.55ML)	N205776	009	Jul 10, 2014	Jun DISC

METHOTREXATE SODIUM

INJECTABLE;INJECTION

METHOTREXATE SODIUM PRESERVATIVE FREE

AP	PHARMACHEMIE BV	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A040843	002	Jan 11, 2010	Apr CMS1
AP		EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A040843	003	Feb 27, 2012	Apr CMS1
AP		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A040843	004	Jan 11, 2010	Apr CMS1

SOLUTION;ORAL
XATMEP

+!	SILVERGATE PHARMS	EQ 2.5MG BASE/ML	N208400	001	Apr 25, 2017	Apr NEWA
----	-------------------	------------------	---------	-----	--------------	----------

TABLET;ORAL

METHOTREXATE SODIUM

AB	ZYDUS PHARMS USA INC	EQ 2.5MG BASE	A207812	001	Jan 13, 2017	Jan NEWA
----	----------------------	---------------	---------	-----	--------------	----------

METHYLDOPATE HYDROCHLORIDE

INJECTABLE;INJECTION

METHYLDOPATE HYDROCHLORIDE

!	LUITPOLD	50MG/ML	A071279	001	Oct 02, 1987	Jan CTEC
---	----------	---------	---------	-----	--------------	----------

METHYLPHENIDATE

>A> TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

>A> COTEMPLA XR-ODT

>A>	+	NEOS THERAPS INC	8.6MG	N205489	001	Jun 19, 2017	Jun NEWA
-----	---	------------------	-------	---------	-----	--------------	----------

>A>	+		17.3MG	N205489	002	Jun 19, 2017	Jun NEWA
-----	---	--	--------	---------	-----	--------------	----------

>A>	+		25.9MG	N205489	003	Jun 19, 2017	Jun NEWA
-----	---	--	--------	---------	-----	--------------	----------

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB2	IMPAX LABS INC	10MG	A205105	001	Jul 28, 2016	Feb CAHN
AB2		20MG	A205105	002	Jul 28, 2016	Feb CAHN
AB2		30MG	A205105	003	Jul 28, 2016	Feb CAHN
AB2		40MG	A205105	004	Jul 28, 2016	Feb CAHN
AB2		50MG	A205105	005	Jul 28, 2016	Feb CAHN
AB2		60MG	A205105	006	Jul 28, 2016	Feb CAHN
!	MAYNE PHARMA	60MG	A078458	004	Jun 23, 2016	Feb CHRS

RITALIN LA

+	@ NOVARTIS	60MG	N021284	005	Oct 27, 2014	Feb DISC
---	------------	------	---------	-----	--------------	----------

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	ABHAI INC	5MG	A206932	001	May 11, 2017	Apr NEWA
AB		10MG	A206932	002	May 11, 2017	Apr NEWA
AB		20MG	A206932	003	May 11, 2017	Apr NEWA
AB	IMPAX LABS INC	5MG	A091159	001	Mar 12, 2014	Feb CAHN
AB		10MG	A091159	002	Mar 12, 2014	Feb CAHN
AB		20MG	A091159	003	Mar 12, 2014	Feb CAHN
AB	NOSTRUM LABS INC	5MG	A207587	001	Mar 03, 2017	Feb NEWA
AB		10MG	A207587	002	Mar 03, 2017	Feb NEWA
AB		20MG	A207587	003	Mar 03, 2017	Feb NEWA

TABLET, CHEWABLE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	NOSTRUM LABS INC	2.5MG	A204954	001	Jan 26, 2017	Jan NEWA
AB		5MG	A204954	002	Jan 26, 2017	Jan NEWA
AB		10MG	A204954	003	Jan 26, 2017	Jan NEWA

TABLET, EXTENDED RELEASE;ORAL

RITALIN-SR

AB	+	NOVARTIS	20MG	N018029	001	Mar 30, 1982	Feb CRLD
----	---	----------	------	---------	-----	--------------	----------

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE ACETATE

AB	SANDOZ INC	40MG/ML	A040719	001	Jan 29, 2009	Mar CAHN
AB		80MG/ML	A040719	002	Jan 29, 2009	Mar CAHN

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE;INJECTION

A-METHAPRED

@ HOSPIRA INC

EQ 40MG BASE/VIAL

A040793 001 Nov 25, 2008 Jan DISC

@

EQ 125MG BASE/VIAL

A040827 001 Nov 25, 2008 Jan DISC

METHYLTESTOSTERONE

TABLET;ORAL

ANDROID 10

@ VALEANT PHARMS NORTH 10MG

A086450 001 May CAHN

METIPRANOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

METIPRANOLOL

AT SANDOZ INC

0.3%

A075720 001 Aug 06, 2001 Feb CAHN

METOCLOPRAMIDE HYDROCHLORIDE

SOLUTION;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AA PHARM ASSOC

EQ 5MG BASE/5ML

A072744 001 May 28, 1991 May CAHN

TABLET;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

@ NORTHSTAR HLTHCARE

EQ 5MG BASE

A078374 001 Nov 30, 2007 Feb DISC

@

EQ 10MG BASE

A078374 002 Nov 30, 2007 Feb DISC

@ SUN PHARM INDS

EQ 5MG BASE

A071536 002 Jan 16, 1997 May DISC

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

TOPROL-XL

AB + ARALEZ PHARMS

EQ 25MG TARTRATE

N019962 004 Feb 05, 2001 Jan CAHN

AB +!

EQ 50MG TARTRATE

N019962 001 Jan 10, 1992 Jan CAHN

AB +

EQ 100MG TARTRATE

N019962 002 Jan 10, 1992 Jan CAHN

AB +!

EQ 200MG TARTRATE

N019962 003 Jan 10, 1992 Jan CAHN

METOPROLOL TARTRATE

INJECTABLE;INJECTION

METOPROLOL TARTRATE

AP SANDOZ INC

1MG/ML

A077360 001 Oct 02, 2007 Mar CAHN

AP WEST-WARD PHARMS INT

1MG/ML

A076495 001 Jul 07, 2003 Jan CAHN

METRONIDAZOLE

CAPSULE;ORAL

METRONIDAZOLE

AB ALEMBIC PHARMS LTD

375MG

A079065 001 Jun 23, 2009 May CAHN

GEL;TOPICAL

METRONIDAZOLE

AB TARO PHARM

1%

A204651 001 Mar 14, 2017 Feb NEWA

INJECTABLE;INJECTION

METRONIDAZOLE

@ WEST-WARD PHARMS INT 500MG/100ML

N018907 001 Mar 30, 1984 May CAHN

METRONIDAZOLE IN PLASTIC CONTAINER

AP MYLAN LABS LTD

500MG/100ML

A205531 001 May 09, 2017 Apr NEWA

TABLET;ORAL

METRONIDAZOLE

>A> @ CHARTWELL MOLECULES

250MG

N018845 001 Aug 18, 1983 Jun CAHN

>A> @

500MG

N018930 001 Aug 18, 1983 Jun CAHN

>A> AB ORIT LABS LLC

250MG

A208681 001 Jun 20, 2017 Jun NEWA

>A> AB

500MG

A208681 002 Jun 20, 2017 Jun NEWA

>D> @ PAR PHARM

250MG

N018845 001 Aug 18, 1983 Jun CAHN

>D> @

500MG

N018930 001 Aug 18, 1983 Jun CAHN

TABLET, EXTENDED RELEASE;ORAL

METRONIDAZOLE

AB ALEMBIC PHARMS LTD

750MG

A090222 001 May 05, 2010 May CAHN

MICONAZOLE NITRATE

SUPPOSITORY;VAGINAL

MICONAZOLE NITRATE

AB ACTAVIS PHARMA

200MG

A073508 001 Nov 19, 1993 May CAHN

MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDEOINTMENT; TOPICAL
VUSION

+! MYLAN PHARMS INC 0.25%; 81.35%; 15% N021026 001 Feb 16, 2006 Jan CAHN

MIDAZOLAM HYDROCHLORIDEINJECTABLE; INJECTION
MIDAZOLAM HYDROCHLORIDE

		FRESENIUS KABI USA	EQ 5MG BASE/ML	A208878	001	Mar 28, 2017	Mar NEWA
AP		WEST-WARD PHARMS INT	EQ 1MG BASE/ML	A075243	001	Jun 20, 2000	Jan CAHN
AP			EQ 1MG BASE/ML	A075247	002	Jun 23, 2000	Jan CAHN
AP			EQ 1MG BASE/ML	A075324	001	Jun 20, 2000	Mar CAHN
AP			EQ 1MG BASE/ML	A075421	002	Jun 20, 2000	Jan CAHN
AP			EQ 5MG BASE/ML	A075243	002	Jun 20, 2000	Jan CAHN
AP			EQ 5MG BASE/ML	A075247	001	Jun 23, 2000	Jan CAHN
AP			EQ 5MG BASE/ML	A075324	002	Jun 20, 2000	Mar CAHN
AP			EQ 5MG BASE/ML	A075421	001	Jun 20, 2000	Jan CAHN
		MIDAZOLAM HYDROCHLORIDE	PRESERVATIVE FREE				
AP		SAGENT AGILA LLC	EQ 1MG BASE/ML	A090315	001	Nov 29, 2010	May CAHN
AP			EQ 5MG BASE/ML	A090315	002	Nov 29, 2010	May CAHN

SYRUP; ORAL

MIDAZOLAM HYDROCHLORIDE

@ SUN PHARM INDS LTD EQ 2MG BASE/ML A076058 001 Mar 15, 2002 May DISC

MIDODRINE HYDROCHLORIDETABLET; ORAL
ORVATEN

>D>	AB	UPSHER SMITH	2.5MG	A076725	001	Nov 03, 2004	Jun CAHN
>D>	AB		5MG	A076725	002	Nov 03, 2004	Jun CAHN
>D>	AB		10MG	A076725	003	Nov 03, 2004	Jun CAHN
>A>	AB	UPSHER-SMITH LABS	2.5MG	A076725	001	Nov 03, 2004	Jun CAHN
>A>	AB		5MG	A076725	002	Nov 03, 2004	Jun CAHN
>A>	AB		10MG	A076725	003	Nov 03, 2004	Jun CAHN
		PROAMATINE					
		+ @ SHIRE LLC	2.5MG	N019815	001	Sep 06, 1996	Feb CRLD
		+ @	5MG	N019815	002	Sep 06, 1996	Feb CRLD
		+ @	10MG	N019815	003	Mar 20, 2002	Feb CRLD

MIDOSTAURINCAPSULE; ORAL
RYDAPT

+! NOVARTIS PHARMS CORP 25MG N207997 001 Apr 28, 2017 Apr NEWA

MILNACIPRAN HYDROCHLORIDETABLET; ORAL
SAVELLA

AB	+	ALLERGAN SALES LLC	12.5MG	N022256	001	Jan 14, 2009	Feb CAHN
AB	+		25MG	N022256	002	Jan 14, 2009	Feb CAHN
AB	+		50MG	N022256	003	Jan 14, 2009	Feb CAHN
AB	+		100MG	N022256	004	Jan 14, 2009	Feb CAHN

MILRINONE LACTATEINJECTABLE; INJECTION
MILRINONE LACTATE

AP		WEST-WARD PHARMS INT	EQ 1MG BASE/ML	A075530	001	May 28, 2002	Jan CAHN
AP			EQ 1MG BASE/ML	A075660	001	May 28, 2002	Jan CAHN
		@	EQ 1MG BASE/ML	A075852	001	May 28, 2002	Mar CAHN
		MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
		@ WEST-WARD PHARMS INT	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A075510	001	May 28, 2002	Mar CAHN
AP			EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A078113	001	May 21, 2008	Jan CAHN
AP			EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A078113	002	May 21, 2008	Jan CAHN
		PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER					
		+ @ SANOFI AVENTIS US	EQ 10MG BASE/100ML	N020343	001	Aug 09, 1994	Jan CRLD
		+ @	EQ 15MG BASE/100ML	N020343	002	Aug 09, 1994	Jan CRLD
		+ @	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	N020343	003	Aug 09, 1994	Jan CRLD
		+ @	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	N020343	004	Aug 09, 1994	Jan CRLD

MINOCYCLINE HYDROCHLORIDE

CAPSULE;ORAL							
MINOCYCLINE HYDROCHLORIDE							
AB	WATSON LABS TEVA	EQ 50MG BASE	A063181	001	Dec 30, 1991	May	CAHN
CAPSULE, EXTENDED RELEASE;ORAL							
XIMINO							
	SUN PHARM INDS LTD	EQ 45MG BASE	N201922	001	Jul 11, 2012	Apr	CMFD
		EQ 90MG BASE	N201922	003	Jul 11, 2012	Apr	CMFD
		EQ 135MG BASE	N201922	005	Jul 11, 2012	Apr	CMFD
TABLET, EXTENDED RELEASE;ORAL							
MINOCYCLINE HYDROCHLORIDE							
	@ BARR LABS INC	EQ 80MG BASE	A065485	007	Apr 26, 2017	Apr	DISC
		EQ 80MG BASE	A065485	007	Apr 26, 2017	Apr	NEWA
	@	EQ 105MG BASE	A065485	008	Apr 26, 2017	Apr	DISC
		EQ 105MG BASE	A065485	008	Apr 26, 2017	Apr	NEWA
	@ MYLAN PHARMS INC	EQ 45MG BASE	A090911	001	Jul 20, 2010	May	DISC
	@	EQ 80MG BASE	A203443	002	Aug 22, 2014	May	DISC
	@	EQ 90MG BASE	A090911	002	Jul 20, 2010	May	DISC
	@	EQ 105MG BASE	A203443	003	Aug 22, 2014	May	DISC
	@	EQ 135MG BASE	A090911	003	Jul 20, 2010	May	DISC
MINOLIRA							
	DR REDDYS LABS LTD	EQ 105MG BASE	N209269	001	May 08, 2017	May	NEWA
		EQ 135MG BASE	N209269	002	May 08, 2017	May	NEWA

MIRABEGRON

TABLET, EXTENDED RELEASE;ORAL

MYRBETRIQ

+	!	APGDI	25MG	N202611	001	Jun 28, 2012	Feb	CHRS
---	---	-------	------	---------	-----	--------------	-----	------

MIRTAZAPINE

TABLET;ORAL

MIRTAZAPINE

>D>	@ UPSHER-SMITH LABS	15MG	A076189	001	Jun 19, 2003	Jun	CAHN
>A>	@	15MG	A076189	001	Jun 19, 2003	Jun	CAHN
>D> AB		15MG	A076219	001	Jun 19, 2003	Jun	CAHN
>A> AB		15MG	A076219	001	Jun 19, 2003	Jun	CAHN
>D>	@	30MG	A076189	002	Jun 19, 2003	Jun	CAHN
>A>	@	30MG	A076189	002	Jun 19, 2003	Jun	CAHN
>D> AB		30MG	A076219	002	Jun 19, 2003	Jun	CAHN
>A> AB		30MG	A076219	002	Jun 19, 2003	Jun	CAHN
>D>	@	45MG	A076189	003	Jun 19, 2003	Jun	CAHN
>A>	@	45MG	A076189	003	Jun 19, 2003	Jun	CAHN
>D> AB		45MG	A076219	003	Jun 19, 2003	Jun	CAHN
>A> AB		45MG	A076219	003	Jun 19, 2003	Jun	CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

MIRTAZAPINE

AB	AUROBINDO PHARMA LTD	15MG	A077376	002	Dec 08, 2005	Jan	CAHN
AB		30MG	A077376	003	Dec 08, 2005	Jan	CAHN
AB		45MG	A077376	004	Feb 28, 2006	Jan	CAHN
AB	ZYDUS PHARMS USA INC	15MG	A205798	001	Jun 01, 2017	May	NEWA
AB		30MG	A205798	002	Jun 01, 2017	May	NEWA
AB		45MG	A205798	003	Jun 01, 2017	May	NEWA

MITOMYCIN

INJECTABLE;INJECTION

MITOMYCIN

AP	WEST-WARD PHARMS INT	5MG/VIAL	A064117	001	Apr 19, 1995	Jan	CAHN	
AP		5MG/VIAL	A064180	001	Dec 23, 1999	Jan	CAHN	
AP		20MG/VIAL	A064117	002	Apr 19, 1995	Jan	CAHN	
AP		20MG/VIAL	A064180	002	Dec 23, 1999	Jan	CAHN	
MUTAMYCIN								
+	@	BRISTOL	5MG/VIAL	N050450	001		Jan	CRLD
+	@		20MG/VIAL	N050450	002		Jan	CRLD

MODAFINIL

TABLET;ORAL

MODAFINIL

AB	ALEMBIC PHARMS LTD	100MG	A202700	001	Oct 18, 2012	May	CAHN
AB		200MG	A202700	002	Oct 18, 2012	May	CAHN

MOEXIPRIL HYDROCHLORIDE

TABLET;ORAL

MOEXIPRIL HYDROCHLORIDE

AB	CHARTWELL RX	7.5MG	A077536	001	Nov 30, 2006	Apr CAHN
AB		15MG	A077536	002	Nov 30, 2006	Apr CAHN

MOLINDONE HYDROCHLORIDE

TABLET;ORAL

MOLINDONE HYDROCHLORIDE

EPIC PHARMA LLC

5MG

A090453 001 Mar 20, 2015 May CAHN

10MG

A090453 002 Mar 20, 2015 May CAHN

!

25MG

A090453 003 Mar 20, 2015 May CAHN

MOMETASONE FUROATE

LOTION;TOPICAL

MOMETASONE FUROATE

AB PERRIGO ISRAEL

0.1%

A077180 001 Apr 06, 2005 Apr CAHN

SPRAY, METERED;NASAL

MOMETASONE FUROATE

AB AMNEAL PHARMS

EQ 0.05MG BASE/SPRAY

A207989 001 Apr 03, 2017 Mar NEWA

MONTELUKAST SODIUM

TABLET;ORAL

MONTELUKAST SODIUM

AB CSPC OUYI PHARM CO

EQ 10MG BASE

A209012 001 Apr 24, 2017 Apr NEWA

AB PERRIGO R AND D

EQ 10MG BASE

A206112 001 Apr 26, 2017 Apr NEWA

TABLET, CHEWABLE;ORAL

MONTELUKAST SODIUM

AB CSPC OUYI PHARM CO

EQ 4MG BASE

A209011 001 Apr 18, 2017 Apr NEWA

AB

EQ 5MG BASE

A209011 002 Apr 18, 2017 Apr NEWA

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

ACTAVIS ELIZABETH

30MG

A079040 001 Jan 16, 2013 Apr CAHN

45MG

A079040 002 Jan 16, 2013 Apr CAHN

60MG

A079040 003 Jan 16, 2013 Apr CAHN

75MG

A079040 004 Jan 16, 2013 Apr CAHN

90MG

A079040 005 Jan 16, 2013 Apr CAHN

!

120MG

A079040 006 Jan 16, 2013 Apr CAHN

>D> AB UPSHER SMITH

10MG

A202104 001 Jun 03, 2013 Jun CAHN

>D> AB

20MG

A202104 002 Jun 03, 2013 Jun CAHN

>D> AB

30MG

A202104 003 Jun 03, 2013 Jun CAHN

>D> AB

50MG

A202104 004 Jun 03, 2013 Jun CAHN

>D> AB

60MG

A202104 005 Jun 03, 2013 Jun CAHN

>D> AB

80MG

A202104 006 Jun 03, 2013 Jun CAHN

>D> AB

100MG

A202104 007 Jun 03, 2013 Jun CAHN

>A> AB UPSHER-SMITH LABS

10MG

A202104 001 Jun 03, 2013 Jun CAHN

>A> AB

20MG

A202104 002 Jun 03, 2013 Jun CAHN

>A> AB

30MG

A202104 003 Jun 03, 2013 Jun CAHN

>A> AB

50MG

A202104 004 Jun 03, 2013 Jun CAHN

>A> AB

60MG

A202104 005 Jun 03, 2013 Jun CAHN

>A> AB

80MG

A202104 006 Jun 03, 2013 Jun CAHN

>A> AB

100MG

A202104 007 Jun 03, 2013 Jun CAHN

INJECTABLE;INJECTION

MORPHINE SULFATE

>D> @ HOSPIRA

0.5MG/ML

N019917 001 Oct 30, 1992 Jun CAHN

>A> @ ICU MEDICAL INC

0.5MG/ML

N019917 001 Oct 30, 1992 Jun CAHN

AP +!

1MG/ML

N019916 001 Oct 30, 1992 Apr CAHN

+!

5MG/ML

N019916 002 Oct 27, 2006 Apr CAHN

@ MALLINCKRODT INC

1MG/ML

N020631 001 Jul 03, 1996 Apr CAHN

@

2MG/ML

N020631 002 Jul 03, 1996 Apr CAHN

SOLUTION;ORAL

MORPHINE SULFATE

>A> AA HI-TECH PHARMACAL

100MG/5ML

A208809 001 Jul 06, 2017 Jun NEWA

>A> AA RHODES PHARMS

10MG/5ML

A206308 001 Jun 22, 2017 Jun NEWA

>A> AA

100MG/5ML

A206308 002 Jun 22, 2017 Jun NEWA

AA + WEST-WARD PHARMS INT

10MG/5ML

N022195 001 Mar 17, 2008 Jan CAHN

AA +

20MG/5ML

N022195 002 Mar 17, 2008 Jan CAHN

AA +!

100MG/5ML

N022195 003 Jan 25, 2010 Jan CAHN

TABLET;ORAL

MORPHINE SULFATE

+ WEST-WARD PHARMS INT 15MG
 +! 30MG

N022207 001 Mar 17, 2008 Jan CAHN
 N022207 002 Mar 17, 2008 Jan CAHN

TABLET, EXTENDED RELEASE;ORAL

ARYMO ER

+ EGALET 15MG
 + 30MG
 + 60MG

N208603 001 Jan 09, 2017 Jan NEWA
 N208603 002 Jan 09, 2017 Jan NEWA
 N208603 003 Jan 09, 2017 Jan NEWA

MORPHABOND ER

+ DAIICHI SANKYO INC 15MG
 + 30MG
 + 60MG
 +! 100MG

N206544 001 Oct 02, 2015 Jan CTNA
 N206544 002 Oct 02, 2015 Jan CTNA
 N206544 003 Oct 02, 2015 Jan CTNA
 N206544 004 Oct 02, 2015 Jan CTNA

MORPHINE SULFATE

AB ACTAVIS ELIZABETH 15MG
 AB 30MG
 AB 60MG
 AB 100MG
 AB 200MG
 AB EPIC PHARMA LLC 15MG
 AB 30MG
 AB 60MG
 AB 100MG
 AB 200MG
 AB SUN PHARM INDS 15MG
 AB 30MG
 AB 60MG
 AB 100MG
 AB 200MG

A203849 001 Apr 06, 2015 Apr CAHN
 A203849 002 Apr 06, 2015 Apr CAHN
 A203849 003 Apr 06, 2015 Apr CAHN
 A203849 004 Apr 06, 2015 Apr CAHN
 A203849 005 Apr 06, 2015 Apr CAHN
 A091357 001 Jun 23, 2016 May CAHN
 A091357 002 Jun 23, 2016 May CAHN
 A091357 003 Jun 23, 2016 May CAHN
 A091357 004 Jun 23, 2016 May CAHN
 A091357 005 Jun 23, 2016 May CAHN
 A205634 001 Aug 25, 2016 Mar CAHN
 A205634 002 Aug 25, 2016 Mar CAHN
 A205634 003 Aug 25, 2016 Mar CAHN
 A205634 004 Aug 25, 2016 Mar CAHN
 A205634 005 Aug 25, 2016 Mar CAHN

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION;IV (INFUSION)

AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER

AP +! BAYER HLTHCARE 400MG/250ML (1.6MG/ML)

N021277 001 Nov 30, 2001 Apr CFTG

MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER

AP MYLAN LABS LTD 400MG/250ML (1.6MG/ML)

A205833 001 May 05, 2017 Apr NEWA

SOLUTION/DROPS;OPHTHALMIC

MOXIFLOXACIN HYDROCHLORIDE

>A> AT1 APOTEX INC EQ 0.5% BASE

A090080 001 Jun 30, 2017 Jun NEWA

TABLET;ORAL

MOXIFLOXACIN HYDROCHLORIDE

AB NOVEL LABS INC EQ 400MG BASE

A207285 001 Feb 13, 2017 Jan NEWA

MUPIROCIN

OINTMENT;TOPICAL

BACTROBAN

+ @ GLAXOSMITHKLINE 2%

N050591 001 Dec 31, 1987 May DISC

MUPIROCIN

AB ! PERRIGO NEW YORK 2%

A065123 001 Nov 07, 2003 May CHRS

MUPIROCIN CALCIUM

CREAM;TOPICAL

MUPIROCIN

AB GLENMARK PHARMS INC EQ 2% BASE

A201587 001 Jan 24, 2013 May CAHN

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE;INJECTION

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

AP AKORN INC 500MG/VIAL

A204043 001 Feb 28, 2017 Feb NEWA

AP MYLAN LABS LTD 500MG/VIAL

A203859 001 Mar 31, 2017 Mar NEWA

NABILONE

CAPSULE;ORAL

CESAMET

+! MYLAN SPECIALITY LP 1MG

N018677 001 Dec 26, 1985 Mar CAHN

NADOLOL

TABLET; ORAL

NADOLOL

AB	AMNEAL PHARMS CO	20MG	A208832	001	Jun 02, 2017	May NEWA
AB		40MG	A208832	002	Jun 02, 2017	May NEWA
AB		80MG	A208832	003	Jun 02, 2017	May NEWA

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL

NAFTIFINE HYDROCHLORIDE

AB	TOLMAR	2%	A206960	001	Apr 10, 2017	Mar NEWA
----	--------	----	---------	-----	--------------	----------

NALDEMEDINE TOSYLATE

TABLET; ORAL

SYMPROIC

	+! SHIONOGI INC	EQ 0.2MG BASE	N208854	001	Mar 23, 2017	Mar NEWA
--	-----------------	---------------	---------	-----	--------------	----------

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

@ WEST-WARD PHARMS INT 0.4MG/ML

A070298 001 Sep 24, 1986 Jan CAHN

@ 0.4MG/ML

A070496 001 Sep 24, 1986 Jan CAHN

NALOXONE HYDROCHLORIDE

AP	AKORN	0.4MG/ML	A208871	001	Feb 28, 2017	Feb NEWA
----	-------	----------	---------	-----	--------------	----------

AP		0.4MG/ML	A208872	001	Mar 14, 2017	Feb NEWA
----	--	----------	---------	-----	--------------	----------

SPRAY, METERED; NASAL

NARCAN

	+ ADAPT	2MG/SPRAY	N208411	002	Jan 24, 2017	Jan NEWA
--	---------	-----------	---------	-----	--------------	----------

NANDROLONE DECANOATE

INJECTABLE; INJECTION

NANDROLONE DECANOATE

>A>	! LUITPOLD PHARMS INC	200MG/ML	A091252	001	Aug 30, 2010	Jun CAHN
-----	-----------------------	----------	---------	-----	--------------	----------

>D>	! PHARMAFORCE	200MG/ML	A091252	001	Aug 30, 2010	Jun CAHN
-----	---------------	----------	---------	-----	--------------	----------

NAPROXEN

TABLET; ORAL

NAPROXEN

AB	AUROBINDO PHARMA LTD	250MG	A200429	001	Nov 08, 2011	Jan CAHN
AB		375MG	A200429	002	Nov 08, 2011	Jan CAHN
AB		500MG	A200429	003	Nov 08, 2011	Jan CAHN
	@ CHARTWELL MOLECULES	250MG	A074410	001	Apr 28, 1995	May CAHN
	@	375MG	A074410	002	Apr 28, 1995	May CAHN
	@	500MG	A074410	003	Apr 28, 1995	May CAHN
	@ HIKMA INTL PHARMS	250MG	A076494	001	Jan 14, 2004	May DISC
	@	375MG	A076494	002	Jan 14, 2004	May DISC
	@	500MG	A076494	003	Jan 14, 2004	May DISC
	@ WATSON LABS TEVA	250MG	A074163	001	Feb 10, 1995	May CAHN
	@	375MG	A074163	002	Feb 10, 1995	May CAHN
	@	500MG	A074163	003	Feb 10, 1995	May CAHN

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

AB	GLENMARK PHARMS LTD	EQ 250MG BASE	A078314	001	Apr 27, 2007	May CAHN
AB		EQ 500MG BASE	A078314	002	Apr 27, 2007	May CAHN

NATAMYCIN

SUSPENSION; OPHTHALMIC

NATACYN

	+! NOVARTIS PHARMS CORP	5%	N050514	001		Jan CAHN
--	-------------------------	----	---------	-----	--	----------

NEBIVOLOL HYDROCHLORIDE

TABLET; ORAL

NEBIVOLOL HYDROCHLORIDE

	@ GLENMARK PHARMS LTD	EQ 2.5MG BASE	A203821	001	May 25, 2017	May DISC
AB		EQ 2.5MG BASE	A203821	001	May 25, 2017	May NEWA
	@	EQ 5MG BASE	A203821	002	May 25, 2017	May DISC
AB		EQ 5MG BASE	A203821	002	May 25, 2017	May NEWA
	@	EQ 10MG BASE	A203821	003	May 25, 2017	May DISC
AB		EQ 10MG BASE	A203821	003	May 25, 2017	May NEWA

	TABLET;ORAL						
	NEBIVOLOL HYDROCHLORIDE						
	@	EQ 20MG BASE	A203821	004	May 25, 2017	May	DISC
AB		EQ 20MG BASE	A203821	004	May 25, 2017	May	NEWA
	<u>NEBIVOLOL HYDROCHLORIDE; VALSARTAN</u>						
	TABLET;ORAL						
	BYVALSON						
	+!	FOREST LABS LLC	EQ 5MG BASE;80MG	N206302	001	Jun 03, 2016	May CRLD
	<u>NELFINAVIR MESYLATE</u>						
	POWDER;ORAL						
	VIRACEPT						
	@	AGOURON PHARMS	EQ 50MG BASE/SCOOPFUL	N020778	001	Mar 14, 1997	Jan CAHN
	TABLET;ORAL						
	VIRACEPT						
	+!	AGOURON PHARMS	EQ 250MG BASE	N020779	001	Mar 14, 1997	Jan CAHN
	+!		EQ 625MG BASE	N021503	001	Apr 30, 2003	Jan CAHN
	<u>NEOMYCIN SULFATE</u>						
	SOLUTION;ORAL						
	NEO-FRADIN						
	@	X GEN PHARMS	EQ 87.5MG BASE/5ML	A065010	001	May 23, 2002	Feb DISC
	<u>NEOMYCIN SULFATE; POLYMYXIN B SULFATE</u>						
	SOLUTION;IRRIGATION						
	NEOSPORIN G.U. IRRIGANT						
AT	!	MONARCH PHARMS	EQ 40MG BASE/ML;200,000 UNITS/ML	A060707	001		Apr CAHN
	<u>NEOSTIGMINE METHYLSULFATE</u>						
	SOLUTION;INTRAVENOUS						
	NEOSTIGMINE METHYLSULFATE						
AP		PAR STERILE PRODUCTS	5MG/10ML (0.5MG/ML)	A208405	001	Apr 26, 2017	Apr NEWA
AP			10MG/10ML (1MG/ML)	A208405	002	Apr 26, 2017	Apr NEWA
	<u>NEVIRAPINE</u>						
	TABLET, EXTENDED RELEASE;ORAL						
	NEVIRAPINE						
AB		AUROBINDO PHARMA LTD	400MG	A207698	001	Feb 28, 2017	Mar CAHN
AB		AUROBINDO PHARMA USA	400MG	A207698	001	Feb 28, 2017	Feb NEWA
	<u>NIACIN</u>						
	TABLET;ORAL						
	NIACOR						
AA	!	UPSHER SMITH	500MG	A040378	001	May 03, 2000	Jun CAHN
AA	!	UPSHER-SMITH LABS	500MG	A040378	001	May 03, 2000	Jun CAHN
	TABLET, EXTENDED RELEASE;ORAL						
	NIACIN						
AB		LANNETT	500MG	A203899	001	Jun 16, 2017	Jun NEWA
AB			1GM	A203899	002	Jun 16, 2017	Jun NEWA
	<u>NICARDIPINE HYDROCHLORIDE</u>						
	INJECTABLE;INJECTION						
	NICARDIPINE HYDROCHLORIDE						
AP		WEST-WARD PHARMS INT	25MG/10ML (2.5MG/ML)	A078714	001	Dec 28, 2009	Jan CAHN
	INJECTABLE;INTRAVENOUS						
	NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE						
		EXELA PHARMA SCIENCE	20MG/200ML (0.1MG/ML)	N022276	002	Apr 07, 2016	Feb NEWA
			40MG/200ML (0.2MG/ML)	N022276	003	Apr 07, 2016	Feb NEWA
	<u>NIFEDIPINE</u>						
	TABLET, EXTENDED RELEASE;ORAL						
	AFEDITAB CR						
AB1		WATSON LABS TEVA	30MG	A075128	001	Mar 10, 2000	May CAHN
	NIFEDIPINE						
	@	MYLAN LABS LTD	30MG	A090602	001	Sep 13, 2010	May DISC
AB2			30MG	A090602	001	Sep 13, 2010	Mar CAHN
	@		60MG	A090602	002	Sep 13, 2010	May DISC
AB2			60MG	A090602	002	Sep 13, 2010	Mar CAHN
	@		90MG	A090602	003	Sep 13, 2010	May DISC
AB2			90MG	A090602	003	Sep 13, 2010	Mar CAHN

TABLET, EXTENDED RELEASE;ORAL
NIFEDIPINE

>D>	AB2	OSMOTICA PHARM	90MG	A077410	001	Oct 03, 2007	Jun CAHN
>A>	AB2	OSMOTICA PHARM US	90MG	A077410	001	Oct 03, 2007	Jun CAHN

NIRAPARIB TOSYLATE

CAPSULE;ORAL
ZEJULA

+	!	TESARO INC	EQ 100MG BASE	N208447	001	Mar 27, 2017	Mar NEWA
---	---	------------	---------------	---------	-----	--------------	----------

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL
SULAR

AB	+	!	COVIS PHARMA BV	8.5MG	N020356	008	Jan 02, 2008	May CAHN
	+	@		10MG	N020356	001	Feb 02, 1995	May CAHN
AB	+	!		17MG	N020356	007	Jan 02, 2008	May CAHN
	+	@		20MG	N020356	002	Feb 02, 1995	May CAHN
	+	@		25.5MG	N020356	006	Jan 02, 2008	May CAHN
	+	@		30MG	N020356	003	Feb 02, 1995	May CAHN
AB	+	!		34MG	N020356	005	Jan 02, 2008	May CAHN
	+	@		40MG	N020356	004	Feb 02, 1995	May CAHN

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

AB		AMNEAL PHARMS	75MG;25MG	A207372	001	May 15, 2017	May NEWA
----	--	---------------	-----------	---------	-----	--------------	----------

NITROGLYCERIN

FILM, EXTENDED RELEASE;TRANSDERMAL
NITRO-DUR

>D>	AB1	+	!	MERCK SHARP DOHME	0.1MG/HR	N020145	001	Apr 04, 1995	Jun CAHN
>D>	AB1	+	!		0.2MG/HR	N020145	002	Apr 04, 1995	Jun CAHN
>D>		+	!		0.3MG/HR	N020145	003	Apr 04, 1995	Jun CAHN
>D>	AB1	+	!		0.4MG/HR	N020145	004	Apr 04, 1995	Jun CAHN
>D>	AB1	+	!		0.6MG/HR	N020145	005	Apr 04, 1995	Jun CAHN
>D>		+	!		0.8MG/HR	N020145	006	Apr 04, 1995	Jun CAHN
>A>	AB1	+	!	USPHARMA	0.1MG/HR	N020145	001	Apr 04, 1995	Jun CAHN
>A>	AB1	+	!		0.2MG/HR	N020145	002	Apr 04, 1995	Jun CAHN
>A>		+	!		0.3MG/HR	N020145	003	Apr 04, 1995	Jun CAHN
>A>	AB1	+	!		0.4MG/HR	N020145	004	Apr 04, 1995	Jun CAHN
>A>	AB1	+	!		0.6MG/HR	N020145	005	Apr 04, 1995	Jun CAHN
>A>		+	!		0.8MG/HR	N020145	006	Apr 04, 1995	Jun CAHN

OINTMENT;TRANSDERMAL

NITROGLYCERIN

!		FOUGERA PHARMS INC	2%	A087355	001	Jul 08, 1988	Jan CAHN
---	--	--------------------	----	---------	-----	--------------	----------

NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

NOREPINEPHRINE BITARTRATE

AP		WEST-WARD PHARMS INT	EQ 1MG BASE/ML	A040462	001	Oct 31, 2003	Jan CAHN
----	--	----------------------	----------------	---------	-----	--------------	----------

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE;ORAL

NORTRIPTYLINE HYDROCHLORIDE

>D>	AB		MYLAN	EQ 10MG BASE	A074234	001	Jul 26, 1993	Jun DISC
>A>		@		EQ 10MG BASE	A074234	001	Jul 26, 1993	Jun DISC
>D>	AB			EQ 25MG BASE	A074234	002	Jul 26, 1993	Jun DISC
>A>		@		EQ 25MG BASE	A074234	002	Jul 26, 1993	Jun DISC
>D>	AB			EQ 50MG BASE	A074234	003	Jul 26, 1993	Jun DISC
>A>		@		EQ 50MG BASE	A074234	003	Jul 26, 1993	Jun DISC
>D>	AB			EQ 75MG BASE	A074234	004	Jul 26, 1993	Jun DISC
>A>		@		EQ 75MG BASE	A074234	004	Jul 26, 1993	Jun DISC
	AB		TARO PHARM	EQ 10MG BASE	A075520	004	May 08, 2000	Mar CAHN
	AB			EQ 25MG BASE	A075520	003	May 08, 2000	Mar CAHN
	AB			EQ 50MG BASE	A075520	001	May 08, 2000	Mar CAHN
	AB			EQ 75MG BASE	A075520	002	May 08, 2000	Mar CAHN

SOLUTION;ORAL

NORTRIPTYLINE HYDROCHLORIDE

AA	!	PHARM ASSOC	EQ 10MG BASE/5ML	A075606	001	Aug 28, 2000	May CAHN
----	---	-------------	------------------	---------	-----	--------------	----------

NYSTATIN

PASTILLE;ORAL

MYCOSTATIN

>D>	@ BRISTOL MYERS SQUIBB	200,000 UNITS	N050619	001	Apr 09, 1987	Jun CAHN
>A>	@ DELCOR ASSET CORP	200,000 UNITS	N050619	001	Apr 09, 1987	Jun CAHN

POWDER;TOPICAL

NYSTATIN

AT	LYNE	100,000 UNITS/GM	A208838	001	May 30, 2017	May NEWA
AT	NESHER PHARMS	100,000 UNITS/GM	A208581	001	Jun 08, 2017	May NEWA
>D> AT	UPSHER SMITH	100,000 UNITS/GM	A065183	001	May 03, 2005	Jun CAHN
>A> AT	UPSHER-SMITH LABS	100,000 UNITS/GM	A065183	001	May 03, 2005	Jun CAHN

SUSPENSION;ORAL

NYSTATIN

AA	FOUGERA PHARMS INC	100,000 UNITS/ML	A062517	001	Jun 07, 1984	Jan CAHN
AA	PHARM ASSOC	100,000 UNITS/ML	A203621	001	Jan 07, 2016	May CAHN
AA	TARO PHARM	100,000 UNITS/ML	A062876	001	Feb 29, 1988	Apr CAHN

TABLET;ORAL

NYSTATIN

>D>	@ USL PHARMA	500,000 UNITS	A062524	001	Nov 26, 1985	Jun CAHN
>A>	@	500,000 UNITS	A062524	001	Nov 26, 1985	Jun CAHN

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

MYCOLOG-II

	@ MYLAN PHARMS INC	100,000 UNITS/GM;0.1%	A062606	001	May 15, 1985	Jan CAHN
AT	FOUGERA PHARMS INC	100,000 UNITS/GM;0.1%	A062599	001	Oct 08, 1985	Jan CAHN

OINTMENT;TOPICAL

MYCOLOG-II

	@ MYLAN PHARMS INC	100,000 UNITS/GM;0.1%	A060572	001	Jun 28, 1985	Jan CAHN
AT	DR REDDYS LABS LTD	100,000 UNITS/GM;0.1%	A207741	001	Jan 31, 2017	Jan NEWA
AT	FOUGERA PHARMS INC	100,000 UNITS/GM;0.1%	A062602	001	Oct 09, 1985	Jan CAHN

OFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

OFLOXACIN

AT	SANDOZ INC	0.3%	A076231	001	May 14, 2004	Feb CAHN
----	------------	------	---------	-----	--------------	----------

SOLUTION/DROPS;OTIC

OFLOXACIN

AT	SANDOZ INC	0.3%	A078222	001	Mar 17, 2008	Feb CAHN
----	------------	------	---------	-----	--------------	----------

OLANZAPINE

TABLET;ORAL

OLANZAPINE

>A> AB	HIKMA PHARMS LLC	2.5MG	A204866	001	Jun 16, 2017	Jun NEWA
>A> AB		5MG	A204866	002	Jun 16, 2017	Jun NEWA
>A> AB		7.5MG	A204866	003	Jun 16, 2017	Jun NEWA
>A> AB		10MG	A204866	004	Jun 16, 2017	Jun NEWA
>A> AB		15MG	A204866	005	Jun 16, 2017	Jun NEWA
>A> AB		20MG	A204866	006	Jun 16, 2017	Jun NEWA
>D> AB	MYLAN PHARMS INC	2.5MG	A076866	001	Apr 23, 2012	Jun DISC
>A>	@	2.5MG	A076866	001	Apr 23, 2012	Jun DISC
AB		2.5MG	A076866	001	Apr 23, 2012	Mar CAHN
>D> AB		5MG	A076866	002	Apr 23, 2012	Jun DISC
>A>	@	5MG	A076866	002	Apr 23, 2012	Jun DISC
AB		5MG	A076866	002	Apr 23, 2012	Mar CAHN
>D> AB		7.5MG	A076866	003	Apr 23, 2012	Jun DISC
>A>	@	7.5MG	A076866	003	Apr 23, 2012	Jun DISC
AB		7.5MG	A076866	003	Apr 23, 2012	Mar CAHN
>D> AB		10MG	A076866	004	Apr 23, 2012	Jun DISC
>A>	@	10MG	A076866	004	Apr 23, 2012	Jun DISC
AB		10MG	A076866	004	Apr 23, 2012	Mar CAHN
>D> AB		15MG	A076866	005	Apr 23, 2012	Jun DISC
>A>	@	15MG	A076866	005	Apr 23, 2012	Jun DISC
AB		15MG	A076866	005	Apr 23, 2012	Mar CAHN
>D> AB		20MG	A076866	006	Apr 23, 2012	Jun DISC
>A>	@	20MG	A076866	006	Apr 23, 2012	Jun DISC
AB		20MG	A076866	006	Apr 23, 2012	Mar CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
OLANZAPINE

AB	AJANTA PHARMA LTD	5MG	A204320	001	May 30, 2017	May NEWA
AB		10MG	A204320	002	May 30, 2017	May NEWA
AB		15MG	A204320	003	May 30, 2017	May NEWA
AB		20MG	A204320	004	May 30, 2017	May NEWA

OLAPARIB

CAPSULE;ORAL
LYNPARZA

+!	ASTRAZENECA PHARMS	50MG	N206162	001	Dec 19, 2014	Mar CRLD
----	--------------------	------	---------	-----	--------------	----------

OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL

AB	ACCORD HLTHCARE	5MG	A207662	001	Apr 24, 2017	Apr NEWA
AB		20MG	A207662	002	Apr 24, 2017	Apr NEWA
AB		40MG	A207662	003	Apr 24, 2017	Apr NEWA
AB	ALEMBIC PHARMS LTD	5MG	A203012	001	Apr 24, 2017	Apr NEWA
AB		20MG	A203012	002	Apr 24, 2017	Apr NEWA
AB		40MG	A203012	003	Apr 24, 2017	Apr NEWA
AB	ALKEM LABS LTD	5MG	A206763	001	Apr 24, 2017	Apr NEWA
AB		20MG	A206763	002	Apr 24, 2017	Apr NEWA
AB		40MG	A206763	003	Apr 24, 2017	Apr NEWA
AB	AUROBINDO PHARMA LTD	5MG	A204798	001	Apr 24, 2017	Apr NEWA
AB		20MG	A204798	002	Apr 24, 2017	Apr NEWA
AB		40MG	A204798	003	Apr 24, 2017	Apr NEWA
AB	GLENMARK PHARMS LTD	5MG	A203281	001	May 25, 2017	May NEWA
AB		20MG	A203281	002	May 25, 2017	May NEWA
AB		40MG	A203281	003	May 25, 2017	May NEWA
AB	JUBILANT GENERICS	5MG	A205482	001	Apr 24, 2017	Apr NEWA
AB		20MG	A205482	002	Apr 24, 2017	Apr NEWA
AB		40MG	A205482	003	Apr 24, 2017	Apr NEWA
AB	LUPIN LTD	5MG	A206631	001	Apr 27, 2017	Apr NEWA
AB		20MG	A206631	002	Apr 27, 2017	Apr NEWA
AB		40MG	A206631	003	Apr 27, 2017	Apr NEWA
AB	MACLEODS PHARMS LTD	5MG	A204814	001	Apr 24, 2017	Apr NEWA
AB		20MG	A204814	002	Apr 24, 2017	Apr NEWA
AB		40MG	A204814	003	Apr 24, 2017	Apr NEWA
AB	TEVA PHARMS USA	5MG	A091079	001	Apr 24, 2017	Apr NEWA
AB		20MG	A091079	002	Apr 24, 2017	Apr NEWA
AB		40MG	A091079	003	Apr 24, 2017	Apr NEWA
AB	TORRENT PHARMS LTD	5MG	A202375	001	Apr 24, 2017	Apr NEWA
AB		20MG	A202375	002	Apr 24, 2017	Apr NEWA
AB		40MG	A202375	003	Apr 24, 2017	Apr NEWA
AB	ZYDUS PHARMS USA INC	5MG	A205192	001	Apr 24, 2017	Apr NEWA
AB		20MG	A205192	002	Apr 24, 2017	Apr NEWA
AB		40MG	A205192	003	Apr 24, 2017	Apr NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
OLOPATADINE HYDROCHLORIDE

>A>	AT	WOCKHARDT LTD	EQ 0.1% BASE	A200810	001	Jun 28, 2017	Jun NEWA
-----	----	---------------	--------------	---------	-----	--------------	----------

SPRAY, METERED;NASAL
OLOPATADINE HYDROCHLORIDE

AB	PERRIGO ISRAEL	0.665MG/SPRAY	A202853	001	Jan 31, 2017	Jan NEWA
----	----------------	---------------	---------	-----	--------------	----------

OLSALAZINE SODIUM

CAPSULE;ORAL
DIPENTUM

+!	MYLAN SPECIALITY LP	250MG	N019715	001	Jul 31, 1990	Mar CAHN
----	---------------------	-------	---------	-----	--------------	----------

OMACETAXINE MEPEUSUCCINATE

POWDER;SUBCUTANEOUS
SYNRIBO

+!	TEVA PHARMS INTL	3.5MG/VIAL	N203585	001	Oct 26, 2012	Apr CAHN
----	------------------	------------	---------	-----	--------------	----------

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL

OMEGA-3-ACID ETHYL ESTERS

AB	AMNEAL PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A204940	001	Nov 27, 2015	May CAHN
----	---------------	--	---------	-----	--------------	----------

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

OMEPRAZOLE

AB	AUROBINDO PHARMA LTD	10MG	A203270	001	Aug 19, 2015	Jan CAHN
AB		20MG	A203270	002	Aug 19, 2015	Jan CAHN
AB		40MG	A203270	003	Aug 19, 2015	Jan CAHN
>A> AB	BRECKENRIDGE PHARM	10MG	A203481	001	Jul 03, 2017	Jun NEWA
>A> AB		20MG	A203481	002	Jul 03, 2017	Jun NEWA
>A> AB		40MG	A203481	003	Jul 03, 2017	Jun NEWA
AB	TEVA PHARMS USA	20MG	A204661	001	Jun 13, 2017	May NEWA
AB		40MG	A204661	002	Jun 13, 2017	May NEWA

OMEPRAZOLE MAGNESIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL

PRILOSEC

+	COVIS PHARMA BV	EQ 2.5MG BASE/PACKET	N022056	001	Mar 20, 2008	May CAHN
+	!	EQ 10MG BASE/PACKET	N022056	002	Mar 20, 2008	May CAHN

OMEPRAZOLE; SODIUM BICARBONATE

FOR SUSPENSION;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

AB	AJANTA PHARMA LTD	20MG/PACKET;1.68GM/PACKET	A205545	001	Jul 27, 2016	Jan CTEC
AB		40MG/PACKET;1.68GM/PACKET	A205545	002	Jul 27, 2016	Jan CTEC
AB	PAR PHARM	20MG/PACKET;1.68GM/PACKET	A079182	001	Apr 19, 2013	Jan CMFD
AB		40MG/PACKET;1.68GM/PACKET	A079182	002	Apr 19, 2013	Jan CMFD
	ZEGERID					
AB	+ SANTARUS INC	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Jan CTEC
AB	+	40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Jan CTEC

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

@	CHARTWELL MOLECULES	4MG	A076506	001	Dec 26, 2006	Mar CAHN
@		8MG	A076506	002	Dec 26, 2006	Mar CAHN
@		16MG	A077406	001	Dec 26, 2006	Mar CAHN
@		24MG	A077406	002	Dec 26, 2006	Mar CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ONDANSETRON HYDROCHLORIDE

AP	SANDOZ INC	EQ 2MG BASE/ML	A077430	001	Jun 27, 2007	Mar CAHN
AP	WEST-WARD PHARMS INT	EQ 2MG BASE/ML	A076967	001	Dec 26, 2006	Jan CAHN
	ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE					
AP	SANDOZ INC	EQ 2MG BASE/ML	A077551	001	Jun 27, 2007	Mar CAHN
AP	WEST-WARD PHARMS INT	EQ 2MG BASE/ML	A077011	001	Dec 26, 2006	Jan CAHN
AP		EQ 2MG BASE/ML	A077541	001	Dec 26, 2006	Jan CAHN
	ZOFRAN					
+	@ NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	001	Jan 04, 1991	Mar CRLD
	ZOFRAN PRESERVATIVE FREE					
+	@ NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	003	Dec 10, 1993	Mar CRLD

ORPHENADRINE CITRATE

INJECTABLE;INJECTION

NORFLEX

@	TELIGENT	30MG/ML	N013055	001		Apr CAHN
---	----------	---------	---------	-----	--	----------

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

AB	AMNEAL PHARMS	EQ 30MG BASE	A209093	001	May 17, 2017	May NEWA
AB		EQ 45MG BASE	A209093	002	May 17, 2017	May NEWA
AB		EQ 75MG BASE	A209093	003	May 17, 2017	May NEWA
AB	NESHER PHARMS	EQ 30MG BASE	A208578	001	Feb 24, 2017	Feb NEWA
AB		EQ 45MG BASE	A208578	002	Feb 24, 2017	Feb NEWA

CAPSULE;ORAL							
OSELTAMIVIR PHOSPHATE							
AB		EQ 75MG BASE		A208578	003	Feb 24, 2017	Feb NEWA
<u>OSPENIFENE</u>							
TABLET;ORAL							
OSPENIFENE							
+	! DUCHESNAY	60MG		N203505	001	Feb 26, 2013	Mar CAHN
<u>OXALIPLATIN</u>							
INJECTABLE;IV (INFUSION)							
ELOXATIN							
+	@ SANOFI AVENTIS US	200MG/40ML (5MG/ML)		N021759	003	Nov 17, 2006	Jan CRLD
OXALIPLATIN							
AP	ACCORD HLTHCARE	50MG/10ML (5MG/ML)		A207474	001	Mar 21, 2017	Mar NEWA
AP		100MG/20ML (5MG/ML)		A207474	002	Mar 21, 2017	Mar NEWA
AP		200MG/40ML (5MG/ML)		A207474	003	Mar 21, 2017	Mar NEWA
AP	CIPLA LTD	50MG/10ML (5MG/ML)		A208523	001	Feb 10, 2017	Jan NEWA
AP		100MG/20ML (5MG/ML)		A208523	002	Feb 10, 2017	Jan NEWA
AP	FRESENIUS KABI USA	50MG/10ML (5MG/ML)		A090030	001	Jan 31, 2017	Jan NEWA
AP		100MG/20ML (5MG/ML)		A090030	002	Jan 31, 2017	Jan NEWA
AP		200MG/40ML (5MG/ML)		A090030	003	Jan 31, 2017	Jan NEWA
AP	GLAND PHARMA LTD	50MG/10ML (5MG/ML)		A207325	001	Feb 10, 2017	Jan NEWA
AP		50MG/VIAL		A207385	001	May 23, 2017	May NEWA
AP		100MG/20ML (5MG/ML)		A207325	002	Feb 10, 2017	Jan NEWA
AP		100MG/VIAL		A207385	002	May 23, 2017	May NEWA
AP	LUITPOLD PHARMS INC	50MG/10ML (5MG/ML)		A204378	001	May 12, 2017	May NEWA
AP		100MG/20ML (5MG/ML)		A204378	002	May 12, 2017	May NEWA
AP	! QILU PHARM CO LTD	200MG/40ML (5MG/ML)		A204368	003	Jun 07, 2016	Jan CTEC
<u>OXANDROLONE</u>							
TABLET;ORAL							
OXANDROLONE							
>D>	AB UPSHER SMITH	2.5MG		A076761	001	Dec 01, 2006	Jun CAHN
>D>	AB	10MG		A078033	001	Mar 22, 2007	Jun CAHN
>A>	AB UPSHER-SMITH LABS	2.5MG		A076761	001	Dec 01, 2006	Jun CAHN
>A>	AB	10MG		A078033	001	Mar 22, 2007	Jun CAHN
<u>OXAPROZIN</u>							
TABLET;ORAL							
OXAPROZIN							
AB	AMNEAL PHARMS CO	600MG		A208633	001	May 04, 2017	Apr NEWA
<u>OXAZEPAM</u>							
CAPSULE;ORAL							
OXAZEPAM							
AB	ACTAVIS ELIZABETH	10MG		A072253	002	Apr 14, 1988	May CMS1
AB		15MG		A072253	003	Apr 14, 1988	May CMS1
	@ WATSON LABS TEVA	10MG		A072952	001	Sep 28, 1990	May CAHN
TABLET;ORAL							
OXAZEPAM							
	@ SUN PHARM INDS	15MG		A070683	001	Jan 16, 1987	Jan CAHN
<u>OXCARBAZEPINE</u>							
TABLET;ORAL							
OXCARBAZEPINE							
AB	GLENMARK PHARMS LTD	150MG		A077802	001	Oct 09, 2007	May CAHN
AB		300MG		A077802	002	Oct 09, 2007	May CAHN
AB		600MG		A077802	003	Oct 09, 2007	May CAHN
AB	JUBILANT CADISTA	150MG		A090239	001	Jan 25, 2010	Apr CAHN
AB		300MG		A090239	002	Jan 25, 2010	Apr CAHN
AB		600MG		A090239	003	Jan 25, 2010	Apr CAHN
<u>OXYBUTYNIN</u>							
GEL, METERED;TRANSDERMAL							
GELNIQUE 3%							
+	@ ALLERGAN SALES LLC	3%		N202513	001	Dec 07, 2011	Feb DISC

OXYBUTYNIN CHLORIDE

		SYRUP;ORAL						
		DITROPAN						
		+ @ ORTHO MCNEIL JANSSEN	5MG/5ML	N018211	001			Jan CRLD
		OXYBUTYNIN CHLORIDE						
AA		PHARM ASSOC	5MG/5ML	A075137	001	Dec 18, 1998		May CAHN
		TABLET;ORAL						
		OXYBUTYNIN CHLORIDE						
>D>	AB	USL PHARMA	5MG	A074625	001	Jul 31, 1996		Jun CAHN
>A>	AB		5MG	A074625	001	Jul 31, 1996		Jun CAHN
		TABLET, EXTENDED RELEASE;ORAL						
		OXYBUTYNIN CHLORIDE						
>A>	AB	ZYDUS PHARMS USA INC	5MG	A202332	001	Jun 26, 2017		Jun NEWA
>A>	AB		10MG	A202332	002	Jun 26, 2017		Jun NEWA
>A>	AB		15MG	A202332	003	Jun 26, 2017		Jun NEWA

OXYCODONE HYDROCHLORIDE

		TABLET;ORAL						
		OXYCODONE HYDROCHLORIDE						
AB		EPIC PHARMA LLC	5MG	A090895	001	Aug 24, 2009		May CAHN
AB			15MG	A090895	002	Aug 24, 2009		May CAHN
AB			30MG	A090895	003	Aug 24, 2009		May CAHN
AB		NOVEL LABS INC	5MG	A204021	001	Jun 12, 2017		May NEWA
AB			10MG	A204021	002	Jun 12, 2017		May NEWA
AB			15MG	A204021	003	Jun 12, 2017		May NEWA
AB			20MG	A204021	004	Jun 12, 2017		May NEWA
AB			30MG	A204021	005	Jun 12, 2017		May NEWA
		ROXYBOND						
		INSPIRION DELIVERY	5MG	N209777	001	Apr 20, 2017		Apr NEWA
			15MG	N209777	002	Apr 20, 2017		Apr NEWA
			30MG	N209777	003	Apr 20, 2017		Apr NEWA

OXYMETAZOLINE HYDROCHLORIDE

		CREAM;TOPICAL						
		RHOFADE						
		+! ALLERGAN INC	1%	N208552	001	Jan 18, 2017		Jan NEWA

OXYMETHOLONE

		TABLET;ORAL						
		ANADROL-50						
		+! MYLAN SPECIALITY LP	50MG	N016848	001			Mar CAHN

OXYMORPHONE HYDROCHLORIDE

		TABLET;ORAL						
		OXYMORPHONE HYDROCHLORIDE						
AB		EPIC PHARMA LLC	5MG	A201187	001	Dec 15, 2014		May CAHN
AB			10MG	A201187	002	Dec 15, 2014		May CAHN
		TABLET, EXTENDED RELEASE;ORAL						
		OXYMORPHONE HYDROCHLORIDE						
AB		ACTAVIS ELIZABETH	5MG	A079046	003	Jul 11, 2013		Apr CAHN
AB			7.5MG	A079046	001	Dec 13, 2010		Apr CAHN
AB			10MG	A079046	004	Jul 11, 2013		Apr CAHN
AB			15MG	A079046	002	Dec 13, 2010		Apr CAHN
AB			20MG	A079046	005	Jul 11, 2013		Apr CAHN
AB			30MG	A079046	006	Jul 11, 2013		Apr CAHN
AB			40MG	A079046	007	Jul 11, 2013		Apr CAHN
		@ PAR PHARM	5MG	A200792	001	Oct 24, 2014		May DISC
		@	7.5MG	A200792	002	Oct 24, 2014		May DISC
		@	10MG	A200792	003	Oct 24, 2014		May DISC
		@	15MG	A200792	004	Oct 24, 2014		May DISC
		@	20MG	A200792	005	Oct 24, 2014		May DISC
		@	30MG	A200792	006	Oct 24, 2014		May DISC
		@	40MG	A200792	007	Oct 24, 2014		May DISC

PANTOPRAZOLE SODIUM

		POWDER;IV (INFUSION)						
		PANTOPRAZOLE SODIUM						
>A>		EXELA PHARMA SCS LLC	EQ 40MG BASE/VIAL	N209463	001	Jun 30, 2017		Jun NEWA

TABLET, DELAYED RELEASE;ORAL
PANTOPRAZOLE SODIUM

AB	SUN PHARM INDS LTD	EQ 20MG BASE	A077058	001	Sep 10, 2007	Mar CAHN
AB		EQ 40MG BASE	A077058	002	Sep 10, 2007	Mar CAHN

PARICALCITOL

CAPSULE;ORAL

	PARICALCITOL					
AB	AMNEAL PHARMS	1MCG	A204327	001	Jan 13, 2016	May CAHN
AB		2MCG	A204327	002	Jan 13, 2016	May CAHN
AB		4MCG	A204327	003	Jan 13, 2016	May CAHN

SOLUTION;INTRAVENOUS

	PARICALCITOL					
AP	AMNEAL PHARMS CO	0.002MG/ML (0.002MG/ML)	A206699	001	Mar 09, 2017	Feb NEWA
AP		0.005MG/ML (0.005MG/ML)	A206699	002	Mar 09, 2017	Feb NEWA
AP		0.01MG/2ML (0.005MG/ML)	A206699	003	Mar 09, 2017	Feb NEWA
AP	SANDOZ INC	0.002MG/ML (0.002MG/ML)	A091108	001	Jul 27, 2011	Apr CAHN
AP		0.005MG/ML (0.005MG/ML)	A091108	002	Jul 27, 2011	Apr CAHN
AP		0.01MG/2ML (0.005MG/ML)	A091108	003	Jul 27, 2011	Apr CAHN

PAROXETINE HYDROCHLORIDE

TABLET;ORAL

PAROXETINE HYDROCHLORIDE

	@ MYLAN PHARMS INC	EQ 10MG BASE	A075716	001	Mar 08, 2004	Apr DISC
	@	EQ 20MG BASE	A075716	002	Mar 08, 2004	Apr DISC
	@	EQ 30MG BASE	A075716	003	Mar 08, 2004	Apr DISC
	@	EQ 40MG BASE	A075716	004	Mar 08, 2004	Apr DISC
>D>	@ UPSHER-SMITH LABS	EQ 10MG BASE	A075566	001	Mar 08, 2004	Jun CAHN
>A>	@	EQ 10MG BASE	A075566	001	Mar 08, 2004	Jun CAHN
>D>	@	EQ 20MG BASE	A075566	002	Mar 08, 2004	Jun CAHN
>A>	@	EQ 20MG BASE	A075566	002	Mar 08, 2004	Jun CAHN
>D>	@	EQ 30MG BASE	A075566	003	Mar 08, 2004	Jun CAHN
>A>	@	EQ 30MG BASE	A075566	003	Mar 08, 2004	Jun CAHN
>D>	@	EQ 40MG BASE	A075566	004	Mar 08, 2004	Jun CAHN
>A>	@	EQ 40MG BASE	A075566	004	Mar 08, 2004	Jun CAHN

TABLET, EXTENDED RELEASE;ORAL

PAROXETINE HYDROCHLORIDE

AB	LUPIN LTD	EQ 12.5MG BASE	A204134	001	Jan 20, 2017	Jan NEWA
AB		EQ 25MG BASE	A204134	002	Jan 20, 2017	Jan NEWA
AB		EQ 37.5MG BASE	A204134	003	Jan 20, 2017	Jan NEWA

PAROXETINE MESYLATE

CAPSULE;ORAL

BRISDELLE

>D>	+! SEBELA IRELAND LTD	EQ 7.5MG BASE	N204516	001	Jun 28, 2013	Jun CFTG
>A>	AB +!	EQ 7.5MG BASE	N204516	001	Jun 28, 2013	Jun CFTG
>A>	PAROXETINE MESYLATE					
>A>	AB ACTAVIS LABS FL INC	EQ 7.5MG BASE	A207139	001	Jun 20, 2017	Jun NEWA

PENCICLOVIR

CREAM;TOPICAL

DENA VIR

+!	MYLAN PHARMS INC	1%	N020629	001	Sep 24, 1996	Jan CAHN
----	------------------	----	---------	-----	--------------	----------

PENICILLAMINE

TABLET;ORAL

DEPEN

+!	MYLAN SPECIALITY LP	250MG	N019854	001		Mar CAHN
----	---------------------	-------	---------	-----	--	----------

PENICILLIN G BENZATHINE

INJECTABLE;INJECTION

BICILLIN L-A

+!	KING PHARMS LLC	300,000 UNITS/ML	N050141	003		May CAHN
BC	+!	600,000 UNITS/ML	N050141	001		May CAHN

PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE

INJECTABLE;INJECTION

BICILLIN C-R

+!	KING PHARMS LLC	150,000 UNITS/ML;150,000 UNITS/ML	N050138	002		Apr CAHN
+!		300,000 UNITS/ML;300,000 UNITS/ML	N050138	001		Apr CAHN

INJECTABLE;INJECTION
BICILLIN C-R 900/300

+!	KING PHARMS LLC	900,000 UNITS/2ML;300,000 UNITS/2ML	N050138	003		Apr	CAHN
----	-----------------	-------------------------------------	---------	-----	--	-----	------

PENICILLIN G PROCAINE

INJECTABLE;INJECTION
PENICILLIN G PROCAINE

>D>	!	KING PHARMS	300,000 UNITS/ML	A060101	002		Jun	CAHN
>D>	!		600,000 UNITS/ML	A060101	001		Jun	CAHN
>A>	!	KING PHARMS LLC	300,000 UNITS/ML	A060101	002		Jun	CAHN
>A>	!		600,000 UNITS/ML	A060101	001		Jun	CAHN

PENTOBARBITAL SODIUM

INJECTABLE;INJECTION
PENTOBARBITAL SODIUM

AP		SAGENT PHARMS	50MG/ML	A206404	001	May 23, 2016	Apr	CAHN
----	--	---------------	---------	---------	-----	--------------	-----	------

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL
PENTOXIL

>D>	AB	UPSHER SMITH	400MG	A074962	001	Mar 31, 1999	Jun	CAHN
>A>	AB	UPSHER-SMITH LABS	400MG	A074962	001	Mar 31, 1999	Jun	CAHN
		TRENTAL						
		+ @ US PHARM HOLDINGS	400MG	N018631	001	Aug 30, 1984	Jan	CRLD

PERINDOPRIL ERBUMINE

TABLET;ORAL
ACEON

		+ @ SYMPLMED PHARMS LLC	2MG	N020184	001	Dec 30, 1993	May	DISC
		+ @	4MG	N020184	002	Dec 30, 1993	May	DISC
		+ @	8MG	N020184	003	Dec 30, 1993	May	DISC
		PERINDOPRIL ERBUMINE						
AB	!	AUROBINDO PHARMA	2MG	A079070	001	Nov 10, 2009	May	CHRS
AB	!		4MG	A079070	002	Nov 10, 2009	May	CHRS
AB	!		8MG	A079070	003	Nov 10, 2009	May	CHRS

PERMETHRIN

CREAM;TOPICAL
ELIMITE

AB	+!	MYLAN PHARMS INC	5%	N019855	001	Aug 25, 1989	Jan	CAHN
		PERMETHRIN						
AB		ACTAVIS LABS	5%	A074806	001	Jan 23, 1998	May	CAHN

PERPHENAZINE

TABLET;ORAL
PERPHENAZINE

AB		MYLAN PHARMS INC	2MG	A206691	001	Apr 14, 2017	Apr	NEWA
AB			4MG	A206691	002	Apr 14, 2017	Apr	NEWA
AB			8MG	A206691	003	Apr 14, 2017	Apr	NEWA
AB			16MG	A206691	004	Apr 14, 2017	Apr	NEWA

PHENDIMETRAZINE TARTRATE

TABLET;ORAL
PHENDIMETRAZINE TARTRATE

>D>		@ USL PHARMA	35MG	A084399	001		Jun	CAHN
>A>		@	35MG	A084399	001		Jun	CAHN

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE;ORAL
PHENOXYBENZAMINE HYDROCHLORIDE

AB		PAR PHARM INC	10MG	A204522	001	Jan 24, 2017	Jan	NEWA
----	--	---------------	------	---------	-----	--------------	-----	------

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL
PHENTERMINE HYDROCHLORIDE

		@ ELITE LABS INC	30MG	A040227	001	Jun 18, 1997	May	CAHN
		@	30MG	A040448	001	Jan 22, 2003	May	CAHN
AA			37.5MG	A040228	001	Jun 19, 1997	May	CAHN
>A>		@ UPSHER-SMITH LABS	30MG	A084487	001	Apr 09, 1982	Jun	CAHN
>A>		@	30MG	A088430	001	Mar 27, 1984	Jun	CAHN
>D>		@ USL PHARMA	30MG	A084487	001	Apr 09, 1982	Jun	CAHN

CAPSULE;ORAL									
PHENTERMINE HYDROCHLORIDE									
>D>	@	30MG	A088430	001	Mar 27, 1984	Jun	CAHN		
TABLET;ORAL									
PHENTERMINE HYDROCHLORIDE									
AA	ELITE LABS INC	37.5MG	A040190	001	May 30, 1997	May	CAHN		
AA	KVK TECH INC	8MG	A203436	001	Mar 17, 2017	Mar	NEWA		
AA	PRINSTON INC	37.5MG	A040377	001	Jan 04, 2002	Feb	CAHN		
TABLET, ORALLY DISINTEGRATING;ORAL									
PHENTERMINE HYDROCHLORIDE									
>A>	ZYDUS PHARMS USA INC	15MG	A204663	001	Jun 28, 2017	Jun	NEWA		
>A>		30MG	A204663	002	Jun 28, 2017	Jun	NEWA		
>A>		37.5MG	A204663	003	Jun 28, 2017	Jun	NEWA		
<u>PHENTOLAMINE MESYLATE</u>									
INJECTABLE;INJECTION									
PHENTOLAMINE MESYLATE									
!	WEST-WARD PHARMS INT	5MG/VIAL	A040235	001	Mar 11, 1998	May	CHRS		
REGITINE									
+	@ NOVARTIS	5MG/VIAL	N008278	003		May	DISC		
<u>PHENYLEPHRINE HYDROCHLORIDE</u>									
SOLUTION;IV (INFUSION)									
VAZCULEP									
+	AVADEL LEGACY	10MG/ML (10MG/ML)	N204300	001	Jun 27, 2014	Jan	CAHN		
+		50MG/5ML (10MG/ML)	N204300	002	Jun 27, 2014	Jan	CAHN		
+	!	100MG/10ML (10MG/ML)	N204300	003	Jun 27, 2014	Jan	CAHN		
<u>PHENYTOIN</u>									
TABLET, CHEWABLE;ORAL									
DILANTIN									
AB	!	PFIZER	50MG	A084427	001		Feb	CAHN	
PHENYTOIN									
AB	EPIC PHARMA LLC	50MG	A040884	001	Nov 28, 2014	May	CAHN		
<u>PHENYTOIN SODIUM</u>									
CAPSULE;ORAL									
DILANTIN									
AB	!	PARKE-DAVIS	30MG EXTENDED	A084349	001		Feb	CAHN	
AB	!		100MG EXTENDED	A084349	002		Feb	CAHN	
INJECTABLE;INJECTION									
PHENYTOIN SODIUM									
AP	ACELLA PHARMS LLC	50MG/ML	A040573	001	Sep 13, 2006	May	CAHN		
	@ HOSPIRA	50MG/ML	A089521	001	Mar 17, 1987	Mar	DISC		
<u>PHYTONADIONE</u>									
INJECTABLE;INJECTION									
AQUAMEPHYTON									
+	@ TELIGENT	1MG/0.5ML	N012223	002		Apr	CAHN		
+	@	10MG/ML	N012223	001		Apr	CAHN		
<u>PILOCARPINE HYDROCHLORIDE</u>									
TABLET;ORAL									
PILOCARPINE HYDROCHLORIDE									
AB	ALLIED PHARMA INC	5MG	A076963	001	Dec 22, 2004	Mar	CAHN		
AB		7.5MG	A076963	002	Feb 27, 2007	Mar	CAHN		
AB	PERRIGO PHARMA INTL	5MG	A076746	001	Nov 16, 2004	Apr	CAHN		
<u>PINDOLOL</u>									
TABLET;ORAL									
PINDOLOL									
AB	IDT AUSTRALIA LTD	5MG	A073608	001	Mar 29, 1993	May	CMFD		
AB		10MG	A073609	001	Mar 29, 1993	May	CMFD		
<u>PIOGLITAZONE HYDROCHLORIDE</u>									
TABLET;ORAL									
PIOGLITAZONE HYDROCHLORIDE									
>A>	AB	CIPLA LTD	EQ 15MG BASE	A076798	001	Oct 26, 2012	Jun	CAHN	
>A>	AB		EQ 30MG BASE	A076798	002	Oct 26, 2012	Jun	CAHN	
>A>	AB		EQ 45MG BASE	A076798	003	Oct 26, 2012	Jun	CAHN	
>D>	AB	WATSON LABS TEVA	EQ 15MG BASE	A076798	001	Oct 26, 2012	Jun	CAHN	

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE

AB		EQ 15MG BASE	A076798	001	Oct 26, 2012	May CAHN
>D>	AB	EQ 30MG BASE	A076798	002	Oct 26, 2012	Jun CAHN
AB		EQ 30MG BASE	A076798	002	Oct 26, 2012	May CAHN
>D>	AB	EQ 45MG BASE	A076798	003	Oct 26, 2012	Jun CAHN
AB		EQ 45MG BASE	A076798	003	Oct 26, 2012	May CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

AP	APOLLO PHARMS INC	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A207847	001	Jan 13, 2017	Jan NEWA
AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A207847	002	Jan 13, 2017	Jan NEWA
AP		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A207848	002	Jan 13, 2017	Jan NEWA
AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A207847	003	Jan 13, 2017	Jan NEWA
AP	WOCKHARDT BIO AG	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A206996	001	Mar 22, 2017	Mar NEWA
AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A206996	002	Mar 22, 2017	Mar NEWA
AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A206996	003	Mar 22, 2017	Mar NEWA
AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A207146	001	Mar 17, 2017	Mar NEWA

PIRFENIDONE

TABLET;ORAL

ESBRIET

+	GENENTECH INC	267MG	N208780	001	Jan 11, 2017	Jan NEWA
+	@	534MG	N208780	002	Jan 11, 2017	Jan DISC
+	!	801MG	N208780	003	Jan 11, 2017	Jan NEWA

PIROXICAM

CAPSULE;ORAL

PIROXICAM

>A>	AB	PII	10MG	A206136	001	Jun 20, 2017	Jun NEWA
>A>	AB		20MG	A206136	002	Jun 20, 2017	Jun NEWA
	AB	UNICHEM LABS LTD	10MG	A208340	001	Apr 13, 2017	Apr NEWA
	AB		20MG	A208340	002	Apr 13, 2017	Apr NEWA

PITAVASTATIN CALCIUM

TABLET;ORAL

PITAVASTATIN CALCIUM

AB	ORIENT PHARMA CO LTD	EQ 1MG BASE	A205932	001	Feb 03, 2017	Jan NEWA
AB		EQ 2MG BASE	A205932	002	Feb 03, 2017	Jan NEWA
AB		EQ 4MG BASE	A205932	003	Feb 03, 2017	Jan NEWA
AB	SAWAI USA	EQ 1MG BASE	A205955	001	Feb 03, 2017	Jan NEWA
AB		EQ 2MG BASE	A205955	002	Feb 03, 2017	Jan NEWA
AB		EQ 4MG BASE	A205955	003	Feb 03, 2017	Jan NEWA

PLECANATIDE

TABLET;ORAL

TRULANCE

+	SYNERGY PHARMS	3MG	N208745	001	Jan 19, 2017	Jan NEWA
---	----------------	-----	---------	-----	--------------	----------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION;ORAL

PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

	@ MYLAN	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A090409	001	Apr 02, 2010	Apr DISC
AA	STRIDES PHARMA	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A204559	001	Apr 13, 2015	Apr CAHN
		PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE				
AA	BRECKENRIDGE PHARM	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A202060	001	Mar 08, 2017	Mar CAHN
AA	BRECKENRIDGE PHARMS	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A202060	001	Mar 08, 2017	Feb NEWA
		TRILYTE				
AA	MYLAN PHARMS INC	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A076491	001	Feb 05, 2004	Mar CAHN

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

COLYTE

	@ MYLAN SPECIALITY LP	120GM/PACKET; 1.49GM/PACKET; 3.36GM/PACKET; 2.92GM/PACKET; 11.36GM/PACKET	N018983	005	Oct 26, 1984	Mar CAHN
	@	227.1GM/PACKET; 2.82GM/PACKET; 6.36GM/PACKET; 5.53GM/PACKET; 21.5GM/PACKET	N018983	004	Oct 26, 1984	Mar CAHN
	@	227.1GM/BOT; 2.82GM/BOT; 6.36GM/BOT; 5.53GM/BOT; 21.5GM/BOT	N018983	010	Jan 31, 1989	Mar CAHN
	@	240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT	N018983	007	Jun 12, 1987	Mar CAHN
	@	360GM/PACKET; 4.47GM/PACKET; 10.08GM/PACKET; 8.76GM/PACKET; 34.08GM/PACKET	N018983	006	Oct 26, 1984	Mar CAHN
	COLYTE WITH FLAVOR PACKS					
AA	MYLAN SPECIALITY LP	240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT	N018983	012	Oct 08, 1998	Mar CAHN
	COLYTE-FLAVORED					
	@ MYLAN SPECIALITY LP	227.1GM/BOT; 2.82GM/BOT; 6.36GM/BOT; 5.53GM/BOT; 21.5GM/BOT	N018983	008	Nov 14, 1991	Mar CAHN
	@	240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT	N018983	009	Nov 14, 1991	Mar CAHN
	PEG 3350 AND ELECTROLYTES					
	@ MYLAN	236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT	A090928	001	Jan 28, 2010	Apr DISC

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT	SANDOZ INC	10,000 UNITS/ML; EQ 1MG BASE/ML	A064211	001	Apr 13, 1998	Feb CAHN
----	------------	---------------------------------	---------	-----	--------------	----------

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

KLOR-CON

>D>	AB	UPSHER-SMITH LABS	8MEQ	A203106	001	Jul 10, 2015	Jun CAHN	
>A>	AB		8MEQ	A203106	001	Jul 10, 2015	Jun CAHN	
>D>	AB		10MEQ	A203106	002	Jul 10, 2015	Jun CAHN	
>A>	AB		10MEQ	A203106	002	Jul 10, 2015	Jun CAHN	
		POTASSIUM CHLORIDE						
	AB	ADARE PHARMS INC	8MEQ	A208864	001	Mar 17, 2017	Mar NEWA	
	AB		10MEQ	A208864	002	Mar 17, 2017	Mar NEWA	
		INJECTABLE;INJECTION						
		POTASSIUM CHLORIDE						
		@ BAXTER HLTHCARE	2MEQ/ML	A085499	001		Apr DISC	
		POTASSIUM CHLORIDE 10MEQ	IN PLASTIC CONTAINER					
AP	+	ICU MEDICAL INC	14.9MG/ML	N020161	005	Nov 30, 1992	Feb CAHN	
AP	+		745MG/100ML	N020161	001	Nov 30, 1992	Feb CAHN	
		POTASSIUM CHLORIDE 20MEQ	IN PLASTIC CONTAINER					
AP	+	ICU MEDICAL INC	29.8MG/ML	N020161	006	Aug 11, 1998	Feb CAHN	
AP	+		1.49GM/100ML	N020161	002	Nov 30, 1992	Feb CAHN	
		POTASSIUM CHLORIDE 30MEQ	IN PLASTIC CONTAINER					
AP	+	ICU MEDICAL INC	2.24GM/100ML	N020161	003	Aug 11, 1998	Feb CAHN	
		POTASSIUM CHLORIDE 40MEQ	IN PLASTIC CONTAINER					
AP	+	ICU MEDICAL INC	2.98GM/100ML	N020161	004	Aug 11, 1998	Feb CAHN	
		TABLET, EXTENDED RELEASE;ORAL						
		KLOR-CON						
>D>	AB2	+	UPSHER-SMITH LABS	8MEQ	N019123	001	Apr 17, 1986	Jun CAHN
>A>	AB2	+		8MEQ	N019123	001	Apr 17, 1986	Jun CAHN
>D>	AB2	+		10MEQ	N019123	002	Apr 17, 1986	Jun CAHN
>A>	AB2	+		10MEQ	N019123	002	Apr 17, 1986	Jun CAHN
		KLOR-CON M10						
>D>	AB1		UPSHER SMITH LABS	10MEQ	A074726	002	Aug 09, 2000	Jun CAHN
>A>	AB1		UPSHER-SMITH LABS	10MEQ	A074726	002	Aug 09, 2000	Jun CAHN
		KLOR-CON M15						
>D>			UPSHER SMITH LABS	15MEQ	A074726	003	Jun 06, 2003	Jun CAHN
>A>			UPSHER-SMITH LABS	15MEQ	A074726	003	Jun 06, 2003	Jun CAHN
		KLOR-CON M20						
>D>	AB1	!	UPSHER SMITH LABS	20MEQ	A074726	001	Nov 20, 1998	Jun CAHN
>A>	AB1	!	UPSHER-SMITH LABS	20MEQ	A074726	001	Nov 20, 1998	Jun CAHN

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ICU MEDICAL INC	149MG/100ML;450MG/100ML	A078446	001	Sep 10, 2008	Feb CAHN
		POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP	ICU MEDICAL INC	149MG/100ML;900MG/100ML	N019686	001	Oct 17, 1988	Feb CAHN
		POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP	ICU MEDICAL INC	298MG/100ML;900MG/100ML	N019686	002	Oct 17, 1988	Feb CAHN

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CITRATE

AB	IMPAX LABS INC	5MEQ	A077440	001	Jun 09, 2006	Feb CAHN
AB		10MEQ	A077440	002	Jun 09, 2006	Feb CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

	@ ACTAVIS GRP PTC	0.125MG	A091254	001	Nov 30, 2010	Jan DISC
	@	0.25MG	A091254	002	Nov 30, 2010	Jan DISC
	@	0.5MG	A091254	003	Nov 30, 2010	Jan DISC
	@	0.75MG	A091254	004	Nov 30, 2010	Jan DISC
	@	1MG	A091254	005	Nov 30, 2010	Jan DISC
	@	1.5MG	A091254	006	Nov 30, 2010	Jan DISC
AB	ALEMBIC PHARMS LTD	0.125MG	A078894	001	Oct 08, 2010	May CAHN
AB		0.25MG	A078894	002	Oct 08, 2010	May CAHN
AB		0.5MG	A078894	003	Oct 08, 2010	May CAHN
AB		1MG	A078894	004	Oct 08, 2010	May CAHN
AB		1.5MG	A078894	005	Oct 08, 2010	May CAHN
	@ SANDOZ	0.125MG	A090190	001	Jul 06, 2010	Feb DISC
	@	0.25MG	A090190	002	Jul 06, 2010	Feb DISC
	@	0.5MG	A090190	003	Jul 06, 2010	Feb DISC
	@	0.75MG	A090190	006	Oct 08, 2010	Feb DISC
	@	1MG	A090190	004	Jul 06, 2010	Feb DISC
	@	1.5MG	A090190	005	Jul 06, 2010	Feb DISC

TABLET, EXTENDED RELEASE;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB	ACTAVIS ELIZABETH	2.25MG	A203615	001	Oct 14, 2016	Apr CAHN
AB		3.75MG	A203615	002	Jan 03, 2017	Apr CAHN
AB	MACLEODS PHARMS LTD	3.75MG	A206156	007	Jan 23, 2017	Jan NEWA

PRASTERONE

INSERT;VAGINAL

INTRAROSA

+	AMAG PHARMS INC	6.5MG	N208470	001	Nov 16, 2016	May CAHN
---	-----------------	-------	---------	-----	--------------	----------

PRASUGREL HYDROCHLORIDE

TABLET;ORAL

EFFIENT

>D>	+	ELI LILLY AND CO	EQ 5MG BASE	N022307	001	Jul 10, 2009	Jun CFTG
>A>	AB	+	EQ 5MG BASE	N022307	001	Jul 10, 2009	Jun CFTG
>D>	+	!	EQ 10MG BASE	N022307	002	Jul 10, 2009	Jun CFTG
>A>	AB	+	EQ 10MG BASE	N022307	002	Jul 10, 2009	Jun CFTG
>A>		PRASUGREL					
>A>	AB	MYLAN PHARMS INC	EQ 5MG BASE	A205927	001	Jul 12, 2017	Jun NEWA
>A>	AB		EQ 10MG BASE	A205927	002	Jul 12, 2017	Jun NEWA

PRAVASTATIN SODIUM

TABLET;ORAL

PRAVASTATIN SODIUM

AB	AUROBINDO PHARMA LTD	10MG	A203367	001	Feb 02, 2017	Jan NEWA
AB		20MG	A203367	002	Feb 02, 2017	Jan NEWA
AB		40MG	A203367	003	Feb 02, 2017	Jan NEWA
AB		80MG	A203367	004	Feb 02, 2017	Jan NEWA

PRAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

PRAZOSIN HYDROCHLORIDE

	IDT AUSTRALIA LTD	EQ 1MG BASE	A072577	002	May 16, 1989	May CMS1
		EQ 5MG BASE	A072577	003	May 16, 1989	May CMS1

PREDNISOLONE

SYRUP; ORAL

PREDNISOLONE

AA	PHARM ASSOC	15MG/5ML	A 040399	001	Mar 05, 2003	May CAHN
AA	VISTAPHARM	15MG/5ML	A 040323	001	May 13, 1999	Mar CAHN

TABLET; ORAL

PREDNISOLONE

	@ CHARTWELL RX	5MG	A 084542	001		Apr CAHN
--	----------------	-----	----------	-----	--	----------

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PREDNISOLONE SODIUM PHOSPHATE

	@ AMNEAL PHARMS	EQ 15MG BASE/5ML	A 078345	001	Mar 10, 2009	May DISC
>A> AA	CHARTWELL RX	EQ 5MG BASE/5ML	A 075988	001	May 25, 2004	Jun CAHN
>D> AA	PADDOCK LLC	EQ 5MG BASE/5ML	A 075988	001	May 25, 2004	Jun CAHN
	@ PHARM ASSOC	EQ 5MG BASE/5ML	A 076123	001	Dec 23, 2002	May CAHN

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

AT	! BAUSCH AND LOMB	EQ 0.23% PHOSPHATE; 10%	A 074449	001	Dec 29, 1995	Feb CAHN
AT	SANDOZ INC	EQ 0.23% PHOSPHATE; 10%	A 073630	001	May 27, 1993	Feb CAHN

PREDNISONE

TABLET; ORAL

METICORTEN

	+ @ SCHERING	1MG	N 009766	002		Mar CMS1
	+ @	5MG	N 009766	001		Mar CMS1

PREDNISONE

	@ CHARTWELL RX	5MG	A 083059	001		Apr CAHN
	@ CONTRACT PHARMACAL	5MG	A 080209	001		Mar DISC
AB	MYLAN PHARMS INC	5MG	A 080292	001		Jan CAHN
AB		10MG	A 088832	001	Dec 04, 1985	Jan CAHN
AB		20MG	A 083677	001		Jan CAHN
AB	SUN PHARM INDS	10MG	A 089246	001	Dec 04, 1985	May CAHN
>D>	@ UPSHER SMITH	5MG	A 087471	001		Jun CAHN
>A>	@	5MG	A 087471	001		Jun CAHN
>D>	@	20MG	A 087470	001		Jun CAHN
>A>	@	20MG	A 087470	001		Jun CAHN

TABLET, DELAYED RELEASE; ORAL

PREDNISONE

AB	ACTAVIS LABS FL INC	1MG	A 204867	001	Apr 25, 2017	Apr NEWA
AB		2MG	A 204867	002	Apr 25, 2017	Apr NEWA
AB		5MG	A 204867	003	Apr 25, 2017	Apr NEWA
	RAYOS					
AB	+ HORIZON PHARMA	1MG	N 202020	001	Jul 26, 2012	Apr CFTG
AB	+	2MG	N 202020	002	Jul 26, 2012	Apr CFTG
AB	+!	5MG	N 202020	003	Jul 26, 2012	Apr CFTG

PROBENECID

TABLET; ORAL

BENEMID

	+ @ MERCK	500MG	N 007898	004		Jan CRLD
--	-----------	-------	----------	-----	--	----------

PROBENECID

AB	WATSON LABS TEVA	500MG	A 084442	004	Mar 29, 1983	May CAHN
----	------------------	-------	----------	-----	--------------	----------

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HYDROCHLORIDE

	@ WEST-WARD PHARMS INT	100MG/ML	A 089029	001	Apr 17, 1986	Jan CAHN
	@	500MG/ML	A 089030	001	Apr 17, 1986	Mar CAHN

PROCARBAZINE HYDROCHLORIDE

CAPSULE; ORAL

MATULANE

	+! LEADIANT BIOSCI INC	EQ 50MG BASE	N 016785	001		Feb CAHN
--	------------------------	--------------	----------	-----	--	----------

PROCHLORPERAZINE EDISYLATE

INJECTABLE;INJECTION
PROCHLORPERAZINE EDISYLATE

	@ ATHENEX INC	EQ 5MG BASE/ML	A040540	001	May 28, 2004	Mar CAHN
	@ WEST-WARD PHARMS INT	EQ 5MG BASE/ML	A089523	001	May 03, 1988	Jan CAHN
AP		EQ 5MG BASE/ML	A089903	001	Aug 29, 1989	Jan CAHN

PROCYCLIDINE HYDROCHLORIDE

TABLET;ORAL
KEMADRIN

	@ MONARCH PHARMS	2MG	N009818	005		Apr CAHN
	@	5MG	N009818	003		Apr CAHN

PROGESTERONE

CAPSULE;ORAL
PROGESTERONE

AB	DR REDDYS LABS INC	100MG	A208801	001	Feb 28, 2017	Feb NEWA
AB		200MG	A208801	002	Feb 28, 2017	Feb NEWA
	INJECTABLE;INJECTION					
	PROGESTERONE					
AO	+! ACTAVIS LABS UT INC	50MG/ML	N017362	002		Feb CAHN

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY;RECTAL
PHENERGAN

	+ @ MYLAN PHARMS INC	50MG	N011689	001		Jan CAHN
--	----------------------	------	---------	-----	--	----------

TABLET;ORAL

PROMETHAZINE HYDROCHLORIDE

AB	PRINSTON INC	12.5MG	A040622	001	Jul 18, 2006	Feb CAHN
AB		25MG	A040622	002	Jul 18, 2006	Feb CAHN
AB		50MG	A040622	003	Jul 18, 2006	Feb CAHN
>A> AB	STRIDES PHARMA	12.5MG	A209177	001	Jun 30, 2017	Jun NEWA
>A> AB		25MG	A209177	002	Jun 30, 2017	Jun NEWA
>A> AB		50MG	A209177	003	Jun 30, 2017	Jun NEWA

PROPIOMAZINE HYDROCHLORIDE

INJECTABLE;INJECTION
LARGON

	@ WEST-WARD PHARMS INT	20MG/ML	N012382	002		Jan CAHN
--	------------------------	---------	---------	-----	--	----------

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
INNOPRAN XL

BX	ANI PHARMS INC	80MG	N021438	001	Mar 12, 2003	Mar CAHN
BX		120MG	N021438	002	Mar 12, 2003	Mar CAHN
	PROPRANOLOL HYDROCHLORIDE					
>D> BX	UPSHER SMITH	60MG	A078311	001	Mar 06, 2009	Jun CAHN
BX		60MG	A078311	001	Mar 06, 2009	Apr CMFD
	@	60MG	A078311	001	Mar 06, 2009	Feb DISC
>D> BX		80MG	A078311	002	Mar 06, 2009	Jun CAHN
BX		80MG	A078311	002	Mar 06, 2009	Apr CMFD
	@	80MG	A078311	002	Mar 06, 2009	Feb DISC
>D> BX		120MG	A078311	003	Mar 06, 2009	Jun CAHN
BX		120MG	A078311	003	Mar 06, 2009	Apr CMFD
	@	120MG	A078311	003	Mar 06, 2009	Feb DISC
>D> BX		160MG	A078311	004	Mar 06, 2009	Jun CAHN
BX		160MG	A078311	004	Mar 06, 2009	Apr CMFD
	@	160MG	A078311	004	Mar 06, 2009	Feb DISC
>A> BX	UPSHER-SMITH LABS	60MG	A078311	001	Mar 06, 2009	Jun CAHN
>A> BX		80MG	A078311	002	Mar 06, 2009	Jun CAHN
>A> BX		120MG	A078311	003	Mar 06, 2009	Jun CAHN
>A> BX		160MG	A078311	004	Mar 06, 2009	Jun CAHN

INJECTABLE;INJECTION
PROPRANOLOL HYDROCHLORIDE

AP	ATHENEX INC	1MG/ML	A075792	001	Aug 29, 2000	Mar CAHN
	@ SANDOZ INC	1MG/ML	A076400	001	Feb 26, 2003	Mar CAHN
	TABLET;ORAL					
	INDERAL					
	+ @ WYETH PHARMS INC	40MG	N016418	002		Jan CRLD

TABLET;ORAL							
PROPRANOLOL HYDROCHLORIDE							
	@ WATSON LABS TEVA	10MG	A070548	001	Jul 10, 1986	May	CAHN
	@	20MG	A070549	001	Apr 11, 1986	May	CAHN
	@	40MG	A070550	001	Apr 11, 1986	May	CAHN
<u>PROPYLTHIOURACIL</u>							
TABLET;ORAL							
PROPYLTHIOURACIL							
	@ CHARTWELL RX	50MG	A084543	001		Apr	CAHN
<u>PROTAMINE SULFATE</u>							
INJECTABLE;INJECTION							
PROTAMINE SULFATE							
	@ WEST-WARD PHARMS INT	10MG/ML	A089474	001	Nov 05, 1986	Mar	CAHN
	@	10MG/ML	A089475	001	Nov 05, 1986	Jan	CAHN
<u>PYRIDOSTIGMINE BROMIDE</u>							
INJECTABLE;INJECTION							
REGONOL							
AP	SANDOZ INC	5MG/ML	N017398	001		May	CAHN
TABLET;ORAL							
PYRIDOSTIGMINE BROMIDE							
	@ IMPAX LABS INC	60MG	A040457	001	Dec 26, 2002	Feb	CAHN
<u>PYRIMETHAMINE</u>							
TABLET;ORAL							
DARAPRIM							
	+! TURING PHARMS LLC	25MG	N008578	001		May	CAHN
<u>QUETIAPINE FUMARATE</u>							
TABLET;ORAL							
QUETIAPINE FUMARATE							
	@ MYLAN PHARMS INC	EQ 25MG BASE	A090323	001	Mar 27, 2012	May	DISC
TABLET, EXTENDED RELEASE;ORAL							
QUETIAPINE FUMARATE							
AB	ACCORD HLTHCARE	EQ 150MG BASE	A090681	001	May 09, 2017	Apr	NEWA
AB		EQ 200MG BASE	A090681	002	May 09, 2017	Apr	NEWA
AB		EQ 300MG BASE	A090681	003	May 09, 2017	Apr	NEWA
AB		EQ 400MG BASE	A090681	004	Nov 01, 2016	Mar	CAHN
AB	INTELLIPHARMACEUTICS	EQ 50MG BASE	A202939	001	May 09, 2017	Apr	NEWA
AB		EQ 150MG BASE	A202939	002	May 09, 2017	Apr	NEWA
AB		EQ 200MG BASE	A202939	003	May 09, 2017	Apr	NEWA
AB		EQ 300MG BASE	A202939	004	May 09, 2017	Apr	NEWA
AB		EQ 400MG BASE	A202939	005	May 09, 2017	Apr	NEWA
AB	LUPIN LTD	EQ 50MG BASE	A204203	001	May 17, 2017	May	NEWA
AB		EQ 150MG BASE	A204203	002	May 17, 2017	May	NEWA
AB		EQ 200MG BASE	A204203	003	May 17, 2017	May	NEWA
AB		EQ 300MG BASE	A204203	004	May 17, 2017	May	NEWA
AB		EQ 400MG BASE	A204203	005	May 17, 2017	May	NEWA
AB	PAR PHARM	EQ 50MG BASE	A090482	001	May 09, 2017	Apr	NEWA
AB		EQ 150MG BASE	A090482	002	May 09, 2017	Apr	NEWA
AB		EQ 200MG BASE	A090482	003	May 09, 2017	Apr	NEWA
AB		EQ 300MG BASE	A090482	004	May 09, 2017	Apr	NEWA
AB		EQ 400MG BASE	A090482	005	May 09, 2017	Apr	NEWA
AB	PHARMADAX INC	EQ 50MG BASE	A206260	001	May 09, 2017	Apr	NEWA
AB		EQ 150MG BASE	A206260	002	May 09, 2017	Apr	NEWA
AB		EQ 200MG BASE	A206260	003	May 09, 2017	Apr	NEWA
AB		EQ 300MG BASE	A206260	004	May 09, 2017	Apr	NEWA
AB		EQ 400MG BASE	A206260	005	May 09, 2017	Apr	NEWA
SEROQUEL XR							
AB	+ ASTRAZENECA	EQ 50MG BASE	N022047	001	May 17, 2007	Apr	CTEC
AB	+	EQ 150MG BASE	N022047	005	Aug 11, 2008	Apr	CTEC
AB	+!	EQ 200MG BASE	N022047	002	May 17, 2007	Apr	CTEC
AB	+	EQ 300MG BASE	N022047	003	May 17, 2007	Apr	CTEC
<u>RABEPRAZOLE SODIUM</u>							
TABLET, DELAYED RELEASE;ORAL							
RABEPRAZOLE SODIUM							
AB	AUROBINDO PHARMA LTD	20MG	A205761	001	Feb 17, 2017	Feb	NEWA
AB	KREMERS URBAN PHARMS	20MG	A090678	001	Nov 08, 2013	Jan	CAHN

RALTEGRAVIR POTASSIUMTABLET; ORAL
ISENTRESS HD

+ MERCK SHARP DOHME EQ 600MG BASE

N022145 002 May 26, 2017 May NEWA

RAMIPRILCAPSULE; ORAL
RAMIPRILAB ACCORD HLTHCARE 1.25MG
AB 2.5MG
AB 5MG
AB 10MGA202392 001 Apr 15, 2014 Mar CAHN
A202392 002 Apr 15, 2014 Mar CAHN
A202392 003 Apr 15, 2014 Mar CAHN
A202392 004 Apr 15, 2014 Mar CAHNRANITIDINE HYDROCHLORIDEINJECTABLE; INJECTION
ZANTACAP +! TELIGENT EQ 25MG BASE/ML
AP +! TELIGENT PHARMA INC EQ 25MG BASE/ML
ZANTAC IN PLASTIC CONTAINER
@ TELIGENT EQ 1MG BASE/ML
@ EQ 50MG BASE/100MLN019090 001 Oct 19, 1984 Apr CAHN
N019090 001 Oct 19, 1984 Jan CAHN
N019593 002 Sep 27, 1991 May CAHN
N019593 001 Dec 17, 1986 May CAHN

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

AA AUROBINDO PHARMA LTD EQ 15MG BASE/ML
AA PHARM ASSOC EQ 15MG BASE/MLA090623 001 Jul 28, 2010 Jan CAHN
A077405 001 Sep 21, 2007 May CAHN

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

AB GLENMARK PHARMS INC EQ 150MG BASE
AB EQ 300MG BASEA078542 001 Nov 19, 2008 May CAHN
A078542 002 Nov 19, 2008 May CAHNRANOLAZINETABLET, EXTENDED RELEASE; ORAL
RANEXA+ GILEAD 500MG
+! 1GMN021526 002 Jan 27, 2006 Feb CTEC
N021526 001 Feb 12, 2007 Feb CTEC

RANOLAZINE

@ LUPIN LTD 500MG
@ 1GMA201046 001 Jul 29, 2013 Feb DISC
A201046 002 Jul 29, 2013 Feb DISCRASAGILINE MESYLATE

TABLET; ORAL

RASAGILINE MESYLATE

>D> AB MYLAN PHARMS INC EQ 0.5MG BASE
>A> @ EQ 0.5MG BASE
AB EQ 0.5MG BASE
>D> AB EQ 1MG BASE
>A> @ EQ 1MG BASE
AB EQ 1MG BASEA201971 001 May 15, 2017 Jun DISC
A201971 001 May 15, 2017 Jun DISC
A201971 001 May 15, 2017 May NEWA
A201971 002 May 15, 2017 Jun DISC
A201971 002 May 15, 2017 Jun DISC
A201971 002 May 15, 2017 May NEWAREPAGLINIDETABLET; ORAL
PRANDINAB + GEMINI LABS LLC 0.5MG
AB + 1MG
AB +! 2MGN020741 001 Dec 22, 1997 Feb CAHN
N020741 002 Dec 22, 1997 Feb CAHN
N020741 003 Dec 22, 1997 Feb CAHN

REPAGLINIDE

>A> AB BOSCOGEN 0.5MG
>A> AB 1MG
>A> AB 2MG
>D> AB STANDARD CHEM PHARM 0.5MG
>D> AB 1MG
>D> AB 2MGA091517 001 Apr 24, 2015 Jun CAHN
A091517 002 Apr 24, 2015 Jun CAHN
A091517 003 Apr 24, 2015 Jun CAHN
A091517 001 Apr 24, 2015 Jun CAHN
A091517 002 Apr 24, 2015 Jun CAHN
A091517 003 Apr 24, 2015 Jun CAHNRESERPINETABLET; ORAL
RESERPINE+ @ SANDOZ 0.1MG
+ @ 0.25MGN009838 001 Apr DISC
N009838 002 Apr DISC

RIBAVIRIN

CAPSULE;ORAL							
RIBASPHERE							
AB	KADMON PHARMS LLC	200MG	A076203	001	Apr 06, 2004	Jan	CAHN
TABLET;ORAL							
RIBAVIRIN							
AB	KADMON PHARMS LLC	200MG	A077456	001	Dec 05, 2005	Jan	CAHN
AB		400MG	A077456	002	Dec 05, 2005	Jan	CAHN
AB	!	600MG	A077456	003	Dec 05, 2005	Jan	CAHN

RIBOCICLIB SUCCINATE

TABLET;ORAL							
KISQALI							
+	NOVARTIS PHARMS CORP	EQ 200MG BASE	N209092	001	Mar 13, 2017	Mar	NEWA

RIFAMPIN

INJECTABLE;INJECTION							
RIFAMPIN							
AP	WATSON PHARMS TEVA	600MG/VIAL	A206736	001	Jan 19, 2016	Feb	CAHN
AP	WEST-WARD PHARMS INT	600MG/VIAL	A064217	001	Oct 29, 1999	Jan	CAHN

RILUZOLE

TABLET;ORAL							
RILUZOLE							
AB	GLENMARK PHARMS LTD	50MG	A091394	001	Jun 18, 2013	May	CAHN

RIMANTADINE HYDROCHLORIDE

TABLET;ORAL							
RIMANTADINE HYDROCHLORIDE							
@	IMPAX LABS INC	100MG	A075916	001	Nov 02, 2001	Feb	CAHN

RISPERIDONE

TABLET;ORAL							
RISPERIDONE							
@	JUBILANT CADISTA	0.25MG	A078828	001	Mar 23, 2009	Apr	CAHN
@		0.5MG	A078828	002	Mar 23, 2009	Apr	CAHN
@		1MG	A078828	003	Mar 23, 2009	Apr	CAHN
@		2MG	A078828	004	Mar 23, 2009	Apr	CAHN
@		3MG	A078828	005	Mar 23, 2009	Apr	CAHN
@		4MG	A078828	006	Mar 23, 2009	Apr	CAHN
AB	PRINSTON INC	0.25MG	A078707	001	Dec 29, 2008	Feb	CAHN
AB		0.5MG	A078707	002	Dec 29, 2008	Feb	CAHN
AB		1MG	A078707	003	Dec 29, 2008	Feb	CAHN
AB		2MG	A078707	004	Dec 29, 2008	Feb	CAHN
AB		3MG	A078707	005	Dec 29, 2008	Feb	CAHN
AB		4MG	A078707	006	Dec 29, 2008	Feb	CAHN

RITONAVIR

>A>	POWDER;ORAL								
>A>	NORVIR								
>A>	+	ABBVIE INC	100MG/PACKET	N209512	001	Jun 07, 2017	Jun	NEWA	

RIVASTIGMINE TARTRATE

CAPSULE;ORAL							
RIVASTIGMINE TARTRATE							
AB	CADILA PHARMS LTD	EQ 1.5MG BASE	A203844	001	Feb 13, 2017	Jan	NEWA
AB		EQ 3MG BASE	A203844	002	Feb 13, 2017	Jan	NEWA
AB		EQ 4.5MG BASE	A203844	003	Feb 13, 2017	Jan	NEWA
AB		EQ 6MG BASE	A203844	004	Feb 13, 2017	Jan	NEWA
AB	SUN PHARM INDS LTD	EQ 1.5MG BASE	A077131	001	Oct 22, 2007	Mar	CAHN
AB		EQ 3MG BASE	A077131	002	Oct 22, 2007	Mar	CAHN
AB		EQ 4.5MG BASE	A077131	003	Oct 22, 2007	Mar	CAHN
AB		EQ 6MG BASE	A077131	004	Oct 22, 2007	Mar	CAHN

RIZATRIPTAN BENZOATE

TABLET;ORAL							
RIZATRIPTAN BENZOATE							
AB	ECI PHARMS LLC	EQ 5MG BASE	A202047	001	Dec 31, 2012	Mar	CAHN
AB		EQ 10MG BASE	A202047	002	Dec 31, 2012	Mar	CAHN
AB	UNICHEM LABS LTD	EQ 5MG BASE	A207836	001	Mar 07, 2017	Feb	NEWA
AB		EQ 10MG BASE	A207836	002	Mar 07, 2017	Feb	NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

RIZATRIPTAN BENZOATE

AB	GLENMARK PHARMS LTD	EQ 5MG BASE	A201914	001	Jul 01, 2013	May CAHN
AB		EQ 10MG BASE	A201914	002	Jul 01, 2013	May CAHN
AB	PANACEA BIOTEC LTD	EQ 5MG BASE	A204722	001	Jan 11, 2017	Jan NEWA
AB		EQ 10MG BASE	A204722	002	Jan 11, 2017	Jan NEWA
AB	UNICHEM LABS LTD	EQ 5MG BASE	A207835	001	Mar 07, 2017	Feb NEWA
AB		EQ 10MG BASE	A207835	002	Mar 07, 2017	Feb NEWA

ROCURONIUM BROMIDE

INJECTABLE;INJECTION

ROCURONIUM BROMIDE

AP	AUROBINDO PHARMA LTD	50MG/5ML (10MG/ML)	A206206	001	Apr 12, 2017	Mar NEWA
AP		100MG/10ML (10MG/ML)	A206206	002	Apr 12, 2017	Mar NEWA
AP	! SANDOZ INC	50MG/5ML (10MG/ML)	A079195	001	Dec 05, 2008	Mar CAHN
AP	!	100MG/10ML (10MG/ML)	A079195	002	Dec 05, 2008	Mar CAHN
AP	WEST WARD PHARM CORP	50MG/5ML (10MG/ML)	A204679	001	Feb 28, 2017	Feb NEWA
AP		100MG/10ML (10MG/ML)	A204679	002	Feb 28, 2017	Feb NEWA

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

AB	ACCORD HLTHCARE	EQ 0.25MG BASE	A204022	001	Feb 28, 2017	Apr CAHN
AB		EQ 0.5MG BASE	A204022	002	Feb 28, 2017	Apr CAHN
AB		EQ 1MG BASE	A204022	003	Feb 28, 2017	Apr CAHN
AB		EQ 2MG BASE	A204022	004	Feb 28, 2017	Apr CAHN
AB		EQ 3MG BASE	A204022	005	Feb 28, 2017	Apr CAHN
AB		EQ 4MG BASE	A204022	006	Feb 28, 2017	Apr CAHN
AB		EQ 5MG BASE	A204022	007	Feb 28, 2017	Apr CAHN
AB	ACCORD HLTHCARE INC	EQ 0.25MG BASE	A204022	001	Feb 28, 2017	Feb NEWA
AB		EQ 0.5MG BASE	A204022	002	Feb 28, 2017	Feb NEWA
AB		EQ 1MG BASE	A204022	003	Feb 28, 2017	Feb NEWA
AB		EQ 2MG BASE	A204022	004	Feb 28, 2017	Feb NEWA
AB		EQ 3MG BASE	A204022	005	Feb 28, 2017	Feb NEWA
AB		EQ 4MG BASE	A204022	006	Feb 28, 2017	Feb NEWA
AB		EQ 5MG BASE	A204022	007	Feb 28, 2017	Feb NEWA
	@ EPIC PHARMA LLC	EQ 0.25MG BASE	A078230	001	May 20, 2008	May CAHN
	@	EQ 0.5MG BASE	A078230	002	May 20, 2008	May CAHN
	@	EQ 1MG BASE	A078230	003	May 20, 2008	May CAHN
	@	EQ 2MG BASE	A078230	004	May 20, 2008	May CAHN
	@	EQ 3MG BASE	A078230	005	May 20, 2008	May CAHN
	@	EQ 4MG BASE	A078230	006	May 20, 2008	May CAHN
	@	EQ 5MG BASE	A078230	007	May 20, 2008	May CAHN

TABLET, EXTENDED RELEASE;ORAL

ROPINIROLE HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	EQ 2MG BASE	A202786	001	Apr 22, 2013	May CAHN
AB		EQ 4MG BASE	A202786	002	Apr 22, 2013	May CAHN
AB		EQ 6MG BASE	A202786	003	Apr 22, 2013	May CAHN
AB		EQ 8MG BASE	A202786	004	Apr 22, 2013	May CAHN
AB		EQ 12MG BASE	A202786	005	Apr 22, 2013	May CAHN
	@ MYLAN PHARMS INC	EQ 3MG BASE	A200462	002	Oct 15, 2012	Apr DISC

ROPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

ROPIVACAINE HYDROCHLORIDE

>D>	AKORN INC	5MG/ML	A203955	001	Apr 11, 2016	Jun CDFR
>A>	SOLUTION;INJECTION					
>A>	ROPIVACAINE HYDROCHLORIDE					
>A>	AKORN INC	150MG/30ML (5MG/ML)	A203955	001	Apr 11, 2016	Jun CDFR

ROSUVASTATIN CALCIUM

TABLET;ORAL

ROSUVASTATIN CALCIUM

AB	ACCORD HLTHCARE	5MG	A206434	001	Oct 31, 2016	Mar CAHN
AB		10MG	A206434	002	Oct 31, 2016	Mar CAHN
AB		20MG	A206434	003	Oct 31, 2016	Mar CAHN
AB		40MG	A206434	004	Oct 31, 2016	Mar CAHN
AB	ALKEM LABS LTD	5MG	A206465	001	Mar 21, 2017	Mar NEWA
AB		10MG	A206465	002	Mar 21, 2017	Mar NEWA
AB		20MG	A206465	003	Mar 21, 2017	Mar NEWA
AB		40MG	A206465	004	Mar 21, 2017	Mar NEWA
AB	TORRENT PHARMS LTD	5MG	A201619	001	Oct 31, 2016	Apr CAHN
AB		10MG	A201619	002	Oct 31, 2016	Apr CAHN

TABLET;ORAL
ROSUVASTATIN CALCIUM

AB		20MG	A201619	003	Oct 31, 2016	Apr CAHN
AB		40MG	A201619	004	Oct 31, 2016	Apr CAHN

RUCAPARIB CAMSYLATE

TABLET;ORAL
RUBRACA

+	CLOVIS ONCOLOGY INC	EQ 250MG BASE	N209115	003	May 01, 2017	May NEWA
---	---------------------	---------------	---------	-----	--------------	----------

SAFINAMIDE MESYLATE

TABLET;ORAL
XADAGO

+	NEWRON PHARMS US INC	50MG	N207145	001	Mar 21, 2017	Mar NEWA
+	!	100MG	N207145	002	Mar 21, 2017	Mar NEWA
+	US WORLDMEDS LLC	50MG	N207145	001	Mar 21, 2017	Apr CAHN
+	!	100MG	N207145	002	Mar 21, 2017	Apr CAHN

SELEGILINE HYDROCHLORIDE

TABLET;ORAL
SELEGILINE HYDROCHLORIDE

AB	BOSCOGEN	5MG	A074912	001	Apr 30, 1998	May CAHN
	@ CHARTWELL MOLECULES	5MG	A074565	001	Aug 02, 1996	Jan CAHN
	@	5MG	A074641	001	Aug 02, 1996	Jan CAHN

SERTRALINE HYDROCHLORIDE

CONCENTRATE;ORAL
SERTRALINE HYDROCHLORIDE

@	ALLIED PHARMA INC	EQ 20MG BASE/ML	A076934	001	Jun 30, 2006	Mar CAHN
---	-------------------	-----------------	---------	-----	--------------	----------

TABLET;ORAL
SERTRALINE HYDROCHLORIDE

>A>	@ ACI HEALTHCARE LTD	EQ 25MG BASE	A076881	001	Feb 06, 2007	Jun CAHN
>A>	@	EQ 50MG BASE	A076881	002	Feb 06, 2007	Jun CAHN
>A>	@	EQ 100MG BASE	A076881	003	Feb 06, 2007	Jun CAHN
>D>	@ ALLIED PHARMA INC	EQ 25MG BASE	A076881	001	Feb 06, 2007	Jun CAHN
	@	EQ 25MG BASE	A076881	001	Feb 06, 2007	Mar CAHN
>D>	@	EQ 50MG BASE	A076881	002	Feb 06, 2007	Jun CAHN
	@	EQ 50MG BASE	A076881	002	Feb 06, 2007	Mar CAHN
>D>	@	EQ 100MG BASE	A076881	003	Feb 06, 2007	Jun CAHN
	@	EQ 100MG BASE	A076881	003	Feb 06, 2007	Mar CAHN
	@ MYLAN	EQ 25MG BASE	A076671	001	Feb 06, 2007	Mar DISC
	@	EQ 50MG BASE	A076671	002	Feb 06, 2007	Mar DISC
	@	EQ 100MG BASE	A076671	003	Feb 06, 2007	Mar DISC
	@ WATSON LABS TEVA	EQ 25MG BASE	A077663	001	Feb 06, 2007	May CAHN
	@	EQ 50MG BASE	A077663	002	Feb 06, 2007	May CAHN
	@	EQ 100MG BASE	A077663	003	Feb 06, 2007	May CAHN

SEVELAMER CARBONATE

FOR SUSPENSION;ORAL
RENEVELA

AB	+	GENZYME	800MG/PACKET	N022318	001	Aug 12, 2009	May CFTG
AB	+	!	2.4GM/PACKET	N022318	002	Feb 18, 2009	May CFTG

SEVELAMER CARBONATE

AB	AUROBINDO PHARMA LTD	800MG/PACKET	A207624	001	Jun 13, 2017	May NEWA
AB		2.4GM/PACKET	A207624	002	Jun 13, 2017	May NEWA

SILDENAFIL CITRATE

TABLET;ORAL
VIAGRA

+	PFIZER INC	EQ 25MG BASE	N020895	001	Mar 27, 1998	May CAHN
+		EQ 50MG BASE	N020895	002	Mar 27, 1998	May CAHN
+	!	EQ 100MG BASE	N020895	003	Mar 27, 1998	May CAHN

SILODOSIN

CAPSULE;ORAL
RAPAFLO

AB	+	ALLERGAN SALES LLC	4MG	N022206	001	Oct 08, 2008	Mar CFTG
AB	+		8MG	N022206	002	Oct 08, 2008	Mar CFTG

SILODOSIN

AB	SANDOZ INC	4MG	A204726	001	Mar 31, 2017	Mar NEWA
AB		8MG	A204726	002	Mar 31, 2017	Mar NEWA

SIMVASTATINSUSPENSION;ORAL
SIMVASTATIN

+	TCG FLUENT PHARMA	20MG/5ML	N206679	001	Apr 21, 2016	Jan CAHN
+	!	40MG/5ML	N206679	002	Apr 21, 2016	Jan CAHN

TABLET;ORAL

SIMVASTATIN

	@ MYLAN PHARMS INC	5MG	A090868	001	Jun 08, 2010	May DISC
	@	10MG	A090868	002	Jun 08, 2010	May DISC
	@	20MG	A090868	003	Jun 08, 2010	May DISC
	@	40MG	A090868	004	Jun 08, 2010	May DISC
	@	80MG	A090868	005	Jun 08, 2010	May DISC
AB	WATSON LABS TEVA	5MG	A076685	001	Dec 20, 2006	May CAHN
AB		10MG	A076685	002	Dec 20, 2006	May CAHN
AB		20MG	A076685	003	Dec 20, 2006	May CAHN
AB		40MG	A076685	004	Dec 20, 2006	May CAHN
AB		80MG	A076685	005	Dec 20, 2006	May CAHN

SODIUM BICARBONATEINJECTABLE;INJECTION
SODIUM BICARBONATE

AP	!	HOSPIRA	0.9MEQ/ML	A077394	001	Nov 09, 2005	Feb CTEC
AP	!		1MEQ/ML	A077394	002	Nov 09, 2005	Feb CTEC
		HOSPIRA INC	0.5MEQ/ML	A202679	001	Mar 07, 2017	Feb NEWA
AP			0.9MEQ/ML	A202494	001	Mar 06, 2017	Feb NEWA
			1MEQ/ML	A202495	001	Mar 06, 2017	Feb NEWA
AP			1MEQ/ML	A202494	002	Mar 06, 2017	Feb NEWA

SODIUM CHLORIDEINJECTABLE;INJECTION
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	+	!	ICU MEDICAL INC	450MG/100ML	N018090	001		Feb CAHN
			SODIUM CHLORIDE 0.9%					
AP			WEST-WARD PHARMS INT	9MG/ML	A201850	001	Jan 20, 2012	Jan CAHN
			SODIUM CHLORIDE 0.9%					
			WEST-WARD PHARMS INT	9MG/ML	A201833	001	Sep 24, 2013	Jan CAHN
			SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AP	+	!	ICU MEDICAL INC	900MG/100ML	N016366	001		Feb CAHN
AP			LABORATORIOS GRIFOLS	900MG/100ML	A207956	001	May 25, 2017	May NEWA
AP	!		TARO	9MG/ML	A077407	001	Aug 11, 2006	Apr CAHN
			SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER					
	+	@	ABRAXIS PHARM	234MG/ML	N019329	001	Apr 22, 1987	Jan CRLD
			SODIUM CHLORIDE IN PLASTIC CONTAINER					
	+		HOSPIRA	2.5MEQ/ML	N018897	001	Jul 20, 1984	Mar CRLD
			SOLUTION;IRRIGATION					
			SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AT			ICU MEDICAL INC	900MG/100ML	N017514	001		Feb CAHN
AT				900MG/100ML	N018314	001		Feb CAHN

SODIUM NITROPRUSSIDEINJECTABLE;INJECTION
SODIUM NITROPRUSSIDE

AP			AKORN	25MG/ML	A208635	001	May 04, 2017	Apr NEWA
AP			NEXUS PHARMS	25MG/ML	A207499	001	May 25, 2017	May NEWA
			SOLUTION;IV (INFUSION)					
			NIPRIDE RTU IN SODIUM CHLORIDE 0.9%					
	+	!	EXELA PHARMA SCS LLC	50MG/100ML (0.5MG/ML)	N209387	001	Mar 08, 2017	Mar NEWA

SODIUM OXYBATESOLUTION;ORAL
SODIUM OXYBATE

AA			WEST-WARD PHARMS INT	500MG/ML	A202090	001	Jan 17, 2017	Jan NEWA
			XYREM					
AA	+	!	JAZZ PHARMS	500MG/ML	N021196	001	Jul 17, 2002	Jan CFTG

SODIUM PHENYLBUTYRATE

TABLET;ORAL

SODIUM PHENYLBUTYRATE

AB	ALVOGEN MALTA	500MG	A090910	001	Nov 18, 2011	Apr CAHN
----	---------------	-------	---------	-----	--------------	----------

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

AA	CMP PHARMA INC	454GM/BOT	A089910	001	Jan 19, 1989	Apr CAHN
----	----------------	-----------	---------	-----	--------------	----------

AA	ECI PHARMS LLC	453.6GM/BOT	A090313	001	Dec 21, 2011	Mar CAHN
----	----------------	-------------	---------	-----	--------------	----------

SUSPENSION;ORAL, RECTAL

SPS

AA	! CMP PHARMA INC	15GM/60ML	A087859	001	Dec 08, 1982	Apr CAHN
----	------------------	-----------	---------	-----	--------------	----------

SOMATROPIN RECOMBINANT

INJECTABLE;INJECTION

VALTROPIN

>A> BX	LG CHEM LTD	5MG/VIAL	N021905	001	Apr 19, 2007	Jun CAHN
--------	-------------	----------	---------	-----	--------------	----------

>D> BX	LG LIFE	5MG/VIAL	N021905	001	Apr 19, 2007	Jun CAHN
--------	---------	----------	---------	-----	--------------	----------

SONIDEGIB PHOSPHATE

CAPSULE;ORAL

ODOMZO

+	! SUN PHARM INDS INC	EQ 200MG BASE	N205266	001	Jul 24, 2015	Mar CAHN
---	----------------------	---------------	---------	-----	--------------	----------

+	! SUN PHARMA GLOBAL	EQ 200MG BASE	N205266	001	Jul 24, 2015	May CAHN
---	---------------------	---------------	---------	-----	--------------	----------

SOTALOL HYDROCHLORIDE

TABLET;ORAL

BETAPACE

AB1	+ COVIS PHARMA BV	80MG	N019865	001	Oct 30, 1992	May CAHN
-----	-------------------	------	---------	-----	--------------	----------

AB1	+	120MG	N019865	005	Apr 20, 1994	May CAHN
-----	---	-------	---------	-----	--------------	----------

AB1	+!	160MG	N019865	002	Oct 30, 1992	May CAHN
-----	----	-------	---------	-----	--------------	----------

AB1	+	240MG	N019865	003	Oct 30, 1992	May CAHN
-----	---	-------	---------	-----	--------------	----------

	@	320MG	N019865	004	Oct 30, 1992	May CAHN
--	---	-------	---------	-----	--------------	----------

BETAPACE AF

	@ COVIS PHARMA BV	40MG	N021151	006	Apr 02, 2003	May CAHN
--	-------------------	------	---------	-----	--------------	----------

	@	60MG	N021151	007	Apr 02, 2003	May CAHN
--	---	------	---------	-----	--------------	----------

AB2	+	80MG	N021151	001	Feb 22, 2000	May CAHN
-----	---	------	---------	-----	--------------	----------

	@	100MG	N021151	005	Mar 14, 2003	May CAHN
--	---	-------	---------	-----	--------------	----------

AB2	+	120MG	N021151	002	Feb 22, 2000	May CAHN
-----	---	-------	---------	-----	--------------	----------

AB2	+!	160MG	N021151	003	Feb 22, 2000	May CAHN
-----	----	-------	---------	-----	--------------	----------

SORINE

>D> AB1	UPSHER SMITH	80MG	A075500	001	Apr 27, 2001	Jun CAHN
---------	--------------	------	---------	-----	--------------	----------

>D> AB1		120MG	A075500	004	Apr 27, 2001	Jun CAHN
---------	--	-------	---------	-----	--------------	----------

>D> AB1		160MG	A075500	002	Apr 27, 2001	Jun CAHN
---------	--	-------	---------	-----	--------------	----------

>D> AB1		240MG	A075500	003	Apr 27, 2001	Jun CAHN
---------	--	-------	---------	-----	--------------	----------

>A> AB1	UPSHER-SMITH LABS	80MG	A075500	001	Apr 27, 2001	Jun CAHN
---------	-------------------	------	---------	-----	--------------	----------

>A> AB1		120MG	A075500	004	Apr 27, 2001	Jun CAHN
---------	--	-------	---------	-----	--------------	----------

>A> AB1		160MG	A075500	002	Apr 27, 2001	Jun CAHN
---------	--	-------	---------	-----	--------------	----------

>A> AB1		240MG	A075500	003	Apr 27, 2001	Jun CAHN
---------	--	-------	---------	-----	--------------	----------

SOTALOL HYDROCHLORIDE

>D> AB1	MYLAN	80MG	A075237	001	May 01, 2000	Jun DISC
---------	-------	------	---------	-----	--------------	----------

>A>	@	80MG	A075237	001	May 01, 2000	Jun DISC
-----	---	------	---------	-----	--------------	----------

>D> AB1		80MG	A075725	001	Dec 19, 2000	Jun DISC
---------	--	------	---------	-----	--------------	----------

>A>	@	80MG	A075725	001	Dec 19, 2000	Jun DISC
-----	---	------	---------	-----	--------------	----------

>D> AB1		120MG	A075237	002	May 01, 2000	Jun DISC
---------	--	-------	---------	-----	--------------	----------

>A>	@	120MG	A075237	002	May 01, 2000	Jun DISC
-----	---	-------	---------	-----	--------------	----------

>D> AB1		120MG	A075725	002	Dec 19, 2000	Jun DISC
---------	--	-------	---------	-----	--------------	----------

>A>	@	120MG	A075725	002	Dec 19, 2000	Jun DISC
-----	---	-------	---------	-----	--------------	----------

>D> AB1		160MG	A075237	003	May 01, 2000	Jun DISC
---------	--	-------	---------	-----	--------------	----------

>A>	@	160MG	A075237	003	May 01, 2000	Jun DISC
-----	---	-------	---------	-----	--------------	----------

>D> AB1		160MG	A075725	003	Dec 19, 2000	Jun DISC
---------	--	-------	---------	-----	--------------	----------

>A>	@	160MG	A075725	003	Dec 19, 2000	Jun DISC
-----	---	-------	---------	-----	--------------	----------

>D> AB1		240MG	A075237	004	May 01, 2000	Jun DISC
---------	--	-------	---------	-----	--------------	----------

>A>	@	240MG	A075237	004	May 01, 2000	Jun DISC
-----	---	-------	---------	-----	--------------	----------

>D> AB1		240MG	A075725	004	Dec 19, 2000	Jun DISC
---------	--	-------	---------	-----	--------------	----------

>A>	@	240MG	A075725	004	Dec 19, 2000	Jun DISC
-----	---	-------	---------	-----	--------------	----------

	@ TEVA	80MG	A076883	001	Jul 26, 2004	Apr DISC
--	--------	------	---------	-----	--------------	----------

	@	120MG	A076883	002	Jul 26, 2004	Apr DISC
--	---	-------	---------	-----	--------------	----------

	@	160MG	A076883	003	Jul 26, 2004	Apr DISC
--	---	-------	---------	-----	--------------	----------

>D> AB1	UPSHER-SMITH LABS	80MG	A075366	001	May 01, 2000	Jun CAHN
---------	-------------------	------	---------	-----	--------------	----------

>A> AB1		80MG	A075366	001	May 01, 2000	Jun CAHN
---------	--	------	---------	-----	--------------	----------

TABLET;ORAL

SOTALOL HYDROCHLORIDE

>D>	AB1	120MG	A075366	002	May 01, 2000	Jun CAHN
>A>	AB1	120MG	A075366	002	May 01, 2000	Jun CAHN
>D>	AB1	160MG	A075366	003	May 01, 2000	Jun CAHN
>A>	AB1	160MG	A075366	003	May 01, 2000	Jun CAHN
>D>	AB1	240MG	A075366	004	May 01, 2000	Jun CAHN
>A>	AB1	240MG	A075366	004	May 01, 2000	Jun CAHN

SPIRONOLACTONE

TABLET;ORAL

SPIRONOLACTONE

AB	ACCORD HLTHCARE	25MG	A203512	001	Sep 19, 2016	Mar CAHN
AB		50MG	A203512	002	Sep 19, 2016	Mar CAHN
AB		100MG	A203512	003	Sep 19, 2016	Mar CAHN
AB	AMNEAL PHARMS	25MG	A091426	001	Jul 02, 2010	May CAHN
AB		25MG	A091426	001	Jul 02, 2010	May CMS1
AB		50MG	A091426	002	Jul 02, 2010	May CAHN
AB		50MG	A091426	002	Jul 02, 2010	May CMS1
AB		100MG	A091426	003	Jul 02, 2010	May CAHN
AB		100MG	A091426	003	Jul 02, 2010	May CMS1
>D>	@ UPSHER SMITH	25MG	A087554	001		Jun CAHN
>A>	@	25MG	A087554	001		Jun CAHN

STAVUDINE

CAPSULE;ORAL

STAVUDINE

	@ MYLAN LABS LTD	30MG	A078775	001	Jan 05, 2009	May DISC
AB		30MG	A078775	001	Jan 05, 2009	Mar CAHN
	@	40MG	A078775	002	Jan 05, 2009	May DISC
AB		40MG	A078775	002	Jan 05, 2009	Mar CAHN

STERILE WATER FOR INJECTION

LIQUID;N/A

STERILE WATER FOR INJECTION

AP	WEST-WARD PHARMS INT	100%	A206369	001	Sep 02, 2015	Jan CAHN
	STERILE WATER FOR INJECTION IN PLASTIC CONTAINER					
AP	+! ICU MEDICAL INC	100%	N018233	001		Feb CAHN
AP	+!	100%	N019869	001	Dec 26, 1989	Apr CAHN
AP	TARO	100%	A077393	001	Aug 11, 2006	Apr CAHN

STERILE WATER FOR IRRIGATION

LIQUID;IRRIGATION

STERILE WATER IN PLASTIC CONTAINER

AT	ICU MEDICAL INC	100%	N017513	001		Feb CAHN
AT		100%	N018313	001		Feb CAHN

SUCCINYLCHOLINE CHLORIDE

INJECTABLE;INJECTION

ANECTINE

AP	+! SANDOZ INC	20MG/ML	N008453	002		May CAHN
	@	50MG/ML	N008453	003		May CAHN
	@	500MG/VIAL	N008453	001		May CAHN
	@	1GM/VIAL	N008453	004		May CAHN

SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC

SULFACETAMIDE SODIUM

AT	SANDOZ INC	10%	A089560	001	Oct 18, 1988	Feb CAHN
----	------------	-----	---------	-----	--------------	----------

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET;ORAL

SEPTRA

AB	MONARCH PHARMS	400MG;80MG	N017376	001		May CAHN
	SEPTRA DS					
AB	MONARCH PHARMS	800MG;160MG	N017376	002		May CAHN
	SULFAMETHOXAZOLE AND TRIMETHOPRIM					
AB	CHARTWELL MOLECULES	400MG;80MG	A078060	002	Jan 25, 2007	Mar CAHN
AB		800MG;160MG	A078060	001	Jan 25, 2007	Mar CAHN
AB	CHARTWELL PHARMS LLC	400MG;80MG	A078060	002	Jan 25, 2007	Jan CAHN
AB		800MG;160MG	A078060	001	Jan 25, 2007	Jan CAHN

SULFANILAMIDECREAM;VAGINAL
AVC+! MYLAN SPECIALITY LP 15% N006530 003 Jan 27, 1987 Mar CAHN
SUPPOSITORY;VAGINAL

AVC

@ MYLAN SPECIALITY LP 1.05GM N006530 004 Jan 27, 1987 Mar CAHN

SUMATRIPTAN SUCCINATEINJECTABLE;SUBCUTANEOUS
SUMATRIPTAN SUCCINATE

@ SANDOZ INC EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) A078067 002 Feb 06, 2009 Mar CAHN

@ EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A078067 001 Feb 06, 2009 Mar CAHN

AP WEST-WARD PHARMS INT EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A079123 001 Feb 06, 2009 Jan CAHN

SYSTEM;IONTOPHORESIS
ZECUITY

+ @ TEVA BRANDED PHARM EQ 6.5MG BASE/4HR N202278 001 Jan 17, 2013 Jan DISC

SUNITINIB MALATECAPSULE;ORAL
SUTENT

+ CPPI CV EQ 12.5MG BASE N021938 001 Jan 26, 2006 Mar CTEC

+ EQ 25MG BASE N021938 002 Jan 26, 2006 Mar CTEC

+ EQ 37.5MG BASE N021938 004 Mar 31, 2009 Mar CTEC

+! EQ 50MG BASE N021938 003 Jan 26, 2006 Mar CTEC

TALCPOWDER;INTRAPLEURAL
STERITALC

+ NOVATECH SA 2GM/VIAL N205555 001 May 01, 2017 Apr NEWA

+ 3GM/VIAL N205555 002 May 01, 2017 Apr NEWA

+! 4GM/VIAL N205555 003 May 01, 2017 Apr NEWA

TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

TAMSULOSIN HYDROCHLORIDE

AB MACLEODS PHARMS LTD 0.4MG A204645 001 Jan 20, 2017 Jan NEWA

TAZAROTENEAEROSOL, FOAM;TOPICAL
FABIOR

+! MAYNE PHARMA 0.1% N202428 001 May 11, 2012 Jan CAHN

CREAM;TOPICAL
AVAGE

AB +! ALLERGAN 0.1% N021184 003 Sep 30, 2002 Mar CFTG

TAZAROTENE

AB TARO 0.1% A208258 001 Apr 03, 2017 Mar NEWA

TAZORAC

AB +! ALLERGAN 0.1% N021184 002 Sep 29, 2000 Mar CFTG

TECHNETIUM TC-99M MEDRONATE KITINJECTABLE;INJECTION
MDP-BRACCO

AP CARDINAL HEALTH 414 N/A N018107 001 Apr CAHN

TECHNETIUM TC-99M SESTAMIBI KITINJECTABLE;INJECTION
TECHNETIUM TC 99M SESTAMIBI

>D> AP DRAXIMAGE N/A A078806 001 Apr 29, 2009 Jun CAHN

>A> AP JUBILANT DRAXIMAGE N/A A078806 001 Apr 29, 2009 Jun CAHN

TECHNETIUM TC-99M TILMANOCEPTINJECTABLE;INJECTION
LYMPHOSEEK KIT

+! CARDINAL HLTH 414 N/A N202207 001 Mar 13, 2013 Mar CAHN

TELAVANCIN HYDROCHLORIDE

POWDER; IV (INFUSION)
VIBATIV

+	THERAVANCE BIOPHARMA	EQ 250MG BASE/VIAL
+	!	EQ 750MG BASE/VIAL

N022110	001	Sep 11, 2009	May CAHN
N022110	002	Sep 11, 2009	May CAHN

TELMISARTAN

TABLET; ORAL
TELMISARTAN

AB	GLENMARK PHARMS LTD	20MG
AB		40MG
AB		80MG
AB	PRINSTON INC	20MG
AB		40MG
AB		80MG

A 090032	001	Jul 07, 2014	May CAHN
A 090032	002	Jul 07, 2014	May CAHN
A 090032	003	Jul 07, 2014	May CAHN
A 207882	001	May 03, 2017	Apr NEWA
A 207882	002	May 03, 2017	Apr NEWA
A 207882	003	May 03, 2017	Apr NEWA

TELOTRISTAT ETIPRATE

TABLET; ORAL
XERMELO

+! LEXICON PHARMS INC EQ 250MG BASE

N208794 001 Feb 28, 2017 Feb NEWA

TEMAZEPAM

CAPSULE; ORAL
TEMAZEPAM

AB	ACTAVIS ELIZABETH	15MG
AB	PRINSTON INC	7.5MG
AB		15MG
AB		22.5MG
AB		30MG

A 071620	002	Aug 07, 1987	May CMS1
A 201781	001	Jun 04, 2015	Feb CAHN
A 201781	002	Jun 04, 2015	Feb CAHN
A 201781	003	Jun 04, 2015	Feb CAHN
A 201781	004	Jun 04, 2015	Feb CAHN

TEMOZOLOMIDE

CAPSULE; ORAL
TEMOZOLOMIDE

AB	ACCORD HLTHCARE	5MG
AB		20MG
AB		100MG
AB		140MG
AB		180MG
AB		250MG
AB	DEVA HOLDING AS	5MG
AB		20MG
AB		100MG
AB		140MG
AB		180MG
AB		250MG
AB	WATSON LABS TEVA	5MG
AB		20MG
AB		100MG
AB		140MG
AB		250MG

A 201528	001	Feb 27, 2017	Feb NEWA
A 201528	002	Feb 27, 2017	Feb NEWA
A 201528	003	Feb 27, 2017	Feb NEWA
A 201528	004	Feb 27, 2017	Feb NEWA
A 201528	005	Feb 27, 2017	Feb NEWA
A 201528	006	Feb 27, 2017	Feb NEWA
A 207658	001	Apr 26, 2017	Apr NEWA
A 207658	002	Apr 26, 2017	Apr NEWA
A 207658	003	Apr 26, 2017	Apr NEWA
A 207658	004	Apr 26, 2017	Apr NEWA
A 207658	005	Apr 26, 2017	Apr NEWA
A 207658	006	Apr 26, 2017	Apr NEWA
A 203959	001	Apr 18, 2017	Apr NEWA
A 203959	002	Apr 18, 2017	Apr NEWA
A 203959	003	Apr 18, 2017	Apr NEWA
A 203959	004	Apr 18, 2017	Apr NEWA
A 203959	005	Apr 18, 2017	Apr NEWA

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
TERAZOSIN HYDROCHLORIDE

AB	MYLAN PHARMS INC	EQ 1MG BASE
AB		EQ 2MG BASE
AB		EQ 5MG BASE
AB		EQ 10MG BASE

A 075140	002	Feb 11, 2000	Mar CAHN
A 075140	003	Feb 11, 2000	Mar CAHN
A 075140	001	Feb 11, 2000	Mar CAHN
A 075140	004	Feb 11, 2000	Mar CAHN

TERBUTALINE SULFATE

INJECTABLE; INJECTION
TERBUTALINE SULFATE

AP	!	ATHENEX INC	1MG/ML
		TABLET;ORAL	
		BRETHINE	
	+	@ ANI PHARMS INC	2.5MG
	+	@	5MG
		TERBUTALINE SULFATE	
	!	LANNETT	5MG

A 076770	001	Apr 23, 2004	Mar	CAHN
N 017849	001		Feb	CAHN
N 017849	002		Feb	CAHN
A 077152	002	Mar 25, 2005	Jan	CHRS

TESTOSTERONEGEL;TRANSDERMAL
ANDROGEL

>D>	+	ABBVIE	1.62% (20.25MG/1.25GM PACKET)	N022309	002	Sep 07, 2012	Jun CFTG
>A>	AB2	+	1.62% (20.25MG/1.25GM PACKET)	N022309	002	Sep 07, 2012	Jun CFTG
>D>		+	1.62% (40.5MG/2.5GM PACKET)	N022309	003	Sep 07, 2012	Jun CFTG
>A>	AB2	+	1.62% (40.5MG/2.5GM PACKET)	N022309	003	Sep 07, 2012	Jun CFTG

TESTIM

	AB2	+	AUXILIUM PHARMS LLC	50MG/5GM PACKET	N021454	001	Oct 31, 2002	May CAHN
>A>			TESTOSTERONE					
>A>	AB2		PERRIGO UK FINCO	1.62% (20.25MG/1.25GM PACKET)	A205781	001	Jul 12, 2017	Jun NEWA
>A>	AB2			1.62% (40.5MG/2.5GM PACKET)	A205781	002	Jul 12, 2017	Jun NEWA

VOGELXO

>D>	AB2		UPSHER-SMITH LABS	50MG/5GM PACKET	N204399	002	Jun 04, 2014	Jun CAHN
>A>	AB2			50MG/5GM PACKET	N204399	002	Jun 04, 2014	Jun CAHN

GEL, METERED;TRANSDERMAL
TESTOSTERONE

	AB		ACTAVIS LABS UT INC	10MG/0.5GM ACTUATION	A204571	001	Aug 05, 2015	Mar CAHN
			VOGELXO					
>D>	BX		UPSHER-SMITH LABS	12.5MG/1.25GM ACTUATION	N204399	003	Jun 04, 2014	Jun CAHN
>A>	BX			12.5MG/1.25GM ACTUATION	N204399	003	Jun 04, 2014	Jun CAHN

SOLUTION, METERED;TRANSDERMAL
AXIRON

AT	+	ELI LILLY AND CO	30MG/1.5ML ACTUATION	N022504	001	Nov 23, 2010	Feb CFTG
		TESTOSTERONE					
AT		PERRIGO ISRAEL	30MG/1.5ML ACTUATION	A204255	001	Feb 28, 2017	Feb NEWA
		TABLET, EXTENDED RELEASE;BUCCAL					
		STRIANT					
	+	AUXILIUM PHARMS LLC	30MG	N021543	001	Jun 19, 2003	May CAHN

TESTOSTERONE CYPIONATEINJECTABLE;INJECTION
TESTOSTERONE CYPIONATE

>A>	AO		LUITPOLD PHARMS INC	200MG/ML	A207742	001	Jun 16, 2017	Jun NEWA
	AO		SANDOZ INC	100MG/ML	A040615	001	Aug 10, 2006	Mar CAHN
	AO			200MG/ML	A040615	002	Aug 10, 2006	Mar CAHN
	AO		WATSON PHARMS INC	200MG/ML	A086030	001		Feb CAHN
	AO		WEST-WARD PHARMS INT	100MG/ML	A090387	001	Jul 15, 2010	Jan CAHN
	AO			200MG/ML	A090387	002	Jul 15, 2010	Jan CAHN

TESTOSTERONE ENANTHATEINJECTABLE;INJECTION
TESTOSTERONE ENANTHATE

AO		WATSON PHARMS INC	200MG/ML	A085598	001		Feb CAHN
----	--	-------------------	----------	---------	-----	--	----------

TETRABENAZINETABLET;ORAL
TETRABENAZINE

>A>	AB		ACTAVIS LABS FL INC	25MG	A206686	001	Jul 07, 2017	Jun NEWA
	AB		APICORE US	12.5MG	A207682	001	Jan 31, 2017	Jan NEWA
	AB			25MG	A207682	002	Jan 31, 2017	Jan NEWA

TETRACYCLINE HYDROCHLORIDECAPSULE;ORAL
ACHROMYCIN V

AB	+	HERITAGE PHARMA	250MG	N050278	003		Jan CAHN
AB	+		500MG	N050278	001		Jan CAHN

TETRACYCLINE HYDROCHLORIDE

AB		CHARTWELL TETRA	250MG	A062752	001	Aug 12, 1988	Apr CAHN
AB			500MG	A062752	002	Aug 12, 1988	Apr CAHN

THEOPHYLLINEELIXIR;ORAL
THEOPHYLLINE

@	CHARTWELL RX	80MG/15ML	A085952	001		Apr CAHN
@	PHARM ASSOC	80MG/15ML	A086720	001		May CAHN

TABLET, EXTENDED RELEASE;ORAL
THEOCHRON

AB		NOSTRUM PHARMS LLC	100MG	A088320	001	Feb 21, 1985	May CAHN
AB			200MG	A088321	001	Feb 21, 1985	May CAHN

TABLET, EXTENDED RELEASE;ORAL										
THEOCHRON										
	@	300MG	A087400	002	Jan 11, 1983	May	CAHN			
THEOPHYLLINE										
!	ALEMBIC LTD	450MG	A090430	002	Oct 27, 2010	Apr	CHRS			
AB	ALEMBIC PHARMS LTD	300MG	A090430	001	Oct 27, 2010	May	CAHN			
!		450MG	A090430	002	Oct 27, 2010	May	CAHN			
<u>THIAMINE HYDROCHLORIDE</u>										
INJECTABLE;INJECTION										
THIAMINE HYDROCHLORIDE										
	@ WEST-WARD PHARMS INT	100MG/ML	A080575	001		Jan	CAHN			
<u>THIORIDAZINE HYDROCHLORIDE</u>										
CONCENTRATE;ORAL										
THIORIDAZINE HYDROCHLORIDE										
	@ ANI PHARMS INC	30MG/ML	A089602	001	Nov 09, 1987	Jan	CAHN			
	@ PHARM ASSOC	30MG/ML	A040187	001	Aug 28, 1997	May	CAHN			
	@	100MG/ML	A040213	001	May 29, 1998	May	CAHN			
TABLET;ORAL										
THIORIDAZINE HYDROCHLORIDE										
	@ WATSON LABS TEVA	15MG	A088477	001	Nov 08, 1983	May	CAHN			
	@	25MG	A088567	001	May 11, 1984	May	CAHN			
	@	200MG	A088872	001	Apr 26, 1985	May	CAHN			
<u>THIOTEPA</u>										
POWDER;IV (INFUSION)										
TEPADINA										
+	ADIENNE SA	15MG/VIAL	N208264	001	Jan 26, 2017	Jan	NEWA			
+		100MG/VIAL	N208264	002	Jan 26, 2017	Jan	NEWA			
<u>TICAGRELOR</u>										
TABLET;ORAL										
BRILINTA										
+	ASTRAZENECA PHARMS	60MG	N022433	002	Sep 03, 2015	Jan	CAHN			
+		90MG	N022433	001	Jul 20, 2011	Jan	CAHN			
<u>TIGECYCLINE</u>										
POWDER;IV (INFUSION)										
TIGECYCLINE										
AP	SANDOZ INC	50MG/VIAL	A091620	001	May 27, 2015	Feb	CDFR			
TYGACIL										
AP	+	PF PRISM CV	50MG/VIAL	N021821	001	Jun 15, 2005	Feb	CDFR		
<u>TIMOLOL MALEATE</u>										
SOLUTION, GEL FORMING/DROPS;OPHTHALMIC										
TIMOLOL MALEATE										
AB	SANDOZ INC	EQ 0.25% BASE	N020963	001	Oct 21, 1998	Feb	CAHN			
AB		EQ 0.5% BASE	N020963	002	Oct 21, 1998	Feb	CAHN			
SOLUTION/DROPS;OPHTHALMIC										
TIMOLOL MALEATE										
AT	!	ALCON RES LTD	EQ 0.25% BASE	A074261	001	Apr 28, 1995	Jan	CHRS		
AT1	!		EQ 0.5% BASE	A074262	001	Apr 28, 1995	Jan	CHRS		
AT	!	SANDOZ INC	EQ 0.25% BASE	A074261	001	Apr 28, 1995	Feb	CAHN		
AT1	!		EQ 0.5% BASE	A074262	001	Apr 28, 1995	Feb	CAHN		
TIMOPTIC										
	+ @ ATON	EQ 0.25% BASE	N018086	001		Jan	DISC			
	+ @	EQ 0.5% BASE	N018086	002		Jan	DISC			
<u>TINIDAZOLE</u>										
TABLET;ORAL										
TINIDAZOLE										
AB	UNIQUE PHARM LABS	250MG	A202489	001	Oct 09, 2013	Jan	CTEC			
AB		500MG	A202489	002	Oct 09, 2013	Jan	CTEC			
<u>TIZANIDINE HYDROCHLORIDE</u>										
CAPSULE;ORAL										
TIZANIDINE HYDROCHLORIDE										
AB	PAR PHARM INC	EQ 2MG BASE	A207199	001	Mar 14, 2017	Feb	NEWA			
AB		EQ 4MG BASE	A207199	002	Mar 14, 2017	Feb	NEWA			
AB		EQ 6MG BASE	A207199	003	Mar 14, 2017	Feb	NEWA			
AB	ZYDUS PHARMS USA INC	EQ 2MG BASE	A208622	001	Mar 03, 2017	Feb	NEWA			

CAPSULE;ORAL

TIZANIDINE HYDROCHLORIDE

AB		EQ 4MG BASE	A208622	002	Mar 03, 2017	Feb NEWA
AB		EQ 6MG BASE	A208622	003	Mar 03, 2017	Feb NEWA

TABLET;ORAL

TIZANIDINE HYDROCHLORIDE

AB	EPIC PHARMA LLC	EQ 2MG BASE	A076347	001	Oct 11, 2002	May CAHN
AB		EQ 4MG BASE	A076347	002	Oct 11, 2002	May CAHN
AB	PAR PHARM INC	EQ 2MG BASE	A207170	001	Jan 26, 2017	Jan NEWA
AB		EQ 4MG BASE	A207170	002	Jan 26, 2017	Jan NEWA

TOBRAMYCIN

SOLUTION;INHALATION

TOBRAMYCIN

AN	AMNEAL PHARMS	300MG/5ML	A205501	001	Jul 13, 2015	May CAHN
AN	LUPIN ATLANTIS	300MG/5ML	A208964	001	Mar 22, 2017	Mar NEWA

SOLUTION/DROPS;OPHTHALMIC

TOBRAMYCIN

>A>	AT	SOMERSET THERAPS LLC	0.3%	A207444	001	Jun 28, 2017	Jun NEWA
		TOBREX					
	AT	SANDOZ INC	0.3%	A062535	001	Dec 13, 1984	Feb CAHN

TOLMETIN SODIUM

TABLET;ORAL

TOLMETIN SODIUM

@	SUN PHARM INDS	EQ 200MG BASE	A073310	001	Nov 27, 1991	Apr DISC
---	----------------	---------------	---------	-----	--------------	----------

TOPIRAMATE

CAPSULE, EXTENDED RELEASE;ORAL

QUDEXY XR

>D>	+	UPSHER-SMITH LABS	25MG	N205122	001	Mar 11, 2014	Jun CAHN
>A>	+		25MG	N205122	001	Mar 11, 2014	Jun CAHN
>D>	+		50MG	N205122	002	Mar 11, 2014	Jun CAHN
>A>	+		50MG	N205122	002	Mar 11, 2014	Jun CAHN
>D>	+		100MG	N205122	003	Mar 11, 2014	Jun CAHN
>A>	+		100MG	N205122	003	Mar 11, 2014	Jun CAHN
>D>	+		150MG	N205122	004	Mar 11, 2014	Jun CAHN
>A>	+		150MG	N205122	004	Mar 11, 2014	Jun CAHN
>D>	+		200MG	N205122	005	Mar 11, 2014	Jun CAHN
>A>	+		200MG	N205122	005	Mar 11, 2014	Jun CAHN

TABLET;ORAL

TOPIRAMATE

@	MYLAN	25MG	A076314	001	Mar 27, 2009	May DISC	
@		50MG	A076314	002	Mar 27, 2009	May DISC	
@		100MG	A076314	003	Mar 27, 2009	May DISC	
@		200MG	A076314	004	Mar 27, 2009	May DISC	
>D>	AB	UPSHER SMITH	25MG	A078499	001	Jan 07, 2010	Jun CAHN
>D>	AB		50MG	A078499	002	Jan 07, 2010	Jun CAHN
>D>	AB		100MG	A078499	003	Jan 07, 2010	Jun CAHN
>D>	AB		200MG	A078499	004	Jan 07, 2010	Jun CAHN
>A>	AB	UPSHER-SMITH LABS	25MG	A078499	001	Jan 07, 2010	Jun CAHN
>A>	AB		50MG	A078499	002	Jan 07, 2010	Jun CAHN
>A>	AB		100MG	A078499	003	Jan 07, 2010	Jun CAHN
>A>	AB		200MG	A078499	004	Jan 07, 2010	Jun CAHN

TOPOTECAN HYDROCHLORIDE

SOLUTION;INTRAVENOUS

TOPOTECAN HYDROCHLORIDE

>A>	AP	ACCORD HLTHCARE	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A204406	001	Jul 06, 2017	Jun NEWA
>A>	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A204406	002	Jul 06, 2017	Jun NEWA

TOREMIFENE CITRATE

TABLET;ORAL

FARESTON

+	KYOWA KIRIN	EQ 60MG BASE	N020497	001	May 29, 1997	Jan CAHN
---	-------------	--------------	---------	-----	--------------	----------

TORSEMIDE

TABLET;ORAL

DEMADEX

AB	+	MYLAN SPECIALITY LP	5MG	N020136	001	Aug 23, 1993	Mar CAHN
AB	+		10MG	N020136	002	Aug 23, 1993	Mar CAHN
AB	+		20MG	N020136	003	Aug 23, 1993	Mar CAHN

TABLET;ORAL							
DEMADEX							
AB	+	100MG	N020136	004	Aug 23, 1993	Mar	CAHN
<u>TRAMADOL HYDROCHLORIDE</u>							
TABLET;ORAL							
TRAMADOL HYDROCHLORIDE							
AB	ACCORD HLTHCARE	50MG	A202390	001	May 16, 2013	Mar	CAHN
AB	AMNEAL PHARMS	50MG	A076003	001	Jun 20, 2002	May	CAHN
TABLET, EXTENDED RELEASE;ORAL							
ULTRAM ER							
	+ @ VALEANT PHARMS	100MG	N021692	001	Sep 08, 2005	Mar	CRLD
	+ @	200MG	N021692	002	Sep 08, 2005	Mar	CRLD
	+ @	300MG	N021692	003	Sep 08, 2005	Mar	CRLD
<u>TRANDOLAPRIL</u>							
TABLET;ORAL							
TRANDOLAPRIL							
	@ EPIC PHARMA LLC	1MG	A077256	001	Jun 12, 2007	May	CAHN
	@	2MG	A077256	002	Jun 12, 2007	May	CAHN
	@	4MG	A077256	003	Jun 12, 2007	May	CAHN
>D> BX	INVAGEN PHARMS	1MG	A078320	001	Jun 12, 2007	Jun	DISC
>A>	@	1MG	A078320	001	Jun 12, 2007	Jun	DISC
BX		1MG	A078320	001	Jun 12, 2007	Apr	CTEC
>D> BX		2MG	A078320	002	Jun 12, 2007	Jun	DISC
>A>	@	2MG	A078320	002	Jun 12, 2007	Jun	DISC
BX		2MG	A078320	002	Jun 12, 2007	Apr	CTEC
>D> BX		4MG	A078320	003	Jun 12, 2007	Jun	DISC
>A>	@	4MG	A078320	003	Jun 12, 2007	Jun	DISC
BX		4MG	A078320	003	Jun 12, 2007	Apr	CTEC
	@ MYLAN	1MG	A078346	001	Apr 28, 2008	May	DISC
	@	2MG	A078346	002	Apr 28, 2008	May	DISC
	@	4MG	A078346	003	Apr 28, 2008	May	DISC
<u>TRANEXAMIC ACID</u>							
INJECTABLE;INJECTION							
TRANEXAMIC ACID							
AP	AMNEAL PHARMS CO	100MG/ML	A208840	001	Feb 28, 2017	Feb	NEWA
AP	GLAND PHARMA LTD	100MG/ML	A207239	001	Feb 13, 2017	Jan	NEWA
>A> AP	MICRO LABS	100MG/ML	A206713	001	Jun 27, 2017	Jun	NEWA
<u>TRAVOPROST</u>							
SOLUTION/DROPS;OPHTHALMIC							
TRAVOPROST							
>A> AT	MYLAN PHARMS INC	0.004%	A205050	001	Jul 07, 2017	Jun	NEWA
<u>TRAZODONE HYDROCHLORIDE</u>							
TABLET;ORAL							
TRAZODONE HYDROCHLORIDE							
	@ MYLAN PHARMS INC	50MG	A090514	001	Jun 02, 2009	May	DISC
	@	100MG	A090514	002	Jun 02, 2009	May	DISC
	@	150MG	A090514	003	Jun 02, 2009	May	DISC
	@	300MG	A090514	004	Jun 02, 2009	May	DISC
<u>TRETINOIN</u>							
CAPSULE;ORAL							
TRETINOIN							
>D> AB	GLENMARK GENERICS	10MG	A208279	001	Dec 23, 2016	Jun	CAHN
>A> AB	GLENMARK PHARMS LTD	10MG	A208279	001	Dec 23, 2016	Jun	CAHN
VESANOID							
	+ @ CHEPLAPHARM	10MG	N020438	001	Nov 22, 1995	May	CAHN
CREAM;TOPICAL							
TRETINOIN							
	@ ALLERGAN SALES LLC	0.0375%	A090098	001	Mar 22, 2010	Feb	DISC
	@	0.075%	A202209	001	Oct 11, 2012	Feb	DISC
AB2	ZO SKIN HEALTH	0.05%	A076498	001	Sep 15, 2005	Feb	CAHN
GEL;TOPICAL							
TRETINOIN							
>A> AB	MYLAN PHARMS INC	0.04%	A202567	001	Jul 17, 2013	Jun	CAHN
>A> AB		0.05%	A207955	001	Aug 13, 2015	Jun	CAHN
>A> AB		0.1%	A202026	001	Jul 17, 2013	Jun	CAHN
>D> AB	SPEAR PHARMS INC	0.04%	A202567	001	Jul 17, 2013	Jun	CAHN

GEL;TOPICAL
TRETINOIN

>D>	AB	0.05%	A207955	001	Aug 13, 2015	Jun CAHN
>D>	AB	0.1%	A202026	001	Jul 17, 2013	Jun CAHN

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

TRIAMCINOLONE ACETONIDE

AT	LUPIN ATLANTIS	0.025%	A208763	001	Feb 01, 2017	Jan NEWA
AT		0.1%	A208763	002	Feb 01, 2017	Jan NEWA
AT		0.5%	A208763	003	Feb 01, 2017	Jan NEWA
AT	+ MYLAN PHARMS INC	0.025%	N011601	003		Jan CAHN
AT	+ @ TARO	0.1%	N011601	006		Jan CAHN
		0.025%	A040038	001	Oct 26, 1994	Apr CAHN
AT		0.1%	A040039	001	Nov 26, 1997	Apr CAHN
AT		0.1%	A040039	001	Nov 26, 1997	Mar CAHN

INJECTABLE;INJECTION

KENALOG-10

>D>	APOTHECON	10MG/ML	N012041	001		Jun CRLD
>A>	+ TRIAMCINOLONE ACETONIDE	10MG/ML	N012041	001		Jun CRLD
	@ SANDOZ INC	10MG/ML	A090166	001	May 27, 2009	Apr CAHN
	@	40MG/ML	A090164	001	Jun 01, 2009	Apr CAHN

OINTMENT;TOPICAL

KENALOG

AT	MYLAN PHARMS INC	0.025%	N011600	003		Jan CAHN
AT		0.1%	N011600	001		Jan CAHN
	TRIAMCINOLONE ACETONIDE					
	@ TARO	0.025%	A040040	001	Sep 30, 1994	Apr CAHN
AT		0.1%	A040037	001	Sep 30, 1994	Apr CAHN
AT	TELIGENT PHARMA INC	0.5%	A208590	001	Mar 03, 2017	Feb NEWA
	TRIAMCINOLONE ACETONIDE IN ABSORBABLE					
	! CMP PHARMA INC	0.05%	A089595	001	Mar 23, 1995	Apr CAHN
	PASTE;DENTAL					
	TRIAMCINOLONE ACETONIDE					
AT	G AND W LABS INC	0.1%	A205592	001	Jan 12, 2017	Jan NEWA
	SPRAY, METERED;NASAL					
	TRIAMCINOLONE ACETONIDE					
	@ PERRIGO ISRAEL	0.055MG/SPRAY	A078104	001	Jul 30, 2009	Jan CAHN

TRIAMCINOLONE DIACETATE

INJECTABLE;INJECTION

ARISTOCORT

>D>	@ SANDOZ	25MG/ML	N011685	003		Jun CAHN
>D>	+ @	40MG/ML	N012802	001		Jun CAHN
>A>	@ SANDOZ INC	25MG/ML	N011685	003		Jun CAHN
>A>	+ @	40MG/ML	N012802	001		Jun CAHN

TRIAMCINOLONE HEXACETONIDE

INJECTABLE;INJECTION

ARISTOSPAN

>D>	+! SANDOZ	5MG/ML	N016466	001		Jun CAHN
>D>	+! SANDOZ INC	20MG/ML	N016466	002		Jun CAHN
>A>	+! SANDOZ INC	5MG/ML	N016466	001		Jun CAHN
>A>	+! SANDOZ INC	20MG/ML	N016466	002		Jun CAHN

TRIFLURIDINE

SOLUTION/DROPS;OPHTHALMIC

TRIFLURIDINE

AT	SANDOZ INC	1%	A074311	001	Oct 06, 1995	Feb CAHN
	VIROPTIC					
AT	+! MONARCH PHARMS	1%	N018299	001		Feb CAHN

TRIHENXYPHENIDYL HYDROCHLORIDE

ELIXIR;ORAL

TRIHENXYPHENIDYL HYDROCHLORIDE

AA	! PHARM ASSOC	2MG/5ML	A040177	001	Apr 17, 1997	May CAHN
	TABLET;ORAL					
	TRIHENXYPHENIDYL HYDROCHLORIDE					
AA	VINTAGE PHARMS LLC	2MG	A040254	001	Dec 24, 1998	Mar CAHN
AA		5MG	A040254	002	Dec 24, 1998	Mar CAHN

TRIMETHOBENZAMIDE HYDROCHLORIDECAPSULE;ORAL
TIGAN

AB	+!	KING PHARMS LLC	300MG	N017531	006	Dec 13, 2001	May CAHN
----	----	-----------------	-------	---------	-----	--------------	----------

TRIMIPRAMINE MALEATECAPSULE;ORAL
TRIMIPRAMINE MALEATE

AB		ELITE LABS INC	EQ 25MG BASE	A077361	001	Aug 02, 2006	May CAHN
AB			EQ 50MG BASE	A077361	002	Aug 02, 2006	May CAHN
AB			EQ 100MG BASE	A077361	003	Aug 02, 2006	May CAHN

TRIPTORELIN PAMOATE

>A> FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
>A> TRIPTODUR KIT

>A>	+!	ARBOR PHARMS LLC	EQ 22.5MG BASE/VIAL	N208956	001	Jun 29, 2017	Jun NEWA
-----	----	------------------	---------------------	---------	-----	--------------	----------

TROPICAMIDESOLUTION/DROPS;OPHTHALMIC
MYDRIACYL

AT	!	SANDOZ INC	0.5%	A084305	001		Feb CAHN
----	---	------------	------	---------	-----	--	----------

TROSPIMUM CHLORIDECAPSULE, EXTENDED RELEASE;ORAL
TROSPIMUM CHLORIDE

>D>	@	UPSHER-SMITH LABS	60MG	A091635	001	Apr 29, 2015	Jun CAHN
>A>	@		60MG	A091635	001	Apr 29, 2015	Jun CAHN

ULIPRISTAL ACETATETABLET;ORAL
ELLA

AB	+!	LAB HRA PHARMA	30MG	N022474	001	Aug 13, 2010	Jan CFTG
----	----	----------------	------	---------	-----	--------------	----------

AB		TEVA PHARMS USA	30MG	A207952	001	Feb 13, 2017	Jan NEWA
----	--	-----------------	------	---------	-----	--------------	----------

URSODIOLCAPSULE;ORAL
URSODIOL

	@	IMPAX LABS INC	300MG	A077895	001	Jul 27, 2006	May DISC
BX			300MG	A077895	001	Jul 27, 2006	Apr CTEC
AB			300MG	A077895	001	Jul 27, 2006	Feb CAHN

VALACYCLOVIR HYDROCHLORIDETABLET;ORAL
VALACYCLOVIR HYDROCHLORIDE

>D>	AB	MYLAN	EQ 500MG BASE	A078070	001	May 24, 2010	Jun DISC
>A>		@	EQ 500MG BASE	A078070	001	May 24, 2010	Jun DISC
>D>	AB		EQ 1GM BASE	A078070	002	May 24, 2010	Jun DISC
>A>		@	EQ 1GM BASE	A078070	002	May 24, 2010	Jun DISC

VALBENAZINE TOSYLATECAPSULE;ORAL
INGREZZA

+!	NEUROCRINE	40MG	N209241	001	Apr 11, 2017	Apr NEWA
----	------------	------	---------	-----	--------------	----------

VALPROATE SODIUMINJECTABLE;INJECTION
VALPROATE SODIUM

AP		ATHENEX INC	EQ 100MG BASE/ML	A076295	001	Nov 14, 2002	Mar CAHN
----	--	-------------	------------------	---------	-----	--------------	----------

VALPROIC ACIDCAPSULE;ORAL
VALPROIC ACID

>D>	@	USL PHARMA	250MG	A070631	001	Jun 11, 1987	Jun CAHN
>A>	@		250MG	A070631	001	Jun 11, 1987	Jun CAHN

SYRUP;ORAL

VALPROIC ACID

AA		ECI PHARMS LLC	250MG/5ML	A090517	001	May 28, 2010	Mar CAHN
AA		PHARM ASSOC	250MG/5ML	A075379	001	Dec 15, 2000	May CAHN
AA		VISTAPHARM	250MG/5ML	A075782	001	Dec 22, 2000	Feb CAHN

VALSARTANTABLET; ORAL
VALSARTAN

AB	AMNEAL PHARMS	40MG	A204011	001	Jan 11, 2016	May CAHN
AB		80MG	A204011	002	Jan 11, 2016	May CAHN
AB		160MG	A204011	003	Jan 11, 2016	May CAHN
AB		320MG	A204011	004	Jan 11, 2016	May CAHN
AB	MYLAN PHARMS INC	40MG	A090866	001	Jan 05, 2015	Feb CAHN
AB		80MG	A090866	002	Jan 05, 2015	Feb CAHN
AB		160MG	A090866	003	Jan 05, 2015	Feb CAHN
AB		320MG	A090866	004	Jan 05, 2015	Feb CAHN

VARDENAFIL HYDROCHLORIDETABLET, ORALLY DISINTEGRATING; ORAL
STAXYN

>D>	AB	+!	BAYER HLTHCARE	10MG	N200179	001	Jun 17, 2010	Jun CTEC
>A>		+!		10MG	N200179	001	Jun 17, 2010	Jun CTEC

VASOPRESSINSOLUTION; IV (INFUSION)
VASOSTRICT

	+!	PAR STERILE PRODUCTS	20UNITS/ML (20UNITS/ML)	N204485	001	Apr 17, 2014	May CMFD
	+	@	20UNITS/ML (20UNITS/ML)	N204485	001	Apr 17, 2014	Apr DISC
	+!		20UNITS/ML (20UNITS/ML)	N204485	002	Mar 18, 2016	Apr NEWA
	+!		200UNITS/10ML (20UNITS/ML)	N204485	002	Dec 17, 2016	May NEWA

VECURONIUM BROMIDEINJECTABLE; INJECTION
VECURONIUM BROMIDE

	@	WEST-WARD PHARMS INT	10MG/VIAL	A075218	001	Aug 23, 1999	Mar CAHN
AP			10MG/VIAL	A075549	001	Jun 13, 2000	Jan CAHN
	@		20MG/VIAL	A075218	002	Aug 23, 1999	Mar CAHN
AP			20MG/VIAL	A075549	002	Jun 13, 2000	Jan CAHN

VENLAFAXINE HYDROCHLORIDETABLET; ORAL
VENLAFAXINE HYDROCHLORIDE

AB	PRINSTON INC	EQ 25MG BASE	A090027	001	Aug 04, 2010	Feb CAHN
AB		EQ 37.5MG BASE	A090027	002	Aug 04, 2010	Feb CAHN
AB		EQ 50MG BASE	A090027	003	Aug 04, 2010	Feb CAHN
AB		EQ 75MG BASE	A090027	004	Aug 04, 2010	Feb CAHN
AB		EQ 100MG BASE	A090027	005	Aug 04, 2010	Feb CAHN

TABLET, EXTENDED RELEASE; ORAL
VENLAFAXINE HYDROCHLORIDE

AB	NOSTRUM LABS INC	EQ 150MG BASE	A205468	002	Mar 24, 2017	Mar NEWA	
AB		EQ 225MG BASE	A205468	003	Mar 24, 2017	Mar NEWA	
AB	+	OSMOTICA PHARM	EQ 225MG BASE	N022104	004	May 20, 2008	Mar CFTG

VERAPAMIL HYDROCHLORIDEINJECTABLE; INJECTION
ISOPTIN

	+	@	MT ADAMS	2.5MG/ML	N018485	001		Apr CRLD
--	---	---	----------	----------	---------	-----	--	----------

TABLET, EXTENDED RELEASE; ORAL
CALAN SR

	+	@	PFIZER	180MG	N019152	002	Dec 15, 1989	Jan CRLD
			COVERA-HS					
	@	GD SEARLE LLC	180MG	N020552	001	Feb 26, 1996	Jan DISC	
	@		240MG	N020552	002	Feb 26, 1996	Jan DISC	

VERAPAMIL HYDROCHLORIDE

AB	CADILA PHARMS LTD	180MG	A206173	001	May 05, 2017	Apr NEWA
AB		240MG	A206173	002	May 05, 2017	Apr NEWA

VIGABATRINFOR SOLUTION; ORAL
SABRIL

AA	+!	LUNDBECK PHARMS LLC	500MG/PACKET	N022006	001	Aug 21, 2009	Apr CFTG
	+!		500MG/PACKET	N022006	001	Aug 21, 2009	Jan CAHN
		VIGABATRIN					
AA		PAR PHARM INC	500MG/PACKET	A208218	001	Apr 27, 2017	Apr NEWA

TABLET;ORAL
SABRIL

+! LUNDBECK PHARMS LLC 500MG N020427 001 Aug 21, 2009 Jan CAHN

VINORELBINE TARTRATE

INJECTABLE;INJECTION
VINORELBINE TARTRATE

AP WEST-WARD PHARMS INT EQ 10MG BASE/ML A075992 001 Jun 10, 2003 Mar CAHN
AP EQ 10MG BASE/ML A076461 001 Dec 11, 2003 Jan CAHN

VORICONAZOLE

POWDER;IV (INFUSION)
VORICONAZOLE

XELLIA PHARMS APS 200MG/VIAL N208562 001 Mar 09, 2017 Mar NEWA

VORTIOXETINE HYDROBROMIDE

TABLET;ORAL
TRINTELLIX

+ @ TAKEDA PHARMS USA EQ 15MG BASE N204447 003 Sep 30, 2013 Mar DISC

WARFARIN SODIUM

TABLET;ORAL
JANTOVEN

>D> AB USL PHARMA 1MG A040416 001 Oct 02, 2003 Jun CAHN
>A> AB 1MG A040416 001 Oct 02, 2003 Jun CAHN
>D> AB 2MG A040416 002 Oct 02, 2003 Jun CAHN
>A> AB 2MG A040416 002 Oct 02, 2003 Jun CAHN
>D> AB 2.5MG A040416 003 Oct 02, 2003 Jun CAHN
>A> AB 2.5MG A040416 003 Oct 02, 2003 Jun CAHN
>D> AB 3MG A040416 004 Oct 02, 2003 Jun CAHN
>A> AB 3MG A040416 004 Oct 02, 2003 Jun CAHN
>D> AB 4MG A040416 005 Oct 02, 2003 Jun CAHN
>A> AB 4MG A040416 005 Oct 02, 2003 Jun CAHN
>D> AB 5MG A040416 006 Oct 02, 2003 Jun CAHN
>A> AB 5MG A040416 006 Oct 02, 2003 Jun CAHN
>D> AB 6MG A040416 007 Oct 02, 2003 Jun CAHN
>A> AB 6MG A040416 007 Oct 02, 2003 Jun CAHN
>D> AB 7.5MG A040416 008 Oct 02, 2003 Jun CAHN
>A> AB 7.5MG A040416 008 Oct 02, 2003 Jun CAHN
>D> AB 10MG A040416 009 Oct 02, 2003 Jun CAHN
>A> AB 10MG A040416 009 Oct 02, 2003 Jun CAHN

WARFARIN SODIUM

@ MYLAN

1MG A040415 001 Sep 27, 2004 Apr DISC
2MG A040415 002 Sep 27, 2004 Apr DISC
2.5MG A040415 003 Sep 29, 2004 Apr DISC
3MG A040415 004 Sep 27, 2004 Apr DISC
4MG A040415 005 Sep 27, 2004 Apr DISC
5MG A040415 006 Sep 27, 2004 Apr DISC
6MG A040415 007 Sep 27, 2004 Apr DISC
7.5MG A040415 008 Sep 27, 2004 Apr DISC
10MG A040415 009 Sep 27, 2004 Apr DISC

AB TARO PHARM 1MG A040301 002 Jul 15, 1999 Mar CAHN
AB 2MG A040301 003 Jul 15, 1999 Mar CAHN
AB 2.5MG A040301 004 Jul 15, 1999 Mar CAHN
AB 3MG A040301 005 Jul 15, 1999 Mar CAHN
AB 4MG A040301 006 Jul 15, 1999 Mar CAHN
AB 5MG A040301 007 Jul 15, 1999 Mar CAHN
AB 6MG A040301 008 Jul 15, 1999 Mar CAHN
AB 7.5MG A040301 009 Jul 15, 1999 Mar CAHN
AB 10MG A040301 001 Jul 15, 1999 Mar CAHN

ZALEPLON

CAPSULE;ORAL
ZALEPLON

>D> @ UPSHER SMITH 5MG A078706 001 Jun 06, 2008 Jun CAHN
>D> @ 10MG A078706 002 Jun 06, 2008 Jun CAHN
>D> @ UPSHER-SMITH LABS 5MG A078095 001 Jun 06, 2008 Jun CAHN
>A> @ 5MG A078095 001 Jun 06, 2008 Jun CAHN
>A> @ 5MG A078706 001 Jun 06, 2008 Jun CAHN
>D> @ 10MG A078095 002 Jun 06, 2008 Jun CAHN
>A> @ 10MG A078095 002 Jun 06, 2008 Jun CAHN
>A> @ 10MG A078706 002 Jun 06, 2008 Jun CAHN

ZIDOVUDINETABLET;ORAL
ZIDOVUDINE

@ HEC PHARM USA INC	300MG	A202058	001	Oct 07, 2011	May CAHN
---------------------	-------	---------	-----	--------------	----------

ZILEUTONTABLET, EXTENDED RELEASE;ORAL
ZILEUTON

AB	PACK PHARMS LLC	600MG	A204929	001	Mar 17, 2017	Mar NEWA
AB	RISING PHARMS INC	600MG	A204929	001	Mar 17, 2017	Mar CAHN
	ZYFLO CR					
AB	+! CHIESI USA INC	600MG	N022052	001	May 30, 2007	Mar CFTG

ZIPRASIDONE HYDROCHLORIDECAPSULE;ORAL
ZIPRASIDONE HYDROCHLORIDE

AB	MACLEODS PHARMS LTD	EQ 20MG BASE	A204375	001	Feb 17, 2017	Feb NEWA
AB		EQ 40MG BASE	A204375	002	Feb 17, 2017	Feb NEWA
AB		EQ 60MG BASE	A204375	003	Feb 17, 2017	Feb NEWA
AB		EQ 80MG BASE	A204375	004	Feb 17, 2017	Feb NEWA

ZOLEDRONIC ACIDINJECTABLE;IV (INFUSION)
ZOLEDRONIC ACID

AP	MYLAN LABS LTD	EQ 5MG BASE/100ML	A203841	001	Feb 14, 2017	Jan NEWA
AP	PII	EQ 4MG BASE/5ML	A202571	001	May 07, 2013	May CAHN

ZOLMITRIPTANTABLET;ORAL
ZOLMITRIPTAN

>A>	AB	APPCO PHARMA LLC	2.5MG	A206973	001	Jun 30, 2017	Jun NEWA
>A>	AB		5MG	A206973	002	Jun 30, 2017	Jun NEWA
	AB	PLD ACQUISITIONS LLC	2.5MG	A207867	001	Feb 27, 2017	Feb NEWA
	AB		5MG	A207867	002	Feb 27, 2017	Feb NEWA

ZOLPIDEM TARTRATETABLET;ORAL
ZOLPIDEM TARTRATE

AB	ALLIED PHARMA INC	5MG	A077214	001	Apr 23, 2007	Mar CAHN
AB		10MG	A077214	002	Apr 23, 2007	Mar CAHN

TABLET;SUBLINGUAL
EDLUAR

AB	+ MYLAN SPECIALITY LP	5MG	N021997	001	Mar 13, 2009	Mar CAHN
AB	+!	10MG	N021997	002	Mar 13, 2009	Mar CAHN

TABLET, EXTENDED RELEASE;ORAL
ZOLPIDEM TARTRATE

AB	SUN PHARMA GLOBAL	6.25MG	A204170	001	Jan 24, 2017	Jan NEWA
AB		12.5MG	A204170	002	Jan 24, 2017	Jan NEWA
	@ SYNTHON PHARMS	6.25MG	A078483	001	Apr 12, 2011	Apr DISC
	@	12.5MG	A078483	002	Jun 06, 2011	Apr DISC

ZONISAMIDECAPSULE;ORAL
ZONISAMIDE

	@ EPIC PHARMA LLC	25MG	A077876	001	Feb 21, 2007	May CAHN	
	@	50MG	A077876	002	Feb 21, 2007	May CAHN	
	@	100MG	A077876	003	Feb 21, 2007	May CAHN	
>D>	AB	MYLAN PHARMS INC	25MG	A077647	001	Dec 22, 2005	Jun DISC
>A>	@	25MG	A077647	001	Dec 22, 2005	Jun DISC	
>D>	AB		50MG	A077647	002	Dec 22, 2005	Jun DISC
>A>	@	50MG	A077647	002	Dec 22, 2005	Jun DISC	
>D>	AB		100MG	A077647	003	Dec 22, 2005	Jun DISC
>A>	@	100MG	A077647	003	Dec 22, 2005	Jun DISC	
>D>	@ UPSHER-SMITH LABS	25MG	A077644	001	Dec 22, 2005	Jun CAHN	
>A>	@	25MG	A077644	001	Dec 22, 2005	Jun CAHN	
>D>	@	50MG	A077644	002	Dec 22, 2005	Jun CAHN	
>A>	@	50MG	A077644	002	Dec 22, 2005	Jun CAHN	
>D>	@	100MG	A077644	003	Dec 22, 2005	Jun CAHN	
>A>	@	100MG	A077644	003	Dec 22, 2005	Jun CAHN	

<u>AVOBENZONE; OCTINOXATE; OXYBENZONE</u>									
>D>	LOTION; TOPICAL								
>D>	SHADE UVAGUARD								
>D>	+!	BAYER HEALTHCARE LLC	3%;7.5%;3%		N020045	001	Dec 07, 1992	Jun	DISC
>A>	+	@	3%;7.5%;3%		N020045	001	Dec 07, 1992	Jun	DISC
<u>CETIRIZINE HYDROCHLORIDE</u>									
SYRUP; ORAL									
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY									
		ALLIED PHARMA INC	5MG/5ML		A091327	001	Oct 17, 2011	Apr	CAHN
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF									
		ALLIED PHARMA INC	5MG/5ML		A091327	002	Oct 17, 2011	Apr	CAHN
TABLET; ORAL									
CETIRIZINE HYDROCHLORIDE ALLERGY									
		JUBILANT CADISTA	5MG		A078933	001	Jun 15, 2010	Apr	CAHN
			10MG		A078933	002	Jun 15, 2010	Apr	CAHN
CETIRIZINE HYDROCHLORIDE HIVES									
		JUBILANT CADISTA	5MG		A078933	003	Jun 15, 2010	Apr	CAHN
			10MG		A078933	004	Jun 15, 2010	Apr	CAHN
<u>CHLORHEXIDINE GLUCONATE</u>									
SPONGE; TOPICAL									
PHARMASEAL SCRUB CARE									
	@	CAREFUSION 2200	4%		N019793	001	Dec 02, 1988	May	CAHN
<u>CHLORPHENIRAMINE MALEATE; IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE</u>									
TABLET; ORAL									
ADVIL MULTI-SYMPTOM COLD & FLU									
>D>	+!	PFIZER	4MG;200MG;10MG		N022113	002	Apr 28, 2017	Apr	NEWA
<u>CIMETIDINE</u>									
TABLET; ORAL									
CIMETIDINE									
		L PERRIGO CO	200MG		A075285	001	Oct 29, 1998	Apr	CAHN
	@	SANDOZ INC	100MG		A075122	001	Jun 19, 1998	Mar	CAHN
	@		200MG		A075122	002	Jun 19, 1998	Mar	CAHN
	@	WATSON LABS TEVA	200MG		A075425	001	Jul 29, 1999	May	CAHN
<u>CLEMASTINE FUMARATE</u>									
TABLET; ORAL									
CLEMASTINE FUMARATE									
		L PERRIGO CO	1.34MG		A074512	001	Nov 22, 1995	Apr	CAHN
TAVIST-1									
>D>	+!	GLAXOSMITHKLINE CONS	1.34MG		N020925	001	Aug 21, 1992	Apr	CAHN
<u>CLOTTRIMAZOLE</u>									
CREAM; VAGINAL									
CLOTTRIMAZOLE									
>D>		ACTAVIS MID ATLANTIC	1%		A074165	001	Jul 16, 1993	Jun	CHRS
>A>	!		1%		A074165	001	Jul 16, 1993	Jun	CHRS
		TARO	1%		A072641	001	Dec 04, 1995	Apr	CAHN
>D>	GYNE-LOTRIMIN								
>D>	+!	BAYER HEALTHCARE LLC	1%		N018052	002	Nov 30, 1990	Jun	DISC
>A>	+	@	1%		N018052	002	Nov 30, 1990	Jun	DISC
>D>	GYNE-LOTRIMIN 3								
>D>	+!	BAYER HEALTHCARE LLC	2%		N020574	001	Nov 24, 1998	Jun	DISC
>A>	+	@	2%		N020574	001	Nov 24, 1998	Jun	DISC
CREAM, TABLET; TOPICAL, VAGINAL									
>D>	GYNE-LOTRIMIN 3 COMBINATION PACK								
>D>	+!	BAYER HEALTHCARE LLC	1%,200MG		N020526	002	Jul 29, 1996	Jun	DISC
>A>	+	@	1%,200MG		N020526	002	Jul 29, 1996	Jun	DISC
>D>	GYNE-LOTRIMIN COMBINATION PACK								
>D>	+!	BAYER HEALTHCARE LLC	1%,100MG		N020289	002	Apr 26, 1993	Jun	DISC
>A>	+	@	1%,100MG		N020289	002	Apr 26, 1993	Jun	DISC
TABLET; VAGINAL									
>D>	GYNE-LOTRIMIN								
>D>	+!	BAYER HEALTHCARE LLC	100MG		N017717	002	Nov 30, 1990	Jun	DISC
>A>	+	@	100MG		N017717	002	Nov 30, 1990	Jun	DISC

	TABLET;VAGINAL						
>D>	GYNE-LOTRIMIN 3						
>D>	+!	BAYER HEALTHCARE LLC	200MG	N020525	001	Jul 29, 1996	Jun DISC
>A>	+ @		200MG	N020525	001	Jul 29, 1996	Jun DISC

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL							
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE							
	ACTAVIS LABS FL	30MG;600MG		A091070	001	Aug 31, 2015	Mar CAHN
		60MG;1.2GM		A091070	002	Aug 31, 2015	Mar CAHN
	AUROBINDO PHARMA LTD	30MG;600MG		A206941	001	Mar 17, 2017	Mar NEWA
		60MG;1.2GM		A206941	002	Mar 17, 2017	Mar NEWA

FAMOTIDINE

TABLET;ORAL							
FAMOTIDINE							
	PERRIGO R AND D	20MG		A077351	001	Sep 25, 2006	Apr CAHN

FLUTICASONE FUROATE

SPRAY, METERED;NASAL							
FLONASE SENSIMIST ALLERGY RELIEF							
>D>	+!	GLAXOSMITHKLINE	0.0275MG/SPRAY	N022051	002	Aug 02, 2016	Jun CAHN
>A>	+!	GLAXOSMITHKLINE CONS	0.0275MG/SPRAY	N022051	002	Aug 02, 2016	Jun CAHN

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL							
GUAIFENESIN							
	ACTAVIS LABS FL	1.2GM		A091009	002	Sep 03, 2015	Mar CAHN

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL							
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE							
	ACTAVIS LABS FL	600MG;60MG		A091071	001	May 27, 2015	Mar CAHN
		1.2GM;120MG		A091071	002	May 27, 2015	Mar CAHN

IBUPROFEN

CAPSULE;ORAL							
IBUPROFEN							
	AMNEAL PHARMS	EQ 200MG FREE ACID AND POTASSIUM SALT		A202300	001	Dec 23, 2011	May CAHN
SUSPENSION;ORAL							
	IBUPROFEN						
>A>	TARO	100MG/5ML		A209207	001	Jun 27, 2017	Jun NEWA
SUSPENSION/DROPS;ORAL							
	IBUPROFEN						
	L PERRIGO CO	40MG/ML		A075217	001	Dec 16, 1998	Apr CAHN
TABLET;ORAL							
	IBUPROFEN						
	AIPING PHARM INC	200MG		A207095	001	May 05, 2017	Apr NEWA
	AMNEAL PHARMS	200MG		A079233	001	Mar 18, 2014	Apr CAHN
>D>	STRIDES PHARMA	200MG		A207052	001	May 30, 2017	Jun CMS2
>A>		200MG		A207052	001	May 30, 2017	Jun CMS2
		200MG		A207052	001	May 30, 2017	May NEWA
JUNIOR STRENGTH IBUPROFEN							
	L PERRIGO CO	100MG		A075367	001	Apr 22, 1999	Apr CAHN

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL							
XYZAL ALLERGY 24HR							
	+	SANOFI-AVENTIS US	2.5MG/5ML (0.5MG/ML)	N209090	001	Jan 31, 2017	Feb CAHN
	+	UCB INC	2.5MG/5ML (0.5MG/ML)	N209090	001	Jan 31, 2017	Jan NEWA
TABLET;ORAL							
XYZAL ALLERGY 24HR							
	+	SANOFI-AVENTIS US	5MG	N209089	001	Jan 31, 2017	Feb CAHN
	+	UCB INC	5MG	N209089	001	Jan 31, 2017	Jan NEWA

LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL

RECKITT BENCKISER

1.5MG

A202246 001 Jun 05, 2015 Apr CAHN

LOPERAMIDE HYDROCHLORIDE

SOLUTION;ORAL

LOPERAMIDE HYDROCHLORIDE

ALLIED PHARMA INC

1MG/5ML

A073079 001 Apr 30, 1992 Mar CAHN

TABLET;ORAL

LOPERAMIDE HYDROCHLORIDE

L PERRIGO CO

2MG

A075232 001 Jan 06, 2000 Apr CAHN

TABLET, CHEWABLE;ORAL

IMODIUM A-D EZ CHEWS

+ @ J AND J CONSUMER INC

2MG

N020448 001 Jul 24, 1997 Jan DISC

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET, CHEWABLE;ORAL

IMODIUM MULTI-SYMPTOM RELIEF

+ @ J AND J CONSUMER INC

2MG;125MG

N020606 001 Jun 26, 1996 Jan DISC

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

! PERRIGO

2MG;125MG

A076029 001 Aug 30, 2002 Jan CHRS

LORATADINE

SYRUP;ORAL

LORATADINE

TARO PHARM

1MG/ML

A201865 001 Jul 31, 2015 Mar CAHN

MICONAZOLE NITRATE

CREAM;VAGINAL

MICONAZOLE NITRATE

TARO

2%

A074444 001 Jan 13, 1997 Apr CAHN

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

M-ZOLE 3 COMBINATION PACK

>D> ACTAVIS MID ATLANTIC

2%,200MG

A074926 001 Apr 16, 1999 Jun CAHN

>A> 2%,200MG

A074926 001 Apr 16, 1999 Jun CAHN

SUPPOSITORY;VAGINAL

MICONAZOLE NITRATE

ACTAVIS PHARMA

100MG

A073507 001 Nov 19, 1993 May CAHN

MINOXIDIL

AEROSOL, FOAM;TOPICAL

MINOXIDIL (FOR MEN)

WATSON LABS INC

5%

A208092 001 Feb 17, 2017 Feb NEWA

SOLUTION;TOPICAL

MINOXIDIL (FOR MEN)

L PERRIGO CO

2%

A075357 001 Jul 30, 1999 Apr CAHN

MINOXIDIL (FOR WOMEN)

L PERRIGO CO

2%

A075357 002 Jul 30, 1999 Apr CAHN

NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM

LNK INTL INC

EQ 200MG BASE

A204872 001 Jan 23, 2017 Jan NEWA

NICOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL

HABITROL

>D> + DR REDDYS LABS INC

7MG/24HR

N020076 004 Nov 12, 1999 Jun CAHN

>D> +

14MG/24HR

N020076 005 Nov 12, 1999 Jun CAHN

>D> +!

21MG/24HR

N020076 006 Nov 12, 1999 Jun CAHN

>A> + DR REDDYS LABS SA

7MG/24HR

N020076 004 Nov 12, 1999 Jun CAHN

>A> +

14MG/24HR

N020076 005 Nov 12, 1999 Jun CAHN

>A> +!

21MG/24HR

N020076 006 Nov 12, 1999 Jun CAHN

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL
NICOTINE POLACRILEX

L PERRIGO CO	EQ 2MG BASE	A076775	001	Sep 16, 2004	Apr CAHN
	EQ 2MG BASE	A076776	001	Sep 16, 2004	Apr CAHN
	EQ 2MG BASE	A076777	001	Sep 16, 2004	Apr CAHN
	EQ 4MG BASE	A076778	001	Sep 16, 2004	Apr CAHN
	EQ 4MG BASE	A076779	001	Sep 16, 2004	Apr CAHN
	EQ 4MG BASE	A076789	001	Sep 16, 2004	Apr CAHN

OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
OCUCLEAR

@ BAYER HEALTHCARE LLC	0.025%	N018471	001	May 30, 1986	May DISC
------------------------	--------	---------	-----	--------------	----------

PERMETHRIN

LOTION;TOPICAL
PERMETHRIN

ACTAVIS MID ATLANTIC	1%	A075014	001	Mar 28, 2000	May CAHN
----------------------	----	---------	-----	--------------	----------

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
PSEUDOEPHEDRINE HYDROCHLORIDE

AUROBINDO PHARMA LTD	120MG	A209008	001	Jun 09, 2017	May NEWA
L PERRIGO CO	120MG	A075153	001	Feb 26, 1999	Apr CAHN

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

STRIDES PHARMA	EQ 150MG BASE	A200536	001	Jun 28, 2011	Jan CAHN
ZANTAC 150					
+! SANOFI US	EQ 150MG BASE	N021698	001	Aug 31, 2004	Mar CAHN
+ ZANTAC 75	EQ 150MG BASE	N021698	002	Mar 13, 2007	Mar CAHN
SANOFI US	EQ 75MG BASE	N020520	001	Dec 19, 1995	Mar CAHN
TABLET, EFFERVESCENT;ORAL					
ZANTAC 75					
+ @ SANOFI US	EQ 75MG BASE	N020745	001	Feb 26, 1998	Mar CAHN

TRIAMCINOLONE ACETONIDE

SPRAY, METERED;NASAL

TRIAMCINOLONE ACETONIDE

PERRIGO ISRAEL	0.055MG/SPRAY	A078104	002	Nov 14, 2014	Jan CAHN
----------------	---------------	---------	-----	--------------	----------

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 06 JUNE 2017

NO JUNE 2017 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO JUNE 2017 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABALOPARATIDE - TYMLOS</u>						
N 208743 001	7803770	Mar 26, 2028	U-2009		NCE	Apr 28, 2022
	8148333	Nov 08, 2027	DP			
	8748382	Oct 03, 2027	U-2009			
<u>ACETAMINOPHEN - OFIRMEV</u>						
N 022450 001	9610265	Nov 13, 2028	U-2000		M-196 PED	Jan 27, 2020 Jul 27, 2020
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 001	9561204	May 08, 2032	U-1373			
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 002	9561204	May 08, 2032	U-1373			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001 >A>	RE46417	Sep 05, 2020	DS DP U-1263			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE</u>						
N 207917 001	8445543	Dec 23, 2022	U-1078			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 001	9539258	Nov 09, 2026	U-1950			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 002	9539258	Nov 09, 2026	U-1950			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 003	9539258	Nov 09, 2026	U-1950			
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT</u>						
N 021747 001	8733341	Oct 16, 2030	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 001	8173663	Dec 02, 2025	U-1338			
	8697125	Jun 16, 2029	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002	8173663	Dec 02, 2025	U-1338			
	8697125	Jun 16, 2029	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003	8173663	Dec 02, 2025	U-1338			
	8697125	Jun 16, 2029	DP			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 001	8288539	Jun 24, 2025	DS			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 002	8288539	Jun 24, 2025	DS			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005	6329404	Jun 19, 2021	DP U-1334			
<u>AMBRISANTAN - LETAIRIS</u>						
N 022081 001	9549926	Oct 14, 2031	U-1965			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMBRISENTAN - LETAIRIS</u>						
N 022081 002	9549926	Oct 14, 2031	U-1965			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - GLEOLAN</u>						
N 208630 001					>A> ODE	Jun 06, 2024
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003 001					NP	Jan 21, 2018
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003 002					NP	Jan 21, 2018
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003 003					NP	Jan 21, 2018
<u>AMPHETAMINE - DYANAVEL XR</u>						
N 208147 001	>A> 9675703	Mar 15, 2027	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063 001					>A> NP	Jun 20, 2020
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063 002					>A> NP	Jun 20, 2020
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063 003					>A> NP	Jun 20, 2020
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063 004					>A> NP	Jun 20, 2020
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	6967208	Sep 17, 2022	DS DP U-1167			
	6967208	Sep 17, 2022	DS DP U-1200			
	6967208	Sep 17, 2022	DS DP U-1301			
	6967208	Sep 17, 2022	DS DP U-1302			
	6967208	Sep 17, 2022	DS DP U-1323			
	6967208	Sep 17, 2022	DS DP U-1501			
	6967208	Sep 17, 2022	DS DP U-1502			
	6967208	Sep 17, 2022	DS DP U-1729			
	6967208	Sep 17, 2022	DS DP U-1730			
<u>APIXABAN - ELIQUIS</u>						
N 202155 002	6967208	Sep 17, 2022	DS DP U-1200			
	6967208	Sep 17, 2022	DS DP U-1301			
	6967208	Sep 17, 2022	DS DP U-1302			
	6967208	Sep 17, 2022	DS DP U-1323			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 001	9526726	Mar 19, 2035	DP			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 002	9526726	Mar 19, 2035	DP			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 003	9526726	Mar 19, 2035	DP			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 004	>A> 8431576	Oct 26, 2030	DS		>A> NCE	Oct 05, 2020
	>A> 8796276	Jun 24, 2030	U-543			
	>A> 9034867	Nov 07, 2032	DP U-543			
	>A> 9193685	Oct 24, 2033	DP U-543			
	>A> 9452131	Mar 19, 2035	U-543			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 004	>A> 8431576	Oct 26, 2030	DS		>A> NCE	Oct 05, 2020
	>A> 8796276	Jun 24, 2030	U-543			
	>A> 9034867	Nov 07, 2032	DP U-543			
	>A> 9193685	Oct 24, 2033	DP U-543			
	>A> 9452131	Mar 19, 2035	U-543			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001	5763476	Jun 09, 2020	DP U-326		D-166	Jan 13, 2020
	5763476	Jun 09, 2020	DP U-1960		I-597	Jan 13, 2020
	5763476	Jun 09, 2020	DP U-1961			
	5763476	Jun 09, 2020	DP U-1962			
	5763476	Jun 09, 2020	DP U-1963			
	5763476*PED	Dec 09, 2020				
	7741358	Apr 06, 2026	DS DP U-1064			
	7741358	Apr 06, 2026	DS DP U-1960			
	7741358	Apr 06, 2026	DS DP U-1961			
	7741358	Apr 06, 2026	DS DP U-1962			
	7741358	Apr 06, 2026	DS DP U-1963			
	7741358*PED	Oct 06, 2026				
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002	5763476	Jun 09, 2020	DP U-326		D-166	Jan 13, 2020
	5763476	Jun 09, 2020	DP U-1960		I-597	Jan 13, 2020
	5763476	Jun 09, 2020	DP U-1961			
	5763476	Jun 09, 2020	DP U-1962			
	5763476	Jun 09, 2020	DP U-1963			
	5763476*PED	Dec 09, 2020				
	7741358	Apr 06, 2026	DS DP U-1064			
	7741358	Apr 06, 2026	DS DP U-1960			
	7741358	Apr 06, 2026	DS DP U-1961			
	7741358	Apr 06, 2026	DS DP U-1962			
	7741358	Apr 06, 2026	DS DP U-1963			
	7741358*PED	Oct 06, 2026				
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 003	5763476	Jun 09, 2020	DP U-1893		D-166	Jan 13, 2020
	5763476	Jun 09, 2020	DP U-1966		I-597	Jan 13, 2020
	5763476*PED	Dec 09, 2020				
	7741358	Apr 06, 2026	DS DP U-1893			
	7741358	Apr 06, 2026	DS DP U-1966			
	7741358*PED	Oct 06, 2026				
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103 001	9539214	Mar 13, 2033	U-1902			
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103 002	9539214	Mar 13, 2033	U-1902			
<u>ATAZANAVIR SULFATE; COBICISTAT - EVOTAZ</u>						
N 206353 001					NCE	Aug 27, 2017
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	9284314	Jun 15, 2032	DS			
<u>AXITINIB - INLYTA</u>						
N 202324 001	>A> 8791140	Dec 14, 2030	DS			
<u>AXITINIB - INLYTA</u>						
N 202324 002	>A> 8791140	Dec 14, 2030	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247 001	5998402	Apr 04, 2018	DS DP U-594		NCE	Oct 13, 2018
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 001	7498343	Dec 01, 2026	DS DP U-1321			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 001	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 002	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	9572796	Jan 28, 2031	DP U-1971			
	9572796	Jan 28, 2031	DP U-1972			
	9572797	Jan 28, 2031	U-1971			
	9572797	Jan 28, 2031	U-1972			
	9572887	Mar 15, 2033	U-1971			
	9572887	Mar 15, 2033	U-1972			
	9579384	Mar 15, 2033	U-1971			
	9579384	Mar 15, 2033	U-1972			
	9597397	Mar 15, 2033	U-1971			
	9597397	Mar 15, 2033	U-1972			
	9597398	Mar 15, 2033	U-1971			
	9597399	Mar 15, 2033	U-1971			
	9597399	Mar 15, 2033	U-1972			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON</u>						
N 050819 002	9561208	Jun 03, 2029	DP U-916			
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079 001	>A> 9655907	Aug 31, 2030	DP U-1858			
<u>BETRIXABAN - BEVYXXA</u>						
N 208383 001					>A> NCE	Jun 23, 2022
<u>BETRIXABAN - BEVYXXA</u>						
N 208383 002					>A> NCE	Jun 23, 2022
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	9579270	Jan 31, 2021	U-1975			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 001	9012462	Feb 06, 2031	DS		NCE	Apr 28, 2022
	9273077	May 21, 2029	U-1927		>A> ODE	Apr 28, 2024
	9611283	Apr 10, 2034	U-1927			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 002	9012462	Feb 06, 2031	DS		NCE	Apr 28, 2022
	9273077	May 21, 2029	U-1927		>A> ODE	Apr 28, 2024
	9611283	Apr 10, 2034	U-1927			
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021770 001	>A> 9687443	Jul 10, 2021	DP			
<u>BROMFENAC SODIUM - PROLENSA</u>						
N 203168 001	9517220	Nov 11, 2033	U-1933			
	9561277	Jan 16, 2024	U-1933			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	9522117	Apr 30, 2032	DP U-976			
	9522117	Apr 30, 2032	DP U-1939			
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	9532954	Jun 09, 2020	DP U-1325			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	6123924	Sep 26, 2017	DP		NPP	Jan 27, 2020
	7367333	Nov 11, 2018	DP		PED	Jul 27, 2020
	7367333*PED	May 11, 2019				
	7587988	Apr 10, 2026	DP			
	7587988*PED	Oct 10, 2026				
	7759328	Jan 29, 2023	DP U-2001			
	7759328	Jan 29, 2023	DP U-2002			
	7759328*PED	Jul 29, 2023				
	7967011	Aug 11, 2021	DP			
	7967011*PED	Feb 11, 2022				
	8143239	Jan 29, 2023	DP U-2001			
	8143239	Jan 29, 2023	DP U-2002			
	8143239*PED	Jul 29, 2023				
	8387615	Nov 10, 2024	DP			
	8387615*PED	May 10, 2025				
	8528545	Oct 16, 2028	DP			
	8528545*PED	Apr 16, 2029				
	8575137	Jan 29, 2023	DP U-2001			
	8575137	Jan 29, 2023	DP U-2002			
	8575137*PED	Jul 29, 2023				
	8616196	Apr 07, 2029	DP			
	8616196*PED	Oct 07, 2029				
	8875699	Nov 10, 2024	DP			
	8875699*PED	May 10, 2025				
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	6123924	Sep 26, 2017	DP			
	7367333	Nov 11, 2018	DP			
	7367333*PED	May 11, 2019				
	7587988	Apr 10, 2026	DP			
	7587988*PED	Oct 10, 2026				
	7759328	Jan 29, 2023	DP U-2001			
	7759328	Jan 29, 2023	DP U-2002			
	7759328*PED	Jul 29, 2023				
	7897646	Sep 09, 2018	U-2002			
	7897646*PED	Mar 09, 2019				
	7967011	Aug 11, 2021	DP			
	7967011*PED	Feb 11, 2022				
	8143239	Jan 29, 2023	DP U-2001			
	8143239	Jan 29, 2023	DP U-2002			
	8143239*PED	Jul 29, 2023				
	8387615	Nov 10, 2024	DP			
	8387615*PED	May 10, 2025				
	8461211	Sep 09, 2018	U-2002			
	8461211*PED	Mar 09, 2019				
	8528545	Oct 16, 2028	DP			
	8528545*PED	Apr 16, 2029				
	8575137	Jan 29, 2023	DP U-2001			
	8575137	Jan 29, 2023	DP U-2002			
	8575137*PED	Jul 29, 2023				
	8616196	Apr 07, 2029	DP			
	8616196*PED	Oct 07, 2029				
	8875699	Nov 10, 2024	DP			
	8875699*PED	May 10, 2025				
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001	9585838	Dec 24, 2021	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002	9585838	Dec 24, 2021	DP			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 001	9642850	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 002	9642850	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 003	9642850	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 004	9642850	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 005	9642850	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 001	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 002	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 003	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 004	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 005	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 006	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 007	9655843	Jul 23, 2027	DP U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 001	9655843	Jul 23, 2027	DP U-2017			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 002	9655843	Jul 23, 2027	DP U-2017			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 003	9655843	Jul 23, 2027	DP U-2017			
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001	5847170	Mar 26, 2021	DS DP		M-201	May 17, 2020
	5847170*PED	Sep 26, 2021			PED	Nov 17, 2020
	7241907	Dec 10, 2025	DS			
	7241907*PED	Jun 10, 2026				
	8927592	Oct 27, 2030	U-1630			
	8927592*PED	Apr 27, 2031				
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001					M-197	Feb 01, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042	002				M-197	Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	001				M-197	Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	002				M-197	Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	003				M-197	Feb 01, 2020
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	004				M-197	Feb 01, 2020
<u>CARBAMAZEPINE - CARNEXIV</u>						
N 206030	001	9493582	Feb 27, 2033	DP		
		9629797	Nov 10, 2028	U-2004		
		9629797	Nov 10, 2028	U-2005		
		9629797	Nov 10, 2028	U-2006		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	001	9533046	Dec 26, 2028	DP U-219		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	002	9533046	Dec 26, 2028	DP U-219		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	003	9533046	Dec 26, 2028	DP U-219		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	004	9533046	Dec 26, 2028	DP U-219		
<u>CARBINOXAMINE MALEATE - KARBINAL ER</u>						
N 022556	001	9522191	Jun 15, 2027	DP		
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714	001	9493582	Feb 27, 2033	DP		
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714	002	9493582	Feb 27, 2033	DP		
<u>CASPOFUNGIN ACETATE - CASPOFUNGIN ACETATE</u>						
N 206110	001	9636407	Dec 21, 2032	DP		
<u>CASPOFUNGIN ACETATE - CASPOFUNGIN ACETATE</u>						
N 206110	002	9636407	Dec 21, 2032	DP		
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327	001	9629861	Sep 21, 2030	DP		
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327	002	9629861	Sep 21, 2030	DP		
<u>CERITINIB - ZYKADIA</u>						
N 205755	001	>A> 8188276	Jan 31, 2023	DS DP	M-199	May 26, 2020
		>A> 8399450	Nov 20, 2027	DS DP	>A> ODE	May 26, 2024
		>A> 8835430	Jan 31, 2023	DS DP		
		>A> 9018204	Jan 31, 2023	DS DP		
		>A> 9416112	Jan 31, 2023	DS DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CERITINIB - ZYKADIA</u>						
N 205755 001	>A> 8188276	Jan 31, 2023	DS DP		M-199	May 26, 2020
	>A> 8399450	Nov 20, 2027	DS DP		>A> ODE	May 26, 2024
	>A> 8835430	Jan 31, 2023	DS DP			
	>A> 9018204	Jan 31, 2023	DS DP			
	>A> 9416112	Jan 31, 2023	DS DP			
<u>CETIRIZINE HYDROCHLORIDE - ZERVIAE</u>						
N 208694 001	>A> 8829005	Mar 15, 2030	U-1680		>A> NDF	May 30, 2020
	>A> 8829005*PED	Sep 15, 2030			>A> PED	Nov 30, 2020
	>A> 9254286	Jul 09, 2032	DP			
	>A> 9254286*PED	Jan 09, 2033				
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 001					M-200	May 23, 2020
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 002					M-200	May 23, 2020
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 003					M-200	May 23, 2020
<u>COBICISTAT - TYBOST</u>						
N 203094 001					NCE	Aug 27, 2017
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395 001					NCE	Aug 27, 2017
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	7176220	Aug 27, 2026	DS DP U-257		NCE	Aug 27, 2017
					NCE	Nov 05, 2020
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	7176220	Aug 27, 2026	DS DP U-257		NCE	Aug 27, 2017
					NPP	Jan 27, 2020
<u>COLCHICINE - MITIGARE</u>						
N 204820 001	9555029	Aug 22, 2033	U-1020			
	>A> 9675613	Aug 22, 2033	U-1020			
<u>CRISABOROLE - EUCRISA</u>						
N 207695 001	8039451	Jun 11, 2026	DS DP		NCE	Dec 14, 2021
	8168614	Jan 20, 2030	U-1932			
	8501712	Feb 16, 2027	U-1932			
<u>CYCLOSPORINE - RESTASIS MULTIDOSE</u>						
N 050790 002	>A> 8292129	Feb 25, 2031	DP			
	>A> 8561859	Apr 16, 2032	DP			
	>A> 9669974	May 11, 2034	DP			
	>A> 9676525	Feb 07, 2034	DP			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001					>A> I-745	Jun 22, 2020
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002					>A> I-745	Jun 22, 2020
<u>DAPAGLIFLOZIN PROPANEDIOL; SAXAGLIPTIN HYDROCHLORIDE - QTERN</u>						
N 209091 001	6414126	Oct 04, 2020	DS DP U-1976		M-175	Apr 05, 2019
	6414126	Oct 04, 2020	DS DP U-1977		NC	Feb 27, 2020
	6515117	Oct 04, 2020	DS DP U-1976		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-1977			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN PROPANEDIOL; SAXAGLIPTIN HYDROCHLORIDE - QTERN</u>						
N 209091 001	6936590	Oct 04, 2020	U-1976			
	6936590	Oct 04, 2020	U-1977			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028	U-1976			
	8361972	Mar 21, 2028	U-1977			
	8501698	Jun 20, 2027	DP U-1976			
	8501698	Jun 20, 2027	DP U-1977			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-1976			
	9198925	Oct 04, 2020	U-1977			
	RE44186	Jul 31, 2023	DS DP U-1976			
	RE44186	Jul 31, 2023	DS DP U-1977			
<u>DAPTOMYCIN - CUBICIN</u>						
N 021572 002					NPP	Mar 29, 2020
<u>DAPTOMYCIN - CUBICIN RF</u>						
N 021572 003					NPP	Mar 29, 2020
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619 001 >A>	9629841	Oct 18, 2033	DP U-1753			
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968 001	6465504	Apr 05, 2019	DS DP			
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968 002	6465504	Apr 05, 2019	DS DP			
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968 003	6465504	Apr 05, 2019	DS DP			
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 001					NCE ODE	Feb 09, 2022 Feb 09, 2024
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 002					NCE ODE	Feb 09, 2022 Feb 09, 2024
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 003					NCE ODE	Feb 09, 2022 Feb 09, 2024
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 004					NCE ODE	Feb 09, 2022 Feb 09, 2024
<u>DEFLAZACORT - EMFLAZA</u>						
N 208685 001					NCE ODE	Feb 09, 2022 Feb 09, 2024
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 001	9579359	Feb 10, 2029	U-1978			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 002	9579359	Feb 10, 2029	U-1978			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DELAFLORACIN MEGLUMINE - BAXDELA</u>						
N 208610 001					>A> NCE >A> GAIN	Jun 19, 2022 Jun 19, 2027
<u>DELAFLORACIN MEGLUMINE - BAXDELA</u>						
N 208611 001					>A> NCE >A> GAIN	Jun 19, 2022 Jun 19, 2027
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333 001	9522155	Feb 21, 2028	DP U-1940			
<u>DESMOPRESSIN ACETATE - NOCTIVA</u>						
N 201656 001	7405203	May 06, 2023	U-1980		NP	Mar 03, 2020
	7579321	May 06, 2023	U-1980			
	7799761	Sep 26, 2024	DP			
	9539302	Jun 15, 2030	DP			
<u>DESMOPRESSIN ACETATE - NOCTIVA</u>						
N 201656 002	7405203	May 06, 2023	U-1980		NP	Mar 03, 2020
	7579321	May 06, 2023	U-1980			
	7799761	Sep 26, 2024	DP			
	9539302	Jun 15, 2030	DP			
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204003 001					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204003 002					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204028 001					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204028 002					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204082 001					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204083 001					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204095 001					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204095 002					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204172 001					PC	Aug 28, 2017
<u>DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE</u>						
A 204172 002					PC	Aug 28, 2017
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 001	8524733	Mar 27, 2031	DS DP		NCE	Apr 03, 2022
	9233959	Sep 18, 2033	DP		ODE	Apr 03, 2024
	9296739	Sep 18, 2033	DP			
	9550780	Sep 18, 2033	DS DP U-1846			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 002	8524733	Mar 27, 2031	DS DP		NCE	Apr 03, 2022
	9233959	Sep 18, 2033	DP		ODE	Apr 03, 2024
	9296739	Sep 18, 2033	DP			
	9550780	Sep 18, 2033	DS DP U-1846			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 003	8524733	Mar 27, 2031	DS DP		NCE	Apr 03, 2022
	9233959	Sep 18, 2033	DP		ODE	Apr 03, 2024
	9296739	Sep 18, 2033	DP			
	9550780	Sep 18, 2033	DS DP U-1846			
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001	9592242	Oct 20, 2020	U-1989			
	9592242	Oct 20, 2020	U-1990			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 002	9616049	Jan 04, 2032	DP			
	9616049*PED	Jul 04, 2032				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 003	9616049	Jan 04, 2032	DP			
	9616049*PED	Jul 04, 2032				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 004	9616049	Jan 04, 2032	DP			
	9616049*PED	Jul 04, 2032				
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N 022202 001	9561200	Feb 24, 2029	U-1482			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623 001	9539335	Oct 17, 2027	U-1614			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 001	9532971	Jun 01, 2029	DP			
	9572814	Jul 20, 2027	U-620			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 002	9532971	Jun 01, 2029	DP			
	9572814	Jul 20, 2027	U-620			
<u>DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - BONJESTA</u>						
N 209661 001	9089489	Feb 18, 2033	DP U-1382			
	9375404	Feb 18, 2033	DP U-1382			
	9526703	Feb 18, 2033	DP U-1382			
<u>DRONABINOL - SYNDROS</u>						
N 205525 001	8222292	Aug 06, 2028	DS DP			
	9345771	Aug 06, 2028	DS DP			
<u>EDARAVONE - RADICAVA</u>						
N 209176 001	6933310	Nov 13, 2020	U-2013		NCE	May 05, 2022
					>A> ODE	May 05, 2024
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937 001 >A>	8598185	Apr 28, 2029	DP			
	9545414	Jun 13, 2026	DP U-750			
	9545414	Jun 13, 2026	DP U-1170			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	9566272	Jan 03, 2028	U-1969			
	9662394	Oct 02, 2034	DP			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 207027 001	>A> 6280959	Oct 30, 2018	DS DP U-1736		>A> ODE	Aug 26, 2021
	>A> 6280959*PED	Apr 30, 2019			>A> PED	Feb 26, 2022
	>A> 7160870	Nov 20, 2022	DS DP U-1736			
	>A> 7160870*PED	May 20, 2023				
	>A> 7332481	May 24, 2021	U-1736			
	>A> 7332481*PED	Nov 24, 2021				
	>A> 7452874	May 24, 2021	DS DP			
	>A> 7452874*PED	Nov 24, 2021				
	>A> 7473686	May 24, 2021	DS DP U-1736			
	>A> 7473686*PED	Nov 24, 2021				
	>A> 7547719	Jul 13, 2025	DS DP U-1736			
	>A> 7547719*PED	Jan 13, 2026				
	>A> 7790704	May 24, 2021	U-1736			
	>A> 7790704*PED	Nov 24, 2021				
	>A> 7795293	May 24, 2023	U-1736			
	>A> 7795293*PED	Nov 24, 2023				
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	8772325	Mar 14, 2025	U-1709			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	8772325	Mar 14, 2025	U-1709			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 001	7176220	Aug 27, 2026	DS DP U-257		NCE	Aug 27, 2017
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 002	7176220	Aug 27, 2026	DS DP U-257		NCE	Aug 27, 2017
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 002	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245*PED	May 04, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 003	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245*PED	May 04, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 004	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245*PED	May 04, 2021				
<u>ENALAPRIL MALEATE - EPANED</u>						
N 208686 001	9669008	Mar 25, 2036	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415 001	8183274	Aug 24, 2026	U-1281			
	8183274	Aug 24, 2026	U-1588			
<u>EPINEPHRINE - EPIPEN</u>						
N 019430 001	9586010	Sep 11, 2025	DP			
<u>EPINEPHRINE - EPIPEN JR.</u>						
N 019430 002	9586010	Sep 11, 2025	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N 020800 003	7905352	Apr 12, 2027	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N 020800 004	7905352	Apr 12, 2027	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204200 001	9295657	Mar 13, 2035	U-1829			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
<u>ESTRADIOL - ESTRADIOL</u>						
A 205256 001					PC	Apr 15, 2017
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 001	>A> 8377880	Jul 29, 2030	DS DP		NCE	Feb 07, 2022
	8999932	Jul 29, 2030	DS DP U-2014			
	>A> 9278995	Jul 29, 2030	DS			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 002	>A> 8377880	Jul 29, 2030	DS DP		NCE	Feb 07, 2022
	8999932	Jul 29, 2030	DS DP U-2014			
	>A> 9278995	Jul 29, 2030	DS			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 003	>A> 8377880	Jul 29, 2030	DS DP		NCE	Feb 07, 2022
	8999932	Jul 29, 2030	DS DP U-2014			
	>A> 9278995	Jul 29, 2030	DS			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - FAYOSIM</u>						
A 205943 001					PC	Sep 30, 2017
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MIBELAS 24 FE</u>						
A 206287 001					PC	Sep 11, 2017

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001					ODE	Feb 26, 2023
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002					ODE	Feb 26, 2023
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003					ODE	Feb 26, 2023
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004					ODE	Feb 26, 2023
<u>FENTANYL - SUBSYS</u>						
N 020788 001	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 020788 002	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 020788 003	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 020788 004	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 020788 005	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 020788 006	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 020788 007	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 001	9597288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 002	9597288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 003	9597288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 004	9597288	Jul 23, 2027	DP U-767			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 005	9597288	Jul 23, 2027	DP U-767			
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648 001					>A> NCE	Jul 13, 2021
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648 002					>A> NCE	Jul 13, 2021
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648 003					>A> NCE	Jul 13, 2021
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001					M-202 NCE	May 15, 2020 May 10, 2018
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002					M-202 NCE	May 15, 2020 May 10, 2018
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9415008	Oct 06, 2034	DP U-645			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	6446627	Dec 18, 2017	DP		NP	Jan 27, 2020
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GANCICLOVIR - GANCICLOVIR</u>						
N 209347 001	9486530	Sep 02, 2034	DP			
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001 >A>	9561197	Sep 22, 2030	U-1383		NPP	Apr 28, 2020
<u>GUAIFENESIN; HYDROCODONE BITARTRATE - OBREDON</u>						
N 205474 001 >A>	9549907	Nov 13, 2035	DS DP U-2023			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001 >A>	9023401	Oct 30, 2020	DP			
	>A> 9056052	Oct 30, 2020	DP			
	>A> 9060940	Oct 30, 2020	U-1556			
	>A> 9198863	Oct 30, 2020	DP			
	>A> 9205056	Oct 30, 2020	DP			
	>A> 9289391	Oct 30, 2020	DP			
	>A> 9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	>A> 9572804	Oct 30, 2020	DP			
	>A> 9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	>A> 9675611	Oct 30, 2020	U-1556			
	>A> 9682077	Oct 30, 2020	U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002 >A>	9023401	Oct 30, 2020	DP			
	>A> 9056052	Oct 30, 2020	DP			
	>A> 9060940	Oct 30, 2020	U-1556			
	>A> 9198863	Oct 30, 2020	DP			
	>A> 9205056	Oct 30, 2020	DP			
	>A> 9289391	Oct 30, 2020	DP			
	>A> 9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	>A> 9572804	Oct 30, 2020	DP			
	>A> 9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	>A> 9675611	Oct 30, 2020	U-1556			
	>A> 9682077	Oct 30, 2020	U-1556			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	>A> 9023401	Oct 30, 2020	DP			
	>A> 9056052	Oct 30, 2020	DP			
	>A> 9060940	Oct 30, 2020	U-1556			
	>A> 9198863	Oct 30, 2020	DP			
	>A> 9205056	Oct 30, 2020	DP			
	>A> 9289391	Oct 30, 2020	DP			
	>A> 9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	>A> 9572804	Oct 30, 2020	DP			
	>A> 9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	>A> 9675611	Oct 30, 2020	U-1556			
	>A> 9682077	Oct 30, 2020	U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	>A> 9023401	Oct 30, 2020	DP			
	>A> 9056052	Oct 30, 2020	DP			
	>A> 9060940	Oct 30, 2020	U-1556			
	>A> 9198863	Oct 30, 2020	DP			
	>A> 9205056	Oct 30, 2020	DP			
	>A> 9289391	Oct 30, 2020	DP			
	>A> 9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	>A> 9572804	Oct 30, 2020	DP			
	>A> 9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	>A> 9675611	Oct 30, 2020	U-1556			
	>A> 9682077	Oct 30, 2020	U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	>A> 9023401	Oct 30, 2020	DP			
	>A> 9056052	Oct 30, 2020	DP			
	>A> 9060940	Oct 30, 2020	U-1556			
	>A> 9198863	Oct 30, 2020	DP			
	>A> 9205056	Oct 30, 2020	DP			
	>A> 9289391	Oct 30, 2020	DP			
	>A> 9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	>A> 9572804	Oct 30, 2020	DP			
	>A> 9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	>A> 9675611	Oct 30, 2020	U-1556			
	>A> 9682077	Oct 30, 2020	U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005	>A> 9056052	Oct 30, 2020	DP			
	>A> 9060940	Oct 30, 2020	U-1556			
	>A> 9198863	Oct 30, 2020	DP			
	>A> 9205056	Oct 30, 2020	DP			
	>A> 9289391	Oct 30, 2020	DP			
	>A> 9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	>A> 9572804	Oct 30, 2020	DP			
	>A> 9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	>A> 9675611	Oct 30, 2020	U-1556			
	>A> 9682077	Oct 30, 2020	U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006	>A> 9056052	Oct 30, 2020	DP			
	>A> 9060940	Oct 30, 2020	U-1556			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006	>A> 9198863	Oct 30, 2020	DP			
	>A> 9205056	Oct 30, 2020	DP			
	>A> 9289391	Oct 30, 2020	DP			
	>A> 9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	>A> 9572804	Oct 30, 2020	DP			
	>A> 9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	>A> 9675611	Oct 30, 2020	U-1556			
	>A> 9682077	Oct 30, 2020	U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007	>A> 9056052	Oct 30, 2020	DP			
	>A> 9060940	Oct 30, 2020	U-1556			
	>A> 9198863	Oct 30, 2020	DP			
	>A> 9205056	Oct 30, 2020	DP			
	>A> 9289391	Oct 30, 2020	DP			
	>A> 9517236	Oct 30, 2020	DP			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	>A> 9572804	Oct 30, 2021	DP			
	>A> 9669023	Oct 30, 2020	DP			
	9669024	Oct 30, 2020	DP			
	>A> 9675611	Oct 30, 2020	U-1556			
	>A> 9682077	Oct 30, 2020	U-1556			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 001	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 002	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 003	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 004	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 005	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8476284	Dec 28, 2026	U-1456		I-741	Jan 18, 2020
	8476284	Dec 28, 2026	U-1491		ODE	Jan 18, 2024
	8476284	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1947			
	9540382	Aug 18, 2033	U-1456			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1684			
	9540382	Aug 18, 2033	U-1946			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	9540382	Aug 18, 2033	U-1947			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002 >A>	9649284	Sep 30, 2029	U-2018			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002 >A>	8188146	Jan 27, 2020	DS DP		NCE	Jul 26, 2017
>A>	8293727	Feb 09, 2030	U-1287			
>A>	8293728	Feb 09, 2030	U-1287			
>A>	8298554	Apr 29, 2030	DP			
>A>	8314086	Feb 09, 2030	U-1287			
>A>	8318715	Feb 09, 2030	U-1287			
>A>	8357677	Feb 09, 2030	U-1287			
>A>	8367652	Feb 09, 2030	U-1287			
>A>	8377920	Feb 09, 2030	U-1287			
>A>	8399446	Feb 09, 2030	U-1287			
>A>	8415335	Feb 09, 2030	U-1287			
>A>	8426399	Feb 09, 2030	U-1287			
>A>	8440650	Feb 09, 2030	U-1287			
>A>	8445003	Apr 29, 2030	U-1287			
>A>	8445013	Apr 29, 2030	U-1287			
>A>	8501225	Apr 29, 2030	U-1287			
>A>	8518929	Apr 29, 2030	U-1287			
>A>	8524698	Apr 29, 2030	U-1287			
>A>	8546372	Apr 29, 2030	U-1287			
>A>	8551521	Apr 29, 2030	U-1287			
>A>	8563608	Apr 29, 2030	U-1287			
>A>	8617593	Apr 29, 2030	U-1287			
>A>	8617594	Apr 29, 2030	U-1287			
>A>	8623406	Apr 29, 2030	U-1287			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	RE46363	Aug 03, 2026	DP			
<u>INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30</u>						
N 203313 001	RE46363	Aug 03, 2026	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 001	RE46363	Aug 03, 2026	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 002	RE46363	Aug 03, 2026	DP			
<u>INSULIN DEGLUDEC; LIRAGLUTIDE - XULTOPHY 100/3.6</u>						
N 208583 001	RE46363	Aug 03, 2026	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	RE46363	Aug 03, 2026	DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
<u>INSULIN GLARGINE; LIXISENATIDE - SOLIQUA 100/33</u>						
N 208673 001	9526764	Oct 09, 2029	DP			
	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	9597374	Oct 08, 2031		U-1987		
	>A> 9662461	Jun 12, 2029	DP	U-2019		
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	9597374	Oct 08, 2031		U-1987		
	>A> 9662461	Jun 12, 2029	DP	U-2019		
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	9597374	Oct 08, 2031		U-1987		
	>A> 9662461	Jun 12, 2029	DP	U-2019		
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	>A> 9670163	Dec 28, 2026	DP	U-1311		
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	>A> 9670163	Dec 28, 2026	DP	U-1311		
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	>A> 9670163	Dec 28, 2026	DP	U-1311		
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	7973038	Nov 08, 2026		U-1973		
	>A> 9670163	Dec 28, 2026	DP	U-1911		
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	7973038	Nov 08, 2026		U-1973		
	>A> 9670163	Dec 28, 2026	DP	U-1911		
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001					NPP ODE	Apr 07, 2020 Apr 07, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	5635517	Oct 04, 2019	DS		ODE	Feb 22, 2024
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISOALI FEMARA CO-PACK (COPACKAGED)</u>						
N 209935 001	8324225	Jun 17, 2028	DS DP		NCE	Mar 13, 2022
	8415355	Feb 19, 2031	DS DP			
	8685980	May 25, 2030	DS DP			
	8962630	Dec 09, 2029		U-1981		
	9193732	Nov 09, 2031	DS DP			
	9416136	Aug 20, 2029		U-1981		
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021343 001	9254307	Oct 28, 2018	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021379 001	8470359	Oct 15, 2023	DS DP U-621			
	8486455	Oct 28, 2018	DS DP			
	8840916	Nov 13, 2020	DP			
	9539333	Nov 13, 2020	DS DP U-621			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021488 001	8470359	Oct 15, 2023	DS DP U-621			
	8486455	Oct 28, 2018	DS DP			
	8840916	Nov 13, 2020	DP			
	9539333	Nov 13, 2020	DS DP U-621			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021731 001	8470359	Oct 15, 2023	DS DP U-621			
	8486455	Oct 28, 2018	DS DP			
	8840916	Nov 13, 2020	DP			
	9539333	Nov 13, 2020	DS DP U-621			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 001	>A> 9669009	Mar 14, 2034		U-1850		
	>A> 9669009	Mar 14, 2034		U-2021		
	>A> 9669009	Mar 14, 2034		U-2022		
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 002	>A> 9669009	Mar 14, 2034		U-1850		
	>A> 9669009	Mar 14, 2034		U-2021		
	>A> 9669009	Mar 14, 2034		U-2022		
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 003	>A> 9669009	Mar 14, 2034		U-1850		
	>A> 9669009	Mar 14, 2034		U-2021		
	>A> 9669009	Mar 14, 2034		U-2022		
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 004	>A> 9669009	Mar 14, 2034		U-1850		
	>A> 9669009	Mar 14, 2034		U-2021		
	>A> 9669009	Mar 14, 2034		U-2022		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOCETIRIZINE DIHYDROCHLORIDE - XYZAL ALLERGY 24HR</u>						
N 209090 001	8633194	Oct 16, 2027	DP			
<u>LEVONORGESTREL - MIRENA</u>						
N 021225 001	9615965	Sep 16, 2029	DP U-2003			
	>A> 9668912	Apr 01, 2031	DP			
<u>LEVONORGESTREL - SKYLA</u>						
N 203159 001	9615965	Sep 16, 2029	DP U-2003			
	>A> 9668912	Apr 01, 2031	DP			
<u>LEVONORGESTREL - KYLEENA</u>						
N 208224 001	9615965	Sep 16, 2029	DP U-2003			
	>A> 9668912	Apr 01, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 003	7304036	Aug 30, 2026	DS DP U-1516		NCE	Aug 30, 2017
	7371727	Jan 28, 2024	DS		NS	Jan 25, 2020
	7704947	Jan 28, 2024	DS DP			
	7745409	Jan 28, 2024	DS DP			
	8080526	Jan 28, 2024	DS DP			
	8110553	Jan 28, 2024	U-1516			
	8933030	Feb 17, 2031	DP U-1516			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	8846695	Jun 04, 2030	U-1503	Y		
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	8846695	Jun 04, 2030	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	8846695	Jun 04, 2030	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	8846695	Jun 04, 2030	U-1503	Y		
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	9555001	Mar 06, 2033	DP U-1967			
	9555001	Mar 06, 2033	DP U-1968			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	9555001	Mar 06, 2033	DP U-1967			
	9555001	Mar 06, 2033	DP U-1968			
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	RE46363	Aug 03, 2026	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 001	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 001	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 002	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 003	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 004	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 005	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 005	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 006	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP		M-188	Oct 14, 2019
	7655630	Feb 24, 2023	DS DP			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-727			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-727			
	7678770	Feb 24, 2023	U-727			
	7678771	Feb 24, 2023	DP U-727			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-727			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-727			
	7723305	Feb 24, 2023	DP U-727			
<u>LISINOPRIL - OBRELIS</u>						
N 208401 001	9616096	Nov 06, 2035	U-3			
	9616096	Nov 06, 2035	U-8			
	9616096	Nov 06, 2035	U-71			
	9616096	Nov 06, 2035	U-185			
	9616096	Nov 06, 2035	U-1723			
	9616096	Nov 06, 2035	U-1864			
	9616096	Nov 06, 2035	U-1991			
<u>LULICONAZOLE - LUZU</u>						
N 204153 001 >A>	5900488	Jul 05, 2018	DS DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	9555027	May 26, 2026	DP U-543		M-195	Jan 27, 2020
					NPP	Jan 27, 2020
					PED	Jul 27, 2020
					PED	Jul 27, 2020
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	9555027	May 26, 2026	DP U-543		NPP	Jan 27, 2020
					PED	Jul 27, 2020
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	9555027	May 26, 2026	DP U-543		M-195	Jan 27, 2020
					NPP	Jan 27, 2020
					PED	Jul 27, 2020
					PED	Jul 27, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	9555027	May 26, 2026	DP U-543			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	9555027	May 26, 2026	DP U-543		M-195 NPP PED PED	Jan 27, 2020 Jan 27, 2020 Jul 27, 2020 Jul 27, 2020
<u>MARAVIROC - SELZENTRY</u>						
N 022128 001					NPP NS	Nov 04, 2019 Nov 04, 2019
<u>MARAVIROC - SELZENTRY</u>						
N 022128 002					NPP NS	Nov 04, 2019 Nov 04, 2019
<u>MARAVIROC - SELZENTRY</u>						
N 022128 003	6586430	Dec 01, 2019	DS DP U-824		NPP	Nov 04, 2019
	6667314	Aug 06, 2021	DS DP U-824		NS	Nov 04, 2019
	7368460	Nov 25, 2022	U-824			
	7576097	May 25, 2021	DS			
<u>MARAVIROC - SELZENTRY</u>						
N 022128 004	6586430	Dec 01, 2019	DS DP U-824		NPP	Nov 04, 2019
	6667314	Aug 06, 2021	DS DP U-824		NS	Nov 04, 2019
	7368460	Nov 25, 2022	U-824			
	7576097	May 25, 2021	DS			
<u>MARAVIROC - SELZENTRY</u>						
N 208984 001					NP	Nov 04, 2019
<u>MELOXICAM - VIVLODEX</u>						
N 207233 001	9649318	Mar 31, 2035	DP			
<u>MELOXICAM - VIVLODEX</u>						
N 207233 002	9649318	Mar 31, 2035	DP			
<u>MELPHALAN HYDROCHLORIDE - EVOMELA</u>						
N 207155 001	9493582	Feb 27, 2033	DP			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001					M-198	Feb 27, 2020
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002	9339472	Jul 13, 2025	DP		M-198	Feb 27, 2020
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003	9339472	Jul 13, 2025	DP		M-198	Feb 27, 2020
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1996			
	7078381	Feb 02, 2019	U-1996			
	7459428	Feb 02, 2019	U-1996			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1996			
	7078381	Feb 02, 2019	U-1996			
	7459428	Feb 02, 2019	U-1996			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 001	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1996			
	7078381	Feb 02, 2019	U-1996			
	7459428	Feb 02, 2019	U-1996			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1996			
	7078381	Feb 02, 2019	U-1996			
	7459428	Feb 02, 2019	U-1996			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 003	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1996			
	7078381	Feb 02, 2019	U-1996			
	7459428	Feb 02, 2019	U-1996			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 005	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 006	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 007	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 008	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400 001	9259427	Jan 02, 2033	DP			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 001	9669096	Apr 08, 2024	DP			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 002	9669096	Apr 08, 2024	DP			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 003	9669096	Apr 08, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 001 >A>	9668981	Oct 07, 2025	U-2024			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 002 >A>	9668981	Oct 07, 2025	U-2024			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 003 >A>	9668981	Oct 07, 2025	U-2024			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 004 >A>	9668981	Oct 07, 2025	U-2024			
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 001					>A> NP	Jun 19, 2020
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 002					>A> NP	Jun 19, 2020
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 003					>A> NP	Jun 19, 2020
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 001	9545399	Aug 14, 2033	DP U-1827			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 002	9545399	Aug 14, 2033	DP U-1827			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 003	9545399	Aug 14, 2033	DP U-1827			
<u>MIDOSTAURIN - RYDAPT</u>						
N 207997 001	7973031	Oct 17, 2024	U-2007		NCE	Apr 28, 2022
	8222244	Oct 29, 2022	U-2007		ODE	Apr 28, 2024
	8575146	Dec 02, 2030	U-2008		ODE	Apr 28, 2024
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603 001	9044402	Jul 01, 2033	DP U-1556			
	9549899	Jul 01, 2033	DP U-1556			
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603 002	9044402	Jul 01, 2033	DP U-1556			
	9549899	Jul 01, 2033	DP U-1556			
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603 003	9044402	Jul 01, 2033	DP U-1556			
	9549899	Jul 01, 2033	DP U-1556			
<u>NALDEMEDINE TOSYLATE - SYMPROIC</u>						
N 208854 001	9108975	Nov 11, 2031	DS DP		NCE	Mar 23, 2022
	RE46365	Jan 11, 2028	DS DP			
	RE46375	Oct 05, 2026	DS DP U-1185			
<u>NALOXONE HYDROCHLORIDE - NARCAN</u>						
N 208411 001	9211253	Mar 16, 2035	DP			
	9561177	Mar 16, 2035	DP U-1903			
	9629965	Mar 16, 2035	DP U-1903			
<u>NALOXONE HYDROCHLORIDE - NARCAN</u>						
N 208411 002	9480644	Mar 16, 2035	DP U-1903			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001	9555000	Apr 04, 2023	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 002	9555000	Apr 04, 2023	DP U-1556			
<u>NEPAFENAC - ILEVRO</u>						
N 203491 001	9662398	Dec 01, 2030	DP			
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 208447 001	8071623	Mar 22, 2030	DS DP		NCE	Mar 27, 2022
	8436185	Apr 24, 2029	DS		ODE	Mar 27, 2024
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531 001	6166197	Dec 26, 2017	DS		ODE	Dec 23, 2023
	6210892	Oct 07, 2018		U-1942		
	7101993	Sep 05, 2023	DS			
	7838657	Jul 11, 2027	DS			
	8110560	Dec 05, 2025		U-1942		
	8110560	Dec 05, 2025		U-1943		
	8110560	Dec 05, 2025		U-1944		
	8361977	May 27, 2030	DS DP			
	8980853	Nov 24, 2030		U-1941		
<u>OLODATEROL HYDROCHLORIDE - STRIVERDI RESPIMAT</u>						
N 203108 001	8733341	Oct 16, 2030	DP			
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001	6149054	Dec 19, 2016	DP			
	6149054*PED	Jun 19, 2017				
	6846413	Aug 28, 2018	DP			
	6846413*PED	Feb 28, 2019				
	6977042	Aug 28, 2018	DP			
	6977042*PED	Feb 28, 2019				
	6988496	Feb 23, 2020	DP			
	6988496*PED	Aug 23, 2020				
	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7802568	Feb 26, 2019	DP			
	7802568*PED	Aug 26, 2019				
	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	8733341	Oct 16, 2030	DP			
<u>OLOPATADINE HYDROCHLORIDE - OLOPATADINE HYDROCHLORIDE</u>						
A 090848 001					>A> PC	Dec 05, 2017
<u>OLOPATADINE HYDROCHLORIDE - PAZEO</u>						
N 206276 001	9533053	May 19, 2032	DP			
<u>OMACETAXINE MEPESUCCINATE - SYNTRIBO</u>						
N 203585 001	6987103	Oct 26, 2026	U-1300			
<u>OMBITASVIR; PARITAPREVIR; RITONAVIR - TECHNIVIE</u>						
N 207931 001					I-743	Jul 24, 2018
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	5792795	May 13, 2018	DP			
	5948818	May 13, 2018	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ORITAVANCIN DIPHOSPHATE - ORBACTIV</u>						
N 206334 001	9649352	Jul 16, 2035	DP			
<u>OSPEMIFENE - OSPHENA</u>						
N 203505 001	6245819	Jul 21, 2020	U-1370			
	9566252	Jul 21, 2020	U-1370			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	9592200	Jul 07, 2023	DP			
	>A> 9682075	Dec 10, 2030	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	9592200	Jul 07, 2023	DP			
	>A> 9682075	Dec 10, 2030	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003	9592200	Jul 07, 2023	DP			
	>A> 9682075	Dec 10, 2030	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004	9592200	Jul 07, 2023	DP			
	>A> 9682075	Dec 10, 2030	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005	9592200	Jul 07, 2023	DP			
	>A> 9682075	Dec 10, 2030	DP U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXAYDO</u>						
N 202080 001	9492443	May 26, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXAYDO</u>						
N 202080 002	9492443	May 26, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 001	7955619	Aug 12, 2028	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 002	7955619	Aug 12, 2028	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 003	7955619	Aug 12, 2028	DP			
<u>OXYMETAZOLINE HYDROCHLORIDE - RHOFADÉ</u>						
N 208552 001	7812049	May 02, 2028	U-1959		NP	Jan 18, 2020
	8420688	Aug 02, 2024	U-1959			
	8883838	Dec 01, 2031	DP			
<u>PACLITAXEL - ABRAXANE</u>						
N 021660 001	9393318	Mar 04, 2032	U-1290			
	9511046	Jan 12, 2034	U-1434			
	9597409	Mar 04, 2032	U-1290			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	7456168	Jan 16, 2023	U-1998			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	7456168	Jan 16, 2023	U-1998			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	7456168	Jan 16, 2023	U-1998			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	9439854	Jan 30, 2024	DP			
	9439854*PED	Jul 30, 2024				
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	9439854	Jan 30, 2024	DP			
	9439854*PED	Jul 30, 2024				
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	9545457	Jan 13, 2019	U-665			
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 001	9566271	Jan 15, 2024	U-1974			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 001					NCE ODE	Oct 16, 2019 Oct 15, 2021
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 002					NCE ODE	Oct 16, 2019 Oct 15, 2021
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 003					NCE ODE	Oct 16, 2019 Oct 15, 2021
<u>PLECANATIDE - TRULANCE</u>						
N 208745 001	7041786	Mar 25, 2023	DS		NCE	Jan 19, 2022
	7799897	Jun 09, 2022	DS			
	8637451	Mar 28, 2022		U-1964		
	9610321	Sep 11, 2031		U-1999		
	9616097	Jul 02, 2032	DP			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001	9493470	Dec 12, 2033	DS DP	U-1700		
	9493470	Dec 12, 2033	DS DP	U-1948		
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002	9493470	Dec 12, 2033	DS DP	U-1700		
	9493470	Dec 12, 2033	DS DP	U-1948		
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003	8114874	Dec 22, 2026	DS DP			
	9493470	Dec 12, 2033	DS DP	U-1700		
	9493470	Dec 12, 2033	DS DP	U-1948		
<u>PREDNISONE - RAYOS</u>						
N 202020 001	9504699	Aug 03, 2027	U-1362			
<u>PREDNISONE - RAYOS</u>						
N 202020 002	9504699	Aug 03, 2027	U-1362			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 022145 001					>A> D-167	May 26, 2020
<u>RALTEGRAVIR POTASSIUM - ISENTRESS HD</u>						
N 022145 002	>A> 7169780	Oct 03, 2023	DS DP		>A> NS	May 26, 2020
	>A> 7217713	Oct 21, 2022		U-257		
	>A> 7435734	Oct 21, 2022		U-257		
	>A> 7754731	Mar 11, 2029	DS DP	U-257		
	>A> 9649311	Oct 21, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201823 001					PC	Jul 01, 2017
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201823 002					PC	Jul 01, 2017
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201950 001					PC	Jul 01, 2017
<u>RASAGILINE MESYLATE - RASAGILINE MESYLATE</u>						
A 201950 002					PC	Jul 01, 2017
<u>REGADENOSON - LEXISCAN</u>						
N 022161 001					M-194	Jan 17, 2020
<u>REGORAFENIB - STIVARGA</u>						
N 203085 001	7351834	Jun 28, 2022	DS		I-744 ODE	Apr 27, 2020 Apr 27, 2024
<u>RIBOCICLIB SUCCINATE - KISOALI</u>						
N 209092 001	8324225	Jun 17, 2028	DS DP		NCE	Mar 13, 2022
	8415355	Feb 19, 2031	DS DP			
	8685980	May 25, 2030	DS DP			
	8962630	Dec 09, 2029		U-1981		
	9193732	Nov 09, 2031	DS DP			
	9416136	Aug 20, 2029		U-1981		
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	9629828	Jul 24, 2029		U-1994		
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	9539218	Feb 17, 2034		U-1953		
	9539218	Feb 17, 2034		U-1954		
	9539218	Feb 17, 2034		U-1955		
	9539218	Feb 17, 2034		U-1956		
	9539218	Feb 17, 2034		U-1957		
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	9539218	Feb 17, 2034		U-1953		
	9539218	Feb 17, 2034		U-1954		
	9539218	Feb 17, 2034		U-1955		
	9539218	Feb 17, 2034		U-1956		
	9539218	Feb 17, 2034		U-1957		
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	9539218	Feb 17, 2034		U-1953		
	9539218	Feb 17, 2034		U-1954		
	9539218	Feb 17, 2034		U-1955		
	9539218	Feb 17, 2034		U-1957		
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 206500 001	8404702	Apr 04, 2027		U-1741		
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 001					M-203	Mar 23, 2020
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 002					M-203	Mar 23, 2020
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 003					M-203	Mar 23, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 004					M-203	Mar 23, 2020
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 005					M-203	Mar 23, 2020
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 006					M-203	Mar 23, 2020
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 001	7351701	Jul 23, 2024	U-2012		ODE	Dec 19, 2023
	7531530	Jul 23, 2024	U-2012			
	8071579	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2012			
	8859562	Aug 04, 2031	U-2012			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 002	7351701	Jul 23, 2024	U-2012		ODE	Dec 19, 2023
	7531530	Jul 23, 2024	U-2012			
	8071579	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2012			
	8859562	Aug 04, 2031	U-2012			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 003	6495541	Jan 10, 2020	DS DP			
	7351701	Jul 23, 2024	U-2012			
	7531530	Jul 23, 2024	U-2012			
	8071579	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2012			
	8754072	Feb 10, 2031	DS DP			
	8859562	Aug 04, 2031	U-2012			
	9045487	Feb 10, 2031	DS DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001 >A>	9662335	Dec 12, 2026	DS			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002 >A>	9662335	Dec 12, 2026	DS			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003 >A>	9662335	Dec 12, 2026	DS			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004 >A>	9662335	Dec 12, 2026	DS			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005 >A>	9662335	Dec 12, 2026	DS			
<u>SACROSIDASE - SUCRAID</u>						
N 020772 001	9469847	Feb 07, 2034	DS DP			
<u>SAFINAMIDE MESYLATE - XADAGO</u>						
N 207145 001	8076515	Dec 10, 2028	DS DP U-1993		NCE	Mar 21, 2022
	8278485	Jun 08, 2027	DS U-1993			
	8283380	Sep 01, 2027	U-1993			
<u>SAFINAMIDE MESYLATE - XADAGO</u>						
N 207145 002	8076515	Dec 10, 2028	DS DP U-1993		NCE	Mar 21, 2022
	8278485	Jun 08, 2027	DS U-1993			
	8283380	Sep 01, 2027	U-1993			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 001					M-198	Feb 27, 2020
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 002					M-198	Feb 27, 2020
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001	9623022	Jul 28, 2026	U-1467			
<u>SIMVASTATIN - SIMVASTATIN</u>						
N 206679 001	9597289	Feb 23, 2030	DP			
<u>SIMVASTATIN - SIMVASTATIN</u>						
N 206679 002	9597289	Feb 23, 2030	DP			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1997			
	7078381	Feb 02, 2019	U-1997			
	7459428	Feb 02, 2019	U-1945			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1997			
	7078381	Feb 02, 2019	U-1997			
	7459428	Feb 02, 2019	U-1945			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003	6303661	Apr 24, 2017	U-1996			
	6890898	Feb 02, 2019	U-1997			
	7078381	Feb 02, 2019	U-1997			
	7459428	Feb 02, 2019	U-1945			
<u>SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE</u>						
N 201444 001	9345724	Mar 29, 2031	DS DP U-2015			
	9585912	Mar 29, 2031	DS DP			
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	9539330	Dec 22, 2019	DP			
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N 203923 001	9345724	Mar 29, 2031	DS DP U-2015			
	9585912	Mar 29, 2031	DS DP			
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	9549941	Mar 26, 2029	U-1958		NPP ODE	Apr 07, 2020 Apr 07, 2024
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 008	RE46363	Aug 03, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 009	RE46363	Aug 03, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 010	RE46363	Aug 03, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 011	RE46363	Aug 03, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SUCROFERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001	9561251	Jan 23, 2030	DP U-1468			
<u>SUMATRIPTAN SUCCINATE - ONZETRA XSAIL</u>						
N 206099 001	9649456	Oct 21, 2030	DP U-1719			
	9649456	Oct 21, 2030	DP U-2010			
	9649456	Oct 21, 2030	DP U-2011			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 001	9549918	May 30, 2028	DP			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 002	9549918	May 30, 2028	DP			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 003	9549918	May 30, 2028	DP			
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	9539234	Jan 25, 2033	U-1934			
	9549913	Jan 25, 2033	U-1486			
<u>TAVABOROLE - KERYDIN</u>						
N 204427 001	7582621	May 26, 2027	U-2016			
	9549938	Feb 16, 2026	U-1951			
	9566289	Feb 16, 2026	DP			
	9566290	Feb 16, 2026	U-1970			
	9572823	Feb 16, 2026	U-1970			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	9539310	Nov 01, 2025	U-1320			
	9545434	Nov 01, 2025	U-1320			
	9545435	Nov 01, 2025	U-1320			
	9555079	Nov 01, 2025	U-1320			
	9572867	Nov 01, 2025	U-1320			
	9592273	Nov 01, 2025	U-1320			
	9592274	Nov 01, 2025	U-1320			
<u>TELOTRIPTAT ETIPRATE - XERMELO</u>						
N 208794 001	7553840	Dec 11, 2027	DS		NCE	Feb 28, 2022
	7709493	Dec 11, 2027	DS	U-1979	ODE	Feb 28, 2024
	7968559	Dec 11, 2027		U-1979		
	8193204	Feb 27, 2031	DS			
	8653094	Dec 19, 2028		U-1979		
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 002 >A>	9622340	Feb 11, 2034	DP U-1531			
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 003 >A>	9622340	Feb 11, 2034	DP U-1531			
<u>THIOTEPA - TEPADINA</u>						
N 208264 001					ODE	Jan 26, 2024
<u>THIOTEPA - TEPADINA</u>						
N 208264 002					ODE	Jan 26, 2024
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	6525060	Dec 02, 2019	DS DP U-1171	Y		
	6525060	Dec 02, 2019	DS DP U-1860	Y		
	6525060	Dec 02, 2019	DS DP U-1862	Y		
	6525060	Dec 02, 2019	DS DP U-1863	Y		
	RE46276	Dec 02, 2019	DS DP U-1935			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	RE46276	Dec 02, 2019	DS DP U-1936			
	RE46276	Dec 02, 2019	DS DP U-1937			
	RE46276	Dec 02, 2019	DS DP U-1938			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	6525060	Dec 02, 2019	DS DP U-1171	Y		
	6525060	Dec 02, 2019	DS DP U-1860	Y		
	6525060	Dec 02, 2019	DS DP U-1862	Y		
	6525060	Dec 02, 2019	DS DP U-1863	Y		
	RE46276	Dec 02, 2019	DS DP U-1935			
	RE46276	Dec 02, 2019	DS DP U-1936			
	RE46276	Dec 02, 2019	DS DP U-1937			
	RE46276	Dec 02, 2019	DS DP U-1938			
<u>TIOTROPIUM BROMIDE - SPIRIVA</u>						
N 021395 001	6777423	Sep 24, 2021	DS DP			
	6777423*PED	Mar 24, 2022				
	6908928	Sep 24, 2021	DS DP U-566			
	6908928	Sep 24, 2021	DS DP U-762			
	6908928*PED	Mar 24, 2022				
	7070800	Jan 22, 2022	DP U-566			
	7070800*PED	Jul 22, 2022				
	7309707	Sep 24, 2021	DS DP			
	7309707*PED	Mar 24, 2022				
	7642268	Sep 24, 2021	DS DP			
	7642268*PED	Mar 24, 2022				
	7694676	Mar 12, 2027	DP			
	7694676*PED	Sep 12, 2027				
	8022082	Jan 19, 2026	DP U-1186			
	8022082*PED	Jul 19, 2026				
	9010323	Apr 19, 2030	DP			
	RE38912	Oct 11, 2021	DP			
	RE38912*PED	Apr 11, 2022				
	RE39820	Jan 30, 2018	DS DP U-566			
	RE39820*PED	Jul 30, 2018				
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 001	5964416	Oct 04, 2016	DP		NPP	Feb 15, 2020
	5964416*PED	Apr 04, 2017			PED	Aug 15, 2020
	6149054	Dec 16, 2016	DP			
	6149054*PED	Jun 16, 2017				
	6176442*PED	Dec 01, 2016				
	6453795	Dec 05, 2016	DP			
	6453795*PED	Jun 05, 2017				
	6726124	Oct 04, 2016	DP			
	6726124*PED	Apr 04, 2017				
	6846413	Aug 28, 2018	DP			
	6846413*PED	Feb 28, 2019				
	6977042	Aug 28, 2018	DP			
	6977042*PED	Feb 28, 2019				
	6988496	Feb 23, 2020	DP			
	6988496*PED	Aug 23, 2020				
	7104470	Oct 04, 2016	DP			
	7104470*PED	Apr 04, 2017				
	7246615*PED	Dec 01, 2016				
	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7802568	Feb 26, 2019	DP			
	7802568*PED	Aug 26, 2019				
	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	7896264	May 26, 2025	DP			
	7896264*PED	Nov 26, 2025				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 001	7988001	Aug 04, 2021	DP			
	7988001*PED	Feb 04, 2022				
	8733341	Oct 16, 2030	DP			
	8733341*PED	Apr 16, 2031				
	RE39820	Jan 30, 2018	DS DP U-1593			
	RE39820*PED	Jul 30, 2018				
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 002	5964416	Oct 04, 2016	DP		NPP	Feb 15, 2020
	6149054	Dec 16, 2016	DP		PED	Aug 15, 2020
	6149054*PED	Jun 16, 2017				
	6453795	Dec 05, 2016	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6846413*PED	Feb 28, 2019				
	6977042	Aug 28, 2018	DP			
	6977042*PED	Feb 28, 2019				
	6988496	Feb 23, 2020	DP			
	6988496*PED	Aug 23, 2020				
	7104470	Oct 04, 2016	DP			
	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7802568	Feb 26, 2019	DP			
	7802568*PED	Aug 26, 2019				
	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	7896264	May 26, 2025	DP			
	7896264*PED	Nov 26, 2025				
	7988001	Aug 04, 2021	DP			
	7988001*PED	Feb 04, 2022				
	8733341	Oct 16, 2030	DP			
	8733341*PED	Apr 16, 2031				
	RE39820	Jan 30, 2018	DS DP			
	RE39820*PED	Jul 30, 2018				
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 001	9527833	Jun 17, 2034	DS DP			
	RE46284	Dec 16, 2026			U-1751	
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 002	9527833	Jun 17, 2034	DS DP			
	RE46284	Dec 16, 2026			U-1751	
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 001	RE41783	Dec 08, 2025	DS			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001	RE41783	Dec 08, 2025	DS			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	9622983	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 001	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 002	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 003	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 004	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 005	9555005	Mar 19, 2033	DP			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001					>A> I-745	Jun 22, 2020
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002					>A> I-745	Jun 22, 2020
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003					>A> I-745	Jun 22, 2020
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 001	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 002	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 003	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2017

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 005	6765117	Oct 24, 2017	DS		D-156	Jan 28, 2019
	7417070	Jul 30, 2026	DS		D-157	Jan 28, 2019
	7544713	Jul 14, 2024		U-1475		
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS			
	8747897	Oct 08, 2029	DP			
	9050311	May 24, 2024	DS DP			
	9278901	May 24, 2024		U-1475		
	9393203	Apr 27, 2026	DP	U-1877		
	9422223	May 24, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TRIPTORELIN PAMOATE - TRIPTODUR KIT</u>						
N 208956 001					>A> NP	Jun 29, 2020
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001					NCE	Dec 18, 2018
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001					NCE	May 10, 2018
					NCE	Dec 18, 2018
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 001	8039627	Oct 06, 2029	DS DP		NCE	Apr 11, 2022
	8357697	Nov 08, 2027		U-1995		
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 022257 001	9642911	Dec 11, 2027	DP			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 001	>A> 9687526	Jan 30, 2035		U-1857		
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 002	9375478	Jan 30, 2035		U-1857		
	>A> 9687526	Jan 30, 2035		U-1857		
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 001	9265720	Feb 25, 2031		U-674		
	9597281	Apr 06, 2027		U-674		
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 002	9265720	Feb 25, 2031		U-674		
	9597281	Apr 06, 2027		U-674		

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 37th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm